U.S. patent application number 15/137502 was filed with the patent office on 2016-08-18 for dihydro-pyrrolopyridinone inhibitors.
The applicant listed for this patent is AbbVie Inc.. Invention is credited to Yujia Dai, Steven D. Fidanze, Lisa A. Hasvold, James H. Holms, Dachun Liu, Robert A. Mantei, William J. McClellan, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang.
Application Number | 20160237084 15/137502 |
Document ID | / |
Family ID | 50942775 |
Filed Date | 2016-08-18 |
United States Patent
Application |
20160237084 |
Kind Code |
A1 |
Wang; Le ; et al. |
August 18, 2016 |
DIHYDRO-PYRROLOPYRIDINONE INHIBITORS
Abstract
The present invention provides for compounds of formula (I)
##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and
R.sup.5 have any of the values defined in the specification, and
pharmaceutically acceptable salts thereof, that are useful as
agents in the treatment of diseases and conditions, including
inflammatory diseases, cancer, and AIDS. Also provided are
pharmaceutical compositions comprising one or more compounds of
formula (I).
Inventors: |
Wang; Le; (Vernon Hills,
IL) ; Pratt; John; (Kenosha, WI) ; Hasvold;
Lisa A.; (Grayslake, IL) ; Liu; Dachun;
(Vernon Hills, IL) ; Dai; Yujia; (Gurnee, IL)
; Fidanze; Steven D.; (Grayslake, IL) ; Holms;
James H.; (Gurnee, IL) ; Mantei; Robert A.;
(Franklin, WI) ; McDaniel; Keith F.; (Wauconda,
IL) ; Sheppard; George S.; (Wilmette, IL) ;
McClellan; William J.; (Waukegan, IL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AbbVie Inc. |
North Chicago |
IL |
US |
|
|
Family ID: |
50942775 |
Appl. No.: |
15/137502 |
Filed: |
April 25, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14206028 |
Mar 12, 2014 |
9321764 |
|
|
15137502 |
|
|
|
|
61777699 |
Mar 12, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 11/00 20180101;
A61P 31/04 20180101; A61P 1/04 20180101; A61P 11/06 20180101; A61P
37/06 20180101; A61P 35/02 20180101; A61P 25/00 20180101; A61P
27/02 20180101; A61P 13/12 20180101; A61P 19/06 20180101; A61P 9/04
20180101; A61P 29/00 20180101; A61P 37/02 20180101; C07D 519/00
20130101; A61P 5/38 20180101; A61P 17/02 20180101; A61P 9/10
20180101; A61P 35/00 20180101; A61P 17/04 20180101; A61P 19/02
20180101; A61P 9/00 20180101; A61P 3/10 20180101; A61P 1/16
20180101; A61P 1/18 20180101; C07D 471/04 20130101 |
International
Class: |
C07D 471/04 20060101
C07D471/04; C07D 519/00 20060101 C07D519/00 |
Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt
thereof, ##STR00017## wherein R.sup.1 is H, C.sub.1-C.sub.3 alkyl,
or C.sub.1-C.sub.3 haloalkyl; R.sup.2 is H, C.sub.1-C.sub.3 alkyl,
or C.sub.1-C.sub.3 haloalkyl; R.sup.3 is H, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
--OR.sup.3a, --NR.sup.3bR.sup.3c, --N(R.sup.3b)C(O)R.sup.3d,
--N(R.sup.3b)C(O)NR.sup.3bR.sup.3c,
--N(R.sup.3b)S(O).sub.2NR.sup.3bR.sup.3c, --C(O)R.sup.3a,
--C(O)OR.sup.3a, --C(O)NR.sup.3bR.sup.3c, --S(O)R.sup.3d,
--S(O).sub.2R.sup.3a, --S(O).sub.2NR.sup.3bR.sup.3c, or G.sup.1;
wherein the C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, and
C.sub.2-C.sub.6 alkynyl are each independently unsubstituted or
substituted with 1 or 2 substituents independently selected from
the group consisting of halogen, G.sup.1, --OR.sup.3a, and
--NR.sup.3bR.sup.3c; R.sup.3a, R.sup.3b, and R.sup.3c, at each
occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.1, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.1, --(C.sub.1-C.sub.6 alkylenyl)-CN,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.z1, or --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4; R.sup.3d, at each occurrence, is
independently C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl,
G.sup.1, or --(C.sub.1-C.sub.6 alkylenyl)-G.sup.1; G.sup.1, at each
occurrence, is independently aryl, heteroaryl, heterocycle,
cycloalkyl, or cycloalkenyl; and each G.sup.1 is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.1g groups; R.sup.4 is H,
C.sub.1-C.sub.6 alkyl, halogen, or C.sub.1-C.sub.6 haloalkyl;
R.sup.5 is a monocyclic or bicyclic ring selected from the group
consisting of aryl and heteroaryl; each of which is substituted
with 1, 2, or 3 substituents independently selected from the group
consisting of C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN,
NO.sub.2, G.sup.2, --OR.sup.a, --OC(O)R.sup.b,
--OC(O)NR.sup.cR.sup.d, --SR.sup.a, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.cR.sup.d, --NR.sup.cR.sup.d, --N(R.sup.e)C(O)R.sup.b,
--N(R.sup.e)S(O).sub.2R.sup.b, --N(R.sup.e)C(O)O(R.sup.b),
--N(R.sup.e)C(O)NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2, --(C.sub.1-C.sub.6 alkylenyl)-OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.a, --(C.sub.1-C.sub.6 alkylenyl)-C(O)OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)O(R.sup.b), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.6 alkylenyl)-CN; R.sup.a, R, R.sup.d, and R.sup.e,
at each occurrence, are each independently H, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl
is optionally substituted with one substituent selected from the
group consisting of --OR.sup.y1, --NR.sup.y3R.sup.y4,
--C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4, --S(O).sub.2R.sup.y1,
--S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2; R.sup.b, at each
occurrence, is independently C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl, G.sup.2, or
C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl is
optionally substituted with one substituent selected from the group
consisting of --OR.sup.y1, --NR.sup.y3R.sup.y4, --C(O)OR.sup.y1,
--C(O)NR.sup.y3R.sup.y4, --S(O).sub.2R.sup.y1,
--S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2; G.sup.2, at each
occurrence, are each independently aryl, heteroaryl, heterocycle,
cycloalkyl, or cycloalkenyl; and each G.sup.2 group is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.2g groups; R.sup.1g, at
each occurrence, is independently C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.z1,
--OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4, --SR.sup.z1,
--S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)(C.sub.3-C.sub.6 cycloalkyl),
--C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4, --NR.sup.z3R.sup.z4,
--N(R.sup.z3)C(O)R.sup.z2, --N(R.sup.z3)S(O).sub.2R.sup.z2,
--N(R.sup.z3)C(O)O(R.sup.z2), --N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --O(phenyl); wherein the
phenyl moiety and the C.sub.3-C.sub.6 cycloalkyl moiety are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from the group consisting of C.sub.1-C.sub.6
alkyl, halogen, C.sub.1-C.sub.6 haloalkyl, --OH, --O(alkyl),
--O(haloalkyl), CN, and NO.sub.2; R.sup.2g, at each occurrence, is
independently C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, oxo,
--CN, NO.sub.2, --OR.sup.y1, --OC(O)R.sup.y2,
--OC(O)NR.sup.y3R.sup.y4, --SR.sup.y1, --S(O).sub.2R.sup.y1,
--S(O).sub.2NR.sup.y3R.sup.y4, --C(O)R.sup.y1, --C(O)OR.sup.y1,
--C(O)NR.sup.y3R.sup.y4, --NR.sup.y3R.sup.y4,
--N(R.sup.y3)C(O)R.sup.y2, --N(R.sup.y3)S(O).sub.2R.sup.y2,
--N(R.sup.y3)C(O)O(R.sup.y2), --N(R.sup.y3)C(O)NR.sup.y3R.sup.y4,
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4, G.sup.2b,
--(C.sub.1-C.sub.6 alkylenyl)-OR, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)O(R.sup.y2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; R.sup.y1, R.sup.y3, and R.sup.y4, at each
occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.2b, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; R.sup.y2, at each occurrence, is independently
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, G.sup.2b, or
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.2b; G.sup.2b, at each
occurrence, is independently aryl, heteroaryl, cycloalkyl,
cycloalkenyl, or heterocycle; and each G.sup.2b group is optionally
substituted with 1, 2, 3, 4, or 5 substituents independently
selected from the group consisting of C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.z1,
--OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4, --SR.sup.z1,
--S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4,
--NR.sup.z3R.sup.z4, --N(R.sup.z3)C(O)R.sup.z2,
--N(R.sup.z3)S(O).sub.2R.sup.z2, --N(R.sup.z3)C(O)O(R.sup.z2),
--N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, and
--(C.sub.1-C.sub.6 alkylenyl)-CN; R.sup.z1, R.sup.z3, and R.sup.z4,
at each occurrence, are each independently H, C.sub.1-C.sub.6
alkyl, or C.sub.1-C.sub.6 haloalkyl; and R.sup.z2, at each
occurrence, is independently C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 haloalkyl.
2. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is C.sub.1-C.sub.3 alkyl.
3. The compound of claim 2, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is H or C.sub.1-C.sub.3 alkyl.
4. The compound of claim 3, or a pharmaceutically acceptable salt
thereof, wherein R.sup.5 is phenyl, pyridinyl, or indolyl, which is
substituted with 1, 2, or 3 substituents independently selected
from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6
haloalkyl, --CN, NO.sub.2, G.sup.2, --OR.sup.a, --OC(O)R.sup.b,
--OC(O)NR.sup.cR.sup.d, --SR.sup.a, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.cR.sup.d, --NR.sup.cR.sup.d, --N(R.sup.e)C(O)R.sup.b,
--N(R.sup.e)S(O).sub.2R.sup.b, --N(R.sup.e)C(O)O(R.sup.b),
--N(R.sup.e)C(O)NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2, --(C.sub.1-C.sub.6 alkylenyl)-OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.a, --(C.sub.1-C.sub.6 alkylenyl)-C(O)OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)O(R.sup.b), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.6 alkylenyl)-CN.
5. The compound of claim 3, or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is H, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, halogen, --C(O)R.sup.3a, --C(O)OR.sup.3a,
--C(O)NR.sup.3bR.sup.3c, or G.sup.1; wherein the C.sub.1-C.sub.6
alkyl and the C.sub.2-C.sub.6 alkenyl are each independently
unsubstituted or substituted with 1 or 2 substituents independently
selected from the group consisting of halogen, G, --OR.sup.3a, and
--NR.sup.3bR.sup.3c.
6. The compound of claim 4, or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is H, C.sub.1-C.sub.3 alkyl,
C.sub.2-C.sub.4 alkenyl, halogen, or G.sup.1; wherein the
C.sub.1-C.sub.3 alkyl and the C.sub.2-C.sub.4 alkenyl are each
independently unsubstituted or substituted with 1 or 2 substituents
independently selected from the group consisting of halogen, --OH,
--O(C.sub.1-C.sub.3 alkyl), --NH.sub.2, --N(H)(C.sub.1-C.sub.3
alkyl), or --N(C.sub.1-C.sub.3 alkyl).sub.2.
7. The compound of claim 3, or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is H, halogen, unsubstituted
C.sub.1-C.sub.3 alkyl, optionally substituted phenyl, optionally
substituted 1,2-oxazolyl, or C.sub.2-C.sub.4 alkenyl which is
substituted with 2 substituents independently selected from the
group consisting of halogen and --OH; and R.sup.5 is phenyl or
pyridinyl, each of which is substituted with 1, 2, or 3
substituents independently selected from the group consisting of
C.sub.1-C.sub.3 alkyl, halogen, C.sub.1-C.sub.3 haloalkyl, --CN,
NO.sub.2, G.sup.2, --OR.sup.a, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.cR.sup.d, --NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.3
alkylenyl)-G.sup.2 wherein G.sup.2 is optionally substituted
heterocycle, --(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.3 alkylenyl)-NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.3 alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b.
8. The compound of claim 3, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is C.sub.1-C.sub.3 alkyl; R.sup.2 is H or
C.sub.1-C.sub.3 alkyl; R.sup.3 is H, unsubstituted C.sub.1-C.sub.3
alkyl, or halogen; R.sup.4 is H, C.sub.1-C.sub.3 alkyl, or halogen;
and R.sup.5 is phenyl or pyridinyl; each of which is substituted
with 1, 2, or 3 substituents, wherein one substituent is selected
from the group consisting of --OR.sup.a and --NR.sup.cR.sup.d, and
the other optional substituents are selected from the group
consisting of C.sub.1-C.sub.3 alkyl, halogen, C.sub.1-C.sub.3
haloalkyl, --S(O).sub.2R.sup.a, --S(O).sub.2NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.3
alkylenyl)-G.sup.2 wherein G.sup.2 is optionally substituted
heterocycle, --(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.3 alkylenyl)-NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.3 alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b.
9. The compound of claim 3, or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is H, unsubstituted C.sub.1-C.sub.3 alkyl,
or halogen; R.sup.4 is H, C.sub.1-C.sub.3 alkyl, or halogen; and
R.sup.5 is indolyl substituted with 1 or 2 substituents
independently selected from the group consisting of --OR.sup.a,
--C(O)OR.sup.a, and --C(O)NR.sup.cR.sup.d.
10. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.5 is represented by the following formula:
##STR00018## wherein A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8),
A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10); or A.sup.1 is N,
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10); or A.sup.1 is C(R.sup.7), A.sup.2 is N, A.sup.3 is
C(R.sup.9), and A.sup.4 is C(R.sup.10); or A.sup.1 is C(R.sup.7),
A.sup.2 is C(R.sup.8), A.sup.3 is N, and A.sup.4 is C(R.sup.10); or
A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is N; R.sup.6 is halogen, --OR.sup.a, or
--NR.sup.cR.sup.d; R.sup.7 is H, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, or C.sub.3-C.sub.6
cycloalkyl optionally substituted with 1, 2, 3, 4, or 5
substituents independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, and CN; R.sup.10 is H,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN, or NO.sub.2;
R.sup.8 is H, halogen, --OR.sup.a, --NR.sup.cR.sup.d,
--C(O)R.sup.a, --C(O)NR.sup.cR.sup.d, G.sup.2, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2, or --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d; R.sup.9 is H, halogen, --CN,
C.sub.1-C.sub.6 haloalkyl, --N(R.sup.e)S(O).sub.2R.sup.b,
--S(O).sub.2R.sup.a, --S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.2 wherein G.sup.2 is optionally
substituted heterocycle, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; R.sup.a, R.sup.c, R.sup.d,
and R.sup.e, at each occurrence, are each independently H,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6
haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with one
substituent selected from the group consisting of --OR.sup.y1,
--NR.sup.y3R.sup.y4, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2;
R.sup.b, at each occurrence, is independently C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl
is optionally substituted with one substituent selected from the
group consisting of --OR.sup.y1, --NR.sup.y3R.sup.y4,
--C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4, --S(O).sub.2R.sup.y1,
--S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2; G.sup.2, at each
occurrence, are each independently aryl, heteroaryl, heterocycle,
cycloalkyl, or cycloalkenyl; and each G.sup.2 group is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.2g groups; R.sup.2g, at
each occurrence, is independently C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.y1,
--OC(O)R.sup.y2, --OC(O)NR.sup.y3R.sup.y4, --SR.sup.y1,
--S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4,
--C(O)R.sup.y1, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--NR.sup.y3R.sup.y4, --N(R.sup.y3)C(O)R.sup.y2,
--N(R.sup.y3)S(O).sub.2R.sup.y2, --N(R.sup.y3)C(O)O(R.sup.y2),
--N(R.sup.y3)C(O)NR.sup.y3R.sup.y4,
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4, G.sup.2b,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)O(R.sup.y2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; R.sup.y1, R.sup.y3, and R.sup.y4, at each
occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.2b, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; R.sup.y2, at each occurrence, is independently
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, G.sup.2b, or
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.2b; G.sup.2b, at each
occurrence, is independently aryl, heteroaryl, cycloalkyl,
cycloalkenyl, or heterocycle; and each G.sup.2b group is optionally
substituted with 1, 2, 3, 4, or 5 substituents independently
selected from the group consisting of C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.z1,
--OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4, --SR.sup.z1,
--S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4,
--NR.sup.z3R.sup.z4, --N(R.sup.z3)C(O)R.sup.z2,
--N(R.sup.z3)S(O).sub.2R.sup.z2, --N(R.sup.z3)C(O)O(R.sup.z2),
--N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, and
--(C.sub.1-C.sub.6 alkylenyl)-CN; R.sup.z1, R.sup.z3, and R.sup.z4,
at each occurrence, are each independently H, C.sub.1-C.sub.6
alkyl, or C.sub.1-C.sub.6 haloalkyl; and R.sup.z2, at each
occurrence, is independently C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 haloalkyl.
11. The compound of claim 10, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is methyl; and R.sup.2 is H or methyl.
12. The compound of claim 11, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is H; R.sup.3 is H, unsubstituted
C.sub.1-C.sub.3 alkyl, or halogen; and R.sup.4 is H,
C.sub.1-C.sub.3 alkyl, or halogen.
13. The compound of claim 12, or a pharmaceutically acceptable salt
thereof wherein A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8),
A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10); or A.sup.1 is N,
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10).
14. The compound of claim 13, or a pharmaceutically acceptable salt
thereof wherein R.sup.7 is H; R.sup.8 is H or halogen; and R.sup.10
is H or C.sub.1-C.sub.6 alkyl.
15. The compound of claim 14, or a pharmaceutically acceptable salt
thereof wherein R.sup.6 is --OR.sup.a or --NR.sup.cR.sup.d, wherein
R.sup.a and R.sup.d are each independently C.sub.1-C.sub.6
haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with one G.sup.2
group; and R.sup.c is H or unsubstituted C.sub.1-C.sub.6 alkyl; and
R.sup.9 is --N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6 alkylenyl)-G.sup.2
wherein G.sup.2 is optionally substituted heterocycle,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b.
16. The compound of claim 14, or a pharmaceutically acceptable salt
thereof wherein R.sup.6 is --OR.sup.a or --NR.sup.cR.sup.d, wherein
R.sup.a and Rd are each independently C.sub.1-C.sub.6 haloalkyl or
unsubstituted C.sub.1-C.sub.6 alkyl; and R.sup.c is H or
unsubstituted C.sub.1-C.sub.3 alkyl; and R.sup.9 is
--S(O).sub.2R.sup.a or --(CH.sub.2)--SO.sub.2R.sup.a, wherein
R.sup.a, at each occurrence, is independently unsubstituted
C.sub.1-C.sub.3 alkyl.
17. The compound of claim 14, or a pharmaceutically acceptable salt
thereof wherein R.sup.6 is --OR.sup.a or --NR.sup.cR.sup.d, wherein
R.sup.a is G.sup.2 or C.sub.1-C.sub.3 alkyl wherein the
C.sub.1-C.sub.3 alkyl is substituted with one G.sup.2 group; and
G.sup.2 is aryl, C.sub.4-C.sub.6 heterocycle, C.sub.3-C.sub.6
cycloalkyl, C.sub.5-C.sub.6 heteroaryl, or adamantyl, each of which
is optionally substituted; R.sup.c is H or unsubstituted
C.sub.1-C.sub.3 alkyl; and R.sup.d is optionally substituted phenyl
or C.sub.1-C.sub.3 alkyl wherein the C.sub.1-C.sub.3 alkyl is
substituted with one G.sup.2 group; and G.sup.2 is phenyl,
C.sub.3-C.sub.6 cycloalkyl, or bicyclo[2.2.1]heptyl, each of which
is optionally substituted; and R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.3 alkylenyl)-G.sup.2
wherein G.sup.2 is optionally substituted C.sub.4-C.sub.6
heterocycle; --(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.3 alkylenyl)-NR.sup.cR.sup.d, or
--(C.sub.1-C.sub.3 alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; wherein
R.sup.a and R.sup.b are each independently C.sub.1-C.sub.6
haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with one G.sup.2
group, and G.sup.2 is phenyl, C.sub.3-C.sub.6 cycloalkyl,
C.sub.5-C.sub.6 heteroaryl, or C.sub.4-C.sub.6 heterocycle, each of
which is optionally substituted; R.sup.e and R.sup.c are each
independently H or unsubstituted C.sub.1-C.sub.3 alkyl; and R.sup.d
is H, C.sub.1-C.sub.6 haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl
wherein the C.sub.1-C.sub.6 alkyl is optionally substituted with
one G.sup.2 group, and G.sup.2 is phenyl, C.sub.3-C.sub.6
cycloalkyl, C.sub.5-C.sub.6 heteroaryl, or C.sub.4-C.sub.6
heterocycle, each of which is optionally substituted.
18. The compound of claim 14, or a pharmaceutically acceptable salt
thereof wherein R.sup.6 is --OR.sup.a; wherein R.sup.a is G.sup.2,
and G.sup.2 is optionally substituted phenyl or optionally
substituted C.sub.3-C.sub.6 cycloalkyl; and R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, or --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; wherein R.sup.a is
unsubstituted C.sub.1-C.sub.3 alkyl or optionally substituted
C.sub.4-C.sub.6 heterocycle, R.sup.b is unsubstituted
C.sub.1-C.sub.3 alkyl or optionally substituted benzyl; R.sup.c is
H or unsubstituted C.sub.1-C.sub.3 alkyl; R.sup.d is H or
unsubstituted C.sub.1-C.sub.3 alkyl; and R.sup.e is H.
19. The compound of claim 14, or a pharmaceutically acceptable salt
thereof wherein R.sup.3 is H; R.sup.4 is H; R.sup.6 is --OR.sup.a;
wherein R.sup.a is G.sup.2, and G.sup.2 is phenyl substituted with
1 or 2 halogen; and R.sup.9 is --N(R.sup.e)S(O).sub.2R.sup.b,
--S(O).sub.2R.sup.a, or --(CH.sub.2)--S(O).sub.2R.sup.a, wherein
R.sup.a and R.sup.b are each independently unsubstituted
C.sub.1-C.sub.3 alkyl, and R.sup.e is H.
20. The compound of claim 14, or a pharmaceutically acceptable salt
thereof, wherein R.sup.6 is --NR.sup.cR.sup.d, wherein R.sup.c is H
or unsubstituted C.sub.1-C.sub.3 alkyl; and R.sup.d is optionally
substituted phenyl or C.sub.1-C.sub.3 alkyl wherein the
C.sub.1-C.sub.3 alkyl is substituted with one G.sup.2 group,
wherein G.sup.2 is optionally substituted C.sub.3-C.sub.6
cycloalkyl, and R.sup.9 is --N(R.sup.e)S(O).sub.2R.sup.b,
--S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, or --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; wherein R.sup.a is
unsubstituted C.sub.1-C.sub.3 alkyl or optionally substituted
C.sub.4-C.sub.6 heterocycle, R.sup.b is unsubstituted
C.sub.1-C.sub.3 alkyl or optionally substituted benzyl; R.sup.c is
H or unsubstituted C.sub.1-C.sub.3 alkyl; R.sup.d is H or
unsubstituted C.sub.1-C.sub.3 alkyl; and R.sup.e is H.
21. The compound of claim 14, or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is H, R.sup.4 is H, R.sup.6 is
--NR.sup.cR.sup.d, wherein R.sup.c is H or methyl; and R.sup.d is
phenyl substituted with 1 or 2 halogen, or R.sup.d is
C.sub.1-C.sub.3 alkyl wherein the C.sub.1-C.sub.3 alkyl is
substituted with one G.sup.2 group, and G.sup.2 is optionally
substituted cyclopropyl, and R.sup.9 is
--(CH.sub.2)--S(O).sub.2R.sup.a; wherein R.sup.a is unsubstituted
C.sub.1-C.sub.3 alkyl.
22. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein the compound is selected from the group consisting
of:
1-methyl-3-(2-phenoxyphenyl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]methanesulfonamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]propane-2-sulfonamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]ethanesulfonamide;
N-[4-(4-chlorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)phenyl]ethanesulfonamide;
N-{4-[(trans-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-py-
rrolo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide;
N-[3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(tetrah-
ydro-2H-pyran-4-yloxy)phenyl]ethanesulfonamide;
N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide;
N-{4-[(cis-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrr-
olo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide;
N-[3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(oxetan-
-3-yloxy)phenyl]ethanesulfonamide;
N-[4-(2,4-difluorophenoxy)-2-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrr-
olo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide;
N-[2-(2,4-difluorophenoxy)-4-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrr-
olo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide;
N-[2,4-bis(2,4-difluorophenoxy)-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[-
2,3-c]pyridin-3-yl)phenyl]methanesulfonamide;
N-[4-(cyclopropylmethoxy)-2-methyl-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl]ethanesulfonamide;
N-[4-(4-fluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)phenyl]ethanesulfonamide;
N-[4-(4-cyanophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyri-
din-3-yl)phenyl]methanesulfonamide;
3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-phenoxyphenyl]-1,6-dihydro-7H-pyrrolo[2,-
3-c]pyridin-7-one;
3-[2-(3,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-methoxy-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,-
3-c]pyridin-7-one;
3-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydrofuran-3-yloxy)phenyl]-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydrofuran-3-ylmethoxy)phenyl]-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-yloxy)phenyl]-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(4,4-difluorocyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-3-yloxy)phenyl]-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2,2-dimethylpropoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(cyclobutylmethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-{2-[1-methylcyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-(oxetan-3-ylmethoxy)phenyl]-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(cis-4-hydroxycyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(trans-4-hydroxycyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2-cyclopentylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2-cyclohexylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-(2-phenylethoxy)phenyl]-1,6-dihydro-7H-p-
yrrolo[2,3-c]pyridin-7-one;
3-[2-(2,3-dihydro-1H-inden-2-yloxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-{5-(methylsulfonyl)-2-[2-(thiophen-2-yl)ethoxy]phenyl}-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(3,3-dimethylbutoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; 3-{2-[(4,
4-difluorocyclohexyl)methoxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1,6-dim-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(cyclopropylmethyl)(methyl)amino]-5-(methylsulfonyl)phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
4-({[2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(meth-
ylsulfonyl)phenyl]amino}methyl)benzonitrile;
3-{2-[(cyclohexylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(4-chlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-p-
yrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(cyclopropylmethoxy)-6-methylphenyl]-1-methyl-1,6-dihydro-7H-pyrrolo-
[2,3-c]pyridin-7-one;
4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]py-
ridin-3-yl)benzenesulfonamide;
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)methyl]phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[2-(ethylsulfonyl)propan-2-yl]phenyl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[1-(ethylsulfonyl)ethyl]phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(1R)-1-(ethylsulfonyl)ethyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(1S)-1-(ethylsulfonyl)ethyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(phenylsulfonyl)methyl]phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)pyridin-3-yl]-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(4-fluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H--
pyrrolo[2,3-c]pyridin-7-one;
3-[2-(4-tert-butylphenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-(naphthalen-2-yloxy)phenyl]-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-(2,2,3,3,3-pentafluoropropoxy)phenyl]-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-[5-(methylsulfonyl)-2-{2-[tricyclo[3.3.1.1.sup.3,7]dec-1-yl]et-
hoxy}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(3-cyclopentylpropoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydr-
o-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(1-acetylpiperidin-4-yl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(cyclopentylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one;
1-methyl-3-{5-(methylsulfonyl)-2-[(2,2,2-trifluoroethyl)amino]phenyl}-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(2,2,3,3,4,4,4-heptafluorobutyl)amino]-5-(methylsulfonyl)phenyl}-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-{[(1S,4R)-bicyclo[2.2.1]hept-2-ylmethyl]amino}-5-(methylsulfonyl)phe-
nyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(2-cyclopentylethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-d-
ihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2-chloro-4-methylphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[5-(ethylsulfonyl)-2-(pyridin-4-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-p-
yrrolo[2,3-c]pyridin-7-one;
3-{2-[(4,6-dimethylpyridin-3-yl)oxy]-5-(ethylsulfonyl)phenyl}-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(3,4-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one;
3-{5-(ethylsulfonyl)-2-[4-(trifluoromethyl)phenoxy]phenyl}-1-methyl-1,6-d-
ihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
4-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyrid-
in-3-yl)phenoxy]benzonitrile;
3-[2-(4-chloro-3-ethylphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one;
4-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyrid-
in-3-yl)phenoxy]-3-methoxybenzonitrile;
3-[5-(ethylsulfonyl)-2-(pyridin-3-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-p-
yrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one;
2-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyrid-
in-3-yl)phenoxy]benzonitrile;
3-[2-(2,3-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2-chloro-4-methoxyphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{5-(ethylsulfonyl)-2-[(6-methylpyrazin-2-yl)oxy]phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[5-(ethylsulfonyl)-2-(pyridazin-4-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one;
3-[5-(ethylsulfonyl)-2-(pyrimidin-5-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one;
3-{5-(ethylsulfonyl)-2-[(3-methylpyrazin-2-yl)oxy]phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{5-(ethylsulfonyl)-2-[(1,3,5-trimethyl-1H-pyrazol-4-yl)oxy]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
5-chloro-3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-ethyl-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3,5-bis{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-(3,5-dimet-
hyl-1,2-oxazol-4-yl)-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(morpholin-4-ylsulfonyl)methyl]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]methanesulfonamide;
3-[2-(cyclopropylmethoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[6-(cyclopropylmethoxy)-1H-indol-7-yl]-1-methyl-1,6-dihydro-7H-pyrrolo[-
2,3-c]pyridin-7-one; ethyl
5-(cyclopropylmethoxy)-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)-1H-indole-2-carboxylate;
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-N-methylmethanesulfonamide;
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-N,N-dimethylmethanesulfonamide;
N-cyclohexyl-1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H--
pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide;
3-{2-(2,4-difluorophenoxy)-5-[(piperidin-1-ylsulfonyl)methyl]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-N-(1,3-thiazol-2-yl)methanesulfonamide;
3-[2-(2,4-difluorophenoxy)-5-(piperazin-1-ylmethyl)phenyl]-1-methyl-1,6-d-
ihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]ethanesulfonamide;
5-(cyclopropylmethoxy)-N-methyl-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[-
2,3-c]pyridin-3-yl)-1H-indole-2-carboxamide;
4-chloro-3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
4-chloro-3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(cyclopropylmethyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{5-[(4-aminopiperidin-1-yl)methyl]-2-(2,4-difluorophenoxy)phenyl}-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(piperidin-4-ylamino)methyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-difluorophenoxy)-5-{[4-(dimethylamino)piperidin-1-yl]methyl}phe-
nyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-difluorophenoxy)-5-{[(3,3-dimethylbutyl)amino]methyl}phenyl]-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(4-methoxypiperidin-1-yl)methyl]phenyl}-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(4-methylpiperazin-1-yl)methyl]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-difluorophenoxy)-5-{[(3-methylbutyl)amino]methyl}phenyl]-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[5-{[(cyclopropylmethyl)amino]methyl}-2-(2,4-difluorophenoxy)phenyl]-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-difluorophenoxy)-5-{[(1H-imidazol-4-ylmethyl)amino]methyl}pheny-
l]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[5-(chloromethyl)-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(4-fluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1-
,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1,4-dimethyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1,4-dimethyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(cyclopropylmethoxy)-5-[(3,3-difluoroazetidin-1-yl)sulfonyl]phenyl}--
1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
5-[(1Z)-2-chloro-4-hydroxybut-1-en-1-yl]-3-[2-(2,4-difluorophenoxy)-5-(et-
hylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-difluorophenoxy)-5-{[(furan-3-ylmethyl)amino]methyl}phenyl]-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[5-{[(2-cyclopentylethyl)amino]methyl}-2-(2,4-difluorophenoxy)phenyl]-1-
-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-difluorophenoxy)-5-{[4-(trifluoromethyl)piperidin-1-yl]methyl}p-
henyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-2-methoxybenzenesulfonamide;
1-(4-chlorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihyd-
ro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-1-(4-methylphenyl)methanesulfonamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-1-[4-(trifluoromethyl)phenyl]methanesulfonamide;
1-(4-cyanophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydr-
o-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-2,2,2-trifluoroethanesulfonamide;
3-[5-(aminomethyl)-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]cyclopentanesulfonamide;
2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H--
pyrrolo[2,3-c]pyridin-3-yl)benzyl]thiophene-3-sulfonamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-5-methyl-1,2-oxazole-4-sulfonamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]benzenesulfonamide;
3-{2-[(cyclopropylmethyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,-
3-c]pyridin-7-one;
3-{2-chloro-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-{[trans-4-(dimethylamino)cyclohexyl]oxy}-5-(pyrrolidin-1-ylsulfonyl)-
phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{5-fluoro-2-[(4-fluorophenyl)amino]pyridin-3-yl}-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one;
3-[5-amino-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo-
[2,3-c]pyridin-7-one;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-4-methylpentanamide;
2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H--
pyrrolo[2,3-c]pyridin-3-yl)phenyl]benzamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(2-methoxyphenyl)acetamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]pyridine-2-carboxamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-5-methylpyrazine-2-carboxamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-3-phenylpropanamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-4-phenoxybutanamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(3-phenoxyphenyl)acetamide;
4-(acetylamino)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro--
1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]benzamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-4-(phenoxymethyl)benzamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-oxo-1-phenylpyrrolidine-3-carboxamide;
2-(1,2-benzoxazol-3-yl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7--
dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide;
2-(5-chloro-2-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo--
6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide;
2-(4-chloro-2-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo--
6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(6-methylpyridin-3-yl)acetamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(3,4-dihydro-2H-chromen-6-yl)acetamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(2-methyl-1,3-thiazol-5-yl)acetamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(1,5-dimethyl-1H-pyrazol-3-yl)acetamide;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-[4-(2-fluorophenyl)-1H-pyrazol-1-yl]acetamide;
methyl (2E)-3-[(4-fluorophenyl)
{2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-[(methyls-
ulfonyl)methyl]phenyl}amino]prop-2-enoate;
4-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-
-c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile;
3-[2-(2,4-difluorophenoxy)-5-{[3-(4-methoxyphenoxy)benzyl]amino}phenyl]-1-
-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[2-(2,4-difluorophenoxy)-5-{[(3-methylpyridin-2-yl)methyl]amino}phenyl]-
-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[5-{[4-(benzyloxy)benzyl]amino}-2-(2,4-difluorophenoxy)phenyl]-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[5-{[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino}-2-(2,4-d-
ifluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one-
;
3-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,-
3-c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile;
3-{2-(2,4-difluorophenoxy)-5-[(4-phenoxybenzyl)amino]phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(3,3-dimethylbutyl)amino]phenyl}-1-methyl-1-
,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{5-[(2,6-difluorobenzyl)amino]-2-(2,4-difluorophenoxy)phenyl}-1-methyl--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl-
methyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-[5-{[2-(benzyloxy)-3-methoxybenzyl]amino}-2-(2,4-difluorophenoxy)phenyl-
]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
2-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-
-c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile;
3-{2-(2,4-difluorophenoxy)-5-[(quinolin-4-ylmethyl)amino]phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-1-phenylmethanesulfonamide;
1-(2-chloro-5-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo--
6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide;
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-5-(morpholin-4-ylmethyl)-7-oxo-6,7-
-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide;
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-7-oxo-5-(piperidin-4-yl)-6,7-dihyd-
ro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide;
N-[6-(2,4-difluorophenoxy)-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)pyridin-3-yl]ethanesulfonamide;
N-[3-{5-[1-(cyclopropylcarbonyl)piperidin-4-yl]-1-methyl-7-oxo-6,7-dihydr-
o-1H-pyrrolo[2,3-c]pyridin-3-yl}-4-(2,4-difluorophenoxy)phenyl]ethanesulfo-
namide;
N-[4-(2,4-difluorophenoxy)-3-{5-[1-(ethylsulfonyl)piperidin-4-yl]--
1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethanesulf-
onamide;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-[3-(-
1H-imidazol-1-yl)propyl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyrid-
ine-5-carboxamide;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-[2-(dimethyl-
amino)ethyl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carbox-
amide;
N-(cyanomethyl)-3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]-
phenyl}-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide-
;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-(3-hydroxyp-
ropyl)-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-5-(morpholin-4-ylcarbonyl)-7-oxo-6-
,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-
-N-(pyridin-3-ylmethyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamid-
e;
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-7-oxo-5-(pyrrolidin-1-ylcarbonyl-
)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide;
N-[4-(2,4-difluorophenoxy)-3-{5-[(4-hydroxypiperidin-1-yl)carbonyl]-1-met-
hyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethanesulfonami-
de;
N-(cyclopentylmethyl)-3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)ami-
no]phenyl}-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxam-
ide;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-N-
-[2-(morpholin-4-yl)ethyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-c-
arboxamide;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-N-[2--
(4-methylpiperazin-1-yl)ethyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-
-5-carboxamide;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-
-N-[2-(piperidin-1-yl)ethyl]-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carbo-
xamide;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methy-
l-7-oxo-N-(tetrahydrofuran-3-ylmethyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridi-
ne-5-carboxamide;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N,1-dimethyl-7-
-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-(furan-3-ylm-
ethyl)-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;
3-{3-cyclopropyl-2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]-
phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; and
1-methyl-3-{5-[(methylsulfonyl)methyl]-2-(pyridin-2-ylamino)phenyl}-1,6-d-
ihydro-7H-pyrrolo[2,3-c]pyridin-7-one.
23. The compound of claim 11 or a pharmaceutically acceptable salt
wherein R.sup.2 is H; R.sup.3 is --C(O)R.sup.3a,
--C(O)NR.sup.3bR.sup.3c, C.sub.4-C.sub.6 heterocycle, or
C.sub.1-C.sub.3 alkyl which is substituted with C.sub.4-C.sub.6
heterocycle; wherein each of the C.sub.4-C.sub.6 heterocycle
moieties is optionally substituted with 1, 2, 3, 4, or 5 R.sup.1g;
R.sup.3a is C.sub.4-C.sub.6 heterocycle which is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.1g; R.sup.3b is H or
C.sub.1-C.sub.6 alkyl; R.sup.3c is H, C.sub.1-C.sub.6 alkyl,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6 alkylenyl)-CN, or
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.1; wherein G.sup.1 is
C.sub.4-C.sub.6 heterocycle, C.sub.5-C.sub.6 heteroaryl,
C.sub.3-C.sub.6 cycloalkyl, or phenyl; each of which is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.1g; R.sup.6 is --OR.sup.a
or --NR.sup.cR.sup.d; wherein R.sup.a and R.sup.d are each
independently G.sup.2 or C.sub.1-C.sub.6 alkyl substituted with a
G.sup.2 group; wherein G.sup.2 is phenyl, C.sub.3-C.sub.6
cycloalkyl, C.sub.4-C.sub.6 heterocycle, or C.sub.5-C.sub.6
heteroaryl; each of which is optionally substituted with 1, 2, 3,
4, or 5 substituents independently selected from the group
consisting of C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN,
NO.sub.2, --OR.sup.y1, --OC(O)R.sup.y2, --OC(O)NR.sup.y3R.sup.y4,
--SR.sup.y1, --S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4,
--C(O)R.sup.y1, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--NR.sup.y3R.sup.y4, --N(R.sup.y3)C(O)R.sup.y2,
--N(R.sup.y3)S(O).sub.2R.sup.y2, --N(R.sup.y3)C(O)O(R.sup.y2),
--N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, and
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4; R.sup.c is hydrogen or
unsubstituted C.sub.1-C.sub.6 alkyl; R.sup.y1, R.sup.y3, and
R.sup.y4, at each occurrence, are each independently H,
C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and R.sup.y2,
at each occurrence, is independently C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 haloalkyl; and R.sup.9 is H, halogen, --CN,
C.sub.1-C.sub.6 haloalkyl, --N(R.sup.e)S(O).sub.2R.sup.b,
--S(O).sub.2R.sup.a, --S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; wherein R.sup.c, R.sup.d,
and R.sup.e, at each occurrence, are each independently H or
unsubstituted C.sub.1-C.sub.6 alkyl; and R.sup.a and R.sup.b, at
each occurrence, is independently C.sub.1-C.sub.6 haloalkyl, or
unsubstituted C.sub.1-C.sub.6 alkyl.
24. The compound of claim 23 or a pharmaceutically acceptable salt
wherein R.sup.3 is --C(O)R.sup.3a or --C(O)NR.sup.3bR.sup.3c;
A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is C(R.sup.10); or A.sup.1 is N, A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10);
R.sup.6 is --OR.sup.a or --NR.sup.cR.sup.d; wherein R.sup.a and
R.sup.d are each independently phenyl, pyridinyl, or
C.sub.1-C.sub.3 alkyl substituted with a C.sub.3-C.sub.6
cycloalkyl; wherein the phenyl, pyridinyl, and the C.sub.3-C.sub.6
cycloalkyl are optionally substituted with 1, 2, 3, 4, or 5
substituents independently selected from the group consisting of
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2,
--OR.sup.y1, --OC(O)R.sup.y2, --OC(O)NR.sup.y3R.sup.y4,
--SR.sup.y1, --S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4,
--C(O)R.sup.y1, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--NR.sup.y3R.sup.y4, --N(R.sup.y3)C(O)R.sup.y2,
--N(R.sup.y3)S(O).sub.2R.sup.y2, --N(R.sup.y3)C(O)O(R.sup.y2),
--N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, and
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4; R.sup.c is hydrogen or
unsubstituted C.sub.1-C.sub.3 alkyl; R.sup.y1, R.sup.y3, and
R.sup.y4, at each occurrence, are each independently H,
C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and R.sup.y2,
at each occurrence, is independently C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 haloalkyl; R.sup.7 is H; R.sup.8 is H or halogen;
R.sup.10 is H or C.sub.1-C.sub.6 alkyl; and R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b or --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a; wherein R.sup.e is H or unsubstituted
C.sub.1-C.sub.3 alkyl; and R.sup.a and R.sup.b, are independently
C.sub.1-C.sub.3 alkyl.
25. A compound of formula (I) or a pharmaceutically acceptable salt
thereof, ##STR00019## wherein R.sup.1 is H, C.sub.1-C.sub.3 alkyl,
or C.sub.1-C.sub.3 haloalkyl; R.sup.2 is H, C.sub.1-C.sub.3 alkyl,
or C.sub.1-C.sub.3 haloalkyl; R.sup.3 is H, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
--OR.sup.3a, --NR.sup.3bR.sup.3c, --N(R.sup.3b)C(O)R.sup.3d,
--N(R.sup.3b)C(O)NR.sup.3bR.sup.3c,
--N(R.sup.3b)S(O).sub.2NR.sup.3bR.sup.3c, --C(O)R.sup.3a,
--C(O)OR.sup.3a, --C(O)NR.sup.3bR.sup.3c, --S(O)R.sup.3d,
--S(O).sub.2R.sup.3a, --S(O).sub.2NR.sup.3bR.sup.3c, or G.sup.1;
wherein the C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, and
C.sub.2-C.sub.6 alkynyl are each independently unsubstituted or
substituted with 1 or 2 substituents independently selected from
the group consisting of halogen, G.sup.1, --OR.sup.3a, and
--NR.sup.3bR.sup.3c; R.sup.3a, R.sup.3b, and R.sup.3c, at each
occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.1, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.1; R.sup.3d, at each occurrence, is independently
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, G.sup.1, or
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.1; G.sup.1, at each occurrence,
is independently aryl, heteroaryl, heterocycle, cycloalkyl, or
cycloalkenyl; and each G.sup.1 is optionally substituted with 1, 2,
3, 4, or 5 R.sup.1g groups; R.sup.4 is H, C.sub.1-C.sub.6 alkyl,
halogen, or C.sub.1-C.sub.6 haloalkyl; R.sup.5 is a monocyclic or
bicyclic ring selected from the group consisting of aryl and
heteroaryl; each of which is substituted with 1, 2, or 3
substituents independently selected from the group consisting of
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2,
G.sup.2, --OR.sup.a, --OC(O)R.sup.b, --OC(O)NR.sup.cR.sup.d,
--SR.sup.a, --S(O).sub.2R.sup.a, --S(O).sub.2NR.sup.cR.sup.d,
--C(O)R.sup.a, --C(O)OR.sup.a, --C(O)NR.sup.cR.sup.d,
--NR.sup.cR.sup.d, --N(R.sup.e)C(O)R.sup.b,
--N(R.sup.e)S(O).sub.2R.sup.b, --N(R.sup.e)C(O)O(R.sup.b),
--N(R.sup.e)C(O)NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2, --(C.sub.1-C.sub.6 alkylenyl)-OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.a, --(C.sub.1-C.sub.6 alkylenyl)-C(O)OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)O(R.sup.b), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.6 alkylenyl)-CN; R.sup.a, R.sup.c, R.sup.d, and
R.sup.e, at each occurrence, are each independently H,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6
haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with one
substituent selected from the group consisting of --OR.sup.y1,
--NR.sup.y3R.sup.y4, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2;
R.sup.b, at each occurrence, is independently C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl
is optionally substituted with one substituent selected from the
group consisting of --OR.sup.y1, --NR.sup.y3R.sup.y4,
--C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4, --S(O).sub.2R.sup.y1,
--S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2; G.sup.2, at each
occurrence, are each independently aryl, heteroaryl, heterocycle,
cycloalkyl, or cycloalkenyl; and each G.sup.2 group is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.2g groups; R.sup.1g, at
each occurrence, is independently C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.z1,
--OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4, --SR.sup.z1,
--S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4,
--NR.sup.z3R.sup.z4, --N(R.sup.z3)C(O)R.sup.z2,
--N(R.sup.z3)S(O).sub.2R.sup.z2, --N(R.sup.z3)C(O)O(R.sup.z2),
--N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --O(phenyl) wherein the phenyl
moiety is optionally substituted with 1, 2, 3, or 4 substituents
independently selected from the group consisting of C.sub.1-C.sub.6
alkyl, halogen, C.sub.1-C.sub.6 haloalkyl, --OH, --O(alkyl),
--O(haloalkyl), CN, and NO.sub.2; R.sup.2g, at each occurrence, is
independently C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN,
NO.sub.2, --OR.sup.y1, --OC(O)R.sup.y2, --OC(O)NR.sup.y3R.sup.y4,
--SR.sup.y1, --S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4,
--C(O)R.sup.y1, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--NR.sup.y3R.sup.y4, --N(R.sup.y3)C(O)R.sup.y2,
--N(R.sup.y3)S(O).sub.2R.sup.y2, --N(R.sup.y3)C(O)O(R.sup.y2),
--N(R.sup.y3)C(O)NR.sup.y3R.sup.y4,
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4, G.sup.2b,
--(C.sub.1-C.sub.6 alkylenyl)-OR, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)O(R.sup.y2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; R.sup.y1, R.sup.y3, and R.sup.y4, at each
occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.2b, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; R.sup.y2, at each occurrence, is independently
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, G.sup.2b, or
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.2b; G.sup.2b, at each
occurrence, is independently aryl, heteroaryl, cycloalkyl,
cycloalkenyl, or heterocycle; and each G.sup.2b group is optionally
substituted with 1, 2, 3, 4, or 5 substituents independently
selected from the group consisting of C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.z1,
--OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4, --SR.sup.z1,
--S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4,
--NR.sup.z3R.sup.z4, --N(R.sup.z3)C(O)R.sup.z2,
--N(R.sup.z3)S(O).sub.2R.sup.z2, --N(R.sup.z3)C(O)O(R.sup.z2),
--N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, and
--(C.sub.1-C.sub.6 alkylenyl)-CN; R.sup.z1, R.sup.z3, and R.sup.z4,
at each occurrence, are each independently H, C.sub.1-C.sub.6
alkyl, or C.sub.1-C.sub.6 haloalkyl; and R.sup.z2, at each
occurrence, is independently C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 haloalkyl.
26. A compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein the compound is selected from the group consisting
of:
3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]pyridin-3-yl)}-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]ethanesulfonamide;
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]methanesulfonamide;
N-[4-(2,4-difluorophenoxy)-3-{5-[1-(ethylsulfonyl)piperidin-4-yl]-1-methy-
l-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethanesulfonamide-
;
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3--
c]pyridin-3-yl)phenyl]-N,N-dimethylmethanesulfonamide;
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-
-N-(pyridin-3-ylmethyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamid-
e;
3-{2-(2,4-difluorophenoxy)-5-[(morpholin-4-ylsulfonyl)methyl]phenyl}-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-ethyl-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
5-chloro-3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-N-methylmethanesulfonamide;
N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide;
N-[4-(2,4-difluorophenoxy)-2-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrr-
olo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide;
3-{2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
3-{2-[(4,4-difluorocyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; and
3-{2-[(cyclopropylmethyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one.
27. A pharmaceutical composition comprising a therapeutically
effective amount of a compound of formula (I) according to claim 1,
or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable carrier.
28. A method for treating cancer in a subject comprising
administering a therapeutically effective amount of a compound of
formula (I) according to claim 1 or a pharmaceutically acceptable
salt thereof, to a subject in need thereof.
29. The method of claim 28 wherein the cancer is selected from the
group consisting of: acoustic neuroma, acute leukemia, acute
lymphocytic leukemia, acute myelocytic leukemia (monocytic,
myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma,
myelomonocytic and promyelocytic), acute t-cell leukemia, basal
cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer,
breast cancer, bronchogenic carcinoma, cervical cancer,
chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia,
chronic lymphocytic leukemia, chronic myelocytic (granulocytic)
leukemia, chronic myelogenous leukemia, colon cancer, colorectal
cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell
lymphoma, dysproliferative changes (dysplasias and metaplasias),
embryonal carcinoma, endometrial cancer, endotheliosarcoma,
ependymoma, epithelial carcinoma, erythroleukemia, esophageal
cancer, estrogen-receptor positive breast cancer, essential
thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma,
germ cell testicular cancer, glioma, glioblastoma, gliosarcoma,
heavy chain disease, hemangioblastoma, hepatoma, hepatocellular
cancer, hormone insensitive prostate cancer, leiomyosarcoma,
leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma,
lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and
non-Hodgkin's), malignancies and hyperproliferative disorders of
the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin
and uterus, lymphoid malignancies of T-cell or B-cell origin,
leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma,
meningioma, mesothelioma, multiple myeloma, myelogenous leukemia,
myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC),
non-small cell lung cancer, oligodendroglioma, oral cancer,
osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary
adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera,
prostate cancer, rectal cancer, renal cell carcinoma,
retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland
carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid
tumors (carcinomas and sarcomas), small cell lung cancer, stomach
cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma,
thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors,
uterine cancer and Wilms' tumor.
30. A method for treating a disease or condition in a subject
comprising administering a therapeutically effective amount of a
compound of formula (I) according to claim 1 or a pharmaceutically
acceptable salt thereof, to a subject in need thereof, wherein said
disease or condition is selected from the group consisting of
Addison's disease, acute gout, ankylosing spondylitis, asthma,
atherosclerosis, Behcet's disease, bullous skin diseases, cardiac
myopathy, cardiac hypertrophy, chronic obstructive pulmonary
disease (COPD), Crohn's disease, dermatitis, eczema, giant cell
arteritis, glomerulonephritis, heart failure, hepatitis,
hypophysitis, inflammatory bowel disease,), Kawasaki disease, lupus
nephritis, multiple sclerosis, myocarditis, myositis, nephritis,
organ transplant rejection, osteoarthritis, pancreatitis,
pericarditis, Polyarteritis nodosa, pneumonitis, primary biliary
cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis,
scleritis, sclerosing cholangitis, sepsis systemic lupus
erythematosus, Takayasu's Arteritis, toxic shock, thyroiditis, type
I diabetes, ulcerative colitis, uveitis, vitiligo, vasculitis, and
Wegener's granulomatosis.
31. A method for treating a chronic kidney disease or condition in
a subject comprising administering a therapeutically effective
amount of a compound of formula (I) according to claim 1 or a
pharmaceutically acceptable salt thereof, to a subject in need
thereof, wherein said disease or condition is selected from the
group consisting of: diabetic nephropathy, hypertensive
nephropathy, HIV-associated nephropathy, glomerulonephritis, lupus
nephritis, IgA nephropathy, focal segmental glomerulosclerosis,
membranous glomerulonephritis, minimal change disease, polycystic
kidney disease and tubular interstitial nephritis.
32. A method for treating an acute kidney disease or condition in a
subject comprising administering a therapeutically effective amount
of a compound of formula (I) according to claim 1 or a
pharmaceutically acceptable salt thereof, to a subject in need
thereof, wherein said acute kidney disease or condition is selected
from the group consisting of: ischemia-reperfusion induced kidney
disease, cardiac and major surgery induced kidney disease,
percutaneous coronary intervention induced kidney disease,
radio-contrast agent induced kidney disease, sepsis induced kidney
disease, pneumonia induced kidney disease, and drug toxicity
induced kidney disease.
33. A method for treating an acquired immunodeficiency syndrome
(AIDS) in a subject comprising administering a therapeutically
effective amount of a compound of formula (I) according to claim 1
or a pharmaceutically acceptable salt thereof, to a subject in need
thereof.
34. A method for treating a disease or condition in a subject
comprising administering a therapeutically effective amount of a
compound of formula (I) according to claim 1 or a pharmaceutically
acceptable salt thereof, to a subject in need thereof, wherein said
disease or condition is selected from the group consisting of:
obesity, dyslipidemia, hypercholesterolemia, Alzheimer's disease,
metabolic syndrome, hepatic steatosis, type II diabetes, insulin
resistance, diabetic retinopathy and diabetic neuropathy.
35. A method of contraception in a male subject comprising
administering a therapeutically effective amount of a compound of
formula (I) according to claim 1 or a pharmaceutically acceptable
salt thereof, to a subject in need thereof.
Description
BACKGROUND
[0001] Bromodomains refer to conserved protein structural folds
which bind to N-acetylated lysine residues that are found in some
proteins. The BET family of bromodomain containing proteins is
comprised of four members (BRD2, BRD3, BRD4 and BRDt). Each member
of the BET family employs two bromodomains to recognize
N-acetylated lysine residues found primarily, but not exclusively,
on the amino-terminal tails of histone proteins. These interactions
modulate gene expression by recruiting transcription factors to
specific genome locations within chromatin. For example,
histone-bound BRD4 recruits the transcription factor P-TEFb to
promoters, resulting in the expression of a subset of genes
involved in cell cycle progression (Yang et al., Mol. Cell. Biol.
28: 967-976 (2008)). BRD2 and BRD3 also function as transcriptional
regulators of growth promoting genes (LeRoy et al., Mol. Cell 30:
51-60 (2008)). BET family members were recently established as
being important for the maintenance of several cancer types (Zuber
et al., Nature 478: 524-528 (2011); Mertz et al; Proc. Nat'l. Acad.
Sci. 108: 16669-16674 (2011); Delmore et al., Cell 146: 1-14,
(2011); Dawson et al., Nature 478: 529-533 (2011)). BET family
members have also been implicated in mediating acute inflammatory
responses through the canonical NF-KB pathway (Huang et al., Mol.
Cell. Biol. 29: 1375-1387 (2009)) resulting in the upregulation of
genes associated with the production of cytokines (Nicodeme et al.,
Nature 468: 1119-1123, (2010)). Suppression of cytokine induction
by BET bromodomain inhibitors has been shown to be an effective
approach to treat inflammation-mediated kidney disease in an animal
model (Zhang, et al., J. Biol. Chem. 287: 28840-28851 (2012)). BRD2
function has been linked to predisposition for dyslipidemia or
improper regulation of adipogenesis, elevated inflammatory profiles
and increased susceptibility to autoimmune diseases (Denis,
Discovery Medicine 10: 489-499 (2010)). The human immunodeficiency
virus utilizes BRD4 to initiate transcription of viral RNA from
stably integrated viral DNA (Jang et al., Mol. Cell, 19: 523-534
(2005)). BET bromodomain inhibitors have also been shown to
reactivate HIV transcription in models of latent T cell infection
and latent monocyte infection (Banerjee, et al, J. Leukocyte Biol.
doi:10.1189/jlb.0312165). BRDt has an important role in
spermatogenesis that is blocked by BET bromodomain inhibitors
(Matzuk, et al., Cell 150: 673-684 (2012)). Thus, compounds that
inhibit the binding of BET family bromodomains to their cognate
acetylated lysine proteins are being pursued for the treatment of
cancer, inflammatory diseases, kidney diseases, diseases involving
metabolism or fat accumulation, and some viral infections, as well
as for providing a method for male contraception. Accordingly,
there is an ongoing medical need to develop new drugs to treat
these indications.
SUMMARY
[0002] In one aspect the present invention provides for compounds
of formula (I) or a salt thereof,
##STR00002## [0003] wherein [0004] R.sup.1 is H, C.sub.1-C.sub.3
alkyl, or C.sub.1-C.sub.3 haloalkyl; [0005] R.sup.2 is H,
C.sub.1-C.sub.3 alkyl, or C.sub.1-C.sub.3 haloalkyl; [0006] R.sup.3
is H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, --OR.sup.3a, --NR.sup.3bR.sup.3c,
--N(R.sup.3b)C(O)R.sup.3d, --N(R.sup.3b)C(O)NR.sup.3bR.sup.3c,
--N(R.sup.3b)S(O).sub.2NR.sup.3bR.sup.3c, --C(O)R.sup.3a,
--C(O)OR.sup.3a, --C(O)NR.sup.3bR.sup.3c, --S(O)R.sup.3d,
--S(O).sub.2R.sup.3a, --S(O).sub.2NR.sup.3bR.sup.3c, or G.sup.1;
wherein the C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, and
C.sub.2-C.sub.6 alkynyl are each independently unsubstituted or
substituted with 1 or 2 substituents independently selected from
the group consisting of halogen, G.sup.1, --OR.sup.3a, and
--NR.sup.3bR.sup.3c; [0007] R.sup.3a, R.sup.3b, and R.sup.3c, at
each occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.1, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.1, --(C.sub.1-C.sub.6 alkylenyl)-CN,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.z1, or --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4; [0008] R.sup.3d, at each occurrence,
is independently C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl,
G.sup.1, or --(C.sub.1-C.sub.6 alkylenyl)-G.sup.1; [0009] G.sup.1,
at each occurrence, is independently aryl, heteroaryl, heterocycle,
cycloalkyl, or cycloalkenyl; and each G.sup.1 is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.1g groups; [0010] R.sup.4
is H, C.sub.1-C.sub.6 alkyl, halogen, or C.sub.1-C.sub.6 haloalkyl;
[0011] R.sup.5 is a monocyclic or bicyclic ring selected from the
group consisting of aryl and heteroaryl; each of which is
substituted with 1, 2, or 3 substituents independently selected
from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6
haloalkyl, --CN, NO.sub.2, G.sup.2, --OR.sup.a, --OC(O)R.sup.b,
--OC(O)NR.sup.cR.sup.d, --SR.sup.a, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.cR.sup.d, --NR.sup.cR.sup.d, --N(R.sup.e)C(O)R.sup.b,
--N(R.sup.e)S(O).sub.2R.sup.b, --N(R.sup.e)C(O)O(R.sup.b),
--N(R.sup.e)C(O)NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2, --(C.sub.1-C.sub.6 alkylenyl)-OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.a, --(C.sub.1-C.sub.6 alkylenyl)-C(O)OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)O(R.sup.b), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.6 alkylenyl)-CN; [0012] R.sup.a, R.sup.c, R.sup.d,
and R.sup.e, at each occurrence, are each independently H,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6
haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with one
substituent selected from the group consisting of --OR.sup.y1,
--NR.sup.y3R.sup.y4, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2;
[0013] R.sup.b, at each occurrence, is independently
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6
haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with one
substituent selected from the group consisting of --OR.sup.y1,
--NR.sup.y3R.sup.y4, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2;
[0014] G.sup.2, at each occurrence, are each independently aryl,
heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; and each
G.sup.2 group is optionally substituted with 1, 2, 3, 4, or 5
R.sup.2g groups; [0015] R.sup.1g, at each occurrence, is
independently C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN,
NO.sub.2, --OR.sup.z1, --OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4,
--SR.sup.z1, --S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)(C.sub.3-C.sub.6 cycloalkyl),
--C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4, --NR.sup.z3R.sup.z4,
--N(R.sup.z3)C(O)R.sup.z2, --N(R.sup.z3)S(O).sub.2R.sup.z2,
--N(R.sup.z3)C(O)O(R.sup.z2), --N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, (C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --O(phenyl); wherein the
phenyl moiety and the C.sub.3-C.sub.6 cycloalkyl moiety are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from the group consisting of C.sub.1-C.sub.6
alkyl, halogen, C.sub.1-C.sub.6 haloalkyl, --OH, --O(alkyl),
--O(haloalkyl), CN, and NO.sub.2; [0016] R.sup.2g, at each
occurrence, is independently C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6
haloalkyl, oxo, --CN, NO.sub.2, --OR.sup.y1, --OC(O)R.sup.y2,
--OC(O)NR.sup.y3R.sup.y4, --SR.sup.y1, --S(O).sub.2R.sup.y1,
--S(O).sub.2NR.sup.y3R.sup.y4, --C(O)R.sup.y1, --C(O)OR.sup.y1,
--C(O)NR.sup.y3R.sup.y4, --NR.sup.y3R.sup.y4,
--N(R.sup.y3)C(O)R.sup.y2, --N(R.sup.y3)S(O).sub.2R.sup.y2,
--N(R.sup.y3)C(O)O(R.sup.y2), --N(R.sup.y3)C(O)NR.sup.y3R.sup.y4,
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4, G.sup.2b,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)O(R.sup.y2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; [0017] R.sup.y1, R.sup.y3, and R.sup.y4, at
each occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.2b, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; [0018] R.sup.y2, at each occurrence, is
independently C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl,
G.sup.2b, or --(C.sub.1-C.sub.6 alkylenyl)-G.sup.2b; [0019]
G.sup.2b, at each occurrence, is independently aryl, heteroaryl,
cycloalkyl, cycloalkenyl, or heterocycle; and each G.sup.2b group
is optionally substituted with 1, 2, 3, 4, or 5 substituents
independently selected from the group consisting of C.sub.1-C.sub.6
alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.z1,
--OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4, --SR.sup.z1,
--S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4,
--NR.sup.z3R.sup.z4, --N(R.sup.z3)C(O)R.sup.z2,
--N(R.sup.z3)S(O).sub.2R.sup.z2, --N(R.sup.z3)C(O)O(R.sup.z2),
--N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, and
--(C.sub.1-C.sub.6 alkylenyl)-CN; [0020] R.sup.z1, R.sup.z3, and
R.sup.z4, at each occurrence, are each independently H,
C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and [0021]
R.sup.z2, at each occurrence, is independently C.sub.1-C.sub.6
alkyl or C.sub.1-C.sub.6 haloalkyl.
[0022] In another aspect, the present invention provides for
methods for treating or preventing disorders that are ameliorated
by inhibition of BET. Such methods comprise of administering to the
subject a therapeutically effective amount of a compound of formula
(I), alone, or in combination with a pharmaceutically acceptable
carrier.
[0023] Some of the methods are directed to treating or preventing
an inflammatory disease or cancer or AIDS.
[0024] In another aspect, the present invention relates to methods
of treating cancer in a subject comprising administering a
therapeutically effective amount of a compound of formula (I) or a
pharmaceutically acceptable salt thereof, to a subject in need
thereof. In certain embodiments, the cancer is selected from the
group consisting of: acoustic neuroma, acute leukemia, acute
lymphocytic leukemia, acute myelocytic leukemia (monocytic,
myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma,
myelomonocytic and promyelocytic), acute t-cell leukemia, basal
cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer,
breast cancer, bronchogenic carcinoma, cervical cancer,
chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia,
chronic lymphocytic leukemia, chronic myelocytic (granulocytic)
leukemia, chronic myelogenous leukemia, colon cancer, colorectal
cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell
lymphoma, dysproliferative changes (dysplasias and metaplasias),
embryonal carcinoma, endometrial cancer, endotheliosarcoma,
ependymoma, epithelial carcinoma, erythroleukemia, esophageal
cancer, estrogen-receptor positive breast cancer, essential
thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma,
germ cell testicular cancer, glioma, glioblastoma, gliosarcoma,
heavy chain disease, hemangioblastoma, hepatoma, hepatocellular
cancer, hormone insensitive prostate cancer, leiomyosarcoma,
leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma,
lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and
non-Hodgkin's), malignancies and hyperproliferative disorders of
the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin
and uterus, lymphoid malignancies of T-cell or B-cell origin,
leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma,
meningioma, mesothelioma, multiple myeloma, myelogenous leukemia,
myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC),
non-small cell lung cancer, oligodendroglioma, oral cancer,
osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary
adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera,
prostate cancer, rectal cancer, renal cell carcinoma,
retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland
carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid
tumors (carcinomas and sarcomas), small cell lung cancer, stomach
cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma,
thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors,
uterine cancer and Wilms' tumor. In certain embodiments, the
methods further comprise administering a therapeutically effective
amount of at least one additional therapeutic agent. In certain
embodiments, the additional therapeutic agent is selected from the
group consisting of cytarabine, bortezomib, and 5-azacitidine.
[0025] In another aspect, the present invention relates to methods
of treating a disease or condition in a subject comprising
administering a therapeutically effective amount of a compound of
formula (I) or a pharmaceutically acceptable salt thereof, to a
subject in need thereof, wherein said disease or condition is
selected from the group consisting of: Addison's disease, acute
gout, ankylosing spondylitis, asthma, atherosclerosis, Behcet's
disease, bullous skin diseases, cardiac myopathy, cardiac
hypertrophy, chronic obstructive pulmonary disease (COPD), Crohn's
disease, dermatitis, eczema, giant cell arteritis,
glomerulonephritis, heart failure, hepatitis, hypophysitis,
inflammatory bowel disease, Kawasaki disease, lupus nephritis,
multiple sclerosis, myocarditis, myositis, nephritis, organ
transplant rejection, osteoarthritis, pancreatitis, pericarditis,
Polyarteritis nodosa, pneumonitis, primary biliary cirrhosis,
psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis,
sclerosing cholangitis, sepsis, systemic lupus erythematosus,
Takayasu's Arteritis, toxic shock, thyroiditis, type I diabetes,
ulcerative colitis, uveitis, vitiligo, vasculitis, and Wegener's
granulomatosis. In certain embodiments, the methods further
comprise administering a therapeutically effective amount of at
least one additional therapeutic agent.
[0026] In another aspect, the present invention relates to methods
of treating a chronic kidney disease or condition in a subject
comprising administering a therapeutically effective amount of a
compound of formula (I) or a pharmaceutically acceptable salt
thereof, to a subject in need thereof, wherein said disease or
condition is selected from the group consisting of: diabetic
nephropathy, hypertensive nephropathy, HIV-associated nephropathy,
glomerulonephritis, lupus nephritis, IgA nephropathy, focal
segmental glomerulosclerosis, membranous glomerulonephritis,
minimal change disease, polycystic kidney disease and tubular
interstitial nephritis. In certain embodiments, the methods further
comprise administering a therapeutically effective amount of at
least one additional therapeutic agent.
[0027] In another aspect, the present invention relates to methods
of treating an acute kidney injury or disease or condition in a
subject comprising administering a therapeutically effective amount
of a compound of formula (I) or a pharmaceutically acceptable salt
thereof, to a subject in need thereof, wherein said acute kidney
injury or disease or condition is selected from the group
consisting of: ischemia-reperfusion induced kidney disease, cardiac
and major surgery induced kidney disease, percutaneous coronary
intervention induced kidney disease, radio-contrast agent induced
kidney disease, sepsis induced kidney disease, pneumonia induced
kidney disease, and drug toxicity induced kidney disease. In
certain embodiments, the methods further comprise administering a
therapeutically effective amount of at least one additional
therapeutic agent.
[0028] In another aspect, the present invention relates to methods
of treating AIDS in a subject comprising administering a
therapeutically effective amount of a compound of formula (I) or a
pharmaceutically acceptable salt thereof, to a subject in need
thereof. In certain embodiments, the methods further comprise
administering a therapeutically effective amount of at least one
additional therapeutic agent.
[0029] In another aspect, the present invention relates to methods
of treating obesity, dyslipidemia, hypercholesterolemia,
Alzheimer's disease, metabolic syndrome, hepatic steatosis, type II
diabetes, insulin resistance, diabetic retinopathy or diabetic
neuropathy in a subject comprising administering a therapeutically
effective amount of a compound of formula (I) or a pharmaceutically
acceptable salt thereof, to a subject in need thereof. In certain
embodiments, the methods further comprise administering a
therapeutically effective amount of at least one additional
therapeutic agent.
[0030] In another aspect, the present invention provides for
methods for contraception in a male subject comprising
administering a therapeutically effective amount of a compound of
formula (I), or a pharmaceutically acceptable salt thereof, to a
subject in need thereof. In certain embodiments, the methods
further comprise administering a therapeutically effective amount
of at least one additional therapeutic agent.
[0031] A further aspect of the invention provides the use of a
compound of formula (I), alone or in combination with a second
active pharmaceutical agent, in the manufacture of a medicament for
treating or preventing conditions and disorders disclosed herein,
with or without a pharmaceutically acceptable carrier.
[0032] Pharmaceutical compositions comprising a compound of formula
(I), or a pharmaceutically acceptable salt, alone or in combination
with a second active pharmaceutical agent, are also provided. In
certain embodiments, pharmaceutical compositions comprise a
therapeutically effective amount of a compound of formula (I), or a
pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable carrier.
DETAILED DESCRIPTION
[0033] Disclosed herein are compounds of formula (I)
##STR00003##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are defined
above in the Summary of the Invention and below in the Detailed
Description. Further, compositions comprising such compounds and
methods for treating conditions and disorders using such compounds
and compositions are also disclosed.
[0034] Compounds disclosed herein may contain one or more
variable(s) that occur more than one time in any substituent or in
the formulae herein. Definition of a variable on each occurrence is
independent of its definition at another occurrence. Further,
combinations of substituents are permissible only if such
combinations result in stable compounds. Stable compounds are
compounds, which can be isolated from a reaction mixture.
a). DEFINITIONS
[0035] It is noted that, as used in this specification and the
intended claims, the singular form "a," "an," and "the" include
plural referents unless the context clearly dictates otherwise.
Thus, for example, reference to "a compound" includes a single
compound as well as one or more of the same or different compounds,
reference to "optionally a pharmaceutically acceptable carrier"
refers to a single optional pharmaceutically acceptable carrier as
well as one or more pharmaceutically acceptable carriers, and the
like.
[0036] As used in the specification and the appended claims, unless
specified to the contrary, the following terms have the meaning
indicated:
[0037] The term "alkenyl" as used herein, means a straight or
branched hydrocarbon chain containing from 2 to 10 carbons and
containing at least one carbon-carbon double bond. The term
"C.sub.2-C.sub.6 alkenyl" means an alkenyl group containing 2-6
carbon atoms. Non-limiting examples of alkenyl include
buta-1,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl,
3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl,
and 3-decenyl.
[0038] The term "alkenylene" means a divalent group derived from a
straight or branched chain hydrocarbon of 2 to 4 carbon atoms and
contains at least one carbon-carbon double bond. Representative
examples of alkenylene include, but are not limited to,
--CH.dbd.CH-- and --CH.sub.2CH.dbd.CH--.
[0039] The term "alkyl" as used herein, means a saturated, straight
or branched hydrocarbon chain radical. In some instances, the
number of carbon atoms in an alkyl moiety is indicated by the
prefix "C.sub.x-C.sub.y", wherein x is the minimum and y is the
maximum number of carbon atoms in the substituent. Thus, for
example, "C.sub.1-C.sub.6 alkyl" means an alkyl substituent
containing from 1 to 6 carbon atoms and "C.sub.1-C.sub.3 alkyl"
means an alkyl substituent containing from 1 to 3 carbon atoms.
Representative examples of alkyl include, but are not limited to,
methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl,
tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 1-methylbutyl,
2-methylbutyl, 3-methylbutyl, 3,3-dimethylbutyl,
1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl,
1-methylpropyl, 2-methylpropyl, 1-ethylpropyl,
1,2,2-trimethylpropyl, 3-methylhexyl, 2,2-dimethylpentyl,
2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
[0040] The term "alkylene" or "alkylenyl" means a divalent radical
derived from a straight or branched, saturated hydrocarbon chain,
for example, of 1 to 10 carbon atoms, or of 1 to 6 carbon atoms
(C.sub.1-C.sub.6 alkylenyl), or of 1 to 4 carbon atoms, or of 2 to
3 carbon atoms (C.sub.2-C.sub.3 alkylenyl). Examples of alkylene
and alkylenyl include, but are not limited to, --CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--, and
--CH.sub.2CH(CH.sub.3)CH.sub.2--.
[0041] The term "alkynyl" as used herein, means a straight or
branched chain hydrocarbon radical containing from 2 to 10 carbon
atoms and containing at least one carbon-carbon triple bond. The
term "C.sub.2-C.sub.6 alkynyl" means an alkynyl group of 2 to 6
carbon atoms. Representative examples of alkynyl include, but are
not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl,
2-pentynyl, and 1-butynyl.
[0042] The term "aryl" as used herein, means phenyl or a bicyclic
aryl. The bicyclic aryl is naphthyl, or a phenyl fused to a
monocyclic cycloalkyl, or a phenyl fused to a monocyclic
cycloalkenyl. Non-limiting examples of the aryl groups include
dihydroindenyl (indanyl), indenyl, naphthyl, dihydronaphthalenyl,
and tetrahydronaphthalenyl. The aryls are attached to the parent
molecular moiety through any carbon atom contained within the
bicyclic ring systems and can be unsubstituted or substituted.
[0043] The term "cycloalkyl" as used herein, means a radical that
is a monocyclic cyclic alkyl, a bicyclic cycloalkyl, or a spiro
cycloalkyl. The monocyclic cycloalkyl is a carbocyclic ring system
containing three to eight carbon atoms, zero heteroatoms and zero
double bonds. Examples of monocyclic ring systems include
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and
cyclooctyl. The bicyclic cycloalkyl is a monocyclic cycloalkyl
fused to a monocyclic cycloalkyl ring. The monocyclic and the
bicyclic cycloalkyl groups may contain one or two alkylene bridges,
each consisting of one, two, three, or four carbon atoms in length,
and each bridge links two non-adjacent carbon atoms of the ring
system. Non-limiting examples of bicyclic ring systems include
bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane,
bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, bicyclo[4.2.1]nonane,
tricyclo[3.3.1.0.sup.3,7]nonane (octahydro-2,5-methanopentalene or
noradamantane), and tricyclo[3.3.1.1.sup.3,7]decane (adamantane). A
spiro cycloalkyl is a monocyclic cycloalkyl wherein two
substituents on the same carbon atom of the monocyclic cycloalkyl
ring together with said carbon atom form a second monocyclic
cycloalkyl ring. The monocyclic, the bicyclic, and the spiro
cycloalkyl groups can be unsubstituted or substituted, and are
attached to the parent molecular moiety through any substitutable
atom contained within the ring system.
[0044] The term "C.sub.3-C.sub.6 cycloalkyl" as used herein, means
cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0045] The term "cycloalkenyl" as used herein, means a monocyclic
or a bicyclic hydrocarbon ring radical. The monocyclic cycloalkenyl
has four-, five-, six-, seven- or eight carbon atoms and zero
heteroatoms. The four-membered ring systems have one double bond,
the five- or six-membered ring systems have one or two double
bonds, and the seven- or eight-membered ring systems have one, two,
or three double bonds. Representative examples of monocyclic
cycloalkenyl groups include, but are not limited to, cyclobutenyl,
cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. The
bicyclic cycloalkenyl is a monocyclic cycloalkenyl fused to a
monocyclic cycloalkyl group, or a monocyclic cycloalkenyl fused to
a monocyclic cycloalkenyl group. The monocyclic or bicyclic
cycloalkenyl ring may contain one or two alkylene bridges, each
consisting of one, two, or three carbon atoms, and each linking two
non-adjacent carbon atoms of the ring system. Representative
examples of the bicyclic cycloalkenyl groups include, but are not
limited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl,
and 1,6-dihydro-pentalene. The monocyclic and bicyclic
cycloalkenyls can be attached to the parent molecular moiety
through any substitutable atom contained within the ring systems,
and can be unsubstituted or substituted.
[0046] The term "halo" or "halogen" as used herein, means Cl, Br,
I, and F.
[0047] The term "haloalkyl" as used herein, means an alkyl group,
as defined herein, in which one, two, three, four, five or six
hydrogen atoms are replaced by halogen. The term "C.sub.1-C.sub.6
haloalkyl" means a C.sub.1-C.sub.6 alkyl group, as defined herein,
in which one, two, three, four, five, six, or seven hydrogen atoms
are replaced by halogen. The term "C.sub.1-C.sub.3 haloalkyl" means
a C.sub.1-C.sub.3 alkyl group, as defined herein, in which one,
two, three, four, five, or six hydrogen atoms are replaced by
halogen. Representative examples of haloalkyl include, but are not
limited to, chloromethyl, 2-fluoroethyl, 2,2-difluoroethyl,
2,2,2-trifluoroethyl, trifluoromethyl, difluoromethyl,
pentafluoroethyl, 2-chloro-3-fluoropentyl, trifluorobutyl,
trifluoropropyl, 2,2,3,3,3-pentafluoropropyl, and
2,2,3,3,4,4,4-heptafluorobutyl.
[0048] The term "heterocycle" or "heterocyclic" as used herein,
means a radical of a monocyclic heterocycle, a bicyclic
heterocycle, and a spiro heterocycle. A monocyclic heterocycle is a
three-, four-, five-, six-, seven-, or eight-membered carbocyclic
ring also containing at least one heteroatom independently selected
from the group consisting of O, N, and S. A three- or four-membered
ring contains zero or one double bond, and one heteroatom selected
from the group consisting of O, N, and S. When two O atoms or one O
atom and one S atom are present in a heterocyclic ring, then the
two O atoms or one O atom and one S atom are not bonded directly to
each other. A five-membered ring contains zero or one double bond
and one, two, or three heteroatoms selected from the group
consisting of O, N, and S. Examples of five-membered heterocyclic
rings include those containing in the ring: 1O; 1 S; 1N; 2N; 3N; 1
S and N; 1 S, and 2N; 1O and 1N; or 1O and 2N. Examples of
5-membered heterocyclic groups include tetrahydrofuranyl,
dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, imidazolidinyl,
oxazolidinyl, imidazolinyl, isoxazolidinyl, pyrrolidinyl,
2-pyrrolinyl, and 3-pyrrolinyl. A six-membered ring contains zero,
one, or two double bonds and one, two, or three heteroatoms
selected from the group consisting of O, N, and S. Examples of
six-membered heterocyclic rings include those containing in the
ring: 1O; 2O; 1S; 2 S; 1N; 2N; 3N; 1S, 1O, and N; 1 S and N; 1 S
and 2N; 1 S and 1O; 1S and 2O; 1Q and 1N; and 1O and 2N. Examples
of 6-membered heterocyclic groups include tetrahydropyranyl,
dihydropyranyl, dioxanyl, 1,3-dioxolanyl, 1,4-dithianyl,
hexahydropyrimidine, morpholinyl, piperazinyl, piperidinyl,
2H-pyranyl, 4H-pyranyl, pyrazolidinyl, pyrazolinyl,
1,2,3,6-tetrahydropyridinyl, tetrahydrothiopyranyl,
1,1-dioxo-hexahydro-1-thiopyranyl,
1,1-dioxo-1.lamda..sup.6-thiomorpholinyl, thiomorpholinyl,
thioxanyl, and trithianyl. Seven- and eight-membered rings contains
zero, one, two, or three double bonds and one, two, or three
heteroatoms selected from the group consisting of O, N, and S.
Representative examples of monocyclic heterocycles include, but are
not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl,
1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl,
imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl,
isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl,
oxadiazolidinyl, oxazolinyl, oxazolidinyl, oxetanyl, piperazinyl,
piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl,
pyrrolidinyl, tetrahydrofuranyl, tetrahydropyridinyl,
tetrahydropyranyl, tetrahydrothienyl, thiadiazolinyl,
thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl,
thiopyranyl, and trithianyl. The bicyclic heterocycle is a
monocyclic heterocycle fused to a phenyl group, or a monocyclic
heterocycle fused to a monocyclic cycloalkyl, or a monocyclic
heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic
heterocycle fused to a monocyclic heterocycle. Representative
examples of bicyclic heterocycles include, but are not limited to,
benzopyranyl, benzothiopyranyl, 2,3-dihydrobenzofuranyl,
2,3-dihydrobenzothienyl, 3,4-dihydro-2H-chromenyl,
2,3-dihydro-1H-indolyl, 3,4-dihydroisoquinolin-2(1H)-yl,
2,3,4,6-tetrahydro-1H-pyrido[1,2-a]pyrazin-2-yl,
hexahydropyrano[3,4-b][1,4]oxazin-1 (5H)-yl. The monocyclic
heterocycle and the bicyclic heterocycle may contain one or two
alkylene bridges or an alkenylene bridge, or mixture thereof, each
consisting of no more than four carbon atoms and each linking two
non adjacent atoms of the ring system. Examples of such bridged
heterocycle include, but are not limited to,
azabicyclo[2.2.1]heptyl (including 2-azabicyclo[2.2.1]hept-2-yl),
8-azabicyclo[3.2.1]oct-8-yl, octahydro-2,5-epoxypentalene,
hexahydro-2H-2,5-methanocyclopenta[b]furan,
hexahydro-1H-1,4-methanocyclopenta[c]furan, aza-admantane
(1-azatricyclo[3.3.1.1.sup.3,7]decane), and oxa-adamantane
(2-oxatricyclo[3.3.1.1.sup.3,7]decane). A spiro heterocycle is a
monocyclic heterocycle wherein two substituents on the same carbon
atom of the monocyclic heterocycle ring together with said carbon
atom form a second ring system selected from a monocyclic
cycloalkyl, a bicyclic cycloalkyl, a monocyclic heterocycle, or a
bicyclic heterocycle. Examples of spiro heterocycle include, but
not limited to, 6-azaspiro[2.5]oct-6-yl, 1'H,
4H-spiro[1,3-benzodioxine-2,4'-piperidin]-1'-yl, 1'H,
3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl, and
1,4-dioxa-8-azaspiro[4.5]dec-8-yl. The monocyclic, the bicyclic,
and the spiro heterocycles can be unsubstituted or substituted. The
monocyclic, the bicyclic and the spiro heterocycles are connected
to the parent molecular moiety through any carbon atom or any
nitrogen atom contained within the ring systems. The nitrogen and
sulfur heteroatoms in the heterocycle rings may optionally be
oxidized (e.g. 1,1-dioxidotetrahydrothienyl,
1,2-dioxido-1,2-thiazolidinyl, 1,1-dioxidothiomorpholinyl)) and the
nitrogen atoms may optionally be quarternized.
[0049] The term "C.sub.4-C.sub.6 heterocycle" as used herein, means
a four-, five-, or six-membered monocyclic heterocycle as defined
herein. Examples of C.sub.4-C.sub.6 heterocycle include azetidinyl,
tetrahydrofuranyl, piperazinyl, piperidinyl, and morpholinyl.
[0050] The term "heteroaryl" as used herein, means a monocyclic
heteroaryl and a bicyclic heteroaryl. The monocyclic heteroaryl is
a five- or six-membered monocyclic ring. The five-membered ring
contains two double bonds. The five membered ring may contain one
heteroatom selected from O or S; or one, two, three, or four
nitrogen atoms and optionally one oxygen or one sulfur atom. The
six-membered ring contains three double bonds and one, two, three
or four nitrogen atoms. Representative examples of monocyclic
heteroaryl include, but are not limited to, furanyl, imidazolyl,
isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl, pyridinyl,
pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl,
tetrazolyl, thiadiazolyl, 1,3-thiazolyl, thienyl, triazolyl, and
triazinyl. The bicyclic heteroaryl consists of a monocyclic
heteroaryl fused to a phenyl, or a monocyclic heteroaryl fused to a
monocyclic cycloalkyl, or a monocyclic heteroaryl fused to a
monocyclic cycloalkenyl, or a monocyclic heteroaryl fused to a
monocyclic heteroaryl, or a monocyclic heteroaryl fused to a
monocyclic heterocycle. Representative examples of bicyclic
heteroaryl groups include, but are not limited to, benzofuranyl,
benzothienyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl,
phthalazinyl, 2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl,
6,7-dihydro-pyrazolo[1,5-a]pyrazin-5(4H)-yl,
6,7-dihydro-1,3-benzothiazolyl, imidazo[1,2-a]pyridinyl, indazolyl,
indolyl, isoindolyl, isoquinolinyl, naphthyridinyl,
pyridoimidazolyl, quinolinyl,
2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl,
thiazolo[5,4-b]pyridin-2-yl, thiazolo[5,4-d]pyrimidin-2-yl,
6,7-dihydro-5H-pyrrolo[1,2-a]imidazolyl, and
5,6,7,8-tetrahydroquinolin-5-yl. The monocyclic and bicyclic
heteroaryl groups can be substituted or unsubstituted and are
connected to the parent molecular moiety through any substitutable
carbon atom or any substitutable nitrogen atom contained within the
ring systems. The nitrogen atom in the heteroaryl rings may
optionally be oxidized and may optionally be quarternized.
[0051] The term "C.sub.5-C.sub.6 heteroaryl" as used herein, means
a monocyclic heteroaryl ring as described above. Examples of
C.sub.5-C.sub.6 heteroaryl include, but are not limited to,
furanyl, thienyl, pyrrolyl, oxazolyl, pyrazolyl, imidazolyl,
1,3-thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, and
pyrazinyl.
[0052] The term "heteroatom" as used herein, means a nitrogen,
oxygen, and sulfur.
[0053] The term "oxo" as used herein, means a .dbd.O group.
[0054] If a moiety is described as "substituted", a non-hydrogen
radical is in the place of hydrogen radical of any substitutable
atom of the moiety. Thus, for example, a substituted heterocycle
moiety is a heterocycle moiety in which at least one non-hydrogen
radical is in the place of a hydrogen radical on the heterocycle.
It should be recognized that if there are more than one
substitution on a moiety, each non-hydrogen radical may be
identical or different (unless otherwise stated).
[0055] If a moiety is described as being "optionally substituted,"
the moiety may be either (1) not substituted or (2) substituted. If
a moiety is described as being optionally substituted with up to a
particular number of non-hydrogen radicals, that moiety may be
either (1) not substituted; or (2) substituted by up to that
particular number of non-hydrogen radicals or by up to the maximum
number of substitutable positions on the moiety, whichever is less.
Thus, for example, if a moiety is described as a heteroaryl
optionally substituted with up to 3 non-hydrogen radicals, then any
heteroaryl with less than 3 substitutable positions would be
optionally substituted by up to only as many non-hydrogen radicals
as the heteroaryl has substitutable positions. To illustrate,
tetrazolyl (which has only one substitutable position) would be
optionally substituted with up to one non-hydrogen radical. To
illustrate further, if an amino nitrogen is described as being
optionally substituted with up to 2 non-hydrogen radicals, then a
primary amino nitrogen will be optionally substituted with up to 2
non-hydrogen radicals, whereas a secondary amino nitrogen will be
optionally substituted with up to only 1 non-hydrogen radical.
[0056] The terms "treat", "treating", and "treatment" refer to a
method of alleviating or abrogating a disease and/or its attendant
symptoms.
[0057] The terms "prevent", "preventing", and "prevention" refer to
a method of preventing the onset of a disease and/or its attendant
symptoms or barring a subject from acquiring a disease. As used
herein, "prevent", "preventing" and "prevention" also include
delaying the onset of a disease and/or its attendant symptoms and
reducing a subject's risk of acquiring a disease.
[0058] The phrase "therapeutically effective amount" means an
amount of a compound, or a pharmaceutically acceptable salt
thereof, sufficient to prevent the development of or to alleviate
to some extent one or more of the symptoms of the condition or
disorder being treated when administered alone or in conjunction
with another pharmaceutical agent or treatment in a particular
subject or subject population. For example in a human or other
mammal, a therapeutically effective amount can be determined
experimentally in a laboratory or clinical setting, or may be the
amount required by the guidelines of the United States Food and
Drug Administration, or equivalent foreign agency, for the
particular disease and subject being treated.
[0059] The term "subject" is defined herein to refer to animals
such as mammals, including, but not limited to, primates (e.g.,
humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats,
mice and the like. In preferred embodiments, the subject is a
human.
b. COMPOUNDS
[0060] Compounds of the invention have the general formula (I) as
described above.
[0061] Particular values of variable groups in compounds of formula
(I) are as follows. Such values may be used where appropriate with
any of the other values, definitions, claims or embodiments defined
hereinbefore or hereinafter.
[0062] In certain embodiments of formula (I), R.sup.1 is H,
C.sub.1-C.sub.3 alkyl, or C.sub.1-C.sub.3 haloalkyl.
[0063] In certain embodiments, R.sup.1 is C.sub.1-C.sub.3 alkyl. In
some such embodiments, R.sup.1 is methyl.
[0064] In certain embodiments of formula (I), R.sup.2 is H,
C.sub.1-C.sub.3 alkyl, or C.sub.1-C.sub.3 haloalkyl.
[0065] In certain embodiments, R.sup.2 is H or C.sub.1-C.sub.3
alkyl. In some such embodiments, R.sup.2 is H or methyl.
[0066] In certain embodiments, R.sup.2 is H.
[0067] In certain embodiments, R.sup.2 is C.sub.1-C.sub.3 alkyl. In
some such embodiments, R.sup.2 is methyl.
[0068] In certain embodiments of formula (I), R.sup.3 is H,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, halogen, --OR.sup.3a, --NR.sup.3bR.sup.3c,
--N(R.sup.3b)C(O)R.sup.3d, --N(R.sup.3b)C(O)NR.sup.3bR.sup.3c,
--N(R.sup.3b)S(O).sub.2NR.sup.3bR.sup.3c, --C(O)R.sup.3a,
--C(O)OR.sup.3a, --C(O)NR.sup.3bR.sup.3c, --S(O)R.sup.3d,
--S(O).sub.2R.sup.3a, --S(O).sub.2NR.sup.3bR.sup.3c, or G.sup.1;
wherein the C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 and alkynyl are each independently unsubstituted or
substituted with 1 or 2 substituents independently selected from
the group consisting of halogen, G.sup.1, --OR.sup.3a, and
--NR.sup.3bR.sup.3c.
[0069] For example, in certain embodiments, R.sup.3 is H,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, halogen,
--C(O)R.sup.3a, --C(O)OR.sup.3a, --C(O)NR.sup.3bR.sup.3c, or
G.sup.1; wherein the C.sub.1-C.sub.6 alkyl and the C.sub.2-C.sub.6
alkenyl are each independently unsubstituted or substituted with 1
or 2 substituents independently selected from the group consisting
of halogen, G.sup.1, --OR.sup.3a, and --NR.sup.3bR.sup.3c.
[0070] In certain embodiments, R.sup.3 is H, C.sub.1-C.sub.3 alkyl,
C.sub.2-C.sub.4 alkenyl, halogen, or G.sup.1; wherein the
C.sub.1-C.sub.3 alkyl and the C.sub.2-C.sub.4 alkenyl are each
independently unsubstituted or substituted with 1 or 2 substituents
independently selected from the group consisting of halogen, --OH,
--O(C.sub.1-C.sub.3 alkyl), --NH.sub.2, --N(H)(C.sub.1-C.sub.3
alkyl), and --N(C.sub.1-C.sub.3 alkyl).sub.2.
[0071] In certain embodiments, R.sup.3 is H, halogen, unsubstituted
C.sub.1-C.sub.3 alkyl, optionally substituted phenyl, optionally
substituted 1,2-oxazolyl, or C.sub.2-C.sub.4 alkenyl which is
substituted with 2 substituents independently selected from the
group consisting of halogen and --OH. In some such embodiments,
R.sup.3 is H, Cl, ethyl, C.sub.4 alkenyl, optionally substituted
phenyl, or optionally substituted 1,2-oxazolyl; wherein the C.sub.4
alkenyl is substituted with 2 substituents independently selected
from the group consisting of Cl and --OH.
[0072] In certain embodiments, R.sup.3 is H, unsubstituted
C.sub.1-C.sub.3 alkyl, or halogen. In some such embodiments,
R.sup.3 is H, unsubstituted C.sub.1-C.sub.3 alkyl, F, or Cl. In
some such embodiments, R.sup.3 is H, unsubstituted C.sub.1-C.sub.3
alkyl, or Cl. In some such embodiments, R.sup.3 is H, ethyl, or
Cl.
[0073] In certain embodiments, R.sup.3 is H.
[0074] In certain embodiments, R.sup.3 is unsubstituted
C.sub.1-C.sub.3 alkyl or halogen. In some such embodiments, R.sup.3
is unsubstituted C.sub.1-C.sub.3 alkyl, F, or Cl. In some such
embodiments, R.sup.3 is unsubstituted C.sub.1-C.sub.3 alkyl or F.
In some such embodiments, R.sup.3 is unsubstituted C.sub.1-C.sub.3
alkyl or Cl. In further such embodiments, R.sup.3 is ethyl or Cl.
[0075] In certain embodiments, R.sup.3 is --C(O)R.sup.3a,
--C(O)NR.sup.3bR.sup.3c, C.sub.4-C.sub.6 heterocycle, or
C.sub.1-C.sub.3 alkyl which is substituted with C.sub.4-C.sub.6
heterocycle; wherein each of the C.sub.4-C.sub.6 heterocycle
moieties is optionally substituted with 1, 2, 3, 4, or 5 R.sup.1g;
R.sup.3a is C.sub.4-C.sub.6 heterocycle which is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.1g; R.sup.3b is H or
C.sub.1-C.sub.6 alkyl; and R.sup.3c is H, C.sub.1-C.sub.6 alkyl,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6 alkylenyl)-CN, or
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.1; wherein G.sup.1 is
C.sub.4-C.sub.6 heterocycle, C.sub.5-C.sub.6 heteroaryl,
C.sub.3-C.sub.6 cycloalkyl, or phenyl; each of which is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.1g; [0076] In certain
embodiments, R.sup.3 is --C(O)R.sup.3a or --C(O)NR.sup.3bR.sup.3c.
In some such embodiments, R.sup.3a is optionally substituted
C.sub.4-C.sub.6 heterocycle. In some such embodiments, R.sup.3a is
piperidinyl, morpholinyl, or piperazinyl, each of which is
optionally substituted. In some such embodiments, R.sup.3b is H or
C.sub.1-C.sub.3 alkyl; and R.sup.3c is H, C.sub.1-C.sub.3 alkyl,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6 alkylenyl)-CN, or
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.1; wherein G.sup.1 is
C.sub.4-C.sub.6 heterocycle, C.sub.5-C.sub.6 heteroaryl,
C.sub.3-C.sub.6 cycloalkyl, or phenyl; each of which is optionally
substituted.
[0077] In certain embodiments of formula (I), R.sup.4 is H,
C.sub.1-C.sub.6 alkyl, halogen, or C.sub.1-C.sub.6 haloalkyl.
[0078] In certain embodiments, R.sup.4 is H, C.sub.1-C.sub.3 alkyl,
or halogen. In some such embodiments, R.sup.4 is H, C.sub.1-C.sub.3
alkyl, F, or Cl. In some such embodiments, R.sup.4 is H,
C.sub.1-C.sub.3 alkyl, or Cl. In some such embodiments, R.sup.4 is
H, methyl, or Cl.
[0079] In certain embodiments, R.sup.4 is H.
[0080] In certain embodiments, R.sup.4 is C.sub.1-C.sub.3 alkyl or
halogen. In some such embodiments, R.sup.4 is C.sub.1-C.sub.3
alkyl, F, or Cl. In some such embodiments, R.sup.4 is
C.sub.1-C.sub.3 alkyl or Cl. In some such embodiments, R.sup.4 is
methyl or Cl.
[0081] In certain embodiments of formula (I), R.sup.5 is a
monocyclic or bicyclic ring selected from the group consisting of
aryl and heteroaryl; each of which is independently substituted
with 1, 2, or 3 substituents independently selected from the group
consisting of C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN,
NO.sub.2, G.sup.2, --OR.sup.a, --OC(O)R.sup.b,
--OC(O)NR.sup.cR.sup.d, --SR.sup.a, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.cR.sup.d, --NR.sup.cR.sup.d, --N(R.sup.e)C(O)R.sup.b,
--N(R.sup.e)S(O).sub.2R.sup.b, --N(R.sup.e)C(O)O(R.sup.b),
--N(R.sup.e)C(O)NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2, --(C.sub.1-C.sub.6 alkylenyl)-OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.a, --(C.sub.1-C.sub.6 alkylenyl)-C(O)OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)O(R.sup.b), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.6 alkylenyl)-CN. In some such embodiments, R.sup.5
is substituted aryl. In some such embodiments, R.sup.5 is
substituted phenyl. In some such embodiments, R.sup.5 is
substituted heteroaryl. In some such embodiments, R.sup.5 is
substituted pyridinyl or substituted indolyl. In some such
embodiments, R.sup.5 is phenyl, pyridinyl, or indolyl, each of
which is substituted. In some such embodiments, R.sup.5 is
substituted phenyl or substituted pyridinyl. In some such
embodiments, R.sup.5 is substituted indolyl.
[0082] In certain embodiments, R.sup.5 is a monocyclic or bicyclic
ring selected from the group consisting of aryl and heteroaryl;
each of which is independently substituted with 1, 2, or 3
substituents independently selected from the group consisting of
C.sub.1-C.sub.3 alkyl, halogen, C.sub.1-C.sub.3 haloalkyl, --CN,
NO.sub.2, G.sup.2, --OR.sup.a, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.cR.sup.d, --NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.3
alkylenyl)-G.sup.2 wherein G.sup.2 is optionally substituted
heterocycle, --(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.3 alkylenyl)-NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.3 alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. In some
such embodiments, R.sup.5 is substituted aryl. In some such
embodiments, R.sup.5 is substituted phenyl. In some such
embodiments, R.sup.5 is substituted heteroaryl. In some such
embodiments, R.sup.5 is substituted pyridinyl or substituted
indolyl. In some such embodiments, R.sup.5 is phenyl, pyridinyl, or
indolyl, each of which is substituted. In some such embodiments,
R.sup.5 is substituted phenyl or substituted pyridinyl. In some
such embodiments, R.sup.5 is substituted indolyl.
[0083] In certain embodiments, R.sup.5 is indolyl substituted with
1 or 2 substituents independently selected from the group
consisting of --OR.sup.a, --C(O)OR.sup.a, and
--C(O)NR.sup.cR.sup.d. In some such embodiments, R.sup.5 is indolyl
substituted with an --OR.sup.a group and optionally further
substituted with another substituent selected from the group
consisting of --C(O)OR.sup.a and --C(O)NR.sup.cR.sup.d.
[0084] In certain embodiments, R.sup.5 is phenyl or pyridinyl; each
of which is substituted with 1, 2, or 3 substituents independently
selected from the group consisting of C.sub.1-C.sub.3 alkyl,
halogen, C.sub.1-C.sub.3 haloalkyl, --CN, NO.sub.2, G.sup.2,
--OR.sup.a, --S(O).sub.2R.sup.a, --S(O).sub.2NR.sup.cR.sup.d,
--C(O)R.sup.a, --C(O)OR.sup.a, --C(O)NR.sup.cR.sup.d,
--NR.sup.cR.sup.d, --N(R.sup.e)S(O).sub.2R.sup.b,
--(C.sub.1-C.sub.3 alkylenyl)-G.sup.2 wherein G.sup.2 is optionally
substituted heterocycle, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.3
alkylenyl)-NR.sup.cR.sup.d, and --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. In some such embodiments,
R.sup.5 is substituted phenyl. In some such embodiments, R.sup.5 is
substituted pyridinyl.
[0085] In certain embodiments, R.sup.5 is phenyl or pyridinyl; each
of which is substituted with 1, 2, or 3 substituents, wherein one
substituent is selected from the group consisting of --OR.sup.a and
--NR.sup.cR.sup.d, and the other optional substituents are selected
from the group consisting of C.sub.1-C.sub.3 alkyl, halogen,
C.sub.1-C.sub.3 haloalkyl, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --N(R.sup.e)S(O).sub.2R.sup.b,
--(C.sub.1-C.sub.3 alkylenyl)-G.sup.2 wherein G.sup.2 is optionally
substituted heterocycle, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.3
alkylenyl)-NR.sup.cR.sup.d, and --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. In some such embodiments,
R.sup.5 is substituted phenyl. In some such embodiments, R.sup.5 is
substituted pyridinyl.
[0086] In certain embodiments, R.sup.5 is phenyl or pyridinyl; each
of which is substituted with two substituents, wherein one
substituent is --OR.sup.a, and the other substituent is selected
from the group consisting of --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --N(R.sup.e)S(O).sub.2R.sup.b,
--(C.sub.1-C.sub.3 alkylenyl)-G.sup.2 wherein G.sup.2 is optionally
substituted C.sub.4-C.sub.6 heterocycle, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.3
alkylenyl)-NR.sup.cR.sup.d, and --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. In some such embodiments,
R.sup.5 is substituted phenyl. In some such embodiments, R.sup.5 is
substituted pyridinyl.
[0087] In certain embodiments, R.sup.5 is phenyl or pyridinyl; each
of which is substituted with two substituents, wherein one
substituent is --NR.sup.cR.sup.d, and the other substituent is
selected from the group consisting of --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --N(R.sup.e)S(O).sub.2R.sup.b,
--(C.sub.1-C.sub.3 alkylenyl)-G.sup.2 wherein G.sup.2 is optionally
substituted C.sub.4-C.sub.6 heterocycle, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.3
alkylenyl)-NR.sup.cR.sup.d, and --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. In some such embodiments,
R.sup.5 is substituted phenyl. In some such embodiments, R.sup.5 is
substituted pyridinyl.
[0088] The compounds of formula (I) wherein R.sup.5 is phenyl or
pyridinyl correspond in structure to the following formula (i.e.
formula (IA)).
##STR00004##
wherein
[0089] A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is C(R.sup.10); or
[0090] A.sup.1 is N, A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9),
and A.sup.4 is C(R.sup.10); or
[0091] A.sup.1 is C(R.sup.7), A.sup.2 is N, A.sup.3 is C(R.sup.9),
and A.sup.4 is C(R.sup.10); or
[0092] A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is N,
and A.sup.4 is C(R.sup.10); or
[0093] A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is N;
[0094] In certain embodiments of compounds of formula (IA), A.sup.1
is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and
A.sup.4 is C(R.sup.10). In these embodiments, the compounds of
formula (IA) correspond in structure to formula (IA-a).
##STR00005##
[0095] In certain embodiments of compounds of formula (IA), A.sup.1
is N, A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10). In these embodiments, the compounds of formula (IA)
correspond in structure to formula (IA-b).
##STR00006##
[0096] In certain embodiments of compounds of formula (IA), A.sup.1
is C(R.sup.7), A.sup.2 is N, A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10). In these embodiments, the compounds of formula (IA)
correspond in structure to formula (IA-c).
##STR00007##
[0097] In certain embodiments of compounds of formula (IA), A.sup.1
is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is N, and A.sup.4 is
C(R.sup.10). In these embodiments, the compounds of formula (IA)
correspond in structure to formula (IA-d).
##STR00008##
[0098] In certain embodiments of compounds of formula (IA), A.sup.1
is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and
A.sup.4 is N. In these embodiments, the compounds of formula (IA)
correspond in structure to formula (IA-e).
##STR00009##
[0099] In certain embodiments of formula (IA), (IA-a), (IA-b),
(IA-c), (IA-d), and (IA-e),
[0100] R.sup.6 is halogen, --OR.sup.a, or --NR.sup.cR.sup.d;
[0101] R.sup.7 is H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6
haloalkyl, --CN, NO.sub.2, or C.sub.3-C.sub.6 cycloalkyl optionally
substituted 1, 2, 3, 4, or 5 substituents independently selected
from the group consisting of halogen, C.sub.1-C.sub.3 alkyl, and
CN.
[0102] R.sup.8 is H, halogen, --OR.sup.a, --NR.sup.cR.sup.d,
--C(O)R.sup.a, --C(O)NR.sup.cR.sup.d, G.sup.2, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2, or --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d;
[0103] R.sup.9 is H, halogen, --CN, C.sub.1-C.sub.6 haloalkyl,
--N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6 alkylenyl)-G.sup.2
wherein G.sup.2 is optionally substituted heterocycle,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; and
[0104] R.sup.10 is H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6
haloalkyl, --CN, or NO.sub.2;
[0105] R.sup.1, R.sup.2, R.sup.3, and R.sup.4 in compounds of
formula (IA), (IA-a), (IA-b), (IA-c), (IA-d), and (IA-e) are as set
forth in formula (I). Various embodiments of R.sup.1, R.sup.2,
R.sup.3, and R.sup.4 of formula (I) as discussed above are also
contemplated for compounds of formula (IA), (IA-a), (IA-b), (IA-c),
(IA-d), and (IA-e).
[0106] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is halogen (e.g. F,
Cl), --OR.sup.a, or --NR.sup.cR.sup.d. In some such embodiments,
R.sup.6 is F, --OR.sup.a, or --NR.sup.cR.sup.d.
[0107] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a or
--NR.sup.cR.sup.d; wherein [0108] R.sup.a is C.sub.1-C.sub.6
haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with one G.sup.2
group; [0109] R.sup.c is H or unsubstituted C.sub.1-C.sub.6 alkyl;
and [0110] R.sup.d is C.sub.1-C.sub.6 haloalkyl, G.sup.2, or
C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl is
optionally substituted with one G.sup.2 group;
[0111] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a or
--NR.sup.cR.sup.d; wherein [0112] R.sup.a is C.sub.1-C.sub.6
haloalkyl or unsubstituted C.sub.1-C.sub.6 alkyl; [0113] R.sup.c is
H or unsubstituted C.sub.1-C.sub.3 alkyl; and [0114] R.sup.d is
C.sub.1-C.sub.6 haloalkyl or unsubstituted C.sub.1-C.sub.6
alkyl.
[0115] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a or
--NR.sup.cR.sup.d; wherein [0116] R.sup.a is methyl,
2,2-dimethylpropyl, 3,3-dimethylbutyl, or
2,2,3,3,3-pentafluoropropyl;
[0117] R.sup.c is H or methyl; and [0118] R.sup.d is
2,2,2-trifluoroethyl or 2,2,3,3,4,4,4-heptafluorobutyl.
[0119] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a or
--NR.sup.cR.sup.d; wherein [0120] R.sup.a is G.sup.2 or
C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl is
substituted with one G.sup.2 group; [0121] R.sup.c is H or
unsubstituted C.sub.1-C.sub.3 alkyl; and [0122] R.sup.d is G.sup.2
or C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl is
substituted with one G.sup.2 group.
[0123] In certain embodiments, of compounds of formula (IA),
(IA-a), (IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a
or --NR.sup.cR.sup.d; wherein [0124] R.sup.a and R.sup.d are each
independently G.sup.2 or C.sub.1-C.sub.6 alkyl substituted with a
G.sup.2 group; wherein G.sup.2 is phenyl, C.sub.3-C.sub.6
cycloalkyl, C.sub.4-C.sub.6 heterocycle, or C.sub.5-C.sub.6
heteroaryl; each of which is optionally substituted with 1, 2, 3,
4, or 5 substituents independently selected from the group
consisting of C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN,
NO.sub.2, --OR.sup.y1, --OC(O)R.sup.y2, --OC(O)NR.sup.y3R.sup.y4,
--SR.sup.y1, --S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4,
--C(O)R.sup.y1, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--NR.sup.y3R.sup.y4, --N(R.sup.y3)C(O)R.sup.y2,
--N(R.sup.y3)S(O).sub.2R.sup.y2, --N(R.sup.y3)C(O)O(R.sup.y2),
--N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, and
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4; [0125] R.sup.c is
hydrogen or unsubstituted C.sub.1-C.sub.6 alkyl; [0126] R.sup.y1,
R.sup.y3, and R.sup.y4, at each occurrence, are each independently
H, C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and [0127]
R.sup.y2, at each occurrence, is independently C.sub.1-C.sub.6
alkyl or C.sub.1-C.sub.6 haloalkyl.
[0128] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a or
--NR.sup.cR.sup.d; wherein [0129] R.sup.a is G.sup.2 or
C.sub.1-C.sub.3 alkyl wherein the C.sub.1-C.sub.3 alkyl is
substituted with one G.sup.2 group; wherein G.sup.2 is aryl,
C.sub.4-C.sub.6 heterocycle, C.sub.3-C.sub.6 cycloalkyl,
C.sub.5-C.sub.6 heteroaryl, or adamantyl, each of which is
optionally substituted; [0130] R.sup.c is H or unsubstituted
C.sub.1-C.sub.3 alkyl; and [0131] R.sup.d is optionally substituted
phenyl or C.sub.1-C.sub.3 alkyl wherein the C.sub.1-C.sub.3 alkyl
is substituted with one G.sup.2 group, wherein G.sup.2 is phenyl,
C.sub.3-C.sub.6 cycloalkyl, or bicyclo[2.2.1]heptyl, each of which
is optionally substituted.
[0132] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a or
--NR.sup.cR.sup.d; wherein [0133] R.sup.a is phenyl, naphthyl,
indanyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl,
cyclohexyl, oxetanyl, tetrahydrofuranyl, piperidinyl,
tetrahydropyranyl, each of which is optionally substituted; or
C.sub.1-C.sub.3 alkyl wherein the C.sub.1-C.sub.3 alkyl is
substituted with one G.sup.2 group, wherein G.sup.2 is phenyl,
thienyl, C.sub.3-C.sub.6 cycloalkyl, adamantyl, oxetanyl,
tetrahydrofuranyl, tetrahydropyranyl, each of which is optionally
substituted;
[0134] R.sup.c is H or methyl; and [0135] R.sup.d is optionally
substituted phenyl or C.sub.1-C.sub.3 alkyl wherein the
C.sub.1-C.sub.3 alkyl is substituted with one G.sup.2 group,
wherein G.sup.2 is phenyl, C.sub.3-C.sub.6 cycloalkyl, or
bicyclo[2.2.1]heptyl, each of which is optionally substituted.
[0136] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a or
--NR.sup.cR.sup.d; wherein [0137] R.sup.a and R.sup.d are each
independently phenyl, pyridinyl, or C.sub.1-C.sub.3 alkyl
substituted with a C.sub.3-C.sub.6 cycloalkyl; wherein the phenyl,
pyridinyl, and the C.sub.3-C.sub.6 cycloalkyl are optionally
substituted with 1, 2, 3, 4, or 5 substituents independently
selected from the group consisting of C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.y1,
--OC(O)R.sup.y2, --OC(O)NR.sup.y3R.sup.y4, --SR.sup.y1,
--S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4,
--C(O)R.sup.y1, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--NR.sup.y3R.sup.y4, --N(R.sup.y3)C(O)R.sup.y2,
--N(R.sup.y3)S(O).sub.2R.sup.y2, --N(R.sup.y3)C(O)O(R.sup.y2),
--N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, and
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4; [0138] R.sup.c is
hydrogen or unsubstituted C.sub.1-C.sub.3 alkyl; [0139] R.sup.y1,
R.sup.y3, and R.sup.y4, at each occurrence, are each independently
H, C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and [0140]
R.sup.y2, at each occurrence, is independently C.sub.1-C.sub.6
alkyl or C.sub.1-C.sub.6 haloalkyl.
[0141] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a wherein
R.sup.a is G.sup.2, and G.sup.2 is optionally substituted phenyl or
optionally substituted C.sub.3-C.sub.6 cycloalkyl. In some such
embodiments, G.sup.2 is optionally substituted phenyl or optionally
substituted cyclohexyl.
[0142] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a wherein
R.sup.a is G.sup.2, and G.sup.2 is phenyl or cyclohexyl; each of
which is optionally substituted with 1 or 2 substituents
independently selected from the group consisting of --CN,
--OR.sup.z1, and halogen. In some such embodiments, the optional
substituents are selected from --CN, --OH, --O(C.sub.1-C.sub.3
alkyl), F, and Cl. In some such embodiments, the optional
substituents are selected from --CN, --OH, --O(CH.sub.3), and
F.
[0143] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a wherein
R.sup.a is G.sup.2, and G.sup.2 is phenyl optionally substituted
with 1 or 2 substituents selected from the group consisting of --CN
and halogen. In some such embodiments, G.sup.2 is phenyl
substituted with 1 or 2 substituents. In some such embodiments,
G.sup.2 is unsubstituted phenyl. In some such embodiments, the
substituents are selected from --CN, F, and Cl. In some such
embodiments, the substituents are selected from --CN and F.
[0144] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a wherein
R.sup.a is G.sup.2, and G.sup.2 is phenyl substituted with 1 or 2
substituents selected from halogen. In some such embodiments,
G.sup.2 is phenyl substituted with two halogen substituents. In
some such embodiments, the halogen is F.
[0145] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --OR.sup.a wherein
R.sup.a is G.sup.2, and G.sup.2 is cyclohexyl optionally
substituted with 1 or 2 substituents selected from the group
consisting of --OR.sup.z1 and halogen. In some such embodiments,
the substituents are selected from --OH, --O(C.sub.1-C.sub.3
alkyl), F, and Cl. In some such embodiments, the substituents are
selected from --OH, --O(CH.sub.3), and F. In some such embodiments,
G.sup.2 is cyclohexyl substituted with one substituent selected
from the group consisting of --OH, --O(CH.sub.3), and F. In some
such embodiments, G.sup.2 is cyclohexyl substituted with two
halogen substituents. In some such embodiments, G.sup.2 is
cyclohexyl substituted with two F.
[0146] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --NR.sup.cR.sup.d;
wherein R.sup.c is H or unsubstituted C.sub.1-C.sub.3 alkyl; and
R.sup.d is optionally substituted phenyl or C.sub.1-C.sub.3 alkyl
wherein the C.sub.1-C.sub.3 alkyl is substituted with one G.sup.2
group, wherein G.sup.2 is optionally substituted C.sub.3-C.sub.6
cycloalkyl. In some such embodiments, G.sup.2 is optionally
substituted cyclopropyl.
[0147] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --NR.sup.cR.sup.d;
wherein R.sup.c is H or methyl; and R.sup.d is phenyl substituted
with 1 or 2 halogen groups, or R.sup.d is C.sub.1-C.sub.3 alkyl
wherein the C.sub.1-C.sub.3 alkyl is substituted with one G.sup.2
group, wherein G.sup.2 is optionally substituted C.sub.3-C.sub.6
cycloalkyl. In some such embodiments, G.sup.2 is optionally
substituted cyclopropyl. In some such embodiments, G.sup.2 is
unsubstituted cyclopropyl. In some such embodiments, the halogen
substituents of the phenyl group are selected from fluoro or
chloro. In some such embodiments, the halogen is fluoro.
[0148] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --NR.sup.cR.sup.d;
wherein R.sup.c is H and R.sup.d is phenyl substituted with 1 or 2
halogen groups. In some such embodiments, the halogen is selected
from fluoro or chloro. In some such embodiments, the halogen is
fluoro.
[0149] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), (IA-d), and (IA-e), R.sup.6 is --NR.sup.cR.sup.d;
wherein R.sup.c is H and R.sup.d is cyclopropylmethyl wherein the
cyclopropyl is optionally substituted. In some such embodiments,
the cyclopropyl is unsubstituted.
[0150] In certain embodiments of formula (IA), (IA-a), (IA-c),
(IA-d), and (IA-e), R.sup.7 is H, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, or C.sub.3-C.sub.6
cycloalkyl optionally substituted with 1, 2, 3, 4, or 5
substituents independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, and CN.
[0151] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-c), (IA-d), and (IA-e), R.sup.7 is H.
[0152] In certain embodiments of formula (IA), (IA-a), (IA-b),
(IA-d), and (IA-e), R.sup.8 is H, halogen, --OR.sup.a,
--NR.sup.cR.sup.d, --C(O)R.sup.a, --C(O)NR.sup.cR.sup.d, G.sup.2,
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.2, or --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d.
[0153] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-d), and (IA-e), R.sup.8 is H, halogen, or --OR.sup.a
wherein R.sup.a is optionally substituted phenyl. In some such
embodiments, R.sup.8 is H or fluoro.
[0154] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-d), and (IA-e), R.sup.8 is H.
[0155] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-d), and (IA-e), R.sup.8 is halogen. In some such
embodiments, R.sup.8 is fluoro.
[0156] In certain embodiments of formula (IA), (IA-a), (IA-b),
(IA-c), and (IA-e), R.sup.9 is H, halogen, --CN, C.sub.1-C.sub.6
haloalkyl, --N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6 alkylenyl)-G.sup.2
wherein G.sup.2 is optionally substituted heterocycle,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b.
[0157] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6 alkylenyl)-G.sup.2
wherein G.sup.2 is optionally substituted heterocycle,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b.
[0158] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is H, halogen, --CN,
C.sub.1-C.sub.6 haloalkyl, --N(R.sup.e)S(O).sub.2R.sup.b,
--S(O).sub.2R.sup.a, --S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; wherein
[0159] R.sup.c, R.sup.d, and R.sup.e, at each occurrence, are each
independently H or unsubstituted C.sub.1-C.sub.6 alkyl; and
[0160] R.sup.a and R.sup.b, at each occurrence, is independently
C.sub.1-C.sub.6 haloalkyl, or unsubstituted C.sub.1-C.sub.6
alkyl.
[0161] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6 alkylenyl)-G.sup.2
wherein G.sup.2 is optionally substituted C.sub.4-C.sub.6
heterocycle, --(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.cR.sup.d, or
--(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. In some
such embodiments, R.sup.a and R.sup.b are each independently
C.sub.1-C.sub.6 haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl
wherein the C.sub.1-C.sub.6 alkyl is optionally substituted with
one G.sup.2 group, and G.sup.2 is phenyl, C.sub.3-C.sub.6
cycloalkyl, C.sub.5-C.sub.6 heteroaryl, or C.sub.4-C.sub.6
heterocycle, each of which is optionally substituted; R.sup.e and
R.sup.c are each independently H or unsubstituted C.sub.1-C.sub.3
alkyl; and R.sup.d is H, C.sub.1-C.sub.6 haloalkyl, G.sup.2, or
C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl is
optionally substituted with one G.sup.2 group, and G.sup.2 is
phenyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heteroaryl, or
C.sub.4-C.sub.6 heterocycle, each of which is optionally
substituted.
[0162] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is --(C.sub.1-C.sub.3
alkylenyl)-G.sup.2 wherein G.sup.2 is optionally substituted
monocyclic heterocycle, or R.sup.9 is --(C.sub.1-C.sub.3
alkylenyl)-NR.sup.cR.sup.d. In some such embodiments, R.sup.9 is
--(C.sub.1-C.sub.3 alkylenyl)-G.sup.2 wherein G.sup.2 is optionally
substituted C.sub.4-C.sub.6 heterocycle (e.g. morpholinyl,
piperidinyl, or piperazinyl, each of which is optionally
substituted), or R.sup.9 is --(C.sub.1-C.sub.3
alkylenyl)-NR.sup.cR.sup.d wherein R.sup.c is H or unsubstituted
C.sub.1-C.sub.3 alkyl, and R.sup.d is H, G.sup.2, or
C.sub.1-C.sub.6 alkyl which is optionally substituted with one
G.sup.2; wherein G.sup.2 is C.sub.5-C.sub.6 heteroaryl,
C.sub.3-C.sub.6 cycloalkyl, or C.sub.4-C.sub.6 heterocycle, each of
which is optionally substituted. In some such embodiments, R.sup.9
is --(C.sub.1-C.sub.3 alkylenyl)-NR.sup.cR.sup.d wherein R.sup.c is
H or unsubstituted C.sub.1-C.sub.3 alkyl, and R.sup.d is H,
G.sup.2, or C.sub.1-C.sub.6 alkyl which is optionally substituted
with one G.sup.2; wherein G.sup.2 is cyclopropyl, cyclopentyl,
piperidinyl, piperazinyl, morpholinyl, imidazolyl, furanyl,
thienyl, thiazolyl, or oxazolyl, wherein each of which is
optionally substituted.
[0163] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, or --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. In some such embodiments,
R.sup.a is unsubstituted C.sub.1-C.sub.3 alkyl or optionally
substituted C.sub.4-C.sub.6 heterocycle, R.sup.b is unsubstituted
C.sub.1-C.sub.3 alkyl or optionally substituted benzyl, R.sup.c is
H or unsubstituted C.sub.1-C.sub.3 alkyl, R.sup.d is H or
unsubstituted C.sub.1-C.sub.3 alkyl, and R.sup.e is H.
[0164] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b or --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a; wherein R.sup.e is H or unsubstituted
C.sub.1-C.sub.3 alkyl; and R.sup.a and R.sup.b, are each
independently C.sub.1-C.sub.3 alkyl.
[0165] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b. In some such embodiments, R.sup.e is
H and R.sup.b is unsubstituted C.sub.1-C.sub.3 alkyl. In some such
embodiments, R.sup.e is H and R.sup.b is methyl, ethyl, or
isopropyl.
[0166] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. In some such embodiments,
R.sup.9 is --(CH.sub.2)--N(R.sup.e)S(O).sub.2R.sup.b. In some such
embodiments, R.sup.e is H or unsubstituted C.sub.1-C.sub.3 alkyl,
and R.sup.b is C.sub.1-C.sub.6 haloalkyl, G.sup.2, or
C.sub.1-C.sub.6 alkyl which is optionally substituted with one
G.sup.2 group, and G.sup.2 is, phenyl, C.sub.3-C.sub.6 cycloalkyl,
C.sub.5-C.sub.6 heteroaryl or C.sub.4-C.sub.6 heterocycle, each of
which is optionally substituted. In some such embodiments, R.sup.e
is H or methyl, and R.sup.b is C.sub.1-C.sub.3 haloalkyl,
unsubstituted C.sub.1-C.sub.3 alkyl, phenyl, benzyl,
C.sub.3-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heteroaryl, wherein the
phenyl, benzyl, C.sub.3-C.sub.6 cycloalkyl, and C.sub.5-C.sub.6
heteroaryl are optionally substituted. In some such embodiments,
R.sup.e is H and R.sup.b is unsubstituted C.sub.1-C.sub.3 alkyl,
C.sub.1-C.sub.3 haloalkyl, phenyl, benzyl, cyclopentyl,
1,2-oxazolyl, or thienyl, wherein the phenyl, benzyl, cyclopentyl,
1,2-oxazolyl, and thienyl are optionally substituted. In some such
embodiments, R.sup.e is H and R.sup.b is unsubstituted
C.sub.1-C.sub.3 alkyl or optionally substituted benzyl. In some
such embodiments, R.sup.9 is
--(CH.sub.2)--N(R.sup.e)S(O).sub.2R.sup.b wherein R.sup.e is H and
R.sup.b is optionally substituted benzyl.
[0167] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is --S(O).sub.2R.sup.a or
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a. In some such
embodiments, R.sup.a is unsubstituted C.sub.1-C.sub.3 alkyl or
optionally substituted heterocycle. In some such embodiments,
R.sup.a is unsubstituted C.sub.1-C.sub.3 alkyl or optionally
substituted C.sub.4-C.sub.6 heterocycle. In some such embodiments,
R.sup.a is unsubstituted C.sub.1-C.sub.3 alkyl. In some such
embodiments, R.sup.a is optionally substituted heterocycle. In some
such embodiments, R.sup.9 is --S(O).sub.2R.sup.a or
--(CH.sub.2)--S(O).sub.2R.sup.a wherein R.sup.a is unsubstituted
C.sub.1-C.sub.3 alkyl. In some such embodiments, R.sup.9 is
--S(O).sub.2R.sup.a or --(CH.sub.2)--S(O).sub.2R.sup.a wherein
R.sup.a is optionally substituted C.sub.4-C.sub.6 heterocycle. In
some further embodiments, the unsubstituted C.sub.1-C.sub.3 alkyl
is methyl or ethyl. In some further embodiments, the
C.sub.4-C.sub.6 heterocycle is azetidinyl, piperidinyl,
piperazinyl, or morpholinyl, each of which is optionally
substituted. In some further embodiments, the C.sub.4-C.sub.6
heterocycle is morpholinyl.
[0168] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d. In some such embodiments,
R.sup.c is H or unsubstituted C.sub.1-C.sub.3 alkyl, and R.sup.d is
H, unsubstituted C.sub.1-C.sub.3 alkyl, optionally substituted
C.sub.3-C.sub.6 cycloalkyl, or optionally substituted
C.sub.5-C.sub.6 heteroaryl. In some such embodiments, R.sup.9 is
--(CH.sub.2)--S(O).sub.2NR.sup.cR.sup.d wherein R.sup.c and R.sup.d
are each independently H or unsubstituted C.sub.1-C.sub.3 alkyl. In
some such embodiments, R.sup.9 is
--(CH.sub.2)--S(O).sub.2NR.sup.cR.sup.d wherein R.sup.c and R.sup.d
are each independently H, methyl, or ethyl.
[0169] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-e), R.sup.9 is S(O).sub.2NR.sup.cR.sup.d.
In some such embodiments, R.sup.c and R.sup.d are each
independently H or unsubstituted C.sub.1-C.sub.3 alkyl. In some
such embodiments, R.sup.c and R.sup.d are each independently H,
methyl, or ethyl.
[0170] In certain embodiments of formula (IA), (IA-a), (IA-b),
(IA-c), and (IA-d), R.sup.10 is H, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, or NO.sub.2.
[0171] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-d), R.sup.10 is H or C.sub.1-C.sub.6 alkyl.
In some such embodiments, R.sup.10 is H or C.sub.1-C.sub.3 alkyl.
In some such embodiments, R.sup.10 is H or methyl.
[0172] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-d), R.sup.10 is H.
[0173] In certain embodiments of compounds of formula (IA), (IA-a),
(IA-b), (IA-c), and (IA-d), R.sup.10 is C.sub.1-C.sub.6 alkyl. In
some such embodiments, R.sup.10 is C.sub.1-C.sub.3 alkyl. In some
such embodiments, R.sup.10 is methyl.
[0174] Various embodiments of substituents R.sup.1, R.sup.2,
R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and
R.sup.10 have been discussed above. These substituents embodiments
can be combined to form various embodiments of compounds of formula
(I), (IA), (IA-a), (IA-b), (IA-c), (IA-d), and (IA-e). All
embodiments of compounds of formula (I), (IA), (IA-a), (IA-b),
(IA-c), (IA-d), and (IA-e) formed by combining the substituent
embodiments discussed above are within the scope of Applicant's
invention, and some illustrative embodiments of the compounds of
formula (I), (IA), (IA-a), (IA-b), (IA-c), (IA-d), and (IA-e) are
provided below. [0175] In certain embodiments, [0176] R.sup.1 is
C.sub.1-C.sub.3 alkyl; and [0177] R.sup.2 is H or C.sub.1-C.sub.3
alkyl. [0178] In certain embodiments, [0179] R.sup.1 is
C.sub.1-C.sub.3 alkyl; [0180] R.sup.2 is H or C.sub.1-C.sub.3
alkyl; and [0181] R.sup.5 is phenyl, pyridinyl, or indolyl, each of
which is substituted. [0182] In certain embodiments, [0183] R.sup.1
is C.sub.1-C.sub.3 alkyl; [0184] R.sup.2 is H or C.sub.1-C.sub.3
alkyl; and [0185] R.sup.3 is H, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, halogen, --C(O)R.sup.3a, --C(O)OR.sup.3a,
--C(O)NR.sup.3bR.sup.3c, or G.sup.1; wherein the C.sub.1-C.sub.6
alkyl and the C.sub.2-C.sub.6 alkenyl are each independently
unsubstituted or substituted with 1 or 2 substituents independently
selected from the group consisting of halogen, G.sup.1,
--OR.sup.3a, and --NR.sup.3bR.sup.3c. [0186] In certain
embodiments, [0187] R.sup.1 is C.sub.1-C.sub.3 alkyl; [0188]
R.sup.2 is H or C.sub.1-C.sub.3 alkyl; [0189] R.sup.3 is H,
C.sub.1-C.sub.3 alkyl, C.sub.2-C.sub.4 alkenyl, halogen, or
G.sup.1; wherein the C.sub.1-C.sub.3 alkyl and the C.sub.2-C.sub.4
alkenyl are each independently unsubstituted or substituted with 1
or 2 substituents independently selected from the group consisting
of halogen, --OH, --O(C.sub.1-C.sub.3 alkyl), --NH.sub.2,
--N(H)(C.sub.1-C.sub.3 alkyl), or --N(C.sub.1-C.sub.3 alkyl).sub.2;
and [0190] R.sup.5 is phenyl, pyridinyl, or indolyl, each of which
is substituted. [0191] In a further embodiment, R.sup.5 is
substituted phenyl or substituted pyridinyl. In some further
embodiments, R.sup.5 is substituted phenyl. In some further
embodiments, R.sup.5 is substituted pyridinyl. In some further
embodiments, R.sup.5 is substituted indolyl. [0192] In certain
embodiments, [0193] R.sup.1 is C.sub.1-C.sub.3 alkyl; [0194]
R.sup.2 is H or C.sub.1-C.sub.3 alkyl; [0195] R.sup.3 is H,
halogen, unsubstituted C.sub.1-C.sub.3 alkyl, optionally
substituted phenyl, optionally substituted 1,2-oxazolyl, or
C.sub.2-C.sub.4 alkenyl which is substituted with 2 substituents
independently selected from the group consisting of halogen and
--OH; and [0196] R.sup.5 is phenyl or pyridinyl, each of which is
substituted with 1, 2, or 3 substituents independently selected
from the group consisting of C.sub.1-C.sub.3 alkyl, halogen,
C.sub.1-C.sub.3 haloalkyl, --CN, NO.sub.2, G.sup.2, --OR.sup.a,
--S(O).sub.2R.sup.a, --S(O).sub.2NR.sup.cR.sup.d, --C(O)R.sup.a,
--C(O)OR.sup.a, --C(O)NR.sup.cR.sup.d, --NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.3
alkylenyl)-G.sup.2 wherein G.sup.2 is optionally substituted
heterocycle, --(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.3 alkylenyl)-NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.3 alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. [0197]
In some further embodiments, R.sup.5 is substituted phenyl. In some
further embodiments, [0198] R.sup.5 is substituted pyridinyl.
[0199] In certain embodiments, [0200] R.sup.1 is C.sub.1-C.sub.3
alkyl; [0201] R.sup.2 is H or C.sub.1-C.sub.3 alkyl; [0202] R.sup.3
is H, unsubstituted C.sub.1-C.sub.3 alkyl, or halogen; [0203]
R.sup.4 is H, C.sub.1-C.sub.3 alkyl, or halogen; and [0204] R.sup.5
is phenyl or pyridinyl; each of which is substituted with 1, 2, or
3 substituents, wherein one substituent is selected from the group
consisting of --OR.sup.a and --NR.sup.cR.sup.d, and the other
optional substituents are selected from the group consisting of
C.sub.1-C.sub.3 alkyl, halogen, C.sub.1-C.sub.3 haloalkyl,
--S(O).sub.2R.sup.a, --S(O).sub.2NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.3
alkylenyl)-G.sup.2 wherein G.sup.2 is optionally substituted
heterocycle, --(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.3 alkylenyl)-NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.3 alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. [0205]
In some further embodiments, R.sup.5 is substituted phenyl. In some
further embodiments, [0206] R.sup.5 is substituted pyridinyl.
[0207] In certain embodiments, [0208] R.sup.1 is C.sub.1-C.sub.3
alkyl; [0209] R.sup.2 is H or C.sub.1-C.sub.3 alkyl; [0210] R.sup.3
is H, unsubstituted C.sub.1-C.sub.3 alkyl, or halogen; [0211]
R.sup.4 is H, C.sub.1-C.sub.3 alkyl, or halogen; and [0212] R.sup.5
is indolyl substituted with 1 or 2 substituents independently
selected from the group consisting of --OR.sup.a, --C(O)OR.sup.a,
and --C(O)NR.sup.cR.sup.d. [0213] In certain embodiments [0214]
R.sup.1 is H, C.sub.1-C.sub.3 alkyl, or C.sub.1-C.sub.3 haloalkyl;
[0215] R.sup.2 is H, C.sub.1-C.sub.3 alkyl, or C.sub.1-C.sub.3
haloalkyl; [0216] R.sup.3 is H, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
--OR.sup.3a, --NR.sup.3bR.sup.3c, --N(R.sup.3b)C(O)R.sup.3d,
--N(R.sup.3b)C(O)NR.sup.3bR.sup.3c,
--N(R.sup.3b)S(O).sub.2NR.sup.3bR.sup.3c, --C(O)R.sup.3a,
--C(O)OR.sup.3a, --C(O)NR.sup.3bR.sup.3c, --S(O)R.sup.3d,
--S(O).sub.2R.sup.3a, --S(O).sub.2NR.sup.3bR.sup.3c, or G.sup.1;
wherein the C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, and
C.sub.2-C.sub.6 alkynyl are each independently unsubstituted or
substituted with 1 or 2 substituents independently selected from
the group consisting of halogen, G.sup.1, --OR.sup.3a, and
--NR.sup.3bR.sup.3c; [0217] R.sup.3a, R.sup.3b, and R.sup.3c, at
each occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.1, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.1; [0218] R.sup.3d, at each occurrence, is
independently C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl,
G.sup.1, or --(C.sub.1-C.sub.6 alkylenyl)-G.sup.1; [0219] G.sup.1,
at each occurrence, is independently aryl, heteroaryl, heterocycle,
cycloalkyl, or cycloalkenyl; and each G.sup.1 is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.1g groups; [0220] R.sup.4
is H, C.sub.1-C.sub.6 alkyl, halogen, or C.sub.1-C.sub.6 haloalkyl;
[0221] R.sup.5 is a monocyclic or bicyclic ring selected from the
group consisting of aryl and heteroaryl; each of which is
substituted with 1, 2, or 3 substituents independently selected
from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6
haloalkyl, --CN, NO.sub.2, G.sup.2, --OR.sup.a, --OC(O)R.sup.b,
--OC(O)NR.sup.cR.sup.d, --SR.sup.a, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)NR.sup.cR.sup.d, --NR.sup.cR.sup.d, --N(R.sup.e)C(O)R.sup.b,
--N(R.sup.e)S(O).sub.2R.sup.b, --N(R.sup.e)C(O)O(R.sup.b),
--N(R.sup.e)C(O)NR.sup.cR.sup.d,
--N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2, --(C.sub.1-C.sub.6 alkylenyl)-OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.a, --(C.sub.1-C.sub.6 alkylenyl)-C(O)OR.sup.a,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)O(R.sup.b), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)C(O)NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2NR.sup.cR.sup.d, and
--(C.sub.1-C.sub.6 alkylenyl)-CN; [0222] R.sup.a, R.sup.c, R.sup.d,
and R.sup.e, at each occurrence, are each independently H,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6
haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with one
substituent selected from the group consisting of --OR.sup.y1,
--NR.sup.y3R.sup.y4, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2;
[0223] R.sup.b, at each occurrence, is independently
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6
haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with one
substituent selected from the group consisting of --OR.sup.y1,
--NR.sup.y3R.sup.y4, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2;
[0224] G.sup.2, at each occurrence, are each independently aryl,
heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; and each
G.sup.2 group is optionally substituted with 1, 2, 3, 4, or 5
R.sup.2g groups; [0225] R.sup.1g, at each occurrence, is
independently C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN,
NO.sub.2, --OR.sup.z1, --OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4,
--SR.sup.z1, --S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4,
--NR.sup.z3R.sup.z4, --N(R.sup.z3)C(O)R.sup.z2,
--N(R.sup.z3)S(O).sub.2R.sup.z2, --N(R.sup.z3)C(O)O(R.sup.z2),
--N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --O(phenyl) wherein the phenyl
moiety is optionally substituted with 1, 2, 3, or 4 substituents
independently selected from the group consisting of C.sub.1-C.sub.6
alkyl, halogen, C.sub.1-C.sub.6 haloalkyl, --OH, --O(alkyl),
--O(haloalkyl), CN, and NO.sub.2; [0226] R.sup.2g, at each
occurrence, is independently C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6
haloalkyl, --CN, NO.sub.2, --OR.sup.y1, --OC(O)R.sup.y2,
--OC(O)NR.sup.y3R.sup.y4, --SR.sup.y1, --S(O).sub.2R.sup.y1,
--S(O).sub.2NR.sup.y3R.sup.y4, --C(O)R.sup.y1, --C(O)OR.sup.y1,
--C(O)NR.sup.y3R.sup.y4, --NR.sup.y3R.sup.y4,
--N(R.sup.y3)C(O)R.sup.y2, --N(R.sup.y3)S(O).sub.2R.sup.y2,
--N(R.sup.y3)C(O)O(R.sup.y2), --N(R.sup.y3)C(O)NR.sup.y3R.sup.y4,
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4, G.sup.2b,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)O(R.sup.y2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; [0227] R.sup.y1, R.sup.y3, and R.sup.y4, at
each occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.2b, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; [0228] R.sup.y2, at each occurrence, is
independently C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl,
G.sup.2b, or --(C.sub.1-C.sub.6 alkylenyl)-G.sup.2b; [0229]
G.sup.2b, at each occurrence, is independently aryl, heteroaryl,
cycloalkyl, cycloalkenyl, or heterocycle; and each G.sup.2b group
is optionally substituted with 1, 2, 3, 4, or 5 substituents
independently selected from the group consisting of C.sub.1-C.sub.6
alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.z1,
--OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4, --SR.sup.z1,
--S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4,
--NR.sup.z3R.sup.z4, --N(R.sup.z3)C(O)R.sup.z2,
--N(R.sup.z3)S(O).sub.2R.sup.z2, --N(R.sup.z3)C(O)O(R.sup.z2),
--N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, and
--(C.sub.1-C.sub.6 alkylenyl)-CN; [0230] R.sup.z1, R.sup.z3, and
R.sup.z4, at each occurrence, are each independently H,
C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and [0231]
R.sup.z2, at each occurrence, is independently C.sub.1-C.sub.6
alkyl or C.sub.1-C.sub.6 haloalkyl.
[0232] In certain embodiments are provided compounds of formula
(IA)
##STR00010## [0233] wherein [0234] A.sup.1 is C(R.sup.7), A.sup.2
is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10);
or [0235] A.sup.1 is N, A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is C(R.sup.10); or [0236] A.sup.1 is
C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is N, and A.sup.4 is
C(R.sup.10); or [0237] A.sup.1 is C(R.sup.7), A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is N; [0238] R.sup.1
is H, C.sub.1-C.sub.3 alkyl, or C.sub.1-C.sub.3 haloalkyl; [0239]
R.sup.2 is H, C.sub.1-C.sub.3 alkyl, or C.sub.1-C.sub.3 haloalkyl;
[0240] R.sup.3 is H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, halogen, --OR.sup.3a,
--NR.sup.3bR.sup.3c, --N(R.sup.3b)C(O)R.sup.3d,
--N(R.sup.3b)C(O)NR.sup.3bR.sup.3c,
--N(R.sup.3b)S(O).sub.2NR.sup.3bR.sup.3c, --C(O)R.sup.3a,
--C(O)OR.sup.3a, --C(O)NR.sup.3bR.sup.3c, --S(O)R.sup.3d,
--S(O).sub.2R.sup.3a, --S(O).sub.2NR.sup.3bR.sup.3c, or G.sup.1;
wherein the C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, and
C.sub.2-C.sub.6 alkynyl are each independently unsubstituted or
substituted with 1 or 2 substituents independently selected from
the group consisting of halogen, G.sup.1, --OR.sup.3a, and
--NR.sup.3bR.sup.3c; [0241] R.sup.3a, R.sup.3b, and R.sup.3c, at
each occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.1, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.1, --(C.sub.1-C.sub.6 alkylenyl)-CN,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.z1, or --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4; [0242] R.sup.3d, at each occurrence,
is independently C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl,
G.sup.1, or --(C.sub.1-C.sub.6 alkylenyl)-G.sup.1; [0243] G.sup.1,
at each occurrence, is independently aryl, heteroaryl, heterocycle,
cycloalkyl, or cycloalkenyl; and each G.sup.1 is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.1g groups; [0244] R.sup.4
is H, C.sub.1-C.sub.6 alkyl, halogen, or C.sub.1-C.sub.6 haloalkyl;
[0245] R.sup.6 is halogen, --OR.sup.a, or --NR.sup.cR.sup.d; [0246]
R.sup.7 is H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN,
NO.sub.2, or C.sub.3-C.sub.6 cycloalkyl optionally substituted with
1, 2, 3, 4, or 5 substituents independently selected from the group
consisting of halogen, C.sub.1-C.sub.3 alkyl, or CN; [0247] R.sup.8
is H, halogen, --OR.sup.a, --NR.sup.cR.sup.d, --C(O)R.sup.a,
--C(O)NR.sup.cR.sup.d, G.sup.2, --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2, or --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d; [0248] R.sup.9 is H, halogen, --CN,
C.sub.1-C.sub.6 haloalkyl, --N(R.sup.e)S(O).sub.2R.sup.b,
--S(O).sub.2R.sup.a, --S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.2 wherein G.sup.2 is optionally
substituted heterocycle, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; [0249] R.sup.10 is H,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN, or NO.sub.2;
[0250] R.sup.a, R.sup.c, R.sup.d, and R.sup.e, at each occurrence,
are each independently H, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, C.sub.1-C.sub.6 haloalkyl, G.sup.2, or C.sub.1-C.sub.6
alkyl wherein the C.sub.1-C.sub.6 alkyl is optionally substituted
with one substituent selected from the group consisting of
--OR.sup.y1, --NR.sup.y3R.sup.y4, --C(O)OR.sup.y1,
--C(O)NR.sup.y3R.sup.y4, --S(O).sub.2R.sup.y1,
--S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2; [0251] R.sup.b, at each
occurrence, is independently C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl, G.sup.2, or
C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl is
optionally substituted with one substituent selected from the group
consisting of --OR.sup.y1, --NR.sup.y3R.sup.y4, --C(O)OR.sup.y1,
--C(O)NR.sup.y3R.sup.y4, --S(O).sub.2R.sup.y1,
--S(O).sub.2NR.sup.y3R.sup.y4, and G.sup.2; [0252] G.sup.2, at each
occurrence, are each independently aryl, heteroaryl, heterocycle,
cycloalkyl, or cycloalkenyl; and each G.sup.2 group is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.2g groups; [0253] R.sup.1g,
at each occurrence, is independently C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.z1,
--OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4, --SR.sup.z1,
--S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)(C.sub.3-C.sub.6 cycloalkyl),
--C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4, --NR.sup.z3R.sup.z4,
--N(R.sup.z3)C(O)R.sup.z2, --N(R.sup.z3)S(O).sub.2R.sup.z2,
--N(R.sup.z3)C(O)O(R.sup.z2), --N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --O(phenyl); wherein the
phenyl moiety and the C.sub.3-C.sub.6 cycloalkyl moiety are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from the group consisting of C.sub.1-C.sub.6
alkyl, halogen, C.sub.1-C.sub.6 haloalkyl, --OH, --O(alkyl),
--O(haloalkyl), CN, and NO.sub.2; [0254] R.sup.2g, at each
occurrence, is independently C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6
haloalkyl, oxo, --CN, NO.sub.2, --OR.sup.y1, --OC(O)R.sup.y2,
--OC(O)NR.sup.y3R.sup.y4, --SR.sup.y1, --S(O).sub.2R.sup.y1,
--S(O).sub.2NR.sup.y3R.sup.y4, --C(O)R.sup.y1, --C(O)OR.sup.y1,
--C(O)NR.sup.y3R.sup.y4, --NR.sup.y3R.sup.y4,
--N(R.sup.y3)C(O)R.sup.y2, --N(R.sup.y3)S(O).sub.2R.sup.y2,
--N(R.sup.y3)C(O)O(R.sup.y2), --N(R.sup.y3)C(O)NR.sup.y3R.sup.y4,
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4, G.sup.2b,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.y1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2R.sup.y2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)O(R.sup.y2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4,
--(C.sub.1-C.sub.6 alkylenyl)-CN, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; [0255] R.sup.y1, R.sup.y3, and R.sup.y4, at
each occurrence, are each independently H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, G.sup.2b, or --(C.sub.1-C.sub.6
alkylenyl)-G.sup.2b; [0256] R.sup.y2, at each occurrence, is
independently C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl,
G.sup.2b, or --(C.sub.1-C.sub.6 alkylenyl)-G.sup.2b; [0257]
G.sup.2b, at each occurrence, is independently aryl, heteroaryl,
cycloalkyl, cycloalkenyl, or heterocycle; and each G.sup.2b group
is optionally substituted with 1, 2, 3, 4, or 5 substituents
independently selected from the group consisting of C.sub.1-C.sub.6
alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, halogen,
C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2, --OR.sup.z1,
--OC(O)R.sup.z2, --OC(O)NR.sup.z3R.sup.z4, --SR.sup.z1,
--S(O).sub.2R.sup.z1, --S(O).sub.2NR.sup.z3R.sup.z4,
--C(O)R.sup.z1, --C(O)OR.sup.z1, --C(O)NR.sup.z3R.sup.z4,
--NR.sup.z3R.sup.z4, --N(R.sup.z3)C(O)R.sup.z2,
--N(R.sup.z3)S(O).sub.2R.sup.z2, --N(R.sup.z3)C(O)O(R.sup.z2),
--N(R.sup.z3)C(O)NR.sup.z3R.sup.z4,
--N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.z2,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.z1,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2NR.sup.z3R.sup.z4,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)R.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2R.sup.z2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)O(R.sup.z2), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)C(O)NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.z3)S(O).sub.2NR.sup.z3R.sup.z4, and
--(C.sub.1-C.sub.6 alkylenyl)-CN; [0258] R.sup.z1, R.sup.z3, and
R.sup.z4, at each occurrence, are each independently H,
C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and [0259]
R.sup.z2, at each occurrence, is independently C.sub.1-C.sub.6
alkyl or C.sub.1-C.sub.6 haloalkyl. [0260] In some further
embodiments, A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3
is C(R.sup.9), and A.sup.4 is C(R.sup.10); [0261] In some further
embodiments, A.sup.1 is N, A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is C(R.sup.10). [0262] In certain
embodiments are provided compounds of formula (IA), wherein [0263]
R.sup.1 is methyl; and [0264] R.sup.2 is H or methyl. [0265] In
certain embodiments are provided compounds of formula (IA), wherein
[0266] R.sup.1 is methyl; [0267] R.sup.2 is H; [0268] R.sup.3 is H,
unsubstituted C.sub.1-C.sub.3 alkyl, or halogen; and [0269] R.sup.4
is H, C.sub.1-C.sub.3 alkyl, or halogen. [0270] In certain
embodiments are provided compounds of formula (IA) wherein [0271]
R.sup.1 is methyl; [0272] R.sup.2 is H; [0273] R.sup.3 is H,
unsubstituted C.sub.1-C.sub.3 alkyl, or halogen; [0274] R.sup.4 is
H, C.sub.1-C.sub.3 alkyl, or halogen; and [0275] A.sup.1 is
C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and
A.sup.4 is C(R.sup.10); or [0276] A.sup.1 is N, A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10).
[0277] In certain embodiments are provided compounds of formula
(IA) wherein [0278] R.sup.1 is methyl; [0279] R.sup.2 is H; [0280]
R.sup.3 is H, unsubstituted C.sub.1-C.sub.3 alkyl, or halogen;
[0281] R.sup.4 is H, C.sub.1-C.sub.3 alkyl, or halogen; [0282]
A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is C(R.sup.10); or [0283] A.sup.1 is N,
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10); [0284] R.sup.7 is H; [0285] R.sup.8 is H or halogen;
and [0286] R.sup.10 is H or C.sub.1-C.sub.6 alkyl. [0287] In some
further embodiments, A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8),
A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10). [0288] In some
further embodiments, A.sup.1 is N, A.sup.2 is C(R.sup.8), A.sup.3
is C(R.sup.9), and A.sup.4 is C(R.sup.10). [0289] In certain
embodiments are provided compounds of formula (IA) wherein [0290]
R.sup.1 is methyl; [0291] R.sup.2 is H; [0292] R.sup.3 is H,
unsubstituted C.sub.1-C.sub.3 alkyl, or halogen; [0293] R.sup.4 is
H, C.sub.1-C.sub.3 alkyl, or halogen; [0294] A.sup.1 is C(R.sup.7),
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10); or [0295] A.sup.1 is N, A.sup.2 is C(R.sup.8), A.sup.3
is C(R.sup.9), and A.sup.4 is C(R.sup.10); [0296] R.sup.7 is H;
[0297] R.sup.8 is H or halogen; [0298] R.sup.10 is H or
C.sub.1-C.sub.6 alkyl; [0299] R.sup.6 is --OR.sup.a or
--NR.sup.cR.sup.d, wherein [0300] R.sup.a and R.sup.d are each
independently C.sub.1-C.sub.6 haloalkyl, G.sup.2, or
C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl is
optionally substituted with one G.sup.2 group; and [0301] R.sup.c
is H or unsubstituted C.sub.1-C.sub.6 alkyl; and [0302] R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6 alkylenyl)-G.sup.2
wherein G.sup.2 is optionally substituted heterocycle,
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b. [0303] In some further
embodiments, A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3
is C(R.sup.9), and A.sup.4 is C(R.sup.10). [0304] In some further
embodiments, A.sup.1 is N, A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is C(R.sup.10). [0305] In certain
embodiments are provided compounds of formula (IA) wherein [0306]
R.sup.1 is methyl; [0307] R.sup.2 is H; [0308] R.sup.3 is H,
unsubstituted C.sub.1-C.sub.3 alkyl, or halogen; [0309] R.sup.4 is
H, C.sub.1-C.sub.3 alkyl, or halogen; [0310] A.sup.1 is C(R.sup.7),
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10); or [0311] A.sup.1 is N, A.sup.2 is C(R.sup.8), A.sup.3
is C(R.sup.9), and A.sup.4 is C(R.sup.10); [0312] R.sup.7 is H;
[0313] R.sup.8 is H or halogen; [0314] R.sup.10 is H or
C.sub.1-C.sub.6 alkyl; [0315] R.sup.6 is --OR.sup.a or
--NR.sup.cR.sup.d, wherein [0316] R.sup.a and R.sup.d are each
independently C.sub.1-C.sub.6 haloalkyl or unsubstituted
C.sub.1-C.sub.6 alkyl; and [0317] R.sup.c is H or unsubstituted
C.sub.1-C.sub.3 alkyl; and [0318] R.sup.9 is --S(O).sub.2R.sup.a or
--(CH.sub.2)--SO.sub.2R.sup.a, wherein R.sup.a, at each occurrence,
is independently unsubstituted C.sub.1-C.sub.3 alkyl. [0319] In
some further embodiments, A.sup.1 is C(R.sup.7), A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10).
[0320] In some further embodiments, A.sup.1 is N, A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10).
[0321] In certain embodiments are provided compounds of formula
(IA) wherein [0322] R.sup.1 is methyl; [0323] R.sup.2 is H; [0324]
R.sup.3 is H, unsubstituted C.sub.1-C.sub.3 alkyl, or halogen;
[0325] R.sup.4 is H, C.sub.1-C.sub.3 alkyl, or halogen; [0326]
A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is C(R.sup.10); or [0327] A.sup.1 is N,
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10); [0328] R.sup.7 is H; [0329] R.sup.8 is H or halogen;
[0330] R.sup.10 is H or C.sub.1-C.sub.6 alkyl; [0331] R.sup.6 is
--OR.sup.a or --NR.sup.cR.sup.d, wherein [0332] R.sup.a is G.sup.2
or C.sub.1-C.sub.3 alkyl wherein the C.sub.1-C.sub.3 alkyl is
substituted with one G.sup.2 group; and G.sup.2 is aryl,
C.sub.4-C.sub.6 heterocycle, C.sub.3-C.sub.6 cycloalkyl,
C.sub.5-C.sub.6 heteroaryl, or adamantyl, each of which is
optionally substituted;
[0333] R.sup.c is H or unsubstituted C.sub.1-C.sub.3 alkyl; and
[0334] R.sup.d is optionally substituted phenyl or C.sub.1-C.sub.3
alkyl wherein the C.sub.1-C.sub.3 alkyl is substituted with one
G.sup.2 group; and G.sup.2 is phenyl, C.sub.3-C.sub.6 cycloalkyl,
or bicyclo[2.2.1]heptyl, each of which is optionally substituted;
and [0335] R.sup.9 is --N(R.sup.e)S(O).sub.2R.sup.b,
--S(O).sub.2R.sup.a, --S(O).sub.2NR.sup.cR.sup.d,
--(C.sub.1-C.sub.3 alkylenyl)-G.sup.2 wherein G.sup.2 is optionally
substituted C.sub.4-C.sub.6 heterocycle; --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.3
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; wherein [0336] R.sup.a and
R.sup.b are each independently C.sub.1-C.sub.6 haloalkyl, G.sup.2,
or C.sub.1-C.sub.6 alkyl wherein the C.sub.1-C.sub.6 alkyl is
optionally substituted with one G.sup.2 group, and G.sup.2 is
phenyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heteroaryl, or
C.sub.4-C.sub.6 heterocycle, each of which is optionally
substituted; [0337] R.sup.e and R.sup.c are each independently H or
unsubstituted C.sub.1-C.sub.3 alkyl; and [0338] R.sup.d is H,
C.sub.1-C.sub.6 haloalkyl, G.sup.2, or C.sub.1-C.sub.6 alkyl
wherein the C.sub.1-C.sub.6 alkyl is optionally substituted with
one G.sup.2 group, and G.sup.2 is phenyl, C.sub.3-C.sub.6
cycloalkyl, C.sub.5-C.sub.6 heteroaryl, or C.sub.4-C.sub.6
heterocycle, each of which is optionally substituted. [0339] In
some further embodiments, A.sup.1 is C(R.sup.7), A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10).
[0340] In some further embodiments, A.sup.1 is N, A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10).
[0341] In certain embodiments are provided compounds of formula
(IA) wherein [0342] R.sup.1 is methyl; [0343] R.sup.2 is H; [0344]
R.sup.3 is H, unsubstituted C.sub.1-C.sub.3 alkyl, or halogen;
[0345] R.sup.4 is H, C.sub.1-C.sub.3 alkyl, or halogen; [0346]
A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is C(R.sup.10); or [0347] A.sup.1 is N,
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10); [0348] R.sup.7 is H; [0349] R.sup.8 is H or halogen;
[0350] R.sup.10 is H or C.sub.1-C.sub.6 alkyl; [0351] R.sup.6 is
--OR.sup.a; wherein [0352] R.sup.a is G.sup.2, and [0353] G.sup.2
is optionally substituted phenyl or optionally substituted
C.sub.3-C.sub.6 cycloalkyl; and [0354] R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, or --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; wherein [0355] R.sup.a is
unsubstituted C.sub.1-C.sub.3 alkyl or optionally substituted
C.sub.4-C.sub.6 heterocycle, [0356] R.sup.b is unsubstituted
C.sub.1-C.sub.3 alkyl or optionally substituted benzyl; [0357]
R.sup.c is H or unsubstituted C.sub.1-C.sub.3 alkyl; [0358] R.sup.d
is H or unsubstituted C.sub.1-C.sub.3 alkyl; and [0359] R.sup.e is
H. [0360] In some further embodiments, A.sup.1 is C(R.sup.7),
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10). [0361] In some further embodiments, A.sup.1 is N,
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10). [0362] In certain embodiments are provided compounds
of formula (IA) wherein [0363] R.sup.1 is methyl; [0364] R.sup.2 is
H; [0365] R.sup.3 is H; [0366] R.sup.4 is H; [0367] A.sup.1 is
C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and
A.sup.4 is C(R.sup.10); or [0368] A.sup.1 is N, A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10);
[0369] R.sup.7 is H; [0370] R.sup.8 is H or halogen; [0371]
R.sup.10 is H or C.sub.1-C.sub.6 alkyl; [0372] R.sup.6 is
--OR.sup.a; wherein [0373] R.sup.a is G.sup.2, and [0374] G.sup.2
is phenyl substituted with 1 or 2 halogen; and [0375] R.sup.9 is
--N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a, or
--(CH.sub.2)--S(O).sub.2R.sup.a, wherein [0376] R.sup.a and R.sup.b
are each independently unsubstituted C.sub.1-C.sub.3 alkyl, and
[0377] R.sup.e is H. [0378] In some further embodiments, A.sup.1 is
C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and
A.sup.4 is C(R.sup.10). [0379] In some further embodiments, A.sup.1
is N, A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10). [0380] In certain embodiments are provided compounds
of formula (IA) wherein [0381] R.sup.1 is methyl; [0382] R.sup.2 is
H; [0383] R.sup.3 is H; [0384] R.sup.4 is H; [0385] A.sup.1 is
C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and
A.sup.4 is C(R.sup.10); or [0386] A.sup.1 is N, A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10);
[0387] R.sup.7 is H; [0388] R.sup.8 is H or halogen; [0389]
R.sup.10 is H or C.sub.1-C.sub.6 alkyl; [0390] R.sup.6 is
--OR.sup.a; wherein [0391] R.sup.a is G.sup.2, and [0392] G.sup.2
is cyclohexyl substituted with one or two substituents selected
from the group consisting of --OH, --O(CH.sub.3), and F; and [0393]
R.sup.9 is --N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a, or
--(CH.sub.2)--S(O).sub.2R.sup.a, wherein [0394] R.sup.a and R.sup.b
are each independently unsubstituted C.sub.1-C.sub.3 alkyl, and
[0395] R.sup.e is H. [0396] In some further embodiments, A.sup.1 is
C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and
A.sup.4 is C(R.sup.10). [0397] In some further embodiments, A.sup.1
is N, A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10). [0398] In certain embodiments are provided compounds
of formula (IA) wherein [0399] R.sup.1 is methyl; [0400] R.sup.2 is
H; [0401] R.sup.3 is H, unsubstituted C.sub.1-C.sub.3 alkyl, or
halogen; [0402] R.sup.4 is H, C.sub.1-C.sub.3 alkyl, or halogen;
[0403] A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is
C(R.sup.9), and A.sup.4 is C(R.sup.10); or [0404] A.sup.1 is N,
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10); [0405] R.sup.7 is H; [0406] R.sup.8 is H or halogen;
[0407] R.sup.10 is H or C.sub.1-C.sub.6 alkyl; [0408] R.sup.6 is
--NR.sup.cR.sup.d, wherein [0409] R.sup.c is H or unsubstituted
C.sub.1-C.sub.3 alkyl; and [0410] R.sup.d is optionally substituted
phenyl or C.sub.1-C.sub.3 alkyl wherein the C.sub.1-C.sub.3 alkyl
is substituted with one G.sup.2 group, wherein G.sup.2 is
optionally substituted C.sub.3-C.sub.6 cycloalkyl, and [0411]
R.sup.9 is --N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--(C.sub.1-C.sub.3 alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.3
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, or --(C.sub.1-C.sub.3
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; wherein [0412] R.sup.a is
unsubstituted C.sub.1-C.sub.3 alkyl or optionally substituted
C.sub.4-C.sub.6 heterocycle, [0413] R.sup.b is unsubstituted
C.sub.1-C.sub.3 alkyl or optionally substituted benzyl; [0414]
R.sup.c is H or unsubstituted C.sub.1-C.sub.3 alkyl; [0415] R.sup.d
is H or unsubstituted C.sub.1-C.sub.3 alkyl; and [0416] R.sup.e is
H. [0417] In some further embodiments, A.sup.1 is C(R.sup.7),
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10). [0418] In some further embodiments, A.sup.1 is N,
A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10). [0419] In certain embodiments are provided compounds
of formula (IA) wherein [0420] R.sup.1 is methyl; [0421] R.sup.2 is
H; [0422] R.sup.3 is H; [0423] R.sup.4 is H; [0424] A.sup.1 is
C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and
A.sup.4 is C(R.sup.10); or [0425] A.sup.1 is N, A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10);
[0426] R.sup.7 is H; [0427] R.sup.8 is H or halogen; [0428]
R.sup.10 is H or C.sub.1-C.sub.6 alkyl; [0429] R.sup.6 is
--NR.sup.cR.sup.d, wherein [0430] R.sup.c is H or methyl; and
[0431] R.sup.d is phenyl substituted with 1 or 2 halogen, or
R.sup.d is C.sub.1-C.sub.3 alkyl wherein the C.sub.1-C.sub.3 alkyl
is substituted with one G.sup.2 group, and G.sup.2 is optionally
substituted cyclopropyl, and [0432] R.sup.9 is
--(CH.sub.2)--S(O).sub.2R.sup.a; wherein R.sup.a is unsubstituted
C.sub.1-C.sub.3 alkyl. [0433] In some further embodiments, A.sup.1
is C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and
A.sup.4 is C(R.sup.10). [0434] In some further embodiments, A.sup.1
is N, A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is
C(R.sup.10). [0435] In certain embodiments are provided compounds
of formula (IA) wherein [0436] R.sup.1 is methyl; [0437] R.sup.2 is
H; [0438] R.sup.3 is --C(O)R.sup.3a, --C(O)NR.sup.3bR.sup.3c,
C.sub.4-C.sub.6 heterocycle, or C.sub.1-C.sub.3 alkyl which is
substituted with C.sub.4-C.sub.6 heterocycle; wherein each of the
C.sub.4-C.sub.6 heterocycle moieties is optionally substituted with
1, 2, 3, 4, or 5 R.sup.1g; [0439] R.sup.3a is C.sub.4-C.sub.6
heterocycle which is optionally substituted with 1, 2, 3, 4, or 5
R.sup.1g; [0440] R.sup.3b is H or C.sub.1-C.sub.6 alkyl; [0441]
R.sup.3c is H, C.sub.1-C.sub.6 alkyl, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6 alkylenyl)-CN, or
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.1; wherein G.sup.1 is
C.sub.4-C.sub.6 heterocycle, C.sub.5-C.sub.6 heteroaryl,
C.sub.3-C.sub.6 cycloalkyl, or phenyl; each of which is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.1g; [0442] R.sup.6 is
--OR.sup.a or --NR.sup.cR.sup.d; wherein [0443] R.sup.a and R.sup.d
are each independently G.sup.2 or C.sub.1-C.sub.6 alkyl substituted
with a G.sup.2 group; wherein G.sup.2 is phenyl, C.sub.3-C.sub.6
cycloalkyl, C.sub.4-C.sub.6 heterocycle, or C.sub.5-C.sub.6
heteroaryl; each of which is optionally substituted with 1, 2, 3,
4, or 5 substituents independently selected from the group
consisting of C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN,
NO.sub.2, --OR.sup.y1, --OC(O)R.sup.y2, --OC(O)NR.sup.y3R.sup.y4,
--SR.sup.y1, --S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4,
--C(O)R.sup.y1, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--NR.sup.y3R.sup.y4, --N(R.sup.y3)C(O)R.sup.y2,
--N(R.sup.y3)S(O).sub.2R.sup.y2; --N(R.sup.y3)C(O)O(R.sup.y2),
--N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, and
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4; [0444] R.sup.c is
hydrogen or unsubstituted C.sub.1-C.sub.6 alkyl; [0445] R.sup.y1,
R.sup.y3, and R.sup.y4, at each occurrence, are each independently
H, C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and [0446]
R.sup.y2, at each occurrence, is independently C.sub.1-C.sub.6
alkyl or C.sub.1-C.sub.6 haloalkyl; and [0447] R.sup.9 is H,
halogen, --CN, C.sub.1-C.sub.6 haloalkyl,
--N(R.sup.e)S(O).sub.2R.sup.b, --S(O).sub.2R.sup.a,
--S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.a, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2NR.sup.cR.sup.d, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.cR.sup.d, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.e)S(O).sub.2R.sup.b; wherein [0448] R.sup.c,
R.sup.d, and R.sup.e, at each occurrence, are each independently H
or unsubstituted C.sub.1-C.sub.6 alkyl; and [0449] R.sup.a and
R.sup.b, at each occurrence, is independently C.sub.1-C.sub.6
haloalkyl, or unsubstituted C.sub.1-C.sub.6 alkyl. [0450] In some
further embodiments, A.sup.1 is C(R.sup.7), A.sup.2 is C(R.sup.8),
A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10). [0451] In some
further embodiments, A.sup.1 is N, A.sup.2 is C(R.sup.8), A.sup.3
is C(R.sup.9), and A.sup.4 is C(R.sup.10). [0452] In certain
embodiments are provided compounds of formula (IA) wherein [0453]
R.sup.1 is methyl; [0454] R.sup.2 is H; [0455] R.sup.3 is
--C(O)R.sup.3a or --C(O)NR.sup.3bR.sup.3c; [0456] R.sup.3a is
C.sub.4-C.sub.6 heterocycle which is optionally substituted with 1,
2, 3, 4, or 5 R.sup.1g; [0457] R.sup.3b is H or C.sub.1-C.sub.6
alkyl; [0458] R.sup.3c is H, C.sub.1-C.sub.6 alkyl,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.z1, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.z3R.sup.z4, --(C.sub.1-C.sub.6 alkylenyl)-CN, or
--(C.sub.1-C.sub.6 alkylenyl)-G.sup.1; wherein G.sup.1 is
C.sub.4-C.sub.6 heterocycle, C.sub.5-C.sub.6 heteroaryl,
C.sub.3-C.sub.6 cycloalkyl, or phenyl; each of which is optionally
substituted with 1, 2, 3, 4, or 5 R.sup.1g; [0459] A.sup.1 is
C(R.sup.7), A.sup.2 is C(R.sup.8), A.sup.3 is C(R.sup.9), and
A.sup.4 is C(R.sup.10); or [0460] A.sup.1 is N, A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10);
[0461] R.sup.6 is --OR.sup.a or --NR.sup.cR.sup.d; wherein [0462]
R.sup.a and R.sup.d are each independently phenyl, pyridinyl, or
C.sub.1-C.sub.3 alkyl substituted with a C.sub.3-C.sub.6
cycloalkyl; wherein the phenyl, pyridinyl, and the C.sub.3-C.sub.6
cycloalkyl are optionally substituted with 1, 2, 3, 4, or 5
substituents independently selected from the group consisting of
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN, NO.sub.2,
--OR.sup.y1, --OC(O)R.sup.y2, --OC(O)NR.sup.y3R.sup.y4,
--SR.sup.y1, --S(O).sub.2R.sup.y1, --S(O).sub.2NR.sup.y3R.sup.y4,
--C(O)R.sup.y1, --C(O)OR.sup.y1, --C(O)NR.sup.y3R.sup.y4,
--NR.sup.y3R.sup.y4, --N(R.sup.y3)C(O)R.sup.y2,
--N(R.sup.y3)S(O).sub.2R.sup.y2, --N(R.sup.y3)C(O)O(R.sup.y2),
--N(R.sup.y3)C(O)NR.sup.y3R.sup.y4, and
--N(R.sup.y3)S(O).sub.2NR.sup.y3R.sup.y4; [0463] R.sup.c is
hydrogen or unsubstituted C.sub.1-C.sub.3 alkyl; [0464] R.sup.y1,
R.sup.y3, and R.sup.y4, at each occurrence, are each independently
H, C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and [0465]
R.sup.y2, at each occurrence, is independently C.sub.1-C.sub.6
alkyl or C.sub.1-C.sub.6 haloalkyl; [0466] R.sup.7 is H; [0467]
R.sup.8 is H or halogen; [0468] R.sup.10 is H or C.sub.1-C.sub.6
alkyl; and [0469] R.sup.9 is --N(R.sup.e)S(O).sub.2R.sup.b or
--(C.sub.1-C.sub.6 alkylenyl)-S(O).sub.2R.sup.a; wherein [0470]
R.sup.e is H or unsubstituted C.sub.1-C.sub.3 alkyl; and [0471]
R.sup.a and R.sup.b, are each independently C.sub.1-C.sub.3 alkyl.
[0472] In some further embodiments, A.sup.1 is C(R.sup.7), A.sup.2
is C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10).
[0473] In some further embodiments, A.sup.1 is N, A.sup.2 is
C(R.sup.8), A.sup.3 is C(R.sup.9), and A.sup.4 is C(R.sup.10).
[0474] Compounds of formula (I) may contain one or more
asymmetrically substituted atoms. Compounds of formula (I) may also
exist as individual stereoisomers (including enantiomers and
diastereomers) and mixtures thereof. Individual stereoisomers of
compounds of formula (I) may be prepared synthetically from
commercially available starting materials that contain asymmetric
or chiral centers or by preparation of racemic mixtures followed by
resolution of the individual stereoisomer using methods that are
known to those of ordinary skill in the art. Examples of resolution
are, for example, (i) attachment of a mixture of enantiomers to a
chiral auxiliary, separation of the resulting mixture of
diastereomers by recrystallization or chromatography, followed by
liberation of the optically pure product; or (ii) separation of the
mixture of enantiomers or diastereomers on chiral chromatographic
columns.
[0475] Compounds of formula (I) may also include the various
geometric isomers and mixtures thereof resulting from the
disposition of substituents around a carbon-carbon double bond, a
carbon-nitrogen double bond, a cycloalkyl group, or a heterocycle
group. Substituents around a carbon-carbon double bond or a
carbon-nitrogen double bond are designated as being of Z or E
configuration and substituents around a cycloalkyl or heterocycle
are designated as being of cis or trans configuration.
[0476] Within the present invention it is to be understood that
compounds disclosed herein may exhibit the phenomenon of
tautomerism and all tautomeric isomers are included in the scope of
the invention.
[0477] Thus, the formula drawings within this specification can
represent only one of the possible tautomeric, geometric, or
stereoisomeric forms. It is to be understood that the invention
encompasses any tautomeric, geometric, or stereoisomeric form, and
mixtures thereof, and is not to be limited merely to any one
tautomeric, geometric, or stereoisomeric form utilized within the
formula drawings.
[0478] Exemplary compounds of formula (I) include, but are not
limited to: [0479]
1-methyl-3-(2-phenoxyphenyl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin--
7-one; [0480]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]methanesulfonamide; [0481]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]propane-2-sulfonamide; [0482]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]ethanesulfonamide; [0483]
N-[4-(4-chlorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)phenyl]ethanesulfonamide; [0484]
N-{4-[(trans-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-py-
rrolo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide; [0485]
N-[3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(tetrah-
ydro-2H-pyran-4-yloxy)phenyl]ethanesulfonamide; [0486]
N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide; [0487]
N-{4-[(cis-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrr-
olo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide; [0488]
N-[3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(oxetan-
-3-yloxy)phenyl]ethanesulfonamide; [0489]
N-[4-(2,4-difluorophenoxy)-2-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrr-
olo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; [0490]
N-[2-(2,4-difluorophenoxy)-4-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrr-
olo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; [0491]
N-[2,4-bis(2,4-difluorophenoxy)-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[-
2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; [0492]
N-[4-(cyclopropylmethoxy)-2-methyl-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl]ethanesulfonamide; [0493]
N-[4-(4-fluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)phenyl]ethanesulfonamide; [0494]
N-[4-(4-cyanophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyri-
din-3-yl)phenyl]methanesulfonamide; [0495]
3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one; [0496]
1-methyl-3-[5-(methylsulfonyl)-2-phenoxyphenyl]-1,6-dihydro-7H-pyrrolo[2,-
3-c]pyridin-7-one; [0497]
3-[2-(3,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one; [0498]
3-[2-methoxy-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,-
3-c]pyridin-7-one; [0499]
3-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; [0500]
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydrofuran-3-yloxy)phenyl]-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0501]
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydrofuran-3-ylmethoxy)phenyl]-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0502]
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-yloxy)phenyl]-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0503]
3-{2-[(4,4-difluorocyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0504]
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-3-yloxy)phenyl]-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0505]
3-[2-(2,2-dimethylpropoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one; [0506]
3-[2-(cyclobutylmethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one; [0507]
1-methyl-3-{2-[(1-methylcyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0508]
1-methyl-3-[5-(methylsulfonyl)-2-(oxetan-3-ylmethoxy)phenyl]-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; [0509]
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0510]
3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one; [0511]
3-{2-[(cis-4-hydroxycyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0512]
3-{2-[(trans-4-hydroxycyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0513]
3-[2-(2-cyclopentylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one; [0514]
3-[2-(2-cyclohexylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; [0515]
1-methyl-3-[5-(methylsulfonyl)-2-(2-phenylethoxy)phenyl]-1,6-dihydro-7H-p-
yrrolo[2,3-c]pyridin-7-one; [0516]
3-[2-(2,3-dihydro-1H-inden-2-yloxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0517]
1-methyl-3-{5-(methylsulfonyl)-2-[2-(thiophen-2-yl)ethoxy]phenyl}-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0518]
3-[2-(3,3-dimethylbutoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; [0519]
3-{2-[(4,4-difluorocyclohexyl)methoxy]-5-(methylsulfonyl)phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0520]
3-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0521]
3-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1,6-dim-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0522]
3-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0523]
3-{2-[(cyclopropylmethyl)(methyl)amino]-5-(methylsulfonyl)phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0524]
4-({[2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(meth-
ylsulfonyl)phenyl]amino}methyl)benzonitrile; [0525]
3-{2-[(cyclohexylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0526]
3-[2-(4-chlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-p-
yrrolo[2,3-c]pyridin-7-one; [0527]
3-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; [0528]
3-[2-(cyclopropylmethoxy)-6-methylphenyl]-1-methyl-1,6-dihydro-7H-pyrrolo-
[2,3-c]pyridin-7-one; [0529]
4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]py-
ridin-3-yl)benzenesulfonamide; [0530]
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0531]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)methyl]phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0532]
3-{2-(2,4-difluorophenoxy)-5-[2-(ethylsulfonyl)propan-2-yl]phenyl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0533]
3-{2-(2,4-difluorophenoxy)-5-[1-(ethylsulfonyl)ethyl]phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0534]
3-{2-(2,4-difluorophenoxy)-5-[(1R)-1-(ethylsulfonyl)ethyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0535]
3-{2-(2,4-difluorophenoxy)-5-[(1
S)-1-(ethylsulfonyl)ethyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]p-
yridin-7-one; [0536]
3-{2-(2,4-difluorophenoxy)-5-[(phenylsulfonyl)methyl]phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0537]
3-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)pyridin-3-yl]-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0538]
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0539]
3-[2-(4-fluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H--
pyrrolo[2,3-c]pyridin-7-one; [0540]
3-[2-(4-tert-butylphenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one; [0541]
1-methyl-3-[5-(methylsulfonyl)-2-(naphthalen-2-yloxy)phenyl]-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; [0542]
1-methyl-3-[5-(methylsulfonyl)-2-(2,2,3,3,3-pentafluoropropoxy)phenyl]-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0543]
1-methyl-3-[5-(methylsulfonyl)-2-{2-[tricyclo[3.3.1.1.sup.3,7]dec-1-yl]et-
hoxy}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0544]
3-[2-(3-cyclopentylpropoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydr-
o-7H-pyrrolo[2,3-c]pyridin-7-one; [0545]
3-{2-[(1-acetylpiperidin-4-yl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0546]
3-{2-[(cyclopentylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0547]
1-methyl-3-{5-(methylsulfonyl)-2-[(2,2,2-trifluoroethyl)amino]phenyl}-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0548]
3-{2-[(2,2,3,3,4,4,4-heptafluorobutyl)amino]-5-(methylsulfonyl)phenyl}-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0549]
3-[2-{[(1S,4R)-bicyclo[2.2.1]hept-2-ylmethyl]amino}-5-(methylsulfonyl)phe-
nyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0550]
3-{2-[(2-cyclopentylethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-d-
ihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0551]
3-[2-(2-chloro-4-methylphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0552]
3-[5-(ethylsulfonyl)-2-(pyridin-4-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-p-
yrrolo[2,3-c]pyridin-7-one; [0553]
3-{2-[(4,6-dimethylpyridin-3-yl)oxy]-5-(ethylsulfonyl)phenyl}-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0554]
3-[2-(3,4-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; [0555]
3-{5-(ethylsulfonyl)-2-[4-(trifluoromethyl)phenoxy]phenyl}-1-methyl-1,6-d-
ihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0556]
4-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyrid-
in-3-yl)phenoxy]benzonitrile; [0557]
3-[2-(4-chloro-3-ethylphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one; [0558]
4-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyrid-
in-3-yl)phenoxy]-3-methoxybenzonitrile; [0559]
3-[5-(ethylsulfonyl)-2-(pyridin-3-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-p-
yrrolo[2,3-c]pyridin-7-one; [0560]
3-[2-(2,4-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; [0561]
2-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyrid-
in-3-yl)phenoxy]benzonitrile; [0562]
3-[2-(2,3-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; [0563]
3-[2-(2-chloro-4-methoxyphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0564]
3-{5-(ethylsulfonyl)-2-[(6-methylpyrazin-2-yl)oxy]phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0565]
3-[5-(ethylsulfonyl)-2-(pyridazin-4-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one; [0566]
3-[5-(ethylsulfonyl)-2-(pyrimidin-5-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one; [0567]
3-{5-(ethylsulfonyl)-2-[(3-methylpyrazin-2-yl)oxy]phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0568]
3-{5-(ethylsulfonyl)-2-[(1,3,5-trimethyl-1H-pyrazol-4-yl)oxy]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0569]
5-chloro-3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0570]
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-ethyl-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0571]
3,5-bis{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0572]
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-(3,5-dimet-
hyl-1,2-oxazol-4-yl)-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
[0573]
3-{2-(2,4-difluorophenoxy)-5-[(morpholin-4-ylsulfonyl)methyl]pheny-
l}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0574]
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]methanesulfonamide; [0575]
3-[2-(cyclopropylmethoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0576]
3-[6-(cyclopropylmethoxy)-1H-indol-7-yl]-1-methyl-1,6-dihydro-7H-pyrrolo[-
2,3-c]pyridin-7-one; [0577] ethyl
5-(cyclopropylmethoxy)-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)-1H-indole-2-carboxylate; [0578]
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-N-methylmethanesulfonamide; [0579]
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-N,N-dimethylmethanesulfonamide; [0580]
N-cyclohexyl-1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H--
pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; [0581]
3-{2-(2,4-difluorophenoxy)-5-[(piperidin-1-ylsulfonyl)methyl]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0582]
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-N-(1,3-thiazol-2-yl)methanesulfonamide;
[0583]
3-[2-(2,4-difluorophenoxy)-5-(piperazin-1-ylmethyl)phenyl]-1-methyl-1,6-d-
ihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0584]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]ethanesulfonamide; [0585]
5-(cyclopropylmethoxy)-N-methyl-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[-
2,3-c]pyridin-3-yl)-1H-indole-2-carboxamide; [0586]
4-chloro-3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0587]
4-chloro-3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0588]
3-{2-[(cyclopropylmethyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0589]
3-{5-[(4-aminopiperidin-1-yl)methyl]-2-(2,4-difluorophenoxy)phenyl}-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0590]
3-{2-(2,4-difluorophenoxy)-5-[(piperidin-4-ylamino)methyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0591]
3-[2-(2,4-difluorophenoxy)-5-{[4-(dimethylamino)piperidin-1-yl]methyl}phe-
nyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0592]
3-[2-(2,4-difluorophenoxy)-5-{[(3,3-dimethylbutyl)amino]methyl}phenyl]-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0593]
3-{2-(2,4-difluorophenoxy)-5-[(4-methoxypiperidin-1-yl)methyl]phenyl}-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0594]
3-{2-(2,4-difluorophenoxy)-5-[(4-methylpiperazin-1-yl)methyl]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0595]
3-[2-(2,4-difluorophenoxy)-5-{[(3-methylbutyl)amino]methyl}phenyl]-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0596]
3-[5-{[(cyclopropylmethyl)amino]methyl}-2-(2,4-difluorophenoxy)phenyl]-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0597]
3-[2-(2,4-difluorophenoxy)-5-{[(1H-imidazol-4-ylmethyl)amino]methyl}pheny-
l]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0598]
3-[5-(chloromethyl)-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one; [0599]
3-{2-[(4-fluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1-
,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0600]
3-{2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0601]
3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1,4-dimethyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0602]
3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1,4-dimethyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one;
[0603]
3-{2-(cyclopropylmethoxy)-5-[(3,3-difluoroazetidin-1-yl)sulfonyl]p-
henyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0604]
5-[(1Z)-2-chloro-4-hydroxybut-1-en-1-yl]-3-[2-(2,4-difluorophenoxy)-5-(et-
hylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
[0605]
3-[2-(2,4-difluorophenoxy)-5-{[(furan-3-ylmethyl)amino]methyl}phen-
yl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0606]
3-[5-{[(2-cyclopentylethyl)amino]methyl}-2-(2,4-difluorophenoxy)phenyl]-1-
-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0607]
3-[2-(2,4-difluorophenoxy)-5-{[4-(trifluoromethyl)piperidin-1-yl]methyl}p-
henyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0608]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-2-methoxybenzenesulfonamide; [0609]
1-(4-chlorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihyd-
ro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide; [0610]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-1-(4-methylphenyl)methanesulfonamide; [0611]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-1-[4-(trifluoromethyl)phenyl]methanesulfonamide;
[0612]
1-(4-cyanophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-
-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide;
[0613]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-2,2,2-trifluoroethanesulfonamide; [0614]
3-[5-(aminomethyl)-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one; [0615]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]cyclopentanesulfonamide; [0616]
2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H--
pyrrolo[2,3-c]pyridin-3-yl)benzyl]thiophene-3-sulfonamide; [0617]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-5-methyl-1,2-oxazole-4-sulfonamide; [0618]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide; and
[0619]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)benzyl]benzenesulfonamide.
[0620] In certain embodiments, a compound of formula (I) is
selected from the group consisting of: [0621]
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0622]
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0623]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]ethanesulfonamide; [0624]
3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one; [0625]
5-chloro-3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0626]
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-ethyl-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0627]
3-{2-(2,4-difluorophenoxy)-5-[(morpholin-4-ylsulfonyl)methyl]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0628]
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]methanesulfonamide; [0629]
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-N-methylmethanesulfonamide; [0630]
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-N,N-dimethylmethanesulfonamide; [0631]
N-{4-[(trans-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-py-
rrolo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide; [0632]
N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide; [0633]
N-[4-(2,4-difluorophenoxy)-2-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrr-
olo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; [0634]
N-[4-(4-fluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)phenyl]ethanesulfonamide; [0635]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]methanesulfonamide; [0636]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)methyl]phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0637]
3-{2-[(4-fluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1-
,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0638]
3-{2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0639]
N-[4-(4-cyanophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyri-
din-3-yl)phenyl]methanesulfonamide; [0640]
3-{2-[(4,4-difluorocyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0641]
3-{2-[(trans-4-hydroxycyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0642]
3-{2-[(cyclopropylmethyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0643]
1-(4-cyanophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydr-
o-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide; [0644]
3-{2-[(cyclopropylmethyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,-
3-c]pyridin-7-one; [0645]
3-{2-chloro-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one; [0646]
3-[2-{[trans-4-(dimethylamino)cyclohexyl]oxy}-5-(pyrrolidin-1-ylsulfonyl)-
phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0647]
3-{5-fluoro-2-[(4-fluorophenyl)amino]pyridin-3-yl}-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one; [0648]
3-[5-amino-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo-
[2,3-c]pyridin-7-one; [0649]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-4-methylpentanamide; [0650]
2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H--
pyrrolo[2,3-c]pyridin-3-yl)phenyl]benzamide; [0651]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(2-methoxyphenyl)acetamide; [0652]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]pyridine-2-carboxamide; [0653]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-5-methylpyrazine-2-carboxamide; [0654]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-3-phenylpropanamide; [0655]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-4-phenoxybutanamide; [0656]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(3-phenoxyphenyl)acetamide; [0657]
4-(acetylamino)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro--
1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]benzamide; [0658]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-4-(phenoxymethyl)benzamide; [0659]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-oxo-1-phenylpyrrolidine-3-carboxamide;
[0660]
2-(1,2-benzoxazol-3-yl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7--
dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide; [0661]
2-(5-chloro-2-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo--
6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide; [0662]
2-(4-chloro-2-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo--
6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide; [0663]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(6-methylpyridin-3-yl)acetamide; [0664]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(3,4-dihydro-2H-chromen-6-yl)acetamide;
[0665]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(2-methyl-1,3-thiazol-5-yl)acetamide;
[0666]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-(1,5-dimethyl-1H-pyrazol-3-yl)acetamide;
[0667]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-2-[4-(2-fluorophenyl)-1H-pyrazol-1-yl]acetamide;
[0668] methyl (2E)-3-[(4-fluorophenyl)
{2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-[(methyls-
ulfonyl)methyl]phenyl}amino]prop-2-enoate; [0669]
4-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-
-c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile; [0670]
3-[2-(2,4-difluorophenoxy)-5-{[3-(4-methoxyphenoxy)benzyl]amino}phenyl]-1-
-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0671]
3-[2-(2,4-difluorophenoxy)-5-{[(3-methylpyridin-2-yl)methyl]amino}phenyl]-
-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0672]
3-[5-{[4-(benzyloxy)benzyl]amino}-2-(2,4-difluorophenoxy)phenyl]-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0673]
3-[5-{[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino}-2-(2,4-d-
ifluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one-
; [0674]
3-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyr-
rolo[2,3-c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile; [0675]
3-{2-(2,4-difluorophenoxy)-5-[(4-phenoxybenzyl)amino]phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0676]
3-{2-(2,4-difluorophenoxy)-5-[(3,3-dimethylbutyl)amino]phenyl}-1-methyl-1-
,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0677]
3-{5-[(2,6-difluorobenzyl)amino]-2-(2,4-difluorophenoxy)phenyl}-1-methyl--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0678]
3-{2-(2,4-difluorophenoxy)-5-[(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl-
methyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
[0679]
3-[5-{[2-(benzyloxy)-3-methoxybenzyl]amino}-2-(2,4-difluorophenoxy-
)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
[0680]
2-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-
-c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile; [0681]
3-{2-(2,4-difluorophenoxy)-5-[(quinolin-4-ylmethyl)amino]phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; [0682]
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]-1-phenylmethanesulfonamide; [0683]
1-(2-chloro-5-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo--
6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide;
[0684]
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-5-(morpholin-4-ylmethyl)-7--
oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide;
[0685]
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-7-oxo-5-(piperidin-4-yl)-6,-
7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide;
[0686]
N-[6-(2,4-difluorophenoxy)-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c-
]pyridin-3-yl)pyridin-3-yl]ethanesulfonamide; [0687]
N-[3-{5-[1-(cyclopropylcarbonyl)piperidin-4-yl]-1-methyl-7-oxo-6,7-dihydr-
o-1H-pyrrolo[2,3-c]pyridin-3-yl}-4-(2,4-difluorophenoxy)phenyl]ethanesulfo-
namide; [0688]
N-[4-(2,4-difluorophenoxy)-3-{5-[1-(ethylsulfonyl)piperidin-4-yl]-1-methy-
l-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethanesulfonamide-
; [0689]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-[3-(-
1H-imidazol-1-yl)propyl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyrid-
ine-5-carboxamide; [0690]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-[2-(dimethyl-
amino)ethyl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carbox-
amide; [0691]
N-(cyanomethyl)-3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl-
}-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;
[0692]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-(3-hy-
droxypropyl)-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carbox-
amide; [0693]
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-5-(morpholin-4-ylcarbonyl)-7-oxo-6-
,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide;
[0694]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-
-N-(pyridin-3-ylmethyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamid-
e; [0695]
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-7-oxo-5-(pyrrolidin-1-ylc-
arbonyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamid-
e; [0696]
N-[4-(2,4-difluorophenoxy)-3-{5-[(4-hydroxypiperidin-1-yl)carbon-
yl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethane-
sulfonamide; [0697]
N-(cyclopentylmethyl)-3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]-
phenyl}-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide-
; [0698]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-meth-
yl-N-[2-(morpholin-4-yl)ethyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-
-5-carboxamide; [0699]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-N-[2--
(4-methylpiperazin-1-yl)ethyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-
-5-carboxamide; [0700]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-
-N-[2-(piperidin-1-yl)ethyl]-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carbo-
xamide; [0701]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-
-N-(tetrahydrofuran-3-ylmethyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-ca-
rboxamide; [0702]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N,1-dimethyl-7-
-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; [0703]
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-(furan-3-ylm-
ethyl)-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;
[0704]
3-{3-cyclopropyl-2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)-
methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
and [0705]
1-methyl-3-{5-[(methylsulfonyl)methyl]-2-(pyridin-2-ylamino)phenyl-
}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one.
[0706] Exemplary compounds are named using the software ACD/NAME
2012.
[0707] Compounds of formula I can be used in the form of
pharmaceutically acceptable salts. The phrase "pharmaceutically
acceptable salt" means those salts which are, within the scope of
sound medical judgement, suitable for use in contact with the
tissues of humans and lower animals without undue toxicity,
irritation, allergic response and the like and are commensurate
with a reasonable benefit/risk ratio.
[0708] Pharmaceutically acceptable salts have been described in S.
M. Berge et al. J. Pharmaceutical Sciences, 1977, 66: 1-19.
[0709] Compounds of formula (I) may contain either a basic or an
acidic functionality, or both, and can be converted to a
pharmaceutically acceptable salt, when desired, by using a suitable
acid or base. The salts may be prepared in situ during the final
isolation and purification of the compounds of the invention.
[0710] Examples of acid addition salts include, but are not limited
to acetate, adipate, alginate, citrate, aspartate, benzoate,
benzenesulfonate, bisulfate, butyrate, camphorate,
camphorsulfonate, digluconate, glycerophosphate, hemisulfate,
heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide,
hydroiodide, 2-hydroxyethansulfonate (isothionate), lactate,
malate, maleate, methanesulfonate, nicotinate,
2-naphthalenesulfonate, oxalate, palmitoate, pectinate, persulfate,
3-phenylpropionate, picrate, pivalate, propionate, succinate,
tartrate, thiocyanate, phosphate, glutamate, bicarbonate,
p-toluenesulfonate and undecanoate. Also, the basic
nitrogen-containing groups can be quaternized with such agents as
lower alkyl halides such as, but not limited to, methyl, ethyl,
propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates
like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain
halides such as, but not limited to, decyl, lauryl, myristyl and
stearyl chlorides, bromides and iodides; arylalkyl halides like
benzyl and phenethyl bromides and others. Water or oil-soluble or
dispersible products are thereby obtained. Examples of acids which
may be employed to form pharmaceutically acceptable acid addition
salts include such inorganic acids as hydrochloric acid,
hydrobromic acid, sulfuric acid, and phosphoric acid and such
organic acids as acetic acid, fumaric acid, maleic acid,
4-methylbenzenesulfonic acid, succinic acid and citric acid.
[0711] Basic addition salts may be prepared in situ during the
final isolation and purification of compounds of this invention by
reacting a carboxylic acid-containing moiety with a suitable base
such as, but not limited to, the hydroxide, carbonate or
bicarbonate of a pharmaceutically acceptable metal cation or with
ammonia or an organic primary, secondary or tertiary amine.
Pharmaceutically acceptable salts include, but are not limited to,
cations based on alkali metals or alkaline earth metals such as,
but not limited to, lithium, sodium, potassium, calcium, magnesium
and aluminum salts and the like and nontoxic quaternary ammonia and
amine cations including ammonium, tetramethylammonium,
tetraethylammonium, methylamine, dimethylamine, trimethylamine,
triethylamine, diethylamine, ethylamine and the like. Other
examples of organic amines useful for the formation of base
addition salts include ethylenediamine, ethanolamine,
diethanolamine, piperidine, piperazine and the like.
[0712] The term "pharmaceutically acceptable prodrug" or "prodrug"
as used herein, represents those prodrugs of the compounds of the
present invention which are, within the scope of sound medical
judgement, suitable for use in contact with the tissues of humans
and lower animals without undue toxicity, irritation, allergic
response, and the like, commensurate with a reasonable benefit/risk
ratio, and effective for their intended use.
[0713] The present invention contemplates compounds of formula (I)
formed by synthetic means or formed by in vivo biotransformation of
a prodrug.
[0714] Compounds described herein can exist in unsolvated as well
as solvated forms, including hydrated forms, such as hemi-hydrates.
In general, the solvated forms, with pharmaceutically acceptable
solvents such as water and ethanol among others are equivalent to
the unsolvated forms for the purposes of the invention.
General Synthesis
[0715] The compounds described herein, including compounds of
general formula (I) and specific examples, can be prepared by
methodologies known in the art, for example, through the reaction
schemes depicted in schemes 1-6. The variables A.sup.1, A.sup.2,
A.sup.3, A.sup.4, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, R.sup.a, R.sup.b, R.sup.c, and R.sup.d, used in the
following schemes have the meanings as set forth in the summary and
detailed description sections, unless otherwise noted.
[0716] Abbreviations used in the descriptions of the schemes and
the specific examples have the following meanings: DMSO for
dimethyl sulfoxide, dppf for 1,1'-bis(diphenylphosphino)ferrocene;
EDAC or EDCI or EDC for
1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride;
HOBT for 1-hydroxybenzotriazole hydrate; MeOH for methanol; mCPBA
for 3-chloroperbenzoic acid; Pd(PPh.sub.3).sub.4 for
tetrakis(triphenylphosphine)palladium(0);
PdCl.sub.2(PPh.sub.3).sub.2 for
bis(triphenylphosphine)palladium(II) dichloride; PdCl.sub.2(dppf)
for [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II);
THF for tetrahydrofuran, TFA for trifluoroacetic acid, and HPLC for
High Performance Liquid chromatography.
[0717] Compounds of general formula (I) may be prepared using the
general procedure as outlined in Scheme 1. Conversion of (1),
wherein Z is Cl, Br, or I, to compounds of general formula (3) may
be achieved by reaction of (1) with a boronic acid of formula (2)
or derivative thereof (e.g. pinacol ester) under Suzuki coupling
conditions (N. Miyama and A. Suzuki, Chem. Rev. 1995, 95:2457-2483,
J. Organomet. Chem. 1999, 576:147-148). For example, the coupling
reaction may be conducted in the presence of a palladium catalyst
and a base, and optionally in the presence of a ligand, and in a
suitable solvent at elevated temperature (about 80.degree. C. to
about 150.degree. C.). The reaction may be facilitated by microwave
irradiation. Examples of the palladium catalyst include, but are
not limited to, tetrakis(triphenylphosphine)palladium(0),
tris(dibenzylideneacetone)dipalladium(0),
bis(triphenylphosphine)palladium(II) dichloride, and
palladium(II)acetate. Examples of suitable bases that may be
employed include, but not limited to, carbonates or phosphates of
sodium, potassium, and cesium, and cesium fluoride. Examples of
suitable ligands include, but are not limited to,
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane,
2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-phos), and
1,1'-bis(diphenylphosphanyl) ferrocene. Non-limiting examples of
suitable solvent include methanol, ethanol, dimethoxyethane,
N,N-dimethylformamide, dimethylsulfoxide, dioxane, tetrahydrofuran,
toluene, and water, or a mixture thereof. Compounds of general
formula (I) wherein R.sup.2 is H may be synthesized by the
treatment of compounds (3) with an acid such as, for example,
hydrochloric acid, acetic acid, or p-toluene sulfonic acid in a
solvent such as, for example, water, dioxane, or dimethylformamide,
at a temperature such as, for example, about 25.degree. C. to about
120.degree. C. Alternatively, compounds of general formula (I)
wherein R.sup.2 is H may be obtained from the reaction of compounds
(3) with trimethylsilyl iodide in a solvent such as, for example,
dichloromethane or chloroform, and at a temperature such as, for
example, about 25.degree. C. to about 75.degree. C. Alkylation of
compounds of general formula (I) wherein R.sup.2 is H with
C.sub.1-C.sub.3 alkyl halides in the presence of a base such as,
for example, sodium hydride, provide compounds of general formula
(I) wherein R.sup.2 is C.sub.1-C.sub.3 alkyl
[0718] Compounds of general formula (3) may also be prepared from
the reaction of (4) or the corresponding boronic acids with halides
(5) wherein X is Cl, Br, or I under Suzuki coupling conditions as
described in the preceding paragraph.
[0719] Pinacol esters of formula (4), may be synthesized, for
example, by treatment of compounds of formula (1), wherein Z is Br,
Cl, or I, with a reagent such as, but not limited to, butyllithium
followed by 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane,
in a solvent such as, for example, tetrahydrofuran, at a
temperature such as, for example, about -78.degree. C. The
corresponding boronic acids of (4) may be prepared by reaction of
compounds of general formula (1), wherein Z is Br, Cl, or I, with a
reagent such as, but not limited to, bis(pinacolato)diboron or
4,4,5,5-tetramethyl-1,3,2-dioxaborolane in the presence of a
palladium catalyst and a base, and optionally in the presence of a
ligand, and in a suitable solvent at elevated temperature (about
80.degree. C. to about 150.degree. C.). The reaction may be
facilitated by microwave irradiation. Examples of the palladium
catalyst include, but are not limited to,
tetrakis(triphenylphosphine)palladium(0),
tris(dibenzylideneacetone)dipalladium(0),
bis(triphenylphosphine)palladium(II) dichloride, and
palladium(II)acetate. Examples of suitable bases that may be
employed include, but not limited to, carbonates or phosphates of
sodium, potassium, and cesium, and cesium fluoride. Examples of
suitable ligands include, but are not limited to,
1,3,5,7-tetramethyl-6-phenyl-2,4, 8-trioxa-6-phosphaadamantane,
2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-phos), and
1,1'-bis(diphenylphosphanyl) ferrocene. Non-limiting examples of
suitable solvent include methanol, ethanol, dimethoxyethane,
N,N-dimethylformamide, dimethylsulfoxide, dioxane, tetrahydrofuran,
and water, or a mixture thereof.
##STR00011##
[0720] Compounds of formula (1) wherein R.sup.1 is C.sub.1-C.sub.3
alkyl may be prepared using synthetic routes such as, for example,
those illustrated in Scheme 2. Reaction of compounds of formula (6)
wherein Z is Br, Cl, I, with a C.sub.1-C.sub.3 alkyl halide, in the
presence of a base such as carbonate of cesium, sodium, or
potassium and in a solvent such as, for example, dimethylformamide,
tetrahydrofuran, or dimethylsulfoxide, provides intermediates of
formula (1) wherein R.sup.1 is C.sub.1-C.sub.3 alkyl. The reaction
may be conducted at temperature such as, for example, about
25.degree. C. to about 60.degree. C.
##STR00012##
[0721] An alternative route for the preparation of compounds (1)
wherein R.sup.1 is C.sub.1-C.sub.3 alkyl is outlined in Scheme 3.
For example, compounds of formula (8), prepared from compounds (7)
using general procedure as outlined in Scheme 2, may be converted
to (9) by treatment with a reagent such as, for example, sodium
methoxide, in a solvent such as, for example, methanol, and at a
temperature of about 80.degree. C. to about 150.degree. C.
Treatment of compounds (9) with a reagent such as, for example,
N-iodosuccinimide or N-bromosuccinimide, in a solvent such as, for
example, dimethylformamide, at temperatures at about 0.degree. C.
to about 50.degree. C., provides compounds (1).
##STR00013##
[0722] Compounds of formula (3) wherein R.sup.5 is phenyl or
pyridine, and each of which is substituted with at least one
substituent selected from the group consisting of OR.sup.a and
NR.sup.cR.sup.d, may be prepared as described in Scheme 4.
Compounds of formula (11) wherein R.sup.101 is fluorine or NH.sub.2
may be obtained from compounds of formula (1) or (4) (or the
corresponding boronic acid) via Suzuki coupling condition as
described in Scheme 1. Displacement of the fluorine atom of (10)
with alcohols of formula R.sup.aOH provides compounds (13) wherein
R.sup.6 is OR.sup.a. Displacement of the fluorine atom may be
accomplished in a solvent such as, for example, dimethylsulfoxide,
dimethylformamide, dioxane, or tetrahydrofuran and in the presence
of a base such as, for example, carbonate of cesium, potassium, or
sodium, or sodium hydride, and at a temperature from about
40.degree. C. to about 120.degree. C.
[0723] Reductive amination of amines (11) wherein R.sup.101 is
NH.sub.2 with a suitable aldehyde or ketone in the presence of a
reducing agent such as, for example, sodium triacetoxyhydroborate,
sodium borohydride, or sodium cyanoborohydride, and an acid (e.g.
acetic acid), provide compounds (13) wherein R.sup.6 is
NR.sup.cR.sup.d. The reaction is generally conducted in a solvent
such as, for example, dichloromethane, methanol, or ethanol, at a
temperature of about 0.degree. C. to about 100.degree. C., provide
compounds (13) wherein R.sup.6 is NR.sup.bR.sup.c.
[0724] Conversion of (11) wherein R.sup.101 is NH.sub.2 to
compounds (13) wherein R.sup.6 is NR.sup.cR.sup.d may also be
achieved using Buchwald reaction conditions wherein (11) is treated
with a suitable aryl halide or heteroaryl halide in the presence of
a catalyst, a ligand, a base, and in a solvent. Examples of
catalysts that may be employed include, but are not limited to,
tetrakis(triphenylphosphine)palladium(0),
tris(dibenzylideneacetone)dipalladium(0),
bis(triphenylphosphine)palladium(II) dichloride, and
palladium(II)acetate. Examples of suitable bases that may be
employed include, but not limited to, carbonates or phosphates of
sodium, potassium, and cesium, and cesium fluoride. Examples of
suitable ligands include, but are not limited to,
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane,
2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-phos), and
1,1'-bis(diphenylphosphanyl) ferrocene. Non-limiting examples of
suitable solvent include toluene, tert-butanol, methanol, ethanol,
dimethoxyethane, N,N-dimethylformamide, dimethylsulfoxide, dioxane,
tetrahydrofuran, and water, or a mixture thereof.
##STR00014##
[0725] Compounds of formula (13) wherein A.sup.3 is C(R.sup.9) and
R.sup.9 is N(H)SO.sub.2R.sup.b may be synthesized as shown in
Scheme 5. Reduction of the nitro compounds of formula (14) to the
amines (15) may be achieved using iron powder in the presence of
ammonium chloride in a solvent such as, for example,
tetrahydrofuran, ethanol, or water, or a mixture thereof, and at a
temperature of about 80.degree. C. to about 120.degree. C. The
reduction may also be achieved by treatment of (14) with tin
chloride in hydrochloric acid at a temperature of about 80.degree.
C. to about 120.degree. C. Transformation of (14) to (15) may also
be conducted in the presence of a catalyst such as platinum oxide
or palladium on charcoal, in a solvent such as ethanol or methanol
and under hydrogen pressure. Treatment of amines (15) with sulfonyl
chlorides of formula R.sup.bSO.sub.2Cl, in the presence of a base
such as triethylamine or diisopropylethylamine in a solvent such as
dichloromethane or tetrahydrofuran and at a temperature of about
0.degree. C. to about 40.degree. C. provides sulfonamides (16).
##STR00015##
[0726] Compounds of formula (13) wherein A.sup.3 is C(R.sup.9) and
R.sup.9 is --CH.sub.2SO.sub.2R.sup.a or is
--CH.sub.2SO.sub.2NR.sup.cR.sup.d may be synthesized as shown in
Scheme 6. Reduction of aldehydes (17) to alcohols of (18) may be
achieved by reaction with a reducing agent such as, for example,
sodium borohydride or lithium aluminum hydride, in a solvent such
as, for example, ethanol, methanol, tetrahydrofuran, dioxane, or
mixtures thereof, and at temperatures of about 0.degree. C. to
about 50.degree. C. Reaction of alcohols (18) with a brominating
agent such as, for example, phosphorus tribromide in a solvent such
as, for example, dichloromethane, at temperatures of about
0.degree. C. to about 50.degree. C. provides compounds of formula
(19). Reaction of compounds (19) with appropriate sodium thiooxides
in a solvent such as, for example, dimethylformamide at a
temperature of about 0.degree. C. to about 50.degree. C., provides
compounds (20). Oxidation of compounds (20) with an oxidizing agent
such as, for example, oxone, m-chloroperoxy benzoic acid, or
hydrogen peroxide in a solvent such as, for example, methanol,
acetonitrile, hexane, dichloromethane, or water, at temperatures of
about 0.degree. C. to about 70.degree. C. yields compounds
(21).
[0727] Reaction of compounds (19) with a reagent such as, for
example, sodium sulfite, in the presence of a reagent such as, for
example, tetrabutylammonium iodide in a solvent, such as, for
example, ethanol, methanol, or water, or mixtures thereof, at a
temperature of about 25.degree. C. to about 100.degree. C., may
generate compounds (22). Treatment of compounds (22) with a reagent
such as, for example, oxalyl chloride or thionyl chloride, in a
solvent such as, for example, dichloromethane, at temperatures of
about 0.degree. C. to about 50.degree. C. followed by reaction of
the thus generated intermediate sulfonyl chloride with an
appropriate amine in a solvent such as, for example,
dichloromethane, provides (23).
##STR00016##
[0728] It can be appreciated that the synthetic schemes and
specific examples as illustrated in the synthetic examples section
are illustrative and are not to be read as limiting the scope of
the invention as it is defined in the appended claims. All
alternatives, modifications, and equivalents of the synthetic
methods and specific examples are included within the scope of the
claims.
[0729] Optimum reaction conditions and reaction times for each
individual step can vary depending on the particular reactants
employed and substituents present in the reactants used. Unless
otherwise specified, solvents, temperatures and other reaction
conditions can be readily selected by one of ordinary skill in the
art. Specific procedures are provided in the Synthetic Examples
section. Reactions can be worked up in the conventional manner,
e.g. by eliminating the solvent from the residue and further
purified according to methodologies generally known in the art such
as, but not limited to, crystallization, distillation, extraction,
trituration and chromatography. Unless otherwise described, the
starting materials and reagents are either commercially available
or can be prepared by one skilled in the art from commercially
available materials using methods described in the chemical
literature.
[0730] Routine experimentations, including appropriate manipulation
of the reaction conditions, reagents and sequence of the synthetic
route, protection of any chemical functionality that can not be
compatible with the reaction conditions, and deprotection at a
suitable point in the reaction sequence of the method are included
in the scope of the invention. Suitable protecting groups and the
methods for protecting and deprotecting different substituents
using such suitable protecting groups are well known to those
skilled in the art; examples of which can be found in T. Greene and
P. Wuts, Protecting Groups in Organic Synthesis (3.sup.rd ed.),
John Wiley & Sons, NY (1999), which is incorporated herein by
reference in its entirety. Synthesis of the compounds of the
invention can be accomplished by methods analogous to those
described in the synthetic schemes described hereinabove and in
specific examples.
[0731] Starting materials, if not commercially available, can be
prepared by procedures selected from standard organic chemical
techniques, techniques that are analogous to the synthesis of
known, structurally similar compounds, or techniques that are
analogous to the above described schemes or the procedures
described in the synthetic examples section.
[0732] When an optically active form of a compound is required, it
can be obtained by carrying out one of the procedures described
herein using an optically active starting material (prepared, for
example, by asymmetric induction of a suitable reaction step), or
by resolution of a mixture of the stereoisomers of the compound or
intermediates using a standard procedure (such as chromatographic
separation, recrystallization or enzymatic resolution).
[0733] Similarly, when a pure geometric isomer of a compound is
required, it can be prepared by carrying out one of the above
procedures using a pure geometric isomer as a starting material, or
by resolution of a mixture of the geometric isomers of the compound
or intermediates using a standard procedure such as chromatographic
separation.
Pharmaceutical Compositions
[0734] This invention also provides for pharmaceutical compositions
comprising a therapeutically effective amount of a compound of
Formula I, or a pharmaceutically acceptable salt thereof together
with a pharmaceutically acceptable carrier, diluent, or excipient
therefor. The phrase "pharmaceutical composition" refers to a
composition suitable for administration in medical or veterinary
use.
[0735] The pharmaceutical compositions that comprise a compound of
formula (I), alone or or in combination with a second active
pharmaceutical agent, may be administered to the subjects orally,
rectally, parenterally, intracistemally, intravaginally,
intraperitoneally, topically (as by powders, ointments or drops),
bucally or as an oral or nasal spray. The term "parenterally" as
used herein, refers to modes of administration which include
intravenous, intramuscular, intraperitoneal, intrasternal,
subcutaneous and intraarticular injection and infusion.
[0736] The term "pharmaceutically acceptable carrier" as used
herein, means a non-toxic, inert solid, semi-solid or liquid
filler, diluent, encapsulating material or formulation auxiliary of
any type. Some examples of materials which can serve as
pharmaceutically acceptable carriers are sugars such as, but not
limited to, lactose, glucose and sucrose; starches such as, but not
limited to, corn starch and potato starch; cellulose and its
derivatives such as, but not limited to, sodium carboxymethyl
cellulose, ethyl cellulose and cellulose acetate; powdered
tragacanth; malt; gelatin; talc; excipients such as, but not
limited to, cocoa butter and suppository waxes; oils such as, but
not limited to, peanut oil, cottonseed oil, safflower oil, sesame
oil, olive oil, corn oil and soybean oil; glycols; such a propylene
glycol; esters such as, but not limited to, ethyl oleate and ethyl
laurate; agar; buffering agents such as, but not limited to,
magnesium hydroxide and aluminum hydroxide; alginic acid;
pyrogen-free water; isotonic saline; Ringer's solution; ethyl
alcohol, and phosphate buffer solutions, as well as other non-toxic
compatible lubricants such as, but not limited to, sodium lauryl
sulfate and magnesium stearate, as well as coloring agents,
releasing agents, coating agents, sweetening, flavoring and
perfuming agents, preservatives and antioxidants can also be
present in the composition, according to the judgment of the
formulator.
[0737] Pharmaceutical compositions for parenteral injection
comprise pharmaceutically acceptable sterile aqueous or nonaqueous
solutions, dispersions, suspensions or emulsions as well as sterile
powders for reconstitution into sterile injectable solutions or
dispersions just prior to use. Examples of suitable aqueous and
nonaqueous carriers, diluents, solvents or vehicles include water,
ethanol, polyols (such as glycerol, propylene glycol, polyethylene
glycol and the like), vegetable oils (such as olive oil),
injectable organic esters (such as ethyl oleate) and suitable
mixtures thereof. Proper fluidity can be maintained, for example,
by the use of coating materials such as lecithin, by the
maintenance of the required particle size in the case of
dispersions and by the use of surfactants.
[0738] These compositions may also contain adjuvants such as
preservatives, wetting agents, emulsifying agents and dispersing
agents. Prevention of the action of microorganisms can be ensured
by the inclusion of various antibacterial and antifungal agents,
for example, paraben, chlorobutanol, phenol sorbic acid and the
like. It may also be desirable to include isotonic agents such as
sugars, sodium chloride and the like. Prolonged absorption of the
injectable pharmaceutical form can be brought about by the
inclusion of agents, which delay absorption such as aluminum
monostearate and gelatin.
[0739] In some cases, in order to prolong the effect of the drug,
it is desirable to slow the absorption of the drug from
subcutaneous or intramuscular injection. This may be accomplished
by the use of a liquid suspension of crystalline or amorphous
material with poor water solubility. The rate of absorption of the
drug then depends upon its rate of dissolution which, in turn, may
depend upon crystal size and crystalline form. Alternatively,
delayed absorption of a parenterally-administered drug form may be
accomplished by dissolving or suspending the drug in an oil
vehicle.
[0740] Injectable depot forms are made by forming microencapsule
matrices of the drug in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of drug to
polymer and the nature of the particular polymer employed, the rate
of drug release can be controlled. Examples of other biodegradable
polymers include poly(orthoesters) and poly(anhydrides). Depot
injectable formulations are also prepared by entrapping the drug in
liposomes or microemulsions which are compatible with body
tissues.
[0741] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium just prior to use.
[0742] Solid dosage forms for oral administration include capsules,
tablets, pills, powders and granules. In certain embodiments, solid
dosage forms may contain from 1% to 95% (w/w) of a compound of
formula I. In certain embodiments, the compound of formula I may be
present in the solid dosage form in a range of from 5% to 70%
(w/w). In such solid dosage forms, the active compound may be mixed
with at least one inert, pharmaceutically acceptable excipient or
carrier, such as sodium citrate or dicalcium phosphate and/or a)
fillers or extenders such as starches, lactose, sucrose, glucose,
mannitol and silicic acid; b) binders such as
carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone,
sucrose and acacia; c) humectants such as glycerol; d)
disintegrating agents such as agar-agar, calcium carbonate, potato
or tapioca starch, alginic acid, certain silicates and sodium
carbonate; e) solution retarding agents such as paraffin; f)
absorption accelerators such as quaternary ammonium compounds; g)
wetting agents such as cetyl alcohol and glycerol monostearate; h)
absorbents such as kaolin and bentonite clay and i) lubricants such
as talc, calcium stearate, magnesium stearate, solid polyethylene
glycols, sodium lauryl sulfate and mixtures thereof. In the case of
capsules, tablets and pills, the dosage form may also comprise
buffering agents.
[0743] The pharmaceutical composition may be a unit dosage form. In
such form the preparation is subdivided into unit doses containing
appropriate quantities of the active component. The unit dosage
form can be a packaged preparation, the package containing discrete
quantities of preparation, such as packeted tablets, capsules, and
powders in vials or ampules. Also, the unit dosage form can be a
capsule, tablet, cachet, or lozenge itself, or it can be the
appropriate number of any of these in packaged form. The quantity
of active component in a unit dose preparation may be varied or
adjusted from 0.1 mg to 1000 mg, from 1 mg to 100 mg, or from 1% to
95% (w/w) of a unit dose, according to the particular application
and the potency of the active component. The composition can, if
desired, also contain other compatible therapeutic agents.
[0744] The dose to be administered to a subject may be determined
by the efficacy of the particular compound employed and the
condition of the subject, as well as the body weight or surface
area of the subject to be treated. The size of the dose also will
be determined by the existence, nature, and extent of any adverse
side-effects that accompany the administration of a particular
compound in a particular subject. In determining the effective
amount of the compound to be administered in the treatment or
prophylaxis of the disorder being treated, the physician can
evaluate factors such as the circulating plasma levels of the
compound, compound toxicities, and/or the progression of the
disease, etc. In general, the dose equivalent of a compound is from
about 1 rig/kg to 100 mg/kg for a typical subject.
[0745] For administration, compounds of the formula I can be
administered at a rate determined by factors that can include, but
are not limited to, the LD.sub.50 of the compound, the
pharmacokinetic profile of the compound, contraindicated drugs, and
the side-effects of the compound at various concentrations, as
applied to the mass and overall health of the subject.
Administration can be accomplished via single or divided doses.
[0746] The compounds utilized in the pharmaceutical method of the
invention can be administered at the initial dosage of about 0.001
mg/kg to about 100 mg/kg daily. In certain embodiments, the daily
dose range is from about 0.1 mg/kg to about 10 mg/kg. The dosages,
however, may be varied depending upon the requirements of the
subject, the severity of the condition being treated, and the
compound being employed. Determination of the proper dosage for a
particular situation is within the skill of the practitioner.
Treatment may be initiated with smaller dosages, which are less
than the optimum dose of the compound. Thereafter, the dosage is
increased by small increments until the optimum effect under
circumstances is reached. For convenience, the total daily dosage
may be divided and administered in portions during the day, if
desired.
[0747] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
carriers as lactose or milk sugar as well as high molecular weight
polyethylene glycols and the like.
[0748] The solid dosage forms of tablets, dragees, capsules, pills
and granules can be prepared with coatings and shells such as
enteric coatings and other coatings well-known in the
pharmaceutical formulating art. They may optionally contain
opacifying agents and may also be of a composition such that they
release the active ingredient(s) only, or preferentially, in a
certain part of the intestinal tract, optionally, in a delayed
manner. Examples of embedding compositions which can be used
include polymeric substances and waxes.
[0749] The active compounds can also be in micro-encapsulated form,
if appropriate, with one or more of the above-mentioned
carriers.
[0750] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups and elixirs. In addition to the active compounds, the liquid
dosage forms may contain inert diluents commonly used in the art
such as, for example, water or other solvents, solubilizing agents
and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan and mixtures thereof.
[0751] Besides inert diluents, the oral compositions may also
include adjuvants such as wetting agents, emulsifying and
suspending agents, sweetening, flavoring and perfuming agents.
[0752] Suspensions, in addition to the active compounds, may
contain suspending agents as, for example, ethoxylated isostearyl
alcohols, polyoxyethylene sorbitol and sorbitan esters,
microcrystalline cellulose, aluminum metahydroxide, bentonite,
agar-agar, tragacanth and mixtures thereof.
[0753] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds of this invention with suitable non-irritating carriers
or carriers such as cocoa butter, polyethylene glycol or a
suppository wax which are solid at room temperature but liquid at
body temperature and therefore melt in the rectum or vaginal cavity
and release the active compound.
[0754] Compounds of formula I may also be administered in the form
of liposomes. Liposomes generally may be derived from phospholipids
or other lipid substances. Liposomes are formed by mono- or
multi-lamellar hydrated liquid crystals which are dispersed in an
aqueous medium. Any non-toxic, physiologically acceptable and
metabolizable lipid capable of forming liposomes can be used. The
present compositions in liposome form may contain, in addition to a
compound of formula (I), stabilizers, preservatives, excipients and
the like. Examples of lipids include, but are not limited to,
natural and synthetic phospholipids and phosphatidyl cholines
(lecithins), used separately or together.
[0755] Methods to form liposomes have been described, see example,
Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press,
New York, N.Y. (1976), p. 33 et seq.
[0756] Dosage forms for topical administration of a compound
described herein include powders, sprays, ointments and inhalants.
The active compound may be mixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives,
buffers or propellants which may be required. Opthalmic
formulations, eye ointments, powders and solutions are also
contemplated as being within the scope of this invention.
Methods of Use
[0757] The compounds of formula I, or pharmaceutically acceptable
salts thereof, and pharmaceutical compositions comprising a
compound of formula I, or a pharmaceutically acceptable salt
thereof, can be administered to a subject suffering from a
bromodomain-mediated disorder or condition. The term
"administering" refers to the method of contacting a compound with
a subject. Thus, the compounds of formula I can be administered by
injection, that is, intravenously, intramuscularly,
intracutaneously, subcutaneously, intraduodenally, parentally, or
intraperitoneally. Also, the compounds described herein can be
administered by inhalation, for example, intranasally.
Additionally, the compounds of formula I can be administered
transdermally, topically, via implantation, transdermally,
topically, and via implantation. In certain embodiments, the
compounds of the formula I may be delivered orally. The compounds
can also be delivered rectally, bucally, intravaginally, ocularly,
andially, or by insufflation. Bromodomain-mediated disorders and
conditions can be treated prophylactically, acutely, and
chronically using compounds of formula I, depending on the nature
of the disorder or condition. Typically, the host or subject in
each of these methods is human, although other mammals can also
benefit from the administration of a compound of formula I.
[0758] A "bromodomain-mediated disorder or condition" is
characterized by the participation of one or more bromodomains
(e.g., BRD4) in the inception, manifestation of one or more
symptoms or disease markers, severity, or progression of a disorder
or condition. Accordingly, compounds of formula I may be used to
treat cancer, including, but not limited to acoustic neuroma, acute
leukemia, acute lymphocytic leukemia, acute myelocytic leukemia
(monocytic, myeloblastic, adenocarcinoma, angiosarcoma,
astrocytoma, myelomonocytic and promyelocytic), acute t-cell
leukemia, basal cell carcinoma, bile duct carcinoma, bladder
cancer, brain cancer, breast cancer, bronchogenic carcinoma,
cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic
leukemia, chronic lymphocytic leukemia, chronic myelocytic
(granulocytic) leukemia, chronic myelogenous leukemia, colon
cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma,
diffuse large B-cell lymphoma, dysproliferative changes (dysplasias
and metaplasias), embryonal carcinoma, endometrial cancer,
endotheliosarcoma, ependymoma, epithelial carcinoma,
erythroleukemia, esophageal cancer, estrogen-receptor positive
breast cancer, essential thrombocythemia, Ewing's tumor,
fibrosarcoma, follicular lymphoma, germ cell testicular cancer,
glioma, glioblastoma, gliosarcoma, heavy chain disease,
hemangioblastoma, hepatoma, hepatocellular cancer, hormone
insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma,
lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma,
lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's),
malignancies and hyperproliferative disorders of the bladder,
breast, colon, lung, ovaries, pancreas, prostate, skin and uterus,
lymphoid malignancies of T-cell or B-cell origin, leukemia,
lymphoma, medullary carcinoma, medulloblastoma, melanoma,
meningioma, mesothelioma, multiple myeloma, myelogenous leukemia,
myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC),
non-small cell lung cancer, oligodendroglioma, oral cancer,
osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary
adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera,
prostate cancer, rectal cancer, renal cell carcinoma,
retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland
carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid
tumors (carcinomas and sarcomas), small cell lung cancer, stomach
cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma,
thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors,
uterine cancer and Wilms' tumor.
[0759] Further, compounds of formula I may be used to treat
inflammatory diseases, inflammatory conditions, and autoimmune
diseases, including, but not limited to: Addison's disease, acute
gout, ankylosing spondylitis, asthma, atherosclerosis, Behcet's
disease, bullous skin diseases, chronic obstructive pulmonary
disease (COPD), Crohn's disease, dermatitis, eczema, giant cell
arteritis, glomerulonephritis, hepatitis, hypophysitis,
inflammatory bowel disease, Kawasaki disease, lupus nephritis,
multiple sclerosis, myocarditis, myositis, nephritis, organ
transplant rejection, osteoarthritis, pancreatitis, pericarditis,
Polyarteritis nodosa, pneumonitis, primary biliary cirrhosis,
psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis,
sclerosing cholangitis, sepsis, systemic lupus erythematosus,
Takayasu's Arteritis, toxic shock, thyroiditis, type I diabetes,
ulcerative colitis, uveitis, vitiligo, vasculitis, and Wegener's
granulomatosis.
[0760] Compounds of formula I, or pharmaceutically acceptable salts
thereof, may be used to treat AIDS.
[0761] The compounds of formula I can be co-administered to a
subject. The term "co-administered" means the administration of two
or more different pharmaceutical agents or treatments (e.g.,
radiation treatment) that are administered to a subject by
combination in the same pharmaceutical composition or separate
pharmaceutical compositions. Thus co-administration involves
administration at the same time of a single pharmaceutical
composition comprising two or more pharmaceutical agents or
administration of two or more different compositions to the same
subject at the same or different times.
[0762] The compounds of the invention can be co-administered with a
therapeutically effective amount of one or more agents to treat a
cancer, where examples of the agents include, such as radiation,
alkylating agents, angiogenesis inhibitors, antibodies,
antimetabolites, antimitotics, antiproliferatives, antivirals,
aurora kinase inhibitors, apoptosis promoters (for example, Bcl-xL,
Bcl-w and Bfl-1) inhibitors, activators of death receptor pathway,
Bcr-Abl kinase inhibitors, BiTE (Bi-Specific T cell Engager)
antibodies, antibody drug conjugates, biologic response modifiers,
cyclin-dependent kinase inhibitors, cell cycle inhibitors,
cyclooxygenase-2 inhibitors, DVDs (dual variable domain
antibodies), leukemia viral oncogene homolog (ErbB2) receptor
inhibitors, growth factor inhibitors, heat shock protein (HSP)-90
inhibitors, histone deacetylase (HDAC) inhibitors, hormonal
therapies, immunologicals, inhibitors of inhibitors of apoptosis
proteins (IAPs), intercalating antibiotics, kinase inhibitors,
kinesin inhibitors, Jak2 inhibitors, mammalian target of rapamycin
inhibitors, microRNA's, mitogen-activated extracellular
signal-regulated kinase inhibitors, multivalent binding proteins,
non-steroidal anti-inflammatory drugs (NSAIDs), poly ADP (adenosine
diphosphate)-ribose polymerase (PARP) inhibitors, platinum
chemotherapeutics, polo-like kinase (Plk) inhibitors,
phosphoinositide-3 kinase (bromodomain) inhibitors, proteosome
inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine
kinase inhibitors, etinoids/deltoids plant alkaloids, small
inhibitory ribonucleic acids (siRNAs), topoisomerase inhibitors,
ubiquitin ligase inhibitors, and the like, and in combination with
one or more of these agents.
[0763] BiTE antibodies are bi-specific antibodies that direct
T-cells to attack cancer cells by simultaneously binding the two
cells. The T-cell then attacks the target cancer cell. Examples of
BiTE antibodies include adecatumumab (Micromet MT201), blinatumomab
(Micromet MT103) and the like. Without being limited by theory, one
of the mechanisms by which T-cells elicit apoptosis of the target
cancer cell is by exocytosis of cytolytic granule components, which
include perforin and granzyme B. In this regard, Bcl-2 has been
shown to attenuate the induction of apoptosis by both perforin and
granzyme B. These data suggest that inhibition of Bcl-2 could
enhance the cytotoxic effects elicited by T-cells when targeted to
cancer cells (V. R. Sutton, D. L. Vaux and J. A. Trapani, J. of
Immunology 1997, 158 (12), 5783).
[0764] SiRNAs are molecules having endogenous RNA bases or
chemically modified nucleotides. The modifications do not abolish
cellular activity, but rather impart increased stability and/or
increased cellular potency. Examples of chemical modifications
include phosphorothioate groups, 2'-deoxynucleotide,
2'-OCH.sub.3-containing ribonucleotides, 2'-F-ribonucleotides,
2'-methoxyethyl ribonucleotides, combinations thereof and the like.
The siRNA can have varying lengths (e.g., 10-200 bps) and
structures (e.g., hairpins, single/double strands, bulges,
nicks/gaps, mismatches) and are processed in cells to provide
active gene silencing. A double-stranded siRNA (dsRNA) can have the
same number of nucleotides on each strand (blunt ends) or
asymmetric ends (overhangs). The overhang of 1-2 nucleotides can be
present on the sense and/or the antisense strand, as well as
present on the 5'- and/or the 3'-ends of a given strand.
[0765] Multivalent binding proteins are binding proteins comprising
two or more antigen binding sites. Multivalent binding proteins are
engineered to have the three or more antigen binding sites and are
generally not naturally occurring antibodies. The term
"multispecific binding protein" means a binding protein capable of
binding two or more related or unrelated targets. Dual variable
domain (DVD) binding proteins are tetravalent or multivalent
binding proteins binding proteins comprising two or more antigen
binding sites. Such DVDs may be monospecific (i.e., capable of
binding one antigen) or multispecific (i.e., capable of binding two
or more antigens). DVD binding proteins comprising two heavy chain
DVD polypeptides and two light chain DVD polypeptides are referred
to as DVD Ig's. Each half of a DVD Ig comprises a heavy chain DVD
polypeptide, a light chain DVD polypeptide, and two antigen binding
sites. Each binding site comprises a heavy chain variable domain
and a light chain variable domain with a total of 6 CDRs involved
in antigen binding per antigen binding site. Multispecific DVDs
include DVD binding proteins that bind DLL4 and VEGF, or C-met and
EFGR or ErbB3 and EGFR.
[0766] Alkylating agents include altretamine, AMD-473, AP-5280,
apaziquone, bendamustine, brostallicin, busulfan, carboquone,
carmustine (BCNU), chlorambucil, CLORETAZINE.RTM. (laromustine, VNP
40101M), cyclophosphamide, decarbazine, estramustine, fotemustine,
glufosfamide, ifosfamide, KW-2170, lomustine (CCNU), mafosfamide,
melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard
N-oxide, ranimustine, temozolomide, thiotepa, TREANDA.RTM.
(bendamustine), treosulfan, rofosfamide and the like.
[0767] Angiogenesis inhibitors include endothelial-specific
receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth
factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor
(IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors,
matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived
growth factor receptor (PDGFR) inhibitors, thrombospondin analogs,
vascular endothelial growth factor receptor tyrosine kinase (VEGFR)
inhibitors and the like.
[0768] Antimetabolites include ALIMTA.RTM. (pemetrexed disodium,
LY231514, MTA), 5-azacitidine, XELODA.RTM. (capecitabine),
carmofur, LEUSTAT.RTM. (cladribine), clofarabine, cytarabine,
cytarabine ocfosfate, cytosine arabinoside, decitabine,
deferoxamine, doxifluridine, eflomithine, EICAR
(5-ethynyl-1-.beta.-D-ribofuranosylimidazole-4-carboxamide),
enocitabine, ethnylcytidine, fludarabine, 5-fluorouracil alone or
in combination with leucovorin, GEMZAR.RTM. (gemcitabine),
hydroxyurea, ALKERAN.RTM.(melphalan), mercaptopurine,
6-mercaptopurine riboside, methotrexate, mycophenolic acid,
nelarabine, nolatrexed, ocfosfate, pelitrexol, pentostatin,
raltitrexed, Ribavirin, triapine, trimetrexate, S-1, tiazofurin,
tegafur, TS-1, vidarabine, UFT and the like.
[0769] Antivirals include ritonavir, hydroxychloroquine and the
like.
[0770] Aurora kinase inhibitors include ABT-348, AZD-1152,
MLN-8054, VX-680, Aurora A-specific kinase inhibitors, Aurora
B-specific kinase inhibitors and pan-Aurora kinase inhibitors and
the like.
[0771] Bcl-2 protein inhibitors include AT-101 ((-)gossypol),
GENASENSE.RTM. (G3139 or oblimersen (Bcl-2-targeting antisense
oligonucleotide)), IPI-194, IPI-565,
N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4--
(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobe-
nzenesulfonamide) (ABT-737),
N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)pip-
erazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl-
)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide
(ABT-263), GX-070 (obatoclax), ABT-199, and the like.
[0772] Bcr-Abl kinase inhibitors include DASATINIB.RTM.
(BMS-354825), GLEEVEC.RTM. (imatinib) and the like.
[0773] CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387,
CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509,
seliciclib (CYC-202, R-roscovitine), ZK-304709 and the like.
[0774] COX-2 inhibitors include ABT-963, ARCOXIA.RTM. (etoricoxib),
BEXTRA.RTM. (valdecoxib), BMS347070, CELEBREX.RTM. (celecoxib),
COX-189 (lumiracoxib), CT-3, DERAMAXX.RTM. (deracoxib), JTE-522,
4-methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoylphenyl-1H-pyrrole),
MK-663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125,
SD-8381, SVT-2016, S-2474, T-614, VIOXX.RTM. (rofecoxib) and the
like.
[0775] EGFR inhibitors include EGFR antibodies, ABX-EGF, anti-EGFR
immunoliposomes, EGF-vaccine, EMD-7200, ERBITUX.RTM. (cetuximab),
HR3, IgA antibodies, IRESSA.RTM. (gefitinib), TARCEVA.RTM.
(erlotinib or OSI-774), TP-38, EGFR fusion protein, TYKERB.RTM.
(lapatinib) and the like.
[0776] ErbB2 receptor inhibitors include CP-724-714, CI-1033
(canertinib), HERCEPTIN.RTM. (trastuzumab), TYKERB.RTM.
(lapatinib), OMNITARG.RTM. (2C4, petuzumab), TAK-165, GW-572016
(ionafamib), GW-282974, EKB-569, PI-166, dHER2 (HER2 vaccine),
APC-8024 (HER-2 vaccine), anti-HER/2neu bispecific antibody,
B7.her2IgG3, AS HER2 trifunctional bispecfic antibodies, mAB
AR-209, mAB 2B-1 and the like.
[0777] Histone deacetylase inhibitors include depsipeptide,
LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA),
TSA, valproic acid and the like.
[0778] HSP-90 inhibitors include 17-AAG-nab, 17-AAG, CNF-101,
CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953,
MYCOGRAB.RTM. (human recombinant antibody to HSP-90), NCS-683664,
PU24FC1, PU-3, radicicol, SNX-2112, STA-9090 VER49009 and the
like.
[0779] Inhibitors of inhibitors of apoptosis proteins include
HGS1029, GDC-0145, GDC-0152, LCL-161, LBW-242 and the like.
[0780] Antibody drug conjugates include anti-CD22-MC-MMAF,
anti-CD22-MC-MMAE, anti-CD22-MCC-DM1, CR-011-vcMMAE, PSMA-ADC,
MEDI-547, SGN-19Am SGN-35, SGN-75 and the like
[0781] Activators of death receptor pathway include TRAIL,
antibodies or other agents that target TRAIL or death receptors
(e.g., DR4 and DR5) such as Apomab, conatumumab, ETR2-ST01,
GDC0145, (lexatumumab), HGS-1029, LBY-135, PRO-1762 and
trastuzumab.
[0782] Kinesin inhibitors include Eg5 inhibitors such as AZD4877,
ARRY-520; CENPE inhibitors such as GSK923295A and the like.
[0783] JAK-2 inhibitors include CEP-701 (lesaurtinib), XL019 and
INCB018424 and the like.
[0784] MEK inhibitors include ARRY-142886, ARRY-438162 PD-325901,
PD-98059 and the like.
[0785] mTOR inhibitors include AP-23573, CCI-779, everolimus,
RAD-001, rapamycin, temsirolimus, ATP-competitive TORC1/TORC2
inhibitors, including PI-103, PP242, PP30, Torin 1 and the
like.
[0786] Non-steroidal anti-inflammatory drugs include AMIGESIC.RTM.
(salsalate), DOLOBID.RTM.(diflunisal), MOTRIN.RTM. (ibuprofen),
ORUDIS.RTM. (ketoprofen), RELAFEN.RTM. (nabumetone), FELDENE.RTM.
(piroxicam), ibuprofen cream, ALEVE.RTM. (naproxen) and
NAPROSYN.RTM. (naproxen), VOLTAREN.RTM. (diclofenac), INDOCIN.RTM.
(indomethacin), CLINORIL.RTM. (sulindac), TOLECTIN.RTM. (tolmetin),
LODINE.RTM. (etodolac), TORADOL.RTM. (ketorolac), DAYPRO.RTM.
(oxaprozin) and the like.
[0787] PDGFR inhibitors include C-451, CP-673, CP-868596 and the
like.
[0788] Platinum chemotherapeutics include cisplatin, ELOXATIN.RTM.
(oxaliplatin) eptaplatin, lobaplatin, nedaplatin, PARAPLATIN.RTM.
(carboplatin), satraplatin, picoplatin and the like.
[0789] Polo-like kinase inhibitors include BI-2536 and the
like.
[0790] Phosphoinositide-3 kinase (PI3K) inhibitors include
wortmannin, LY294002, XL-147, CAL-120, ONC-21, AEZS-127, ETP-45658,
PX-866, GDC-0941, BGT226, BEZ235, XL765 and the like.
[0791] Thrombospondin analogs include ABT-510, ABT-567, ABT-898,
TSP-1 and the like.
[0792] VEGFR inhibitors include AVASTIN.RTM. (bevacizumab),
ABT-869, AEE-788, ANGIOZYME.TM. (a ribozyme that inhibits
angiogenesis (Ribozyme Pharmaceuticals (Boulder, Colo.) and Chiron,
(Emeryville, Calif.)), axitinib (AG-13736), AZD-2171, CP-547,632,
IM-862, MACUGEN (pegaptamib), NEXAVAR.RTM. (sorafenib, BAY43-9006),
pazopanib (GW-786034), vatalanib (PTK-787, ZK-222584), SUTENT.RTM.
(sunitinib, SU-11248), VEGF trap, ZACTIMA.TM. (vandetanib,
ZD-6474), GA101, ofatumumab, ABT-806 (mAb-806), ErbB3 specific
antibodies, BSG2 specific antibodies, DLL4 specific antibodies and
C-met specific antibodies, and the like.
[0793] Antibiotics include intercalating antibiotics aclarubicin,
actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE.RTM.
(bleomycin), daunorubicin, CAELYX.RTM. or MYOCET.RTM. (liposomal
doxorubicin), elsamitrucin, epirbucin, glarbuicin, ZAVEDOS.RTM.
(idarubicin), mitomycin C, nemorubicin, neocarzinostatin,
peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin,
VALSTAR.RTM. (valrubicin), zinostatin and the like.
[0794] Topoisomerase inhibitors include aclarubicin,
9-aminocamptothecin, amonafide, amsacrine, becatecarin, belotecan,
BN-80915, CAMPTOSAR.RTM. (irinotecan hydrochloride), camptothecin,
CARDIOXANE.RTM. (dexrazoxine), diflomotecan, edotecarin,
ELLENCE.RTM. or PHARMORUBICIN.RTM. (epirubicin), etoposide,
exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan,
mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan,
sobuzoxane, SN-38, tafluposide, topotecan and the like.
[0795] Antibodies include AVASTIN.RTM. (bevacizumab), CD40-specific
antibodies, chTNT-1/B, denosumab, ERBITUX.RTM. (cetuximab),
HUMAX-CD4.RTM. (zanolimumab), IGF1R-specific antibodies,
lintuzumab, PANOREX.RTM. (edrecolomab), RENCAREX.RTM. (WX G250),
RITUXAN.RTM. (rituximab), ticilimumab, trastuzimab, CD20 antibodies
types I and II and the like.
[0796] Hormonal therapies include ARIMIDEX.RTM. (anastrozole),
AROMASIN.RTM. (exemestane), arzoxifene, CASODEX.RTM.
(bicalutamide), CETROTIDE.RTM. (cetrorelix), degarelix, deslorelin,
DESOPAN.RTM. (trilostane), dexamethasone, DROGENIL.RTM.
(flutamide), EVISTA.RTM. (raloxifene), AFEMA.TM. (fadrozole),
FARESTON.RTM. (toremifene), FASLODEX.RTM. (fulvestrant),
FEMARA.RTM. (letrozole), formestane, glucocorticoids, HECTOROL.RTM.
(doxercalciferol), RENAGEL.RTM.(sevelamer carbonate), lasofoxifene,
leuprolide acetate, MEGACE.RTM. (megesterol), MIFEPREX.RTM.
(mifepristone), NILANDRON.TM. (nilutamide), NOLVADEX.RTM.
(tamoxifen citrate), PLENAXIS.TM. (abarelix), prednisone,
PROPECIA.RTM. (finasteride), rilostane, SUPREFACT.RTM. (buserelin),
TRELSTAR.RTM. (luteinizing hormone releasing hormone (LHRH)),
VANTAS.RTM. (Histrelin implant), VETORYL.RTM. (trilostane or
modrastane), ZOLADEX.RTM. (fosrelin, goserelin) and the like.
[0797] Deltoids and retinoids include seocalcitol (EB1089, CB1093),
lexacalcitrol (KH1060), fenretinide, PANRETIN.RTM. (aliretinoin),
ATRAGEN.RTM. (liposomal tretinoin), TARGRETIN.RTM. (bexarotene),
LGD-1550 and the like.
[0798] PARP inhibitors include ABT-888 (veliparib), olaparib,
KU-59436, AZD-2281, AG-014699, BSI-201, BGP-15, INO-1001, ONO-2231
and the like.
[0799] Plant alkaloids include, but are not limited to,
vincristine, vinblastine, vindesine, vinorelbine and the like.
[0800] Proteasome inhibitors include VELCADE.RTM. (bortezomib),
MG132, NPI-0052, PR-171 and the like.
[0801] Examples of immunologicals include interferons and other
immune-enhancing agents. Interferons include interferon alpha,
interferon alpha-2a, interferon alpha-2b, interferon beta,
interferon gamma-1a, ACTIMMUNE.RTM. (interferon gamma-1b) or
interferon gamma-n1, combinations thereof and the like. Other
agents include ALFAFERONE.RTM., (IFN-.alpha.), BAM-002 (oxidized
glutathione), BEROMUN.RTM. (tasonermin), BEXXAR.RTM. (tositumomab),
CAMPATH.RTM. (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4),
decarbazine, denileukin, epratuzumab, GRANOCYTE.RTM. (lenograstim),
lentinan, leukocyte alpha interferon, imiquimod, MDX-010
(anti-CTLA-4), melanoma vaccine, mitumomab, molgramostim,
MYLOTARG.TM. (gemtuzumab ozogamicin), NEUPOGEN.RTM. (filgrastim),
OncoVAC-CL, OVAREX.RTM. (oregovomab), pemtumomab (Y-muHMFG1),
PROVENGE.RTM. (sipuleucel-T), sargaramostim, sizofilan, teceleukin,
THERACYS.RTM. (Bacillus Calmette-Guerin), ubenimex, VIRULIZIN.RTM.
(immunotherapeutic, Lorus Pharmaceuticals), Z-100 (Specific
Substance of Maruyama (SSM)), WF-10 (Tetrachlorodecaoxide (TCDO)),
PROLEUKIN.RTM. (aldesleukin), ZADAXIN.RTM. (thymalfasin),
ZENAPAX.RTM. (daclizumab), ZEVALIN.RTM. (90Y-Ibritumomab tiuxetan)
and the like.
[0802] Biological response modifiers are agents that modify defense
mechanisms of living organisms or biological responses, such as
survival, growth or differentiation of tissue cells to direct them
to have anti-tumor activity and include krestin, lentinan,
sizofiran, picibanil PF-3512676 (CpG-8954), ubenimex and the
like.
[0803] Pyrimidine analogs include cytarabine (ara C or Arabinoside
C), cytosine arabinoside, doxifluridine, FLUDARA.RTM.
(fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR.RTM.
(gemcitabine), TOMUDEX.RTM. (ratitrexed), TROXATYL.TM.
(triacetyluridine troxacitabine) and the like.
[0804] Purine analogs include LANVIS.RTM. (thioguanine) and
PURI-NETHOL.RTM. (mercaptopurine).
[0805] Antimitotic agents include batabulin, epothilone D
(KOS-862),
N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide,
ixabepilone (BMS 247550), paclitaxel, TAXOTERE.RTM. (docetaxel),
PNU100940 (109881), patupilone, XRP-9881 (larotaxel), vinflunine,
ZK-EPO (synthetic epothilone) and the like.
[0806] Ubiquitin ligase inhibitors include MDM2 inhibitors, such as
nutlins, NEDD8 inhibitors such as MLN4924 and the like.
[0807] Compounds of this invention can also be used as
radiosensitizers that enhance the efficacy of radiotherapy.
Examples of radiotherapy include external beam radiotherapy,
teletherapy, brachytherapy and sealed, unsealed source radiotherapy
and the like.
[0808] Additionally, compounds having Formula (I) may be combined
with other chemotherapeutic agents such as ABRAXANE.TM. (ABI-007),
ABT-100 (famesyl transferase inhibitor), ADVEXIN.RTM. (Ad5CMV-p53
vaccine), ALTOCOR.RTM. or MEVACOR.RTM. (lovastatin), AMPLIGEN.RTM.
(poly I:poly C12U, a synthetic RNA), APTOSYN.RTM. (exisulind),
AREDIA.RTM. (pamidronic acid), arglabin, L-asparaginase, atamestane
(1-methyl-3,17-dione-androsta-1,4-diene), AVAGE.RTM. (tazarotene),
AVE-8062 (combreastatin derivative) BEC2 (mitumomab), cachectin or
cachexin (tumor necrosis factor), canvaxin (vaccine), CEAVAC.RTM.
(cancer vaccine), CELEUK.RTM. (celmoleukin), CEPLENE.RTM.
(histamine dihydrochloride), CERVARIX.RTM. (human papillomavirus
vaccine), CHOP.RTM. (C: CYTOXAN.RTM. (cyclophosphamide); H:
ADRIAMYCIN.RTM. (hydroxydoxorubicin); O: Vincristine
(ONCOVIN.RTM.); P: prednisone), CYPAT.TM. (cyproterone acetate),
combrestatin A4P, DAB(389)EGF (catalytic and translocation domains
of diphtheria toxin fused via a His-Ala linker to human epidermal
growth factor) or TransMID-107R.TM. (diphtheria toxins),
dacarbazine, dactinomycin, 5,6-dimethylxanthenone-4-acetic acid
(DMXAA), eniluracil, EVIZON.TM. (squalamine lactate),
DIMERICINE.RTM. (T4N5 liposome lotion), discodermolide, DX-8951f
(exatecan mesylate), enzastaurin, EP0906 (epithilone B),
GARDASIL.RTM. (quadrivalent human papillomavirus (Types 6, 11, 16,
18) recombinant vaccine), GASTRIMMUNE.RTM., GENASENSE.RTM., GMK
(ganglioside conjugate vaccine), GVAX.RTM. (prostate cancer
vaccine), halofuginone, histerelin, hydroxycarbamide, ibandronic
acid, IGN-101, IL-13-PE38, IL-13-PE38QQR (cintredekin besudotox),
IL-13-pseudomonas exotoxin, interferon-.alpha., interferon-.gamma.,
JUNOVAN.TM. or MEPACT.TM. (mifamurtide), lonafamib,
5,10-methylenetetrahydrofolate, miltefosine
(hexadecylphosphocholine), NEOVASTAT.RTM.(AE-941), NEUTREXIN.RTM.
(trimetrexate glucuronate), NIPENT.RTM. (pentostatin),
ONCONASE.RTM. (a ribonuclease enzyme), ONCOPHAGE.RTM. (melanoma
vaccine treatment), ONCOVAX.RTM. (IL-2 Vaccine), ORATHECIN.TM.
(rubitecan), OSIDEM.RTM. (antibody-based cell drug), OVAREX.RTM.
MAb (murine monoclonal antibody), paclitaxel, PANDIMEX.TM.
(aglycone saponins from ginseng comprising 20(S)protopanaxadiol
(aPPD) and 20(S)protopanaxatriol (aPPT)), panitumumab,
PANVAC.RTM.-VF (investigational cancer vaccine), pegaspargase, PEG
Interferon A, phenoxodiol, procarbazine, rebimastat, REMOVAB.RTM.
(catumaxomab), REVLIMID.RTM. (lenalidomide), RSR13 (efaproxiral),
SOMATULINE.RTM. LA (lanreotide), SORIATANE.RTM.(acitretin),
staurosporine (Streptomyces staurospores), talabostat (PT100),
TARGRETIN.RTM. (bexarotene), TAXOPREXIN.RTM. (DHA-paclitaxel),
TELCYTA.RTM. (canfosfamide, TLK286), temilifene, TEMODAR.RTM.
(temozolomide), tesmilifene, thalidomide, THERATOPE.RTM. (STn-KLH),
thymitaq
(2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline
dihydrochloride), TNFERADE.TM. (adenovector: DNA carrier containing
the gene for tumor necrosis factor-.alpha.), TRACLEER.RTM. or
ZAVESCA.RTM. (bosentan), tretinoin (Retin-A), tetrandrine,
TRISENOX.RTM. (arsenic trioxide), VIRULIZIN.RTM., ukrain
(derivative of alkaloids from the greater celandine plant), vitaxin
(anti-alphavbeta3 antibody), XCYTRIN.RTM. (motexafin gadolinium),
XINLAY.TM. (atrasentan), XYOTAX.TM. (paclitaxel poliglumex),
YONDELIS.RTM. (trabectedin), ZD-6126, ZINECARD.RTM. (dexrazoxane),
ZOMETA.RTM. (zolendronic acid), zorubicin and the like.
[0809] The compounds of the invention can also be co-administered
with a therapeutically effective amount of one or more agents to
treat an inflammatory disease or condition, or autoimmune disease,
where examples of the agents include, such as methotrexate,
6-mercaptopurine, azathioprine sulphasalazine, mesalazine,
olsalazine chloroquinine/hydroxychloroquine, pencillamine,
aurothiomalate (intramuscular and oral), azathioprine, cochicine,
corticosteroids (oral, inhaled and local injection), beta-2
adrenoreceptor agonists (salbutamol, terbutaline, salmeteral),
xanthines (theophylline, aminophylline), cromoglycate, nedocromil,
ketotifen, ipratropium and oxitropium, cyclosporin, FK506,
rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, for example,
ibuprofen, corticosteroids such as prednisolone, phosphodiesterase
inhibitors, adensosine agonists, antithrombotic agents, complement
inhibitors, adrenergic agents, agents which interfere with
signalling by proinflammatory cytokines such as TNF.alpha. or IL-1
(e.g., NIK, IKK, p38 or MAP kinase inhibitors), IL-1.beta.
converting enzyme inhibitors, T-cell signalling inhibitors such as
kinase inhibitors, metalloproteinase inhibitors, sulfasalazine,
6-mercaptopurines, angiotensin converting enzyme inhibitors,
soluble cytokine receptors and derivatives thereof (e.g. soluble
p55 or p75 TNF receptors and the derivatives p75TNFRIgG
(etanercept) and p55TNFRIgG (Lenercept), sIL-1RI, sIL-1RII,
sIL-6R), antiinflammatory cytokines (e.g. IL-4, IL-10, IL-11, IL-13
and TGF.beta.), celecoxib, folic acid, hydroxychloroquine sulfate,
rofecoxib, etanercept, infliximab, naproxen, valdecoxib,
sulfasalazine, methylprednisolone, meloxicam, methylprednisolone
acetate, gold sodium thiomalate, aspirin, triamcinolone acetonide,
propoxyphene napsylate/apap, folate, nabumetone, diclofenac,
piroxicam, etodolac, diclofenac sodium, oxaprozin, oxycodone HCl,
hydrocodone bitartrate/apap, diclofenac sodium/misoprostol,
fentanyl, anakinra, tramadol HCl, salsalate, sulindac,
cyanocobalamin/fa/pyridoxine, acetaminophen, alendronate sodium,
prednisolone, morphine sulfate, lidocaine hydrochloride,
indomethacin, glucosamine sulf/chondroitin, amitriptyline HCl,
sulfadiazine, oxycodone HCl/acetaminophen, olopatadine HCl
misoprostol, naproxen sodium, omeprazole, cyclophosphamide,
rituximab, IL-1 TRAP, MRA, CTLA4-IG, IL-18 BP, anti-IL-12,
Anti-IL15, BIRB-796, SCIO-469, VX-702, AMG-548, VX-740,
Roflumilast, IC-485, CDC-801, S1P1 agonists (such as FTY720), PKC
family inhibitors (such as Ruboxistaurin or AEB-071) and Mesopram.
In certain embodiments, combinations include methotrexate or
leflunomide and in moderate or severe rheumatoid arthritis cases,
cyclosporine and anti-TNF antibodies as noted above.
[0810] Non-limiting examples of therapeutic agents for inflammatory
bowel disease with which a compound of Formula (I) of the invention
may be co-administered include the following: budenoside; epidermal
growth factor; corticosteroids; cyclosporin, sulfasalazine;
aminosalicylates; 6-mercaptopurine; azathioprine; metronidazole;
lipoxygenase inhibitors; mesalamine; olsalazine; balsalazide;
antioxidants; thromboxane inhibitors; IL-1 receptor antagonists;
anti-IL-1.beta. monoclonal antibodies; anti-IL-6 monoclonal
antibodies; growth factors; elastase inhibitors;
pyridinyl-imidazole compounds; antibodies to or antagonists of
other human cytokines or growth factors, for example, TNF, LT,
IL-1, IL-2, IL-6, IL-7, IL-8, IL-12, IL-15, IL-16, IL-23, EMAP-II,
GM-CSF, FGF, and PDGF; cell surface molecules such as CD2, CD3,
CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their
ligands; methotrexate; cyclosporine; FK506; rapamycin;
mycophenolate mofetil; leflunomide; NSAIDs, for example, ibuprofen;
corticosteroids such as prednisolone; phosphodiesterase inhibitors;
adenosine agonists; antithrombotic agents; complement inhibitors;
adrenergic agents; agents which interfere with signalling by
proinflammatory cytokines such as TNF.alpha. or IL-1 (e.g. NIK,
IKK, or MAP kinase inhibitors); IL-1.beta. converting enzyme
inhibitors; TNF.alpha. converting enzyme inhibitors; T-cell
signalling inhibitors such as kinase inhibitors; metalloproteinase
inhibitors; sulfasalazine; azathioprine; 6-mercaptopurines;
angiotensin converting enzyme inhibitors; soluble cytokine
receptors and derivatives thereof (e.g. soluble p55 or p75 TNF
receptors, sIL-1RII, sIL-1RII, sIL-6R) and antiinflammatory
cytokines (e.g. IL-4, IL-10, IL-11, IL-13 and TGF.beta.). Preferred
examples of therapeutic agents for Crohn's disease with which a
compound of Formula (I) can be combined include the following: TNF
antagonists, for example, anti-TNF antibodies, D2E7 (adalimumab),
CA2 (infliximab), CDP 571, TNFR-Ig constructs, (p75TNFRIgG
(etanercept) and p55TNFRIgG (LENERCEPT.TM.) inhibitors and PDE4
inhibitors. A compound of Formula (I) can be combined with
corticosteroids, for example, budenoside and dexamethasone;
sulfasalazine, 5-aminosalicylic acid; olsalazine; and agents which
interfere with synthesis or action of proinflammatory cytokines
such as IL-1, for example, IL-1.beta. converting enzyme inhibitors
and IL-1ra; T cell signaling inhibitors, for example, tyrosine
kinase inhibitors; 6-mercaptopurine; IL-11; mesalamine; prednisone;
azathioprine; mercaptopurine; infliximab; methylprednisolone sodium
succinate; diphenoxylate/atrop sulfate; loperamide hydrochloride;
methotrexate; omeprazole; folate; ciprofloxacin/dextrose-water;
hydrocodone bitartrate/apap; tetracycline hydrochloride;
fluocinonide; metronidazole; thimerosal/boric acid;
cholestyramine/sucrose; ciprofloxacin hydrochloride; hyoscyamine
sulfate; meperidine hydrochloride; midazolam hydrochloride;
oxycodone HCl/acetaminophen; promethazine hydrochloride; sodium
phosphate; sulfamethoxazole/trimethoprim; celecoxib; polycarbophil;
propoxyphene napsylate; hydrocortisone; multivitamins; balsalazide
disodium; codeine phosphate/apap; colesevelam HCl; cyanocobalamin;
folic acid; levofloxacin; methylprednisolone; natalizumab and
interferon-gamma.
[0811] Non-limiting examples of therapeutic agents for multiple
sclerosis with which a compound of Formula (I) may be
co-administered include the following: corticosteroids;
prednisolone; methylprednisolone; azathioprine; cyclophosphamide;
cyclosporine; methotrexate; 4-aminopyridine; tizanidine;
interferon-.beta.1a (AVONEX.RTM.; Biogen); interferon-.beta.1b
(BETASERON.RTM.; Chiron/Berlex); interferon .alpha.-n3) (Interferon
Sciences/Fujimoto), interferon-.alpha. (Alfa Wassermann/J&J),
interferon .beta.1A-IF (Serono/Inhale Therapeutics), Peginterferon
.alpha. 2b (Enzon/Schering-Plough), Copolymer 1 (Cop-1;
COPAXONE.RTM.; Teva Pharmaceutical Industries, Inc.); hyperbaric
oxygen; intravenous immunoglobulin; cladribine; antibodies to or
antagonists of other human cytokines or growth factors and their
receptors, for example, TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8,
IL-12, IL-23, IL-15, IL-16, EMAP-II, GM-CSF, FGF, and PDGF. A
compound of Formula (I) can be combined with antibodies to cell
surface molecules such as CD2, CD3, CD4, CD8, CD19, CD20, CD25,
CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or their ligands. A
compound of Formula (I) may also be combined with agents such as
methotrexate, cyclosporine, FK506, rapamycin, mycophenolate
mofetil, leflunomide, an S1P1 agonist, NSAIDs, for example,
ibuprofen, corticosteroids such as prednisolone, phosphodiesterase
inhibitors, adensosine agonists, antithrombotic agents, complement
inhibitors, adrenergic agents, agents which interfere with
signalling by proinflammatory cytokines such as TNF.alpha. or IL-1
(e.g., NIK, IKK, p38 or MAP kinase inhibitors), IL-1.beta.
converting enzyme inhibitors, TACE inhibitors, T-cell signaling
inhibitors such as kinase inhibitors, metalloproteinase inhibitors,
sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin
converting enzyme inhibitors, soluble cytokine receptors and
derivatives thereof (e.g. soluble p55 or p75 TNF receptors,
sIL-1RI, sIL-1RII, sIL-6R) and antiinflammatory cytokines (e.g.
IL-4, IL-10, IL-13 and TGF.beta.).
[0812] A compound of Formula (I) may also be co-administered with
agents, such as alemtuzumab, dronabinol, daclizumab, mitoxantrone,
xaliproden hydrochloride, fampridine, glatiramer acetate,
natalizumab, sinnabidol, .alpha.-immunokine NNSO3, ABR-215062,
AnergiX.MS, chemokine receptor antagonists, BBR-2778, calagualine,
CPI-1189, LEM (liposome encapsulated mitoxantrone), THC.CBD
(cannabinoid agonist), MBP-8298, mesopram (PDE4 inhibitor),
MNA-715, anti-IL-6 receptor antibody, neurovax, pirfenidone
allotrap 1258 (RDP-1258), sTNF-R1, talampanel, teriflunomide,
TGF-beta2, tiplimotide, VLA-4 antagonists (for example, TR-14035,
VLA4 Ultrahaler, Antegran-ELAN/Biogen), interferon gamma
antagonists and IL-4 agonists.
[0813] Non-limiting examples of therapeutic agents for ankylosing
spondylitis with which a compound of Formula (I) can be
co-administered include the following: ibuprofen, diclofenac,
misoprostol, naproxen, meloxicam, indomethacin, diclofenac,
celecoxib, rofecoxib, sulfasalazine, methotrexate, azathioprine,
minocyclin, prednisone, and anti-TNF antibodies, D2E7
(HUMIRA.RTM.), CA2 (infliximab), CDP 571, TNFR-Ig constructs,
(p75TNFRIgG (ENBREL.RTM.) and p55TNFRIgG (LENERCEPT.RTM.).
[0814] Non-limiting examples of therapeutic agents for asthma with
which a compound of Formula (I) may be co-administered include the
following: albuterol, salmeterol/fluticasone, montelukast sodium,
fluticasone propionate, budesonide, prednisone, salmeterol
xinafoate, levalbuterol HCl, albuterol sulfate/ipratropium,
prednisolone sodium phosphate, triamcinolone acetonide,
beclomethasone dipropionate, ipratropium bromide, azithromycin,
pirbuterol acetate, prednisolone, theophylline anhydrous,
methylprednisolone sodium succinate, clarithromycin, zafirlukast,
formoterol fumarate, influenza virus vaccine, amoxicillin
trihydrate, flunisolide, allergy injection, cromolyn sodium,
fexofenadine hydrochloride, flunisolide/menthol,
amoxicillin/clavulanate, levofloxacin, inhaler assist device,
guaifenesin, dexamethasone sodium phosphate, moxifloxacin HCl,
doxycycline hyclate, guaifenesin/d-methorphan,
p-ephedrine/cod/chlorphenir, gatifloxacin, cetirizine
hydrochloride, mometasone furoate, salmeterol xinafoate,
benzonatate, cephalexin, pe/hydrocodone/chlorphenir, cetirizine
HCl/pseudoephed, phenylephrine/cod/promethazine,
codeine/promethazine, cefprozil, dexamethasone,
guaifenesin/pseudoephedrine, chlorpheniramine/hydrocodone,
nedocromil sodium, terbutaline sulfate, epinephrine,
methylprednisolone, anti-IL-13 antibody, and metaproterenol
sulfate.
[0815] Non-limiting examples of therapeutic agents for COPD with
which a compound of Formula (I) may be co-administered include the
following: albuterol sulfate/ipratropium, ipratropium bromide,
salmeterol/fluticasone, albuterol, salmeterol xinafoate,
fluticasone propionate, prednisone, theophylline anhydrous,
methylprednisolone sodium succinate, montelukast sodium,
budesonide, formoterol fumarate, triamcinolone acetonide,
levofloxacin, guaifenesin, azithromycin, beclomethasone
dipropionate, levalbuterol HCl, flunisolide, ceftriaxone sodium,
amoxicillin trihydrate, gatifloxacin, zafirlukast,
amoxicillin/clavulanate, flunisolide/menthol,
chlorpheniramine/hydrocodone, metaproterenol sulfate,
methylprednisolone, mometasone furoate,
p-ephedrine/cod/chlorphenir, pirbuterol acetate,
p-ephedrine/loratadine, terbutaline sulfate, tiotropium bromide,
(R,R)-formoterol, TgAAT, cilomilast and roflumilast.
[0816] Non-limiting examples of therapeutic agents for psoriasis
with which a compound of Formula (I) may be co-administered include
the following: calcipotriene, clobetasol propionate, triamcinolone
acetonide, halobetasol propionate, tazarotene, methotrexate,
fluocinonide, betamethasone diprop augmented, fluocinolone
acetonide, acitretin, tar shampoo, betamethasone valerate,
mometasone furoate, ketoconazole, pramoxine/fluocinolone,
hydrocortisone valerate, flurandrenolide, urea, betamethasone,
clobetasol propionate/emoll, fluticasone propionate, azithromycin,
hydrocortisone, moisturizing formula, folic acid, desonide,
pimecrolimus, coal tar, diflorasone diacetate, etanercept folate,
lactic acid, methoxsalen, hc/bismuth subgal/znox/resor,
methylprednisolone acetate, prednisone, sunscreen, halcinonide,
salicylic acid, anthralin, clocortolone pivalate, coal extract,
coal tar/salicylic acid, coal tar/salicylic acid/sulfur,
desoximetasone, diazepam, emollient, fluocinonide/emollient,
mineral oil/castor oil/nalact, mineral oil/peanut oil,
petroleum/isopropyl myristate, psoralen, salicylic acid,
soap/tribromsalan, thimerosal/boric acid, celecoxib, infliximab,
cyclosporine, alefacept, efalizumab, tacrolimus, pimecrolimus,
PUVA, UVB, sulfasalazine, ABT-874 and ustekinamab.
[0817] Non-limiting examples of therapeutic agents for psoriatic
arthritis with which a compound of Formula (I) may be
co-administered include the following: methotrexate, etanercept,
rofecoxib, celecoxib, folic acid, sulfasalazine, naproxen,
leflunomide, methylprednisolone acetate, indomethacin,
hydroxychloroquine sulfate, prednisone, sulindac, betamethasone
diprop augmented, infliximab, methotrexate, folate, triamcinolone
acetonide, diclofenac, dimethylsulfoxide, piroxicam, diclofenac
sodium, ketoprofen, meloxicam, methylprednisolone, nabumetone,
tolmetin sodium, calcipotriene, cyclosporine, diclofenac
sodium/misoprostol, fluocinonide, glucosamine sulfate, gold sodium
thiomalate, hydrocodone bitartrate/apap, ibuprofen, risedronate
sodium, sulfadiazine, thioguanine, valdecoxib, alefacept, D2E7
(adalimumab), and efalizumab.
[0818] Preferred examples of therapeutic agents for SLE (Lupus)
with which a compound of Formula (I) may be co-administered include
the following: NSAIDS, for example, diclofenac, naproxen,
ibuprofen, piroxicam, indomethacin; COX2 inhibitors, for example,
celecoxib, rofecoxib, valdecoxib; anti-malarials, for example,
hydroxychloroquine; steroids, for example, prednisone,
prednisolone, budenoside, dexamethasone; cytotoxics, for example,
azathioprine, cyclophosphamide, mycophenolate mofetil,
methotrexate; inhibitors of PDE4 or purine synthesis inhibitor, for
example Cellcept.RTM.. A compound of Formula (I) may also be
combined with agents such as sulfasalazine, 5-aminosalicylic acid,
olsalazine, Imuran.RTM. and agents which interfere with synthesis,
production or action of proinflammatory cytokines such as IL-1, for
example, caspase inhibitors like IL-1.beta. converting enzyme
inhibitors and IL-1ra. A compound of Formula (I) may also be used
with T cell signaling inhibitors, for example, tyrosine kinase
inhibitors; or molecules that target T cell activation molecules,
for example, CTLA-4-IgG or anti-B7 family antibodies, anti-PD-1
family antibodies. A compound of Formula (I) can be combined with
IL-11 or anti-cytokine antibodies, for example, fonotolizumab
(anti-IFNg antibody), or anti-receptor receptor antibodies, for
example, anti-IL-6 receptor antibody and antibodies to B-cell
surface molecules. A compound of Formula (I) may also be used with
LJP 394 (abetimus), agents that deplete or inactivate B-cells, for
example, Rituximab (anti-CD20 antibody), lymphostat-B (anti-BlyS
antibody), TNF antagonists, for example, anti-TNF antibodies, D2E7
(adalimumab), CA2 (infliximab), CDP 571, TNFR-Ig constructs,
(p75TNFRIgG (etanercept) and p55TNFRIgG (LENERCEPT.TM.).
[0819] The compounds of the invention can also be co-administered
with a therapeutically effective amount of one or more agents used
in the prevention or treatment of AIDS, where examples of the
agents include, HIV reverse transcriptase inhibitors, HIV protease
inhibitors, immunomodulators, and other retroviral drugs. Examples
of reverse transcriptase inhibitors include, but are not limited
to, abacavir, adefovir, didanosine, dipivoxil delavirdine,
efavirenz, lamivudine, nevirapine, stavudine zalcitabine, and
zidovudine. Examples of protease inhibitors include, but are not
limited to, amprenavir, indinavir, lopinavir, nelfinavir,
ritonavir, and saquinavir.
[0820] A compound of Formula (I) may also be co-administered with
insulin for the treatment of type I diabetes.
[0821] The compounds of the invention can also be co-administered
with a therapeutically effective amount of one or more agents used
in the prevention or treatment of AIDS, where examples of the
agents include, HIV reverse transcriptase inhibitors, HIV protease
inhibitors, immunomodulators, and other retroviral drugs. Examples
of reverse transcriptase inhibitors include, but are not limited
to, abacavir, adefovir, didanosine, dipivoxil delavirdine,
efavirenz, emtricitabine, lamivudine, nevirapine, rilpivirine,
stavudine, tenofovir, zalcitabine, and zidovudine. Examples of
protease inhibitors include, but are not limited to, amprenavir,
atazanavir, darunavir, indinavir, fosamprenavir, lopinavir,
nelfinavir, ritonavir, saquinavir, and tipranavir. Examples of
other retroviral drugs include, but are not limited to,
elvitegravir, enfuvirtide, maraviroc and raltegravir.
[0822] The compounds of the invention can also be co-administered
with a therapeutically effective amount of one or more agents used
in the treatment of obesity, where examples of the agents include
orlistat.
[0823] The compounds of the invention can also be co-administered
with a therapeutically effective amount of one or more agents used
in the treatment of type II diabetes, where examples of the agents
include, alpha glucosidase inhibitors, insulin, metformin,
sulfonylureas (e.g., carbutamide, acetohexamide, chlorpropamide,
glibenclamide, glibomuride, gliclazide, glimepiride, glipizide,
gliquidone, glisoxepide, glyclopyramide, tolbutamide, and
tolazamide), nonsulfonylureas (e.g., nateglinide, and repaglinide),
and thiazolidinediones (e.g., pioglitazone).
[0824] The compounds of the invention can be co-administered with a
therapeutically effective amount of one or more agents to prevent
or treat type II diabetes, hepatic steatosis, insulin resistance,
metabolic syndrome and related disorders, where examples of the
agents include, but are not limited to, insulin and insulins that
have been modified to improve the duration of action in the body;
agents that stimulate insulin secretion such as acetohexamide,
chlorpropamide, glyburide, glimepiride, glipizide, glicazide,
glycopyramide, gliquidone, rapaglinide, nataglinide, tolazamide and
tolbutamide; agents that are glucagon-like peptide agonists such as
exanatide, liraglutide and taspoglutide; agents that inhibit
dipeptidyl-peptidase IV such as vildagliptin, sitagliptin,
saxagliptin, linagliptin, allogliptin and septagliptin; agents that
bind to the peroxisome proliferator-activated receptor gamma such
as rosiglitazone and pioglitazone; agents that decrease insulin
resistance such as metformin; agents that reduce glucose absorbance
in the small intestine such as acarbose, miglitol and
voglibose.
[0825] The compounds of the invention can be co-administered with a
therapeutically effective amount of one or more agents to prevent
or treat acute kidney disorders and chronic kidney diseases, where
examples of the agents include, but are not limited to, dopamine,
diuretics such as furosemide, bumetanide, thiazide and the like,
mannitol, calcium gluconate, sodium bicarbonate, albuterol,
paricalcitol, doxercalciferol, and cinacalcet.
[0826] The following Examples may be used for illustrative purposes
and should not be deemed to narrow the scope of the invention.
EXAMPLES
Example 1
1-methyl-3-(2-phenoxyphenyl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 1A
7-methoxy-3-(2-phenoxyphenyl)-1H-pyrrolo[2,3-c]pyridine
[0827] A mixture of 3-iodo-7-methoxy-1H-pyrrolo[2,3-c]pyridine
(0.274 g, 1.0 mmol), 2-phenoxyphenylboronic acid (0.278 g, 1.3
mmol, 1.3 equivalents), Pd(PPh.sub.3).sub.4(0.058 g, 0.05 mmol),
and cesium fluoride (0.456 g, 3 mmol) in dimethxoyethane (3 mL) and
methanol (1.5 mL) was heated under microwave conditions
(120.degree. C., 30 minutes). The reaction mixture was partitioned
between water and ethyl acetate. The aqueous layer was extracted
three times with ethyl acetate. The combined organic layers were
washed with saturated aqueous sodium chloride, dried over anhydrous
magnesium sulfate, filtered, and concentrated. The residue was
purified by flash column chromatography (silica gel, 30% ethyl
acetate/hexanes) to give the title compound (0.122 g, 38.6%
yield).
Example 1B
7-methoxy-1-methyl-3-(2-phenoxyphenyl)-1H-pyrrolo[2,3-c]pyridine
[0828] Example 1A (0.058 g, 0.183 mmol) in dimethylformamide (2 mL)
was treated with 60% sodium hydride in mineral oil (0.015 g, 0.367
mmol) at room temperature for 10 minutes. To this solution was
added methyl iodide (0.052 g, 0.367 mmol). The reaction mixture was
stirred for 3 hours at room temperature. The reaction mixture was
partitioned between water and ethyl acetate. The aqueous layer was
extracted three times with ethyl acetate. The combined organic
layers were washed with saturated aqueous sodium chloride, dried
over anhydrous magnesium sulfate, filtered, and concentrated. The
residue was purified by flash column chromatography (silica gel,
10% ethyl acetate/hexanes) to give the title compound (0.051 g
84%).
Example 1C
1-methyl-3-(2-phenoxyphenyl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0829] Example 1B (0.045 g, 0.136 mmol) in dioxane (2 mL) was
treated with 4.0 N HCl in dioxane (1 mL). The reaction mixture was
heated at 90.degree. C. overnight. The solvent was removed, and the
residue was purified by reverse phase HPLC (C18, CH.sub.3CN/water
(0.1% TFA), 10-100%) to afford the title compound (0.035 g, 81%).
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 10.90 (d, J=4.88
Hz, 1H), 7.54 (dd, J=7.63, 1.83 Hz, 1H), 7.47 (s, 1H), 7.22-7.32
(m, 4H), 6.98-7.05 (m, 2H), 6.85-6.90 (m, 3H), 6.53 (d, J=6.1 Hz,
1H), 4.05 (s, 3H). MS (ESI+) m/z 317.2 (M+H).sup.+.
Example 2
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]methanesulfonamide
Example 2A
3-iodo-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[0830] 3-Iodo-7-methoxy-1H-pyrrolo[2,3-c]pyridine (0.75 g, 2.74
mmol) in dimethylformamide (10 mL) was treated with 60% sodium
hydride in mineral oil (0.219 g, 5.47 mmol) at room temperature for
20 minutes. To this solution was added methyl iodide (0.505 g, 3.56
mmol). The reaction mixture was stirred for 3 hours at room
temperature. The reaction mixture was partitioned between water and
ethyl acetate. The aqueous layer was extracted three times with
ethyl acetate. The combined organic layers were washed with
saturated aqueous sodium chloride, dried over anhydrous magnesium
sulfate, filtered, and concentrated. The residue was purified by
flash column chromatography (silica gel, 10% ethyl acetate/hexanes
to give 0.75 g (95%) of the title compound.
Example 2B
3-(2-fluoro-5-nitrophenyl)-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[0831] Example 2A (0.56 g, 1.944 mmol),
2-fluoro-5-nitrophenylboronic acid (0.467 g, 2.53 mmol),
Pd(PPh.sub.3).sub.4(0.112 g, 0.097 mmol) and sodium carbonate
(0.412 g, 3.89 mmol) were combined in toluene (8 mL), ethanol (2
mL) and water (2 mL) and the mixture was degassed and purged with
nitrogen. The reaction mixture was heated at 90.degree. C.
overnight, and then cooled to room temperature. The mixture was
partitioned between ethyl acetate and water. The organic layer was
washed with saturated aqueous sodium chloride, dried over anhydrous
magnesium sulfate, filtered, and concentrated. The crude product
was purified by flash chromatography (silica gel, 20-50% ethyl
acetate in hexanes) to provide 0.398 g (20.5%) of the title
compound.
Example 2C
3-(2-(2,4-difluorophenoxy)-5-nitrophenyl)-7-methoxy-1-methyl-1H-pyrrolo[2,-
3-c]pyridine
[0832] A mixture of Example 2B (0.123 g, 0.408 mmol),
2,4-difluorophenol (0.069 g, 0.531 mmol) and cesium carbonate
(0.173 g, 0.531 mmol) in dimethylsulfoxide (5 mL) was heated at
110.degree. C. for 1 hour. After cooling, the reaction mixture was
partitioned between water and ethyl acetate. The aqueous layer was
extracted three times with ethyl acetate. The combined organic
layers were washed with saturated aqueous sodium chloride, dried
over anhydrous magnesium sulfate, filtered, and concentrated. The
crude product was purified by flash chromatography (silica gel,
20-50% ethyl acetate in hexanes) to provide 0.16 g (95%) of the
title compound.
Example 2D
4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-y-
l)aniline
[0833] A mixture of Example 2C (0.165 g, 0.401 mmol) and 10%
palladium on carbon (0.043 g, 0.040 mmol) in ethyl acetate (10 mL)
was treated with a balloon of hydrogen gas. The reaction mixture
was stirred for 10 hours at ambient temperature. The solid was
removed by filtration, and the filtrate was concentrated to give
the title compound (0.152 g, 0.399 mmol, 99% yield).
Example 2E
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)phenyl)methanesulfonamide
[0834] A mixture of Example 2D (0.05 g, 0.131 mmol),
methanesulfonyl chloride (0.031 mL, 0.393 mmol), and triethylamine
(0.080 g, 0.787 mmol) in dichloromethane (3 mL) was stirred at room
temperature for 2 hours. The solvent was removed, and the residue
was treated with sodium hydroxide (0.656 mL, 1.31 mmol) and dioxane
(3 mL). The reaction mixture was heated at 80.degree. C. for 3
hours. After cooling, the reaction mixture was partitioned between
water and ethyl acetate. The aqueous layer was extracted three
times with ethyl acetate. The combined organic layers were washed
with saturated aqueous sodium chloride, dried over anhydrous
magnesium sulfate, filtered, and concentrated to the title
compound.
Example 2F
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]methanesulfonamide
[0835] Example 2E (0.055 g, 0.120 mmol) in dioxane (3 ml) was
treated with hydrogen chloride (2.99 ml, 11.97 mmol). The reaction
mixture was heated at 75.degree. C. overnight. The solvent was
removed, and the residue was purified by reverse phase HPLC (C18,
CH.sub.3CN/water (0.1% TFA), 0-100%) to give title compound (0.042
g, 0.094 mmol, 79% yield). .sup.1H NMR (500 MHz, DMSO-d.sub.6)
.delta. ppm 10.97 (d, J=5.19 Hz, 1H), 9.68 (s, 1H), 7.54 (s, 1H),
7.40-7.45 (m, 2H), 7.02-7.13 (m, 3H), 6.93 (dd, J=7.02, 5.8 Hz,
1H), 6.86 (d, J=8.85 Hz, 1H), 6.56 (d, J=6.41 Hz, 1H), 4.08 (s,
3H), 3.00 (s, 3H). MS (ESI+) m/z 446.1 (M+H).sup.+.
Example 3
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]propane-2-sulfonamide
Example 3A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)phenyl)propane-2-sulfonamide
[0836] Example 3A was prepared according to the procedure used for
the preparation of Example 2E, substituting propane-2-sulfonyl
chloride for methanesulfonyl chloride.
Example 3B
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]propane-2-sulfonamide
[0837] Example 3B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 3A for Example
1B. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 10.97 (d,
J=5.49 Hz, 1H), 9.75 (s, 1H), 7.52 (s, 1H), 7.45 (d, J=2.75 Hz,
1H), 7.39-7.43 (m, 1H), 7.03-7.13 (m, 3H), 6.90-6.93 (m, 1H), 6.84
(d, J=8.85 Hz, 1H), 6.55 (d, J=6.41 Hz, 1H), 4.08 (s, 3H), 3.00 (s,
3H), 3.21-3.26 (m, 1H), 1.26 (d, J=7.02 Hz, 6H). MS (ESI+) m/z
474.1 (M+H).sup.+.
Example 4
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]ethanesulfonamide
Example 4A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)phenyl)ethanesulfonamide
[0838] A mixture of Example 2D (0.05 g, 0.131 mmol), ethanesulfonyl
chloride (0.051 g, 0.393 mmol), and triethylamine (0.080 g, 0.787
mmol) in dichloromethane (3 mL) was stirred at ambient temperature
for 2 hours. The solvent was removed, and the residue was treated
with sodium hydroxide (0.656 mL, 1.31 mmol) and dioxane (3 mL). The
reaction mixture was heated at 80.degree. C. for 3 hours. After
cooling, the reaction mixture was partitioned between water and
ethyl acetate. The aqueous layer was extracted three times with
ethyl acetate. The combined organic layers were washed with
saturated aqueous sodium chloride, dried over anhydrous magnesium
sulfate, filtered, and concentrated to give the title compound.
Example 4B
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]ethanesulfonamide
[0839] Example 4A (0.038 g, 0.080 mmol) in dioxane (2 mL) was
treated with hydrogen chloride (2.006 mL, 8.03 mmol). The reaction
mixture was stirred at 75.degree. C. overnight. The solvent was
removed, and the residue was purified by reverse phase HPLC (C18,
CH.sub.3CN/water (0.1% TFA), 0-100%) to provide the title compound
(0.031 g, 0.067 mmol, 84% yield). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 10.97 (d, J=5.19 Hz, 1H), 9.76 (s, 1H),
7.53 (s, 1H), 7.40-7.45 (m, 1H), 7.01-7.11 (m, 3H), 6.89-6.92 (m,
1H), 6.84 (d, J=8.85 Hz, 1H), 6.55 (d, J=6.41 Hz, 1H), 4.08 (s,
3H), 3.09 (q, J=7.32 Hz, 2H), 1.22 (t, J=7.48 Hz, 3H). MS (ESI+)
m/z 460.1 (M+H).sup.+.
Example 5
N-[4-(4-chlorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyri-
din-3-yl)phenyl]ethanesulfonamide
Example 5A
3-(2-(4-chlorophenoxy)-5-nitrophenyl)-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]-
pyridine
[0840] Example 5A was prepared according to the procedure used for
the preparation of Example 2C, substituting 4-chlorophenol for
2,4-difluorophenol, with the exception that the reaction mixture
was heated at 100.degree. C. for 18 hours, and the residue was
purified by flash column chromatography (silica gel, 0-1% methanol
in dichloromethane) to provide the title compound.
Example 5B
4-(4-chlorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)an-
iline
[0841] A mixture of Example 5A (0.162 g, 0.395 mmol) in
tetrahydrofuran (20 mL) was added to platinum oxide (0.034 g, 0.150
mmol) in a 50 mL pressure bottle and stirred at ambient temperature
under hydrogen at 30 psi for 1 hour. The solid was removed by
filtration, and the filtrate was concentrated to provide the title
compound (0.140 g, 93% yield).
Example 5C
N-4-(4-chlorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-
phenyl)ethanesulfonamide
[0842] A mixture of Example 5B (0.137 g, 0.361 mmol) and
triethylamine (0.201 mL, 1.44 mmol) in dichloromethane (9 mL) was
treated with ethanesulfonyl chloride (0.103 mL, 1.08 mmol). The
mixture was stirred for 18 hours at ambient temperature under
nitrogen. The reaction mixture was concentrated and the residue was
dissolved in a mixture of dioxane (14 mL) and 1M aqueous sodium
hydroxide, (8.66 mL, 8.66 mmol). The mixture was stirred at
50.degree. C. for 1 hour. Upon cooling, the mixture was diluted
with saturated ammonium chloride (100 mL) and extracted with ethyl
acetate (100 mL, 50 mL). The combined organics were dried over
anhydrous sodium sulfate, filtered, and concentrated. The residue
was purified by flash column chromatography (silica gel, 0-5%
methanol in dichloromethane) to provide the title compound (0.139
g, 82%).
Example 5D
N-[4-(4-chlorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyri-
din-3-yl)phenyl]ethanesulfonamide
[0843] Example 5D was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 5C for Example
1B, with the exception that the reaction mixture was heated at
70.degree. C., and the material was purified by flash
chromatography (silica gel, 1-7.5% methanol in dichloromethane) to
provide the title compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 10.96 (d, J=5.19 Hz, 1H), 9.83 (s, 1H), 7.44-7.50 (m,
2H), 7.27-7.34 (m, 2H), 7.12-7.19 (m, 1H), 7.03-7.10 (m, 1H),
6.83-6.94 (m, 3H), 6.55 (d, J=7.02 Hz, 1H), 4.03 (s, 3H), 3.12 (q,
J=7.32 Hz, 2H), 1.24 (t, J=7.32 Hz, 3H). MS (ESI+) m/z 458.0
(M+H).sup.+.
Example 6
N-{4-[(trans-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyr-
rolo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide
Example 6A
4-methoxycyclohexanol
[0844] A mixture of 4-methoxyphenol (0.10 g, 0.806 mmol) in acetic
acid (10 mL) was added to platinum oxide (0.020 g, 0.088 mmol) in a
50 mL pressure bottle and heated at 50.degree. C. under hydrogen at
30 psi for 1 hour. The solid was removed by filtration, and the
filtrate was concentrated to provide the title compound.
Example 6B
7-methoxy-3-(2-((trans)-4-methoxycyclohexyloxy)-5-nitrophenyl)-1-methyl-1H-
-pyrrolo[2,3-c]pyridine
[0845] A solution of Example 6A (0.130 g, 0.996 mmol) in
tetrahydrofuran (4 mL) was treated with sodium hydride (0.080 g,
2.0 mmol). The resulting white suspension was stirred for 30
minutes at ambient temperature and Example 2B (0.150 g, 0.498 mmol)
was added. The mixture was heated at 60.degree. C. for 18 hours.
Separately a solution of Example 6A (130 mg, 0.996 mmol) in
tetrahydrofuran (4 mL) was treated with sodium hydride (0.080 g,
1.99 mmol). The resulting white suspension was stirred for 30
minutes at ambient temperature and then added to the reaction
mixture which was heated at 60.degree. C. for 18 hours. Upon
cooling, the reaction mixture was quenched with saturated aqueous
ammonium chloride solution (5 mL), diluted with 50% aqueous sodium
chloride solution (75 mL) and extracted with ethyl acetate (75 mL,
50 mL). The combined organics were dried over anhydrous sodium
sulfate, filtered, and concentrated. The residue was purified by
flash chromatography (silica gel, 10-100% ethyl acetate in hexane).
Pure fractions of the trans isomer, which was first to elute, were
concentrated to provide the title compound (27.2 mg, 13%).
Example 6C
3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-((trans)-4-methoxyc-
yclohexyloxy)aniline
[0846] A mixture of Example 6B (0.025 g, 0.061 mmol) in
tetrahydrofuran (10 mL) was added to 10% palladium on carbon (0.005
g, 0.047 mmol) in a 50 mL pressure bottle and stirred at ambient
temperature under hydrogen at 30 psi for 2 hours. The solid was
removed by filtration, and the filtrate was concentrated to provide
the title compound (0.023 g, 100% yield).
Example 6D
N-(3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-((trans)-4-metho-
xycyclohexyloxy)phenyl)ethanesulfonamide
[0847] Example 6D was prepared according to the procedure used for
the preparation of Example 5C, substituting Example 6C for Example
5B.
Example 6E
N-{4-[(trans-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyr-
rolo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide
[0848] Example 6E was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 6D for Example
1B, with the exception that the reaction mixture was heated at
70.degree. C., and the material was purified by flash
chromatography (silica gel, 1-7.5% methanol in dichloromethane) to
provide the title compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 10.91 (d, J=5.19 Hz, 1H), 9.49 (s, 1H), 7.45-7.52 (m,
1H), 7.31 (d, J=1.83 Hz, 1H), 7.02-7.13 (m, 2H), 6.83-6.93 (m, 1H),
6.51 (d, J=7.02 Hz, 1H), 4.26-4.38 (m, 1H), 4.10 (s, 3H), 3.14-3.24
(m, 4H), 3.02 (q, J=7.32 Hz, 2H), 1.92 (d, J=8.24 Hz, 2H),
1.78-1.88 (m, 2H), 1.26-1.48 (m, 4H), 1.21 (t, J=7.32 Hz, 3H). MS
(ESI+) m/z 460.0 (M+H).sup.+.
Example 7
N-[3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(tetrahy-
dro-2H-pyran-4-yloxy)phenyl]ethanesulfonamide
Example 7A
7-methoxy-1-methyl-3-(5-nitro-2-(tetrahydro-2H-pyran-4-yloxy)phenyl)-1H-py-
rrolo[2,3-c]pyridine
[0849] A solution of tetrahydro-2H-pyran-4-ol (102 mg, 0.996 mmol)
in tetrahydrofuran (4 mL) was treated with sodium hydride (80 mg,
1.992 mmol) at ambient temperature. The resulting white suspension
was stirred for 30 minutes at ambient temperature and Example 2B
(150 mg, 0.498 mmol) was added. The mixture was heated at
60.degree. C. for 18 hours. Upon cooling, the reaction mixture was
quenched with saturated ammonium chloride solution (5 mL), diluted
with 50% saturated aqueous sodium chloride (75 mL) and extracted
with ethyl acetate (75 mL, 50 mL). The combined organics were dried
over anhydrous sodium sulfate, filtered, and concentrated. The
residue was purified by flash chromatography (silica gel, 0-5%
methanol in dichloromethane) to provide the title compound (0.074
g, 39%).
Example 7B
3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(tetrahydro-2H-pyra-
n-4-yloxy)aniline
[0850] Example 7B was prepared according to the procedure used for
the preparation of Example 6C, substituting Example 7A for Example
6B.
Example 7C
N-(3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(tetrahydro-2H-p-
yran-4-yloxy)phenyl)ethanesulfonamide
[0851] Example 7C was prepared according to the procedure used for
the preparation of Example 5C, substituting Example 7B for Example
5B.
Example 7D
N-[3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(tetrahy-
dro-2H-pyran-4-yloxy)phenyl]ethanesulfonamide
[0852] Example 7D was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 7C for Example
1B, with the exception that the reaction mixture was heated at
70.degree. C., and the material was purified by flash
chromatography (silica gel, 1-7.5% methanol in dichloromethane) to
provide the title compound. .sup.1H NMR (300 MHz, DMSO-d.sub.6) ppm
10.91 (d, J=5.43 Hz, 1H), 9.50 (s, 1H), 7.50-7.54 (m, 1H), 7.32 (d,
J=2.37 Hz, 1H), 7.04-7.15 (m, 2H), 6.85-6.92 (m, 1H), 6.51 (d,
J=6.10 Hz, 1H), 4.44-4.55 (m, 1H), 4.12 (s, 3H), 3.66-3.77 (m, 2H),
3.36-3.47 (m, 2H), 3.02 (q, J=7.12 Hz, 2H), 1.84-1.96 (m, 2H),
1.49-1.64 (m, 2H), 1.21 (t, J=7.29 Hz, 3H). MS (ESI+) m/z 432.0
(M+H).sup.+.
Example 8
N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrol-
o[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide
Example 8A
3-(2-(4,4-difluorocyclohexyloxy)-5-nitrophenyl)-7-methoxy-1-methyl-1H-pyrr-
olo[2,3-c]pyridine
[0853] Example 8A was prepared according to the procedure used for
the preparation of Example 7A, substituting
4,4-difluorocyclohexanol for tetrahydro-2H-pyran-4-ol.
Example 8B
4-(4,4-difluorocyclohexyloxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyrid-
in-3-yl)aniline
[0854] Example 8B was prepared according to the procedure used for
the preparation of Example 6C, substituting Example 8A for Example
6B.
Example 8C
N-(4-(4,4-difluorocyclohexyloxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]py-
ridin-3-yl)phenyl)ethanesulfonamide
[0855] Example 8C was prepared according to the procedure used for
the preparation of Example 5C, substituting Example 8B for Example
5B.
Example 8D
N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrol-
o[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide
[0856] Example 8D was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 8C for Example
1B, with the exception that the reaction mixture was heated at
70.degree. C., and the material was purified by flash
chromatography (silica gel, 1-7.5% methanol in dichloromethane) to
provide the title compound. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. ppm 10.91 (d, J=5.43 Hz, 1H), 9.52 (s, 1H), 7.49 (s, 1H),
7.30 (d, J=2.71 Hz, 1H), 7.05-7.20 (m, 2H), 6.87 (dd, J=7.12, 5.76
Hz, 1H), 6.48 (d, J=6.10 Hz, 1H), 4.52 (d, J=3.39 Hz, 1H), 4.10 (s,
3H), 3.03 (q, J=7.35 Hz, 2H), 1.70-1.94 (m, 8H), 1.21 (t, J=7.29
Hz, 3H). MS (ESI+) m/z 466.1 (M+H).sup.+.
Example 9
N-{4-[(cis-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide
Example 9A
7-methoxy-3-(2-((cis)-4-methoxycyclohexyloxy)-5-nitrophenyl)-1-methyl-1H-p-
yrrolo[2,3-c]pyridine
[0857] The title compound (98.5 mg, 48.1%) was obtained as the
second eluting isomer from the flash chromatography purification
described in Example 6B.
Example 9B
3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-((cis)-4-methoxycyc-
lohexyloxy)aniline
[0858] Example 9B was prepared according to the procedure used for
the preparation of Example 6C, substituting Example 9A for Example
6B.
Example 9C
N-(3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-((cis)-4-methoxy-
cyclohexyloxy)phenyl)ethanesulfonamide
[0859] Example 9C was prepared according to the procedure used for
the preparation of Example 5C, substituting Example 9B for Example
5B.
Example 9D
N-{4-[(cis-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide
[0860] Example 9D was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 9C for Example
1B, with the exception that the reaction mixture was heated at
70.degree. C., and the material was purified by flash
chromatography (silica gel, 1-7.5% methanol in dichloromethane) to
provide the title compound. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. ppm 10.91 (d, J=5.43 Hz, 1H), 9.47 (s, 1H), 7.49 (s, 1H),
7.32 (s, 1H), 7.07 (s, 2H), 6.87 (dd, J=7.12, 5.76 Hz, 1H), 6.52
(d, J=5.76 Hz, 1H), 4.31-4.42 (m, 1H), 4.06-4.14 (m, 3H), 3.18-3.26
(m, 1H), 3.15-3.18 (m, 3H), 3.02 (q, J=7.46 Hz, 2H), 1.67-1.79 (m,
2H), 1.46-1.66 (m, 6H), 1.16-1.27 (m, 3H). MS (ESI+) m/z 460.0
(M+H).sup.+.
Example 10
N-[3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(oxetan--
3-yloxy)phenyl]ethanesulfonamide
Example 10A
7-methoxy-1-methyl-3-(5-nitro-2-(oxetan-3-yloxy)phenyl)-1H-pyrrolo[2,3-c]p-
yridine
[0861] Example 10A was prepared according to the procedure used for
the preparation of Example 7A, substituting oxetan-3-ol for
tetrahydro-2H-pyran-4-ol.
Example 10B
3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(oxetan-3-yloxy)ani-
line
[0862] Example 10B was prepared according to the procedure used for
the preparation of Example 6C, substituting Example 10A for Example
6B.
Example 10C
N-(3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(oxetan-3-yloxy)-
phenyl)ethanesulfonamide
[0863] Example 10C was prepared according to the procedure used for
the preparation of Example 5C, substituting Example 10B for Example
5B.
Example 10D
N-(4-(1-chloro-3-hydroxypropan-2-yloxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-p-
yrrolo[2,3-c]pyridin-3-yl)phenyl)ethanesulfonamide
[0864] Example 10D was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 10C for Example
1B, and with the exception that the reaction mixture was heated at
70.degree. C.
Example 10E
N-[3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(oxetan--
3-yloxy)phenyl]ethanesulfonamide
[0865] A solution of Example 10D (82 mg, 0.188 mmol) in a mixture
of tetrahydrofuran (7.5 mL) and N,N-dimethylformamide (0.5 mL) was
treated with sodium hydride (66 mg, 1.6 mmol) at ambient
temperature. The reaction mixture was heated at 62.degree. C. for
72 hours. The reaction mixture was concentrated and the residue was
quenched with water. The mixture was treated with ammonium chloride
to neutral pH, diluted with saturated aqueous sodium chloride and
extracted with dichloromethane. The organics were dried over
anhydrous sodium sulfate, filtered, and concentrated. The residue
was purified by flash chromatography (silica gel, 1-7.5% methanol
in dichloromethane) to provide the title compound (25.4 mg, 34%
yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.94 (d,
J=5.19 Hz, 1H), 9.55 (s, 1H), 7.60 (s, 1H), 7.36 (d, J=2.75 Hz,
1H), 7.05 (dd, J=8.70, 2.59 Hz, 1H), 6.86-6.94 (m, 1H), 6.65 (d,
J=8.54 Hz, 1H), 6.52 (d, J=7.02 Hz, 1H), 5.17-5.30 (m, 1H), 4.90
(t, J=6.71 Hz, 2H), 4.56 (dd, J=7.02, 5.19 Hz, 2H), 4.13 (s, 3H),
3.02 (q, J=7.32 Hz, 2H), 1.20 (t, J=7.48 Hz, 3H). MS (ESI+) m/z
404.0 (M+H).sup.+.
Example 11
N-[4-(2,4-difluorophenoxy)-2-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide
Example 11A
1-bromo-2-(2,4-difluorophenoxy)-4-fluoro-5-nitrobenzene
[0866] A mixture of 1-bromo-2,4-difluoro-5-nitrobenzene (0.5 g,
2.10 mmol) and cesium carbonate (0.685 g, 2.10 mmol) in DMSO (10.50
mL) was treated dropwise with 2,4-difluorophenol (0.273 g, 2.10
mmol), stirred for 60 minutes at ambient temperature and
partitioned between ethyl acetate and water, adjusting the pH to 6
with 1 M HCl. The organic layer was washed with water, saturated
aqueous sodium chloride, dried (MgSO.sub.4), filtered, and
concentrated. Purification by chromatography (silica gel, 0-30%
ethyl acetate in heptanes) afforded the title compound and
1-bromo-4-(2,4-difluorophenoxy)-2-fluoro-5-nitrobenzene as an
inseparable mixture (0.59 g, 81%).
Example 11B
5-bromo-4-(2,4-difluorophenoxy)-2-fluoroaniline
[0867] The product from Example 11A (0.59 g, 1.69 mmol), iron (0.47
g, 8.48 mmol) and ammonium chloride (0.136 g, 2.54 mmol) were
combined in a solvent mixture of ethanol (9 mL), tetrahydrofuran (9
mL) and water (3 mL) and heated at 90.degree. C. for 2 hours. The
mixture was cooled, filtered through Celite and the Celite pad was
washed repeatedly with methanol. The filtrate was concentrated and
the residue was partitioned between ethyl acetate and water. The
organic layer was washed with saturated aqueous sodium chloride,
dried (anhydrous Na.sub.2SO.sub.4), filtered, and concentrated.
Purification by chromatography (silica gel, 0-60% ethyl acetate in
heptanes) afforded the title compound and
5-bromo-2-(2,4-difluorophenoxy)-4-fluoroaniline as an inseparable
mixture (0.43 g, 80%).
Example 11C
N-(5-bromo-4-(2,4-difluorophenoxy)-2-fluorophenyl)methanesulfonamide
[0868] A mixture of the product from Example 11B (0.428 g, 1.35
mmol) and triethylamine (0.469 mL, 3.36 mmol) in dichloromethane
(13.5 mL) was treated dropwise with methanesulfonyl chloride (0.23
mL, 2.96 mmol), stirred for 2 hours and concentrated. The residue
was dissolved in a mixture of dioxane (4 mL) and 1M sodium
hydroxide (1 mL), heated for 1 hour at 90.degree. C., cooled and
diluted with ethyl acetate. The mixture was brought to pH 7 with 1
M HCl and the organic layer was separated, dried (anhydrous
Na.sub.2SO.sub.4), filtered, and concentrated. Purification by
chromatography (silica gel, 0-60% ethyl acetate in heptanes)
afforded the title compound as the second eluting regioisomer
(0.346 g, 65%).
Example 11D
N-(5-bromo-2-(2,4-difluorophenoxy)-4-fluorophenyl)methanesulfonamide
[0869] A mixture of the product from Example 11B (0.428 g, 1.35
mmol) and triethylamine (0.469 mL, 3.36 mmol) in dichloromethane
(13.5 mL) was treated dropwise with methanesulfonyl chloride (0.23
mL, 2.96 mmol), stirred for 2 hours at ambient temperature and
concentrated. The residue was dissolved in a mixture of dioxane (4
mL) and 1M sodium hydroxide (1 mL), heated for 1 hour at 90.degree.
C., cooled and diluted with ethyl acetate. The mixture was brought
to pH 7 with 1 M HCl and the organic layer was separated, dried
(anhydrous Na.sub.2SO.sub.4), filtered, and concentrated.
Purification by chromatography (silica gel, 0-60% ethyl acetate in
heptanes) afforded the title compound as the first eluting
regioisomer (0.057 g, 11%).
Example 11E
N-(4-(2,4-difluorophenoxy)-2-fluoro-5-(7-methoxy-1-methyl-1H-pyrrro[2,3-c]-
pyridin-3-yl)phenyl)methanesulfonamide
[0870] The product from Example 59A (0.073 g, 0.252 mmol), the
product from Example 11C (0.1 g, 0.252 mmol),
tris(dibenzylideneacetone)dipalladium(0) (6.93 mg, 7.57 .mu.mol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (7.38
mg, 0.025 mmol) and sodium carbonate (0.094 g, 0.883 mmol) were
combined and sparged with argon for 15 minutes. Meanwhile a
solution of 4:1 dioxane/water (2 mL) was sparged with nitrogen for
15 minutes and transferred by syringe into the reaction vessel
under argon. The mixture was stirred at 60.degree. C. for 4 hours
under argon and partitioned between ethyl acetate and water. The
organic layer was washed with saturated aqueous sodium chloride,
dried (anhydrous Na.sub.2SO.sub.4), treated with 3-mercaptopropyl
functionalized silica gel, filtered, and concentrated to afford the
title compound (0.12 g, 99%).
Example 11F
N-[4-(2,4-difluorophenoxy)-2-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide
[0871] The product from Example 11E (0.120 g, 0.252 mmol) and 4 M
hydrogen chloride in dioxane (10 mL, 40.0 mmol) were combined and
heated at 70.degree. C. for 24 hours, cooled and concentrated. The
residue was purified by reverse phase HPLC (C18, CH.sub.3CN/water
(0.1% TFA), 10-100%) to afford the title compound (0.080 g, 68%).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.95 (d, J=5.43
Hz, 1H) 9.57 (s, 1H) 7.41-7.55 (m, 3H) 7.23-7.34 (m, 1H) 7.05-7.15
(m, 1H) 6.86-6.93 (m, 1H) 6.79 (d, J=11.19 Hz, 1H) 6.51 (d, J=5.76
Hz, 1H) 4.09 (s, 3H) 3.03 (s, 3H). MS (ESI+) m/z 464
(M+H).sup.+.
Example 12
N-[2-(2,4-difluorophenoxy)-4-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide
Example 12A
N-(2-(2,4-difluorophenoxy)-4-fluoro-5-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl)methanesulfonamide
[0872] Example 59A (0.040 g, 0.139 mmol), Example 11D (0.055 g,
0.139 mmol), tris(dibenzylideneacetone)dipalladium(0) (3.81 mg,
4.16 mol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (4.06
mg, 0.014 mmol) and sodium carbonate (0.051 g, 0.486 mmol) were
combined and sparged with argon for 15 minutes. Meanwhile a
solution of 4:1 dioxane/water (2 mL) was sparged with nitrogen gas
for 15 minutes and transferred by syringe into the reaction vessel
under argon. The mixture was stirred at 60.degree. C. for 4 hours
and partitioned between ethyl acetate and water. The organic layer
was washed with brine, dried (anhydrous Na.sub.2SO.sub.4), treated
with mercaptopropyl silica gel, filtered, and concentrated to
afford the title compound (0.066 g, 99%).
Example 12B
N-[2-(2,4-difluorophenoxy)-4-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrro-
lo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide
[0873] The product from Example 12A (0.066 g, 0.138 mmol) and 4 M
hydrogen chloride in dioxane (10 mL, 40.0 mmol) were combined and
heated at 70.degree. C. for 24 hours, cooled and concentrated. The
residue was purified by reverse phase HPLC (C18, CH.sub.3CN/water
(0.1% TFA), 10-100%) to afford the title compound (0.022 g, 34%).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 11.00 (d, J=5.09
Hz, 1H) 9.53 (s, 1H) 7.47-7.59 (m, 3H) 7.30-7.41 (m, 1H) 7.11-7.20
(m, 1H) 6.90-6.96 (m, 1H) 6.78 (d, J=10.85 Hz, 1H) 6.49 (d, J=7.12
Hz, 1H) 4.11 (s, 3H) 3.05 (s, 3H). MS (ESI+) m/z 464
(M+H).sup.+.
Example 13
N-[2,4-bis(2,4-difluorophenoxy)-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2-
,3-c]pyridin-3-yl)phenyl]methanesulfonamide
Example 13A
4,4'-(4-bromo-6-nitro-1,3-phenylene)bis(oxy)bis(1,3-difluorobenzene)
[0874] To a solution of 1-bromo-2,4-difluoro-5-nitrobenzene (0.3 g,
1.26 mmol) and cesium carbonate (0.86 g, 2.65 mmol) in DMSO (6.3
mL) was added dropwise 2,4-difluorophenol (0.27 g, 2.10 mmol). The
mix was stirred for 60 minutes at ambient temperature and
partitioned between ethyl acetate and water, adjusting the pH to 6
with HCl. The organic layer was washed with water, saturated
aqueous sodium chloride, dried (MgSO.sub.4), filtered, and
concentrated to afford the title compound (0.578 g, 100%).
Example 13B
5-bromo-2,4-bis(2,4-difluorophenoxy)aniline
[0875] The product from Example 13A (0.578 g, 1.26 mmol), iron
(0.352 g, 6.31 mmol), and ammonium chloride (0.101 g, 1.89 mmol)
were combined in a mixture of tetrahydrofuran (9 mL), ethanol (9
mL), water (3 mL) and heated at 90.degree. C. for 2 hours. The
mixture was cooled, filtered through Celite and the Celite pad was
washed repeatedly with methanol. The filtrate was concentrated and
the residue was partitioned between ethyl acetate and water. The
organic layer was washed with saturated aqueous sodium chloride,
dried (anhydrous Na.sub.2SO.sub.4), filtered, and concentrated to
afford the title compound (0.52 g, 96%).
Example 13C
N-(5-bromo-2,4-bis(2,4-difluorophenoxy)phenyl)methanesulfonamide
[0876] To the product from Example 13B (0.52 g, 1.214 mmol) and
triethylamine (0.423 mL, 3.04 mmol) in dichloromethane (12.14 mL)
was added dropwise methanesulfonyl chloride (0.207 mL, 2.67 mmol).
The mixture was stirred for 2 hours at ambient temperature, and
concentrated. The residue was dissolved in a mixture of dioxane (4
mL) and 1 M sodium hydroxide (1 mL) and heated for 1 hour at
90.degree. C. The mixture was cooled and diluted with ethyl
acetate, brought to pH 7 with 1 M HCl and the organic layer was
separated, dried (anhydrous Na.sub.2SO.sub.4), filtered, and
concentrated. Purification by chromatography (silica gel, 20-60%
ethyl acetate in heptanes) afforded the title compound (0.5 g,
81%).
Example 13D
N-(2,4-bis(2,4-difluorophenoxy)-5-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)phenyl)methanesulfonamide
[0877] Example 13D (0.122 g, 99%) was prepared according to the
procedure for the preparation of Example 11E substituting Example
13C for Example 11C.
Example 13E
N-[2,4-bis(2,4-difluorophenoxy)-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2-
,3-c]pyridin-3-yl)phenyl]methanesulfonamide
[0878] Example 13D (0.122 g, 0.208 mmol) and 4 M hydrogen chloride
in dioxane (5 mL, 20.0 mmol) were combined and heated at 70.degree.
C. for 24 hours, cooled and concentrated. The residue was purified
by reverse phase HPLC (C18, CH.sub.3CN/water (0.1% TFA), 10-100%)
to afford the title compound (0.055 g, 46%). .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. ppm 10.94 (d, J=5.43 Hz, 1H) 9.48 (s, 1H)
7.53 (d, J=12.21 Hz, 2H) 7.32-7.48 (m, 2H) 6.94-7.28 (m, 4H) 6.90
(dd, J=7.12, 5.76 Hz, 1H) 6.55 (d, J=6.10 Hz, 1H) 6.22 (s, 1H) 4.08
(s, 3H) 3.04 (s, 3H). MS (ESI+) m/z 574 (M+H).sup.+.
Example 14
N-[4-(cyclopropylmethoxy)-2-methyl-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrol-
o[2,3-c]pyridin-3-yl)phenyl]ethanesulfonamide
Example 14A
2-bromo-1-(cyclopropylmethoxy)-3-methyl-4-nitrobenzene
[0879] A flask with stirbar was charged with
2-bromo-3-methyl-4-nitrophenol (Parkway Scientific, 1.15 g, 4.96
mmol), (bromomethyl)cyclopropane (0.60 mL, 6.19 mmol) and cesium
carbonate (2.65 g, 8.13 mmol) in dimethylformamide (16 mL). The
mixture was stirred overnight at ambient temperature. The mixture
was then heated to 50.degree. C. in an oil bath. After 3 hours, the
mixture was cooled and shaken in a separatory funnel with 100 mL
each of ethyl acetate and saturated aqueous sodium chloride. The
organics were washed twice with saturated aqueous sodium chloride,
dried over sodium sulfate, filtered, and concentrated. The crude
product was purified by flash chromatography (silica gel, 0-30%
ethyl acetate in hexanes) to provide 1.24 g (87%) of the title
compound
Example 14B
3-bromo-4-(cyclopropylmethoxy)-2-methylaniline
[0880] Example 14A (0.656 g, 2.293 mmol) in ethanol (18.00 mL) and
tetrahydrofuran (18.00 mL) at 65.degree. C. was treated
sequentially with iron powder, <10 micron (1.32 g, 23.64 mmol)
and a solution of ammonium chloride (0.310 g, 5.80 mmol) in water
(9 mL). The resulting mixture was stirred vigorously at 65.degree.
C. for 20 hours. The reaction mixture was cooled and filtered
through a fritted funnel containing a pad of Celite 503 filter aid,
rinsing with ethyl acetate. The filtrate was washed with aqueous
sodium bicarbonate and saturated aqueous sodium chloride, dried
over sodium sulfate, filtered, and concentrated. The crude product
was purified by flash chromatography (silica gel, 0-30% ethyl
acetate in hexanes) to provide 0.38 g (65%) of the title
compound.
Example 14C
4-(cyclopropylmethoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl-
)-2-methylaniline
Example 59A
[0881] 0.0743 g, 0.258 mmol),
tris(dibenzylidineacetone)dipalladium(0 (0.0070 g, 7.64 .mu.mol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane
(0.0080 g, 0.027 mmol) and tris-potassium phosphate (0.175 g, 0.824
mmol) were combined in a sealed 2 mL microwave tube with stir bar
and sparged with nitrogen for 15 minutes. A solution of Example 14B
(0.0750 g, 0.293 mmol) in degassed mixture of 4:1 dioxane/water
(1.25 mL) was added by syringe into the reaction vessel which was
then heated at 65.degree. C. for 2 hours in an oil bath, then
cooled to ambient temperature. The reaction mixture was shaken in a
separatory funnel with 30 mL ethyl acetate and 20 mL saturated
aqueous sodium chloride. The organics were dried over sodium
sulfate filtered, and concentrated. The crude product was purified
by flash chromatography (silica gel, 0-100% ethyl acetate in
hexanes) to provide 0.070 g (80%) of the title compound.
Example 14D
N-(4-(cyclopropylmethoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-
-yl)-2-methylphenyl)ethanesulfonamide
[0882] Example 14D was prepared according to the procedure used for
the preparation of Example 2E, substituting Example 14C for Example
2D and substituting ethanesulfonyl chloride for methanesulfonyl
chloride, respectively.
Example 14E
N-(4-(cyclopropylmethoxy)-2-methyl-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrol-
o[2,3-c]pyridin-3-yl)phenyl)ethanesulfonamide
[0883] Example 14E was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 14D for Example
1B. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 10.69 (d, J=4.9
Hz, 1H), 8.76 (bds, 1H), 7.08 (s, 1H), 7.04 (d, J=8.9 Hz, 1H), 6.75
(d, J=8.9 Hz, 1H), 6.66 (m, 1H), 5.81 (d, J=6.7 Hz, 1H), 3.60 (d,
J=6.4 Hz, 2H), 2.93 (q, J=7.6 Hz, 2H), 2.37 (s, 3H), 1.96 (s, 3H),
1.15 (t, =7.3 Hz, 3H), 0.87 (m, 1H), 0.26 (dt, J=7.6, 3.8 Hz, 2H),
0.01 (m, 2H). MS (ESI+) m/z 416.1 (M+H).sup.+.
Example 15
N-[4-(4-fluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyri-
din-3-yl)phenyl]ethanesulfonamide
Example 15A
3-(2-(4-fluorophenoxy)-5-nitrophenyl)-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]-
pyridine
[0884] A 5 mL microwave vial was charged with Example 2B (150 mg,
0.498 mmol), 4-fluorophenol (84 mg, 0.747 mmol), cesium carbonate
(243 mg, 0.747 mmol), and dimethylsulfoxide (5 mL). The reaction
mixture was heated at 110.degree. C. overnight under a nitrogen
bubbler. Upon cooling, the reaction was partitioned between 50%
brine (75 mL) and ethyl acetate (75 mL). The layers were separated
and the aqueous layer was extracted with ethyl acetate (40 ml). The
combined organics were dried over sodium sulfate, filtered and
concentrated. The residue was purified by flash chromatography
(silica gel, 0-1% methanol in dichloromethane) to give the title
compound (171 mg, 87%).
Example 15B
4-(4-fluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)an-
iline
[0885] A solution of Example 15A (167 mg, 0.425 mmol) in
tetrahydrofuran (20 mL) was added to 10% palladium on carbon (34
mg, 0.319 mmol) in a 50 mL pressure bottle and stirred at ambient
temperature under hydrogen at 30 psi for 1 hour. The solution was
filtered through a syringe filter and concentrated to give the
title compound (152 mg, 99%).
Example 15C
N-(4-(4-fluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl-
)phenyl)ethanesulfonamide
[0886] A 50 mL flask was charged with Example 15B (149 mg, 0.410
mmol) and dichloromethane (10 mL). Triethylamine (0.229 mL, 1.640
mmol) was added, followed by ethanesulfonyl chloride (0.117 mL,
1.230 mmol). The reaction mixture was stirred overnight at ambient
temperature and then concentrated. The residue was diluted with
dioxane (16 mL) and 1M aqueous sodium hydroxide (9.84 mL, 9.84
mmol). The mixture was stirred at 50.degree. C. for 1 hour. Upon
cooling to ambient temperature, the mixture was diluted with
saturated ammonium chloride (100 mL) and extracted with ethyl
acetate (80 mL). The organic layer was dried over sodium sulfate,
filtered, and concentrated. The residue was purified by flash
chromatography (silica gel, 0-10% methanol in methylene chloride)
to provide the title compound (166 mg, 89%).
Example 15D
N-[4-(4-fluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyri-
din-3-yl)phenyl]ethanesulfonamide
[0887] A 100 mL flask was charged with Example 15C (163 mg, 0.358
mmol) and dioxane (4 mL). Hydrogen chloride in dioxane (4N, 4.61
mL, 18.43 mmol) was added and the reaction mixture was heated at
70.degree. C. for 18 hours. The reaction mixture was concentrated
and purified by flash chromatography (silica gel, 1-7.5% methanol
in dichloromethane) to provide the title compound (96.6 mg, 61%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.96 (d, J=5.49
Hz, 1H), 9.79 (s, 1H), 7.50 (s, 1H), 7.45 (d, J=2.75 Hz, 1H),
7.07-7.18 (m, 3H), 6.98 (d, J=8.54 Hz, 1H), 6.86-6.95 (m, 3H), 6.56
(d, J=6.71 Hz, 1H), 4.05 (s, 3H), 3.11 (q, J=7.32 Hz, 2H), 1.23 (t,
J=7.32 Hz, 3H). MS (ESI+) m/z 442.1 (M+H).sup.+.
Example 16
N-[4-(4-cyanophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyrid-
in-3-yl)phenyl]methanesulfonamide
Example 16A
4-(2-bromo-4-nitrophenoxy)benzonitrile
[0888] A mixture of 2-bromo-1-fluoro-4-nitrobenzene (2.20 g, 10
mmol), 4-hydroxybenzonitrile (1.31 g, 11 mmol), and cesium
carbonate (3.58 g, 11 mmol) in DMSO (20 mL) was heated at
90.degree. C. for 2 hours. After cooling, the reaction mixture was
partitioned between water and ethyl acetate. The aqueous layer was
extracted three times with ethyl acetate. The combined organic
layers were washed with saturated aqueous sodium chloride, dried
over anhydrous magnesium sulfate, filtered, and concentrated to
give 3.19 g (110%) of the title compound.
Example 16B
4-(4-amino-2-bromophenoxy)benzonitrile
[0889] Example 16A (3.21 g, 10.06 mmol) in tetrahydrofuran (70 mL)
was added to platinum(IV) oxide (0.642 g, 2.83 mmol) in a 250 mL
stainless steel pressure bottle. The mixture was stirred for 45
minutes at 30 psi and room temperature. The solid was filtered off,
and the filtrate was concentrated. The residue was purified by
flash chromatography on silica gel, eluting with 30% ethyl acetate
in hexanes to provide 1.75 g (60%) of the title compound.
Example 16C
4-(4-amino-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)benzonit-
rile
[0890] A mixture of Example 16B (1.75 g, 6.05 mmol),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (3.07
g, 12.11 mmol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane
(0.159 g, 0.545 mmol), tris(dibenzylideneacetone)dipalladium(0)
(0.166 g, 0.182 mmol), and potassium acetate (1.307 g, 13.32 mmol)
in dioxane (30 mL) was degassed and back-filled with nitrogen
several times. The reaction mixture was heated at 80.degree. C. for
20 hours. The solvent was removed, and the residue was partitioned
between water and ethyl acetate. The aqueous layer was extracted
with additional ethyl acetate three times. The combined organic
layers were washed with saturated aqueous sodium chloride, dried
over anhydrous magnesium sulfate, filtered, and concentrated. The
crude product was purified by flash chromatography (silica gel,
40-70% ethyl acetate in hexanes) to provide 2.0 g (98%) of the
title compound.
Example 16D
4-(4-amino-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)phenoxy)ben-
zonitrile
[0891] A mixture of Example 2A (0.086 g, 0.3 mmol), Example 16C
(0.121 g, 0.360 mmol, 1.3 equivalents),
tetrakis(triphenylphosphine)palladium(0) (0.017 g, 0.015 mmol), and
cesium fluoride (0.137 g, 0.9 mmol) in dimethxoyethane (2 mL) and
methanol (1.0 mL) was heated under microwave conditions
(120.degree. C., 30 minutes). The reaction mixture was partitioned
between water and ethyl acetate. The aqueous layer was extracted
three times with ethyl acetate. The combined organic layers were
washed with saturated aqueous sodium chloride, dried over anhydrous
magnesium sulfate, filtered, and concentrated. The residue was
purified by flash column chromatography (silica gel, 40% ethyl
acetate/hexanes) to give the title compound (0.03 g, 27%
yield).
Example 16E
N-(4-(4-cyanophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-
phenyl)methanesulfonamide
[0892] A mixture of Example 16D (0.03 g, 0.081 mmol),
methanesulfonyl chloride (0.028 g, 0.243 mmol), and triethylamine
(0.049 g, 0.486 mmol) in dichloromethane (3 mL) was stirred at
ambient temperature for 2 hours. The solvent was removed, and the
residue was treated with sodium hydroxide (0.656 mL, 1.31 mmol) and
dioxane (3 mL). The reaction mixture was heated at 80.degree. C.
for 3 hours. After cooling, the reaction mixture was partitioned
between water and ethyl acetate. The aqueous layer was extracted
three times with ethyl acetate. The combined organic layers were
washed with saturated aqueous sodium chloride, dried over anhydrous
magnesium sulfate, filtered, and concentrated to give the title
compound.
Example 16F
N-[4-(4-cyanophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyrid-
in-3-yl)phenyl]methanesulfonamide
[0893] Example 16E (0.032 g, 0.071 mmol) in dioxane (2 ml) was
treated with hydrogen chloride (0.9 ml, 3.6 mmol). The reaction
mixture was heated at 75.degree. C. overnight. The solvent was
removed, and the residue was purified by reverse phase HPLC (C18,
CH.sub.3CN/water (0.1% TFA), 0-100%) to provide the title compound
(0.024 g, 0.055 mmol, 77% yield). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 10.97 (d, J=5.19 Hz, 1H), 9.86 (s, 1H),
7.69-7.73 (m, 2H), 7.47-7.48 (m, 1H), 7.46 (s, 1H), 7.18-7.23 (m,
2H), 6.93-6.97 (m, 1H), 6.88-6.92 (m, 1H), 6.55 (d, J=6.71 Hz, 1H),
4.01 (s, 3H), 3.06 (s, 3H). MS (ESI+) m/z 435.2 (M+H).sup.+.
Example 17
3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one
Example 17A
2-bromo-1-fluoro-4-(methylsulfonyl)benzene
[0894] 1-Fluoro-4-(methylsulfonyl)benzene (5.0 g, 28.7 mmol) in
conc. sulfuric acid (30 mL) was cooled to 0.degree. C. To this
solution was added N-bromosuccinimide (5.62 g, 31.6 mmol). The
reaction mixture was stirred at room temperature for 6 hours and
then poured into ice-water. The resulting solid was collected by
filtration, washed with cold water three times, and dried in a
vacuum oven overnight to give the title compound (6.95 g, 27.5
mmol, 96% yield).
Example 17B
2-(2-fluoro-5-(methylsulfonyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborol-
ane
[0895] A mixture of Example 17A (1.6 g, 5.33 mmol),
bis(pinacolato)diboron (1.625 g, 6.40 mmol),
PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (0.218 g, 0.267 mmol), and
potassium acetate (0.785 g, 8.00 mmol) in dimethylsulfoxide (20 mL)
was degassed and back-filled with nitrogen several times. The
reaction mixture was heated at 80.degree. C. overnight. The
reaction mixture was partitioned between water and ethyl acetate.
The aqueous layer was extracted with additional ethyl acetate
twice. The combined organic layers were washed with saturated
aqueous sodium chloride, dried over anhydrous magnesium sulfate,
filtered, and concentrated. The residue was purified by flash
column chromatography (silica gel, 10% ethyl acetate/hexanes) to
afford the title compound (0.67 g, 42% yield).
Example 17C
3-(2-fluoro-5-(methylsulfonyl)phenyl)-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]-
pyridine
[0896] A mixture of Example 2A (0.086 g, 0.3 mmol), Example 17B
(0.108 g, 0.360 mmol), tetrakis(triphenylphosphine)palladium(0)
(0.017 g, 0.015 mmol), and sodium carbonate (0.064 g, 0.600 mmol)
in toluene (2 mL), ethanol (0.5 mL), and water (0.5 mL) was
degassed and back-filled with nitrogen gas several times. The
reaction mixture was heated at 95.degree. C. for 3 hours. The
reaction mixture was partitioned between water and ethyl acetate.
The aqueous layer was extracted with additional ethyl acetate
twice. The combined organic layers were washed with brine, dried
over MgSO.sub.4, filtered, and concentrated. The residue was
purified by flash column chromatography on silica gel eluting with
30% ethyl acetate in hexanes to afford the title compound (0.045 g,
0.135 mmol, 44.9% yield).
Example 17D
3-(2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl)-7-methoxy-1-methyl-1H-
-pyrrolo[2,3-c]pyridine
[0897] A mixture of Example 17C (0.02 g, 0.060 mmol),
2,4-difluorophenol (2) (0.012 g, 0.090 mmol), and cesium carbonate
(0.029 g, 0.090 mmol) in DMSO was heated at 110.degree. C.
overnight. The reaction mixture was partitioned between water and
ethyl acetate. The aqueous layer was extracted with additional
ethyl acetate twice. The combined organic layers were washed with
brine, dried over MgSO.sub.4, filtered, and concentrated to give
the title compound (0.025 g, 0.056 mmol, 94% yield).
Example 17E
3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one
[0898] Example 17D (0.025 g, 0.056 mmol) in dioxane (1 mL) was
treated with hydrogen chloride (1.406 mL, 5.62 mmol). The reaction
mixture was heated at 70.degree. C. overnight. The solvent was
removed, and the residue was purified by reverse phase HPLC (C18,
CH.sub.3CN/water (0.1% TFA), 0-100%) to give the title compound
(0.021 g, 0.049 mmol, 87% yield). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 11.00 (d, J=5.19 Hz, 1H), 7.99 (d, J=2.14
Hz, 1H), 7.77 (dd, J=8.54, 2.44 Hz, 1H), 7.70 (s, 1H), 7.52-7.58
(m, 1H), 7.42-7.48 (m, 1H), 7.17-7.22 (m, 1H), 6.92-6.95 (m, 2H),
6.54 (d, J=6.71 Hz, 1H), 4.13 (s, 3H), 3.25 (s, 3H). MS (DCI+) m/z
430.0 (M+H).sup.+.
Example 18
1-methyl-3-[5-(methylsulfonyl)-2-phenoxyphenyl]-1,6-dihydro-7H-pyrrolo[2,3-
-c]pyridin-7-one
Example 18A
7-methoxy-1-methyl-3-(5-(methylsulfonyl)-2-phenoxyphenyl)-1H-pyrrolo[2,3-c-
]pyridine
[0899] Example 18A was prepared according to the procedure used for
the preparation of Example 2C, substituting Example 17C for Example
2B, and substituting phenol for 2,4-difluorophenol,
respectively.
Example 18B
1-methyl-3-[5-(methylsulfonyl)-2-phenoxyphenyl]-1,6-dihydro-7H-pyrrolo[2,3-
-c]pyridin-7-one
[0900] Example 18B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 18A for Example
1B. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 10.99 (d,
J=5.19 Hz, 1H), 8.01 (d, J=2.14 Hz, 1H), 7.79 (dd, J=8.85, 2.44 Hz,
1H), 7.68 (s, 1H), 7.42-7.46 (m, 2H), 7.20-7.24 (m, 1H), 7.13 (d,
J=7.63 Hz, 2H), 7.02 (d, J=8.54 Hz, 1H), 6.91-6.94 (m 1H), 6.71 (d,
J=6.71 Hz, 1H), 4.11 (s, 3H), 3.25 (s, 3H). MS (DCI+) m/z 395.1
(M+H).sup.+.
Example 19
3-[2-(3,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one
[0901] A mixture of Example 17C (0.1 g, 0.299 mmol),
3,4-difluorophenol (0.058 g, 0.449 mmol) and Cs.sub.2CO.sub.3
(0.146 g, 0.449 mmol) in DMSO (5 mL) was stirred at 110.degree. C.
for 12 hours, cooled and partitioned between ethyl acetate and
water. The organic layer was washed with saturated aqueous sodium
chloride, dried (anhydrous Na.sub.2SO.sub.4), filtered, and
concentrated. The resulting residue (0.13 g, 0.405 mmol) and 4M HCl
in dioxane (4 M, 13 mL) was heated at 70.degree. C. for 12 hours,
cooled and concentrated. The residue was purified by reverse phase
HPLC (C18, CH.sub.3CN/water (0.1% TFA), 10-100%) to afford the
title compound (0.05 g, 0.116 mmol, 38.7%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 11.00 (d, J=5.3 Hz, 1H), 8.01 (d, J=2.4
Hz, 1H), 7.80 (dd, J=8.7, 2.4 Hz, 1H), 7.68 (s, 1H), 7.50 (dd,
J=19.6, 9.2 Hz, 1H), 7.40 (ddd, J=11.5, 6.8, 2.9 Hz, 1H), 7.11 (d,
J=8.6 Hz, 1H), 7.00 (d, J=7.7 Hz, 1H), 6.95-6.88 (m, 1H), 6.54 (d,
J=6.3 Hz, 1H), 4.11 (s, 3H), 3.26 (s, 3H). MS (ESI+) m/z 431.0
(M+H).sup.+.
Example 20
3-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
Example 20A
3-(2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl)-7-methoxy-1-methyl-1H--
pyrrolo[2,3-c]pyridine
[0902] Cyclopropylmethanol (0.086 g, 1.196 mmol) in tetrahydrofuran
(5 mL) was treated with sodium hydride (0.029 g, 1.20 mmol) at
ambient temperature. The reaction mixture was stirred at room
temperature for 5 minutes. To this solution was added Example 17C
(0.10 g, 0.30 mmol). The reaction mixture was heated at 60.degree.
C. for 12 hours. The solvent was removed under reduced pressure to
provide the title compound.
Example 20B
3-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
[0903] Example 20B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 20A for Example
1B. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 9.90-9.72 (m,
1H), 7.98 (d, J=2.2 Hz, 1H), 7.79 (dd, J=8.6, 2.3 Hz, 1H), 7.44 (s,
1H), 7.04 (d, J=8.7 Hz, 1H), 6.90 (s, 1H), 6.66 (d, J=6.9 Hz, 1H),
4.24 (s, 3H), 3.96 (d, J=6.9 Hz, 2H), 3.06 (s, 3H), 1.29 (s, 1H),
0.67 (d, J=7.4 Hz, 2H), 0.38 (d, J=5.3 Hz, 2H). MS (ESI+) m/z 373.1
(M+H).
Example 21
3-[2-methoxy-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-
-c]pyridin-7-one
Example 21A
7-methoxy-3-(2-methoxy-5-(methylsulfonyl)phenyl)-1-methyl-1H-pyrrolo[2,3-c-
]pyridine
[0904] Sodium methanolate (0.048 g, 0.90 mmol) in tetrahydrofuran
(6 mL) was treated with Example 17C (0.20 g, 0.60 mmol). The
reaction mixture was heated at 60.degree. C. for 12 hours. The
solvent was removed to provide the title compound (0.17 g, 54%
yield).
Example 21B
3-[2-methoxy-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-
-c]pyridin-7-one
[0905] Example 21B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 21A for Example
1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.86 (s, 1H),
8.00 (d, J=2.4 Hz, 1H), 7.87 (dd, J=8.7, 2.4 Hz, 1H), 7.34 (s, 1H),
7.11 (d, J=8.7 Hz, 1H), 6.93 (d, J=6.7 Hz, 1H), 6.57 (d, J=6.9 Hz,
1H), 4.26 (s, 3H), 3.96 (s, 3H), 3.08 (s, 3H). MS (ESI) m/z 335.1
(M+H).
Example 22
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydrofuran-3-yloxy)phenyl]-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 22A
[0906] Example 22A was prepared according to the procedure used for
the preparation of Example 20A, substituting tetrahydrofuran-3-ol
for cyclopropylmethanol.
Example 22B
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydrofuran-3-yloxy)phenyl]-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one
[0907] Example 22B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 22A for Example
1B. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 10.98 (d, J=5.3
Hz, 1H), 7.86 (d, J=2.4 Hz, 1H), 7.83-7.74 (m, 1H), 7.57 (s, 1H),
7.30 (d, J=8.8 Hz, 1H), 6.94-6.86 (m, 1H), 6.43 (d, J=6.8 Hz, 1H),
5.22 (s, 1H), 4.12 (s, 3H), 3.93 (dd, J=10.2, 4.5 Hz, 1H), 3.77
(ddd, J=16.6, 16.1, 9.7 Hz, 3H), 3.21 (s, 3H), 2.35-2.22 (m, 1H),
2.04-1.93 (m, 1H). MS (ESI) m/z 389.1 (M+H).
Example 23
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydrofuran-3-ylmethoxy)phenyl]-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 23A
7-methoxy-1-methyl-3-(5-(methylsulfonyl)-2-((tetrahydrofuran-3-yl)methoxy)-
phenyl)-1H-pyrrolo[2,3-c]pyridine
[0908] Example 23A was prepared according to the procedure used for
the preparation of Example 20A, substituting
(tetrahydrofuran-3-yl)methanol for cyclopropylmethanol.
Example 23B
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydrofuran-3-ylmethoxy)phenyl]-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0909] Example 23B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 23A for Example
1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 11.00 (s, 1H),
7.86 (d, J=2.3 Hz, 1H), 7.79 (dd, J=8.7, 2.3 Hz, 1H), 7.58 (s, 1H),
7.34 (d, J=8.7 Hz, 1H), 6.92 (d, J=7.0 Hz, 1H), 6.44 (d, J=7.0 Hz,
1H), 4.12 (d, J=6.4 Hz, 4H), 4.09-4.02 (m, 1H), 3.72 (dd, J=14.8,
7.8 Hz, 2H), 3.62 (dd, J=15.2, 7.6 Hz, 1H), 3.50 (dd, J=8.6, 5.8
Hz, 1H), 3.21 (s, 3H), 2.67 (s, 1H), 1.98 (d, J=8.1 Hz, 1H), 1.64
(dd, J=12.4, 6.7 Hz, 1H). MS (ESI) m/z 403.1 (M+H).
Example 24
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-yloxy)phenyl]-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 24A
7-methoxy-1-methyl-3-(5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-yloxy)ph-
enyl)-1H-pyrrolo[2,3-c]pyridine
[0910] Example 24A was prepared according to the procedure used for
the preparation of Example 20A, substituting
tetrahydro-2H-pyran-4-ol for cyclopropylmethanol.
Example 24B
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-yloxy)phenyl]-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0911] Example 24B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 24A for Example
1B. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 9.74 (s, 1H),
8.00 (d, J=2.4 Hz, 1H), 7.82 (dd, J=8.7, 2.4 Hz, 1H), 7.34 (s, 1H),
7.10 (d, J=8.8 Hz, 1H), 6.92 (s, 1H), 6.61 (d, J=7.0 Hz, 1H), 4.68
(d, J=3.8 Hz, 1H), 4.25 (s, 3H), 3.83 (dd, J=12.3, 5.5 Hz, 2H),
3.57 (ddd, J=11.5, 8.0, 3.2 Hz, 2H), 3.08 (s, 3H), 2.02 (d, J=7.4
Hz, 2H), 1.79 (dd, J=13.2, 3.9 Hz, 2H). MS (ESI) m/z 403.1
(M+H).
Example 25
3-{2-[(4,4-difluorocyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 25A
3-(2-(4,4-difluorocyclohexyloxy)-5-(methylsulfonyl)phenyl)-7-methoxy-1-met-
hyl-1H-pyrrolo[2,3-c]pyridine
[0912] Example 25A was prepared according to the procedure used for
the preparation of Example 20A, substituting
4,4-difluorocyclohexanol for cyclopropylmethanol.
Example 25B
3-{2-[(4,4-difluorocyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0913] Example 25B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 25A for Example
1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.98 (d, J=5.2
Hz, 1H), 7.86 (d, J=2.4 Hz, 1H), 7.80 (dd, J=8.7, 2.4 Hz, 1H), 7.58
(s, 1H), 7.43 (d, J=8.9 Hz, 1H), 6.93-6.87 (m, 1H), 6.43 (d, J=6.9
Hz, 1H), 4.83 (s, 1H), 4.12 (s, 3H), 3.22 (s, 3H), 1.99-1.77 (m,
8H). MS (ESI+) m/z 437.2 (M+H).
Example 26
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-3-yloxy)phenyl]-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 26A
7-methoxy-1-methyl-3-(5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-3-yloxy)ph-
enyl)-1H-pyrrolo[2,3-c]pyridine
[0914] Example 26A was prepared according to the procedure used for
the preparation of Example 20A, substituting
tetrahydro-2H-pyran-3-ol for cyclopropylmethanol.
Example 26B
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-3-yloxy)phenyl]-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0915] Example 26B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 26A for Example
1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.98 (s, 1H),
7.87 (d, J=2.4 Hz, 1H), 7.76 (dd, J=8.7, 2.4 Hz, 1H), 7.64 (s, 1H),
7.38 (d, J=8.9 Hz, 1H), 6.92 (d, J=6.9 Hz, 1H), 6.50 (d, J=7.0 Hz,
1H), 4.64 (s, 1H), 4.12 (s, 3H), 3.81 (d, J=9.3 Hz, 1H), 3.57 (dd,
J=11.7, 5.8 Hz, 3H), 3.21 (s, 3H), 2.04 (s, 1H), 1.73 (s, 2H), 1.51
(s, 1H). MS (ESI) m/z 403.1 (M+H).
Example 27
3-[2-(2,2-dimethylpropoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one
Example 27A
7-methoxy-1-methyl-3-(5-(methylsulfonyl)-2-(neopentyloxy)phenyl)-1H-pyrrol-
o[2,3-c]pyridine
[0916] Example 27A was prepared according to the procedure used for
the preparation of Example 20A, substituting
2,2-dimethylpropan-1-ol for cyclopropylmethanol.
Example 27B
3-[2-(2,2-dimethylpropoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one
[0917] Example 27B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 27A for Example
1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.99 (d, J=5.5
Hz, 1H), 7.84 (d, J=2.4 Hz, 1H), 7.79 (dd, J=8.7, 2.4 Hz, 1H), 7.55
(s, 1H), 7.33 (d, J=8.8 Hz, 1H), 6.93-6.89 (m, 1H), 6.42 (d, J=6.9
Hz, 1H), 4.12 (s, 3H), 3.80 (s, 2H), 3.20 (s, 3H), 0.93 (s, 9H). MS
(ESI) m/z 389.1 (M+H).
Example 28
3-[2-(cyclobutylmethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one
Example 28A
3-(2-(cyclobutylmethoxy)-5-(methylsulfonyl)phenyl)-7-methoxy-1-methyl-1H-p-
yrrolo[2,3-c]pyridine
[0918] Example 28A was prepared according to the procedure used for
the preparation of Example 20A, substituting cyclobutylmethanol for
cyclopropylmethanol.
Example 28B
3-[2-(cyclobutylmethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one
[0919] Example 28B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 28A for Example
1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.97 (d, J=4.1
Hz, 1H), 7.86 (d, J=2.4 Hz, 1H), 7.78 (dd, J=8.7, 2.3 Hz, 1H), 7.55
(s, 1H), 7.32 (d, J=8.7 Hz, 1H), 6.93-6.88 (m, 1H), 6.43 (d, J=7.0
Hz, 1H), 4.11 (d, J=8.7 Hz, 5H), 3.20 (s, 3H), 2.73 (qd, J=11.0,
5.1 Hz, 1H), 2.08-1.98 (m, 2H), 1.94-1.79 (m, 4H). MS (ESI) m/z
387.1 (M+H).
Example 29
1-methyl-3-{2-[(1-methylcyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 29A
7-methoxy-1-methyl-3-(2-((1-methylcyclopropyl)methoxy)-5-(methylsulfonyl)p-
henyl)-1H-pyrrolo[2,3-c]pyridine
[0920] Example 29A was prepared according to the procedure used for
the preparation of Example 20A, substituting
(1-methylcyclopropyl)methanol for cyclopropylmethanol.
Example 29B
1-methyl-3-{2-[(1-methylcyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0921] Example 29B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 29A for Example
1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.98 (d, J=5.1
Hz, 1H), 7.86 (d, J=2.4 Hz, 1H), 7.77 (dd, J=8.7, 2.4 Hz, 1H), 7.60
(s, 1H), 7.26 (d, J=8.8 Hz, 1H), 6.95-6.89 (m, 1H), 6.48 (d, J=6.8
Hz, 1H), 4.13 (s, 3H), 3.93 (s, 2H), 3.19 (s, 3H), 1.09 (s, 3H),
0.53 (t, J=4.7 Hz, 2H), 0.37 (t, J=5.0 Hz, 2H). MS (ESI) m/z 387.1
(M+H).
Example 30
1-methyl-3-[5-(methylsulfonyl)-2-(oxetan-3-ylmethoxy)phenyl]-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
Example 30A
7-methoxy-1-methyl-3-(5-(methylsulfonyl)-2-(oxetan-3-ylmethoxy)phenyl)-1H--
pyrrolo[2,3-c]pyridine
[0922] Example 30A was prepared according to the procedure used for
the preparation of Example 20A, substituting oxetan-3-ylmethanol
for cyclopropylmethanol.
Example 30B
3-chloro-2-((2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(methy-
lsulfonyl)phenoxy)methyl)propan-1-ol
[0923] Example 30A (0.15 g, 0.373 mmol) in dioxane 12.2 mL) was
treated with HCl (1.132 mL, 37.3 mmol). The reaction mixture was
heated at 70.degree. C. for 12 hours. The reaction mixture was
cooled to room temperature and combined with ethyl acetate. The
solution was washed with saturated aqueous sodium chloride
solution, and the organic layer separated, dried over anhydrous
magnesium sulfate, filtered, and concentrated under reduced
pressure to provide the title compound.
Example 30C
1-methyl-3-[5-(methylsulfonyl)-2-(oxetan-3-ylmethoxy)phenyl]-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
[0924] Example 30B (0.15 g, 0.353 mmol) in ethanol (6 mL) was
treated with K.sub.2CO.sub.3 (0.098 g, 0.706 mmol). The reaction
mixture was heated at 80.degree. C. for 4 hours. The solvent was
evaporated under reduced pressure, and the residue was purified by
reverse phase HPLC (C18, water (10 mM ammonium
carbonate)/acetonitrile) to provide the title compound (0.13 g,
0.269 mmol, 72% yield).sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
9.50 (s, 1H), 7.98 (dd, J=5.6, 2.4 Hz, 1H), 7.84 (dd, J=8.7, 2.3
Hz, 1H), 7.33 (d, J=7.6 Hz, 1H), 7.13 (dd, J=8.7, 4.2 Hz, 1H), 6.92
(dd, J=23.4, 7.0 Hz, 1H), 6.55 (dd, J=9.6, 7.1 Hz, 1H), 5.25 (d,
J=27.4 Hz, 2H), 4.73 (d, J=5.2 Hz, 2H), 4.22 (d, J=5.2 Hz, 3H),
4.16 (d, J=11.9 Hz, 2H), 3.97 (s, 1H), 3.07 (d, J=1.5 Hz, 3H). MS
(ESI) m/z 389.1 (M+H).
Example 31
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 31A
7-methoxy-1-methyl-3-(5-(methylsulfonyl)-2-((tetrahydro-2H-pyran-4-yl)meth-
oxy)phenyl)-1H-pyrrolo[2,3-c]pyridine
[0925] Example 31A was prepared according to the procedure used for
the preparation of Example 20A, substituting
(tetrahydro-2H-pyran-4-yl)methanol for cyclopropylmethanol.
Example 31B
1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0926] Example 31B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 31A for Example
1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.98 (s, 1H),
7.85 (d, J=2.4 Hz, 1H), 7.79 (dd, J=8.7, 2.4 Hz, 1H), 7.56 (s, 1H),
7.34 (d, J=8.8 Hz, 1H), 6.95-6.87 (m, 1H), 6.42 (d, J=6.9 Hz, 1H),
4.12 (s, 3H), 4.00 (d, J=6.5 Hz, 2H), 3.83 (d, J=8.4 Hz, 2H), 3.27
(dd, J=11.6, 1.4 Hz, 2H), 3.20 (s, 3H), 2.04 (s, 1H), 1.59 (dd,
J=12.6, 1.1 Hz, 2H), 1.29 (ddd, J=24.9, 12.3, 4.4 Hz, 2H). MS (ESI)
m/z 417.1 (M+H).
Example 32
3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one
Example 32A
3-(2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl)-7-methoxy-1-methyl-1H-
-pyrrolo[2,3-c]pyridine
[0927] Example 32A was prepared according to the procedure used for
the preparation of Example 20A, substituting 2-cyclopropylethanol
for cyclopropylmethanol.
Example 32B
3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one
[0928] Example 32B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 32A for Example
1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.96 (d, J=3.8
Hz, 1H), 7.85 (d, J=2.4 Hz, 1H), 7.79 (dd, J=8.7, 2.4 Hz, 1H), 7.59
(s, 1H), 7.34 (d, J=8.7 Hz, 1H), 6.94-6.87 (m, 1H), 6.43 (d, J=7.0
Hz, 1H), 4.18 (t, J=6.6 Hz, 2H), 4.12 (s, 3H), 3.20 (s, 3H), 1.65
(q, J=6.6 Hz, 2H), 0.80-0.70 (m, 1H), 0.46-0.33 (m, 2H), 0.14-0.02
(m, 2H). MS (ESI) m/z 387.1 (M+H).
Example 33
3-{2-[(cis-4-hydroxycyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 33A
4-(2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(methylsulfonyl)-
phenoxy)cyclohexanol
[0929] Example 33A was prepared according to the procedure used for
the preparation of Example 20A, substituting cyclohexane-1,4-diol
(cis/trans mixture) for cyclopropylmethanol.
Example 33B
3-{2-[(cis-4-hydroxycyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0930] Example 33B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 33A for Example
1B. This material was separated from the trans isomer (Example 34)
by preparative HPLC (C18, water (0.1% TFA): acetonitrile, 34-80%
gradient). Example 33B was the second isomer to elute (retention
time=1.509 minutes). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.98 (s, 1H), 7.86 (d, J=2.4 Hz, 1H), 7.76 (d, J=8.7 Hz, 1H),
7.59 (s, 1H), 7.34 (d, J=8.9 Hz, 1H), 6.96-6.87 (m, 1H), 6.48 (d,
J=6.9 Hz, 1H), 4.65 (s, 1H), 4.13 (s, 4H), 3.58 (s, 1H), 3.20 (s,
3H), 1.85 (s, 2H), 1.67 (s, 2H), 1.55 (s, 2H), 1.45 (s, 2H). MS
(ESI) m/z 417.1 (M+H).
Example 34
3-{2-[(trans-4-hydroxycyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1-
,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0931] Example 34 was isolated as the first eluting isomer
(retention time=1.493 minutes) from the preparative HPLC
purification described in Example 33B. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.95 (d, J=5.2 Hz, 1H), 7.83 (d, J=2.4
Hz, 1H), 7.75 (dd, J=2.4, 6.4 Hz, 1H), 7.58 (s, 1H), 7.36 (d, J=9.2
Hz, 1H), 6.90 (t, J=6.4 Hz, 1H), 6.43 (d, J=6.8 Hz, 1H), 4.58-4.53
(m, 2H), 4.13 (s, 3H), 3.52-3.49 (m, 1H), 3.19 (s, 3H), 2.04-2.01
(m, 2H), 1.79-1.75 (m, 2H), 1.46-1.32 (m, 4H). MS (ESI) m/z 417.1
(M+H).
Example 35
3-[2-(2-cyclopentylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one
[0932] 2-cyclopentylethanol (0.137 g, 1.196 mmol) in
tetrahydrofuran (5 mL) was treated with NaH (0.029 g, 1.196 mmol)
at ambient temperature, stirred for 5 minutes and treated with the
product from Example 17C (0.1 g, 0.299 mmol). The reaction mixture
was heated at 60.degree. C. for 12 hours and partitioned with ethyl
acetate and water. The organic layer was washed with saturated
aqueous sodium chloride, dried (anhydrous Na.sub.2SO.sub.4),
filtered, and concentrated. The resulting residue (0.15 g) was
treated with 4 M HCl in dioxane (15 mL), heated at 70.degree. C.
for 12 hours, cooled, concentrated and the residue was purified by
reverse phase HPLC (C18, CH.sub.3CN/water (0.1% TFA), 10-100%) to
give the title compound (0.05 g, 0.121 mmol, 34.5%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 10.96 (d, J=5.0 Hz, 1H), 7.84
(d, J=2.4 Hz, 1H), 7.79 (dd, J=8.7, 2.4 Hz, 1H), 7.57 (s, 1H), 7.33
(d, J=8.7 Hz, 1H), 6.94-6.86 (m, 1H), 6.42 (d, J=6.5 Hz, 1H),
4.31-3.99 (m, 5H), 3.20 (s, 3H), 1.85 (dd, J=14.6, 7.3 Hz, 1H),
1.79-1.63 (m, 4H), 1.62-1.39 (m, 4H), 1.11 (dd, J=12.0, 7.9 Hz,
2H). MS (ESI+) m/z 415.1 (M+H).sup.+.
Example 36
3-[2-(2-cyclohexylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
[0933] The title compound was prepared according to the procedure
in Example 35 substituting 2-cyclohexylethanol for
2-cyclopentylethanol. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.97 (d, J=5.1 Hz, 1H), 7.84 (d, J=2.3 Hz, 1H), 7.79 (dd,
J=8.7, 2.3 Hz, 1H), 7.55 (s, 1H), 7.33 (d, J=8.7 Hz, 1H), 6.97-6.86
(m, 1H), 6.42 (d, J=6.8 Hz, 1H), 4.26-4.01 (m, 5H), 3.20 (s, 3H),
1.77-1.51 (m, 7H), 1.38 (s, 1H), 1.13 (t, J=9.5 Hz, 3H), 0.90 (d,
J=11.3 Hz, 2H). MS (ESI+) m/z 429.1 (M+H).sup.+.
Example 37
1-methyl-3-[5-(methylsulfonyl)-2-(2-phenylethoxy)phenyl]-1,6-dihydro-7H-py-
rrolo[2,3-c]pyridin-7-one
[0934] The title compound was prepared according to the procedure
in Example 35 substituting 2-phenylethanol for
2-cyclopentylethanol. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.98 (d, J=5.1 Hz, 1H), 7.84 (d, J=2.4 Hz, 1H), 7.78 (dd,
J=8.7, 2.4 Hz, 1H), 7.36 (d, J=8.8 Hz, 1H), 7.33-7.14 (m, 6H),
6.93-6.86 (m, 1H), 6.43 (d, J=6.4 Hz, 1H), 4.41 (t, J=6.5 Hz, 2H),
4.06 (s, 3H), 3.19 (s, 3H), 3.08 (t, J=6.5 Hz, 2H). MS (ESI+) m/z
423.1 (M+H).sup.+.
Example 38
3-[2-(2,3-dihydro-1H-inden-2-yloxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0935] The title compound was prepared according to the procedure
in Example 35 substituting 2,3-dihydro-1H-inden-2-ol for
2-cyclopentylethanol. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.88 (d, J=5.2 Hz, 1H), 7.88-7.79 (m, 2H), 7.45 (d, J=8.5 Hz,
1H), 7.27 (dd, J=5.2, 3.4 Hz, 2H), 7.23-7.11 (m, 3H), 6.74-6.64 (m,
1H), 6.25 (d, J=6.4 Hz, 1H), 5.47 (s, 1H), 3.95 (s, 3H), 3.42 (dd,
J=16.9, 5.8 Hz, 2H), 3.22 (s, 3H), 3.06 (d, J=16.9 Hz, 2H). MS
(ESI+) m/z 435.1 (M+H).sup.+.
Example 39
1-methyl-3-{5-(methylsulfonyl)-2-[2-(thiophen-2-yl)ethoxy]phenyl}-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one
[0936] The title compound was prepared according to the procedure
in Example 35 substituting 2-(thiophen-2-yl)ethanol for
2-cyclopentylethanol. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.98 (d, J=5.2 Hz, 1H), 7.87 (d, J=2.4 Hz, 1H), 7.78 (dd,
J=8.7, 2.4 Hz, 1H), 7.36 (dd, J=4.9, 3.6 Hz, 2H), 7.32 (s, 1H),
7.05-6.94 (m, 2H), 6.93-6.86 (m, 1H), 6.46 (d, J=6.3 Hz, 1H), 4.39
(t, J=6.3 Hz, 2H), 4.07 (s, 3H), 3.30 (s, 2H), 3.20 (s, 3H). MS
(ESI+) m/z 429.1 (M+H).sup.+.
Example 40
3-[2-(3,3-dimethylbutoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
[0937] The title compound was prepared according to the procedure
in Example 35 substituting 3,3-dimethylbutan-1-ol for
2-cyclopentylethanol. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.96 (d, J=5.3 Hz, 1H), 7.84 (d, J=2.4 Hz, 1H), 7.79 (dd,
J=8.7, 2.4 Hz, 1H), 7.58 (s, 1H), 7.37 (d, J=8.7 Hz, 1H), 6.94-6.87
(m, 1H), 6.42 (d, J=6.3 Hz, 1H), 4.18 (t, J=7.4 Hz, 2H), 4.11 (s,
3H), 3.20 (s, 3H), 1.69 (t, J=7.3 Hz, 2H), 0.92 (s, 9H). MS (ESI+)
m/z 403.1 (M+H).sup.+.
Example 41
3-{2-[(4,4-difluorocyclohexyl)methoxy]-5-(methylsulfonyl)phenyl}-1-methyl--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 41A
3-(2-((4,4-difluorocyclohexyl)methoxy)-5-(methylsulfonyl)phenyl)-7-methoxy-
-1-methyl-1H-pyrrolo[2,3-c]pyridine
[0938] A solution of (4,4-difluorocyclohexyl)methanol (0.156 g,
1.04 mmol) in anhydrous tetrahydrofuran (4.33 mL) under nitrogen
was treated with sodium hydride (0.042 g, 1.040 mmol) at ambient
temperature, stirred for 10 minutes, treated with the product from
Example 17C (0.087 g, 0.26 mmol) and heated under nitrogen at
60.degree. C. for 18 hours. The mixture was cooled and partitioned
into ethyl acetate/water. The organic layer was washed with
saturated aqueous sodium chloride, dried (anhydrous
Na.sub.2SO.sub.4), filtered, and concentrated. Purification by
chromatography (silica gel, 0-60% ethyl acetate in heptanes)
afforded the title compound (0.1 g, 83%).
Example 41B
3-{2-[(4,4-difluorocyclohexyl)methoxy]-5-(methylsulfonyl)phenyl}-1-methyl--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0939] The product from Example 41A (0.1 g, 0.215 mmol) and 4 M
hydrogen chloride in dioxane (5 mL, 20.00 mmol) were combined and
heated at 70.degree. C. for 24 hours, cooled and concentrated.
Purification by chromatography (silica gel, 0-4% MeOH in
dichloromethane) afforded the title compound (0.078 g, 80%).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.96 (d, J=5.43
Hz, 1H) 7.86 (d, J=2.37 Hz, 1H) 7.79 (dd, J=8.65, 2.54 Hz, 1H) 7.55
(s, 1H) 7.33 (d, J=8.48 Hz, 1H) 6.88-6.95 (m, 1H) 6.43 (d, J=6.10
Hz, 1H) 4.12 (s, 3H) 4.04 (d, J=6.10 Hz, 2H) 3.20 (s, 3H) 1.60-2.12
(m, 7H) 1.24-1.41 (m, 2H). MS(ESI+) m/z 451 (M+H).sup.+.
Example 42
3-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 42A
3-(2-((2,2-difluorocyclopropyl)methoxy)-5-(methylsulfonyl)phenyl)-7-methox-
y-1-methyl-1H-pyrrolo[2,3-c]pyridine
[0940] Example 42A was prepared according to the procedure used for
the preparation of Example 20A, substituting
(2,2-difluorocyclopropyl)methanol for cyclopropylmethanol.
Example 42B
3-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0941] Example 42B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 42A for Example
1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
Example 43
3-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1,6-dime-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0942] A solution of the product from Example 42B (0.027 g, 0.066
mmol) in dimethylformamide (0.5 mL) was treated with sodium hydride
(5.29 mg, 0.132 mmol) at ambient temperature, stirred until gas
evolution had subsided (10 minutes) and treated with iodomethane
(0.019 g, 0.132 mmol). The mixture was stirred for 20 minutes at
ambient temperature and partitioned between ethyl acetate and water
adjusting the pH to 7 with HCl. The organic layer was washed with
water, saturated aqueous sodium chloride, dried (anhydrous
Na.sub.2SO.sub.4), filtered, and concentrated. Purification by
chromatography (silica gel, 0-3% MeOH in dichloromethane) afforded
the title compound (0.013 g, 46%). .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. ppm 7.87 (d, J=2.71 Hz, 1H) 7.80 (dd, J=8.65,
2.54 Hz, 1H) 7.60 (s, 1H) 7.34 (d, J=8.82 Hz, 1H) 7.21 (d, J=7.12
Hz, 1H) 6.49 (d, J=7.12 Hz, 1H) 4.15-4.36 (m, 2H) 4.13 (s, 3H) 3.48
(s, 3H) 3.21 (s, 3H) 2.16-2.34 (m, 1H) 1.65-1.80 (m, 1H) 1.45-1.60
(m, 1H). MS (ESI+) m/z 423 (M+H).sup.+.
Example 44
3-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 44A
2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(methylsulfonyl)ani-
line
[0943] The product from Example 59A (1.0 g, 3.47 mmol),
2-bromo-4-methanesulfonylaniline (Oakwood, 0.868 g, 3.47 mmol),
tris(dibenzylideneacetone)dipalladium(0) (0.095 g, 0.104 mmol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (0.101
g, 0.347 mmol) and sodium carbonate (1.287 g, 12.15 mmol) were
combined and sparged with argon for 15 minutes. Meanwhile a
solution of 4:1 dioxane/water (35 mL) was sparged with nitrogen for
15 minutes and transferred by syringe into the reaction vessel
under argon. The mixture was stirred at 60.degree. C. for 4 hours,
diluted with water and filtered to collect a solid. The solid was
dissolved in 100 mL of hot 1:1 ethyl acetate/methanol, filtered to
remove the solid palladium and the filtrate was concentrated to
afford the title compound (0.98 g, 85%).
Example 44B
N-(cyclopropylmethyl)-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-
-4-(methylsulfonyl)aniline
[0944] The product from Example 44A (0.1 g, 0.302 mmol),
cyclopropanecarboxaldehyde (0.063 g, 0.905 mmol) and sodium
triacetoxyhydroborate (0.192 g, 0.905 mmol) were combined in
dichloromethane (1.0 mL) and acetic acid (1.0 mL) under nitrogen,
stirred for 6 hours and partitioned into water/ethyl acetate. The
organic layer was washed with 5% aqueous sodium bicarbonate,
saturated aqueous sodium chloride, dried (anhydrous
Na.sub.2SO.sub.4), filtered, and concentrated to afford the title
compound (0.116 g, 100%).
Example 44C
3-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0945] The product from Example 44B (0.035 g, 0.091 mmol) and 4 M
hydrogen chloride in dioxane (0.023 mL, 0.091 mmol) were combined
and heated at 70.degree. C. for 24 hours, cooled and concentrated.
Purification by reverse phase chromatography (C18, CH.sub.3CN/water
(0.1% TFA), 10-100%) afforded the title compound (0.024 g, 53%) as
the TFA salt. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.95
(d, J=5.43 Hz, 1H) 7.62 (dd, J=8.82, 2.37 Hz, 1H) 7.45-7.48 (m, 2H)
6.86-6.91 (m, 1H) 6.84 (d, J=8.82 Hz, 1H) 6.21 (dd, J=6.78, 1.02
Hz, 1H) 5.50 (s, 1H) 4.12 (s, 3H) 3.09 (s, 3H) 3.05 (d, J=6.44 Hz,
2H) 0.95-1.14 (m, 1H) 0.38-0.45 (m, 2H) 0.17-0.24 (m, 2H). MS
(ESI+) m/z 372 (M+H).sup.+.
Example 45
3-{2-[(cyclopropylmethyl)(methyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 45A
N-(cyclopropylmethyl)-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-
-N-methyl-4-(methylsulfonyl)aniline
[0946] A solution of the product from Example 44B (0.116 g, 0.301
mmol) in dimethylformamide (2 mL) under nitrogen was treated with
sodium hydride (0.018 g, 0.451 mmol) at ambient temperature,
stirred for 30 minutes, treated with iodomethane (0.038 mL, 0.602
mmol), stirred for 30 minutes at ambient temperature and quenched
into cold water. The mixture was extracted into ethyl acetate and
the organic layer was washed with saturated aqueous sodium
chloride, dried (anhydrous Na.sub.2SO.sub.4), filtered, and
concentrated to afford the title compound (0.12 g, 100%).
Example 45B
3-{2-[(cyclopropylmethyl)(methyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0947] The product from Example 45A (0.12 g, 0.30 mmol) and 4 M
hydrogen chloride in dioxane (5 mL, 20.00 mmol) were combined and
heated at 70.degree. C. for 24 hours, cooled and concentrated.
Purification by reverse phase chromatography (C18, CH.sub.3CN/water
(0.1% TFA), 10-100%) afforded the title compound (0.068 g, 45%) as
the TFA salt. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.91
(d, J=5.09 Hz, 1H) 7.70 (dd, J=8.48, 2.37 Hz, 1H) 7.61 (d, J=2.37
Hz, 1H) 7.54-7.56 (m, 1H) 7.21 (d, J=8.48 Hz, 1H) 6.84 (dd, J=7.12,
5.76 Hz, 1H) 6.31 (d, J=5.76 Hz, 1H) 4.11 (s, 3H) 3.15 (s, 3H) 2.77
(s, 3H) 2.74 (d, J=6.78 Hz, 2H) 0.64-0.78 (m, 1H) 0.28-0.37 (m, 2H)
-0.11--0.05 (m, 2H). MS (ESI+) m/z 386 (M+H).sup.+.
Example 46
4-({[2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(methy-
lsulfonyl)phenyl]amino}methyl)benzonitrile
Example 46A
4-((2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(methylsulfonyl-
)phenylamino)methyl)benzonitrile
[0948] The title compound was prepared according to the procedure
in Example 44B substituting 4-cyanobenzaldehyde for
cyclopropanecarboxaldehyde (0.067 g, 100%).
Example 46B
4-({[2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(methy-
lsulfonyl)phenyl]amino}methyl)benzonitrile
[0949] The product from Example 46A (0.067 g, 0.15 mmol) and 4 M
hydrogen chloride in dioxane (5 mL, 20.00 mmol) were combined and
heated at 70.degree. C. for 24 hours, cooled and concentrated
Purification by reverse phase chromatography (C18, CH.sub.3CN/water
(0.1% TFA), 10-100%) afforded the title compound (0.01 g, 15%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.97 (d, J=5.19
Hz, 1H) 7.80 (d, J=8.54 Hz, 2H) 7.45-7.61 (m, 5H) 6.87-6.95 (m, 1H)
6.54 (d, J=8.85 Hz, 1H) 6.48-6.53 (m, 1H) 6.23 (d, J=6.71 Hz, 1H)
4.48 (d, J=6.10 Hz, 2H) 4.14 (s, 3H) 3.07 (s, 3H). MS (ESI+) m/z
433 (M+H).sup.+.
Example 47
3-{2-[(cyclohexylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 47A
N-(cyclohexylmethyl)-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)--
4-(methylsulfonyl)aniline
[0950] The title compound was prepared according to the procedure
in Example 44B substituting cyclohexylcarboxaldehyde for
cyclopropanecarboxaldehyde (0.050 g, 63%).
Example 47B
3-{2-[(cyclohexylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one
[0951] The title compound was prepared according to the procedure
in Example 44C substituting the product from Example 47A for the
product from Example 44C (0.027 g, 53%). .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.64 (dd, J=8.70, 2.29 Hz, 1H)
7.44-7.46 (m, 2H) 6.93 (d, J=7.02 Hz, 1H) 6.83 (d, J=8.85 Hz, 1H)
6.24 (d, J=6.71 Hz, 1H) 4.12 (s, 3H) 3.09 (s, 3H) 3.06 (d, J=7.32
Hz, 2H) 2.10-2.17 (m, 1H) 1.61-1.69 (m, 2H) 1.51-1.58 (m, 2H)
1.44-1.50 (m, 4H) 1.15-1.24 (m, 2H). MS (ESI+) m/z 414
(M+H).sup.+.
Example 48
3-[2-(4-chlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-py-
rrolo[2,3-c]pyridin-7-one
Example 48A
ethyl(4-fluorophenyl)sulfane
[0952] A solution of 4-fluorobenzenethiol (10 g, 78 mmol) and
iodoethane (7.57 mL, 94 mmol) in tetrahydrofuran (100 mL) was
treated with triethylamine (13.05 mL, 94 mmol) at room temperature
for 2 hours. The reaction mixture was filtered and the filtrate was
concentrated, washed with hexane and dried under vacuum to provide
the title compound (10.5 g, 81%).
Example 48B
1-(ethylsulfonyl)-4-fluorobenzene
[0953] Example 48A (10 g, 64.0 mmol) was treated with
3-chloroperoxybenzoic acid (28.6 g, 141 mmol) at room temperature
for 4 hours. The reaction mixture was filtered, and the solids were
washed with dichloromethane. The filtrate was washed twice with 10%
sodium hydroxide, and saturated sodium bicarbonate. The organic
solvent was removed under reduced pressure to provide the title
compound (11.5 g (95%).
Example 48C
2-bromo-4-(ethylsulfonyl)-1-fluorobenzene
[0954] Example 48C was prepared according to the procedure of
Example 17A, substituting Example 48B for
1-fluoro-4-(methylsulfonyl)benzene to provide the title
compound.
Example 48D
2-(5-(ethylsulfonyl)-2-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborola-
ne
[0955] Example 48D was prepared according to the procedure of
Example 17B, substituting Example 48C for Example 17A to provide
the title compound.
Example 48E
3-(5-(ethylsulfonyl)-2-fluorophenyl)-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]p-
yridine
[0956] Example 48E was prepared according to the procedure of
Example 2B, substituting Example 48D for
2-fluoro-5-nitrophenylboronic acid to provide the title
compound.
Example 48F
3-(2-(4-chlorophenoxy)-5-(ethylsulfonyl)phenyl)-7-methoxy-1-methyl-1H-pyrr-
olo[2,3-c]pyridine
[0957] Example 48F was prepared according to the procedure used for
the preparation of Example 2C, substituting Example 48E for Example
2B and 4-chlorophenol for 2,4-difluorophenol, with the exception
that the reaction mixture was heated at 100.degree. C. for 18
hours, and the residue was purified by flash column chromatography
(silica gel, 0-2.5% methanol in dichloromethane) to provide the
title compound.
Example 48G
3-[2-(4-chlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-py-
rrolo[2,3-c]pyridin-7-one
[0958] Example 48G was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 48F for Example
1B, with the exception that the reaction mixture was heated at
70.degree. C. to provide the title compound. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 9.80 (s, 1H), 8.10 (d, J=2.44 Hz, 1H), 7.72
(dd, J=8.54, 2.44 Hz, 1H), 7.29-7.40 (m, 3H), 7.02 (d, J=8.54 Hz,
1H), 6.91-6.99 (m, 3H), 6.66 (d, J=7.02 Hz, 1H), 4.22 (s, 3H), 3.16
(q, J=7.53 Hz, 2H), 1.33 (t, J=7.48 Hz, 3H). MS (ESI+) m/z 443.2
(M+H).sup.+.
Example 49
[0959]
3-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 49A
3-(2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl)-7-methoxy-1-methyl-1H--
pyrrolo[2,3-c]pyridine
[0960] Example 49A was prepared according to the procedure used for
the preparation of Example 2C, substituting Example 48E for Example
2B with the exception that the reaction mixture was heated at
100.degree. C. for 18 hours, and the residue was purified by flash
column chromatography (silica gel, 0-2.5% methanol in
dichloromethane) to provide the title compound.
Example 49B
3-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
[0961] Example 49B was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 49A for Example
1B, with the exception that the reaction mixture was heated at
70.degree. C. to provide the title compound. .sup.1H NMR (500 MHz,
CDCl.sub.3) .delta. ppm 9.95 (s, 1H), 8.07 (d, J=2.44 Hz, 1H), 7.71
(dd, J=8.70, 2.29 Hz, 1H), 7.43 (s, 1H), 7.06-7.15 (m, 1H),
6.98-7.05 (m, 1H), 6.89-6.98 (m, 2H), 6.85 (d, J=8.54 Hz, 1H), 6.71
(d, J=7.02 Hz, 1H), 4.25 (s, 3H), 3.15 (q, J=7.53 Hz, 2H), 1.32 (t,
J=7.48 Hz, 3H). MS (ESI+) m/z 445.1 (M+H).sup.+.
Example 50
3-[2-(cyclopropylmethoxy)-6-methylphenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[-
2,3-c]pyridin-7-one
Example 50A
2-bromo-1-(cyclopropylmethoxy)-3-methylbenzene
[0962] Example 50A was prepared according to the procedure used for
the preparation of Example 14A, substituting
2-bromo-3-methyl-phenol for 2-bromo-3-methyl-4-nitrophenol.
Example 50B
3-(2-(cyclopropylmethoxy)-6-methylphenyl)-7-methoxy-1-methyl-1H-pyrrolo[2,-
3-c]pyridine
[0963] Example 50B was prepared according to the procedure used for
the preparation of Example 14C, substituting Example 50A for
Example 14B.
Example 50C
3-(2-(cyclopropylmethoxy)-6-methylphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridi-
n-7(6H)-one
[0964] Example 50C was prepared according to the procedure used for
the preparation of Example 1C, substituting Example 50B for Example
1B. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 10.79 (d, J=4.9
Hz, 1H), 7.22 (s, 1H), 7.16 (t, J=7.9 Hz, 1H), 6.87 (dd, J=7.8, 3.2
Hz, 1H), 6.79-6.75 (m, 2H), 5.97 (d, J=6.7 Hz, 1H), 3.72 (d, J=6.4
Hz, 2H), 2.50 (s, 3H), 2.09 (s, 3H), 0.99 (m, 1H), 0.38 (m, 2H),
0.15 (m, 2H). MS (DCI+) m/z 309.0 (M+H).sup.+.
Example 51
4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)benzenesulfonamide
Example 51A
4-(2,4-difluorophenoxy)-3-nitrobenzenesulfonamide
[0965] A solution of 2,4-difluorophenol (5.39 g, 41.4 mmol) in
dimethylformamide (34.5 mL) at 10.degree. C. under nitrogen was
treated portionwise with sodium hydride (1.657 g, 41.4 mmol),
stirred for 15 minutes and treated portionwise with
4-fluoro-3-nitrobenzenesulfonamide (2.28 g, 10.36 mmol). The
solution was stirred at ambient temperature for 1.5 hours, diluted
into ethyl acetate and carefully quenched with 0.5 M HCl to a
constant pH of 6. The organic layer was washed with saturated
aqueous sodium chloride, dried (MgSO.sub.4), filtered, and
concentrated. The residue was triturated in 3:1 hexane/ethyl
acetate to afford the title compound (3.24 g, 95%).
Example 51B
3-amino-4-(2,4-difluorophenoxy)benzenesulfonamide
[0966] The product from Example 51A (3.24 g, 9.81 mmol), iron (2.74
g, 49.1 mmol), and ammonium chloride (0.787 g, 14.72 mmol) were
combined in the solvent mixture of tetrahydrofuran (21.0 mL),
ethanol (21.0 mL) and water (7.0 mL) and heated at 95.degree. C.
with vigorous stirring for 3 hours. The mixture was cooled and
filtered through a plug of Celite to remove solids. The plug was
rinsed repeatedly with methanol and tetrahydrofuran. The filtrate
was concentrated and the residue partitioned between ethyl acetate
and water. The organic layer was washed with saturated aqueous
sodium chloride, dried (anhydrous Na.sub.2SO.sub.4), filtered, and
concentrated to afford the title compound (2.81 g, 95%).
Example 51C
4-(2,4-difluorophenoxy)-3-iodobenzenesulfonamide
[0967] A solution of the product from Example 51B (2.8 g, 9.32
mmol) in dioxane (20.0 mL) at 0.degree. C. was treated with
concentrated hydrogen chloride (40 mL, 9.32 mmol), stirred for 15
minutes and treated with a solution of sodium nitrite (0.772 g,
11.19 mmol) in water (10 mL). The mixture was stirred for 1 hour at
0.degree. C., treated with a solution of potassium iodide (3.10 g,
18.65 mmol) in water (10 mL) and stirred for 1 hour at ambient
temperature. The mixture was partitioned between ethyl acetate and
water. The organic layer was washed with saturated sodium
thiosulfate, water, saturated aqueous sodium chloride, dried
(MgSO.sub.4), filtered, and concentrated. Purification by
chromatography (silica gel, 0-60% ethyl acetate in hexane) afforded
the title compound (2.24 g, 58%).
Example 51D
4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-y-
l)benzenesulfonamide
[0968] The product from Example 59A (0.075 g, 0.260 mmol), the
product from Example 51C (0.107 g, 0.260 mmol),
tris(dibenzylideneacetone)dipalladium(0) (7.15 mg, 7.81 .mu.mol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (7.61
mg, 0.026 mmol) and sodium carbonate (0.097 g, 0.911 mmol) were
combined and sparged with argon for 15 minutes. Meanwhile a
solution of 4:1 dioxane/water (2 mL) was sparged with nitrogen for
15 minutes and transferred by syringe into the reaction vessel
under argon. The mixture was stirred at 60.degree. C. for 4 hours
and partitioned between ethyl acetate and water. The organic layer
was washed with saturated aqueous sodium chloride, dried (anhydrous
Na.sub.2SO.sub.4), treated with 3-mercaptopropyl functionalized
silica gel, filtered, and concentrated to afford the title compound
(0.116 g, 100%).
Example 51E
4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)benzenesulfonamide
[0969] The product from Example 51D (0.116 g, 0.26 mmol) and 4 M
hydrogen chloride (5 mL, 20.0 mmol) in dioxane were combined and
heated at 70.degree. C. for 24 hours, cooled and concentrated.
Purification by reverse phase chromatography (C18, CH.sub.3CN/water
(0.1% TFA), 10-100%) afforded the title compound (0.051 g, 45%).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.99 (d, J=5.09
Hz, 1H) 7.96 (d, J=2.37 Hz, 1H) 7.66 (dd, J=8.82, 2.37 Hz, 1H) 7.64
(s, 1H) 7.46-7.57 (m, 1H) 7.35-7.43 (m, 1H) 7.33 (s, 2H) 7.12-7.21
(m, 1H) 6.94 (d, J=6.78 Hz, 1H) 6.90 (d, J=8.48 Hz, 1H) 6.55 (d,
J=6.10 Hz, 1H) 4.12 (s, 3H). MS (ESI+) m/z 432 (M+H).sup.+.
Example 52
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 52A
3-bromo-4-(2,4-difluorophenoxy)benzaldehyde
[0970] A mixture of 3-bromo-4-fluorobenzaldehyde (4.06 g, 20 mmol),
2,4-difluorophenol (2.60 g, 20 mmol) and cesium carbonate (7.17 g,
22 mmol) in dimethyl sulfoxide (20 mL) was heated at 100.degree. C.
for 1 hour. The reaction mixture was partitioned with ethyl acetate
and water. The organic layer was washed with saturated aqueous
sodium chloride twice, dried with anhydrous sodium sulfate,
filtered, and concentrated. The residue was purified by flash
chromatography (silica gel, 20% ethyl acetate in heptanes) to
provide the title compound (5.94 g, 95%).
Example 52B
(3-bromo-4-(2,4-difluorophenoxy)phenyl)methanol
[0971] Example 52A (3.76 g, 12 mmol) in the mixture of ethanol (10
mL) and tetrahydrofuran (10 mL) was added sodium borohydride (0.136
g, 3.60 mmol). The reaction mixture was stirred at room temperature
for 1 hour. The solvent was evaporated and the residue was
partitioned with ethyl acetate and water. The organic layer was
washed with saturated aqueous sodium chloride, dried with anhydrous
sodium sulfate, filtered, and concentrated to provide the title
compound (3.72 g, 98%).
Example 52C
2-bromo-4-(bromomethyl)-1-(2,4-difluorophenoxy)benzene
[0972] Example 52B (3.70 g, 11.74 mmol) in dichloromethane (20 mL)
was added phosphorus tribromide (1.107 mL, 11.74 mmol) dropwise.
The reaction mixture was stirred at room temperature for 3 hours,
poured into ice water, adjusted the pH to basic by saturated
aqueous sodium bicarbonate slowly and extracted by dichloromethane.
The organic layer was washed with saturated aqueous sodium
chloride, dried with anhydrous sodium sulfate, filtered, and
concentrated to provide the title compound (4.15 g, 93%).
Example 52D
(3-bromo-4-(2,4-difluorophenoxy)benzyl)(methyl)sulfane
[0973] A mixture of Example 52C (1.512 g, 4.00 mmol) and sodium
thiomethoxide (0.280 g, 4.00 mmol) in dimethylformamide (8 mL) was
stirred at room temperature for 6 hours. The reaction mixture was
partitioned with ethyl acetate and water. The organic layer was
washed with saturated aqueous sodium chloride twice, dried with
anhydrous sodium sulfate, filtered, and concentrated to provide the
title compound (1.38 g, 100%).
Example 52E
2-bromo-1-(2,4-difluorophenoxy)-4-(methylsulfonylmethyl)benzene
[0974] Example 52D (1.38 g, 4.00 mmol) in methanol (15 mL) was
added oxone (5.16 g, 8.40 mmol) in water (15 mL) at 0.degree. C.
The reaction mixture was stirred at room temperature for 1 hour.
The reaction mixture was partitioned with ethyl acetate and water.
The organic layer was washed with saturated aqueous sodium
chloride, dried with anhydrous sodium sulfate, filtered, and
concentrated. The residue was purified by flash chromatography
(silica gel, 20 to 40% ethyl acetate in heptanes) to provide the
title compound (1.485 g, 98%).
Example 52F
3-(2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)phenyl)-7-methoxy-1-met-
hyl-1H-pyrrolo[2,3-c]pyridine
[0975] Example 52E (0.453 g, 1.20 mmol), Example 59A (0.415 g, 1.44
mmol), potassium phosphate (0.892 g, 4.20 mmol),
tris(dibenzylideneacetone)dipalladium (0.033 g, 0.036 mmol) and
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane
(0.032 g, 0.108 mmol) were combined in a microwave tube and purged
with nitrogen for 15 minutes. The mixture of dioxane (8 mL) and
water (2 mL) was purged with nitrogen for 15 minutes and
transferred to the microwave tube. The reaction mixture was heated
at 60.degree. C. for 4 hours. The reaction mixture was partitioned
with ethyl acetate and water. The organic layer was washed with
saturated aqueous sodium chloride, dried with anhydrous sodium
sulfate, treated with 3-mercaptopropyl functionalized silica gel,
filtered, and concentrated. The residue was purified by flash
chromatography (silica gel, 20 to 60% ethyl acetate in heptanes) to
provide the title compound (0.492 g, 89%).
Example 52G
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0976] Example 52F (0.490 g, 1.069 mmol) in a solution of 4 M HCl
in dioxane (20 mL, 80 mmol) was heated at 70.degree. C. for 16
hours, cooled and concentrated. The residue was added water,
adjusted to pH 7 by saturated aqueous sodium bicarbonate and added
ethyl acetate. The resulting solid was filtered and dissolved in
warm ethyl acetate. The filtrate was separated and the organic
layer was washed with saturated aqueous sodium chloride. Both of
the ethyl acetate solutions were combined, dried with anhydrous
sodium sulfate, filtered, and concentrated. The residue was
triturated with ethyl acetate to provide the title compound (0.413
g, 87%). .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.94 (d,
J=5.43 Hz, 1H) 7.59 (d, J=2.03 Hz, 1H) 7.55 (s, 1H) 7.40-7.51 (m,
1H) 7.18-7.29 (m, 2H) 7.04-7.14 (m, 1H) 6.86-6.93 (m, 1H) 6.82 (d,
J=8.14 Hz, 1H) 6.60 (d, J=6.44 Hz, 1H) 4.51 (s, 2H) 4.10 (s, 3H)
2.93 (s, 3H). MS (ESI+) m/z 445 (M+H).sup.+.
Example 53
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)methyl]phenyl}-1-methyl-1,6-d-
ihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 53A
(3-bromo-4-(2,4-difluorophenoxy)benzyl)(ethyl)sulfane
[0977] A mixture of Example 52C (1.10 g, 2.91 mmol) and sodium
ethanethiolate (0.245 g, 2.91 mmol) in dimethylformamide (10 mL)
was stirred at ambient temperature for 4 hours. The reaction
mixture was partitioned with ethyl acetate and water. The organic
layer was washed with saturated aqueous sodium chloride twice,
dried with anhydrous sodium sulfate, filtered, and concentrated to
provide the title compound (1.04 g, 99%).
Example 53B
2-bromo-1-(2,4-difluorophenoxy)-4-(ethylsulfonylmethyl)benzene
[0978] To Example 53A (1.04 g, 2.90 mmol) in methanol (15 mL) was
added oxone (3.74 g, 6.08 mmol) in water (15 mL) at 0.degree. C.
The reaction mixture was stirred at ambient temperature for 1 hour.
The reaction mixture was partitioned with ethyl acetate and water.
The organic layer was washed with saturated aqueous sodium
chloride, dried with anhydrous sodium sulfate, filtered, and
concentrated. The residue was purified by flash chromatography
(silica gel, 20 to 40% ethyl acetate in heptanes) to provide the
title compound (1.01 g, 89%).
Example 53C
3-(2-(2,4-difluorophenoxy)-5-(ethylsulfonylmethyl)phenyl)-7-methoxy-1-meth-
yl-1H-pyrrolo[2,3-c]pyridine
[0979] Example 53B (98 mg, 0.25 mmol), Example 59A (86 mg, 0.30
mmol), potassium phosphate (186 mg, 0.875 mmol),
tris(dibenzylideneacetone)dipalladium (6.9 mg, 7.5 .mu.mol), and
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane (6.6
mg, 0.023 mmol) were combined in a microwave tube and purged with
nitrogen for 15 minutes. The mixture of dioxane (2 mL) and water
(0.5 mL) was purged with nitrogen for 15 minutes and transferred to
the microwave tube. The reaction mixture was heated at 60.degree.
C. for 4 hours. The reaction mixture was partitioned with ethyl
acetate and water. The organic layer was washed with saturated
aqueous sodium chloride, dried with anhydrous sodium sulfate,
treated with 3-mercaptopropyl functionalized silica gel, filtered,
and concentrated. The residue was purified by flash chromatography
(silica gel, 0 to 50% ethyl acetate in heptanes) to provide the
title compound (113 g, 96%).
Example 53D
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)methyl]phenyl}-1-methyl-1,6-d-
ihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0980] Example 53C (11 mg, 0.235 mmol) in a solution of 4 M HCl in
dioxane (8 mL, 32.0 mmol) was heated at 70.degree. C. for 24 hours,
cooled and concentrated. The residue was purified by flash
chromatography (silica gel, 0 to 4% methanol in dichloromethane) to
provide the title compound (88 mg, 82%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.95 (d, J=5.49 Hz, 1H) 7.59 (d, J=2.14
Hz, 1H) 7.55 (s, 1H) 7.42-7.50 (m, 1H) 7.20-7.29 (m, 2H) 7.05-7.14
(m, 1H) 6.86-6.93 (m, 1H) 6.81 (d, J=8.24 Hz, 1H) 6.61 (d, J=6.41
Hz, 1H) 4.50 (s, 2H) 4.10 (s, 3H) 3.06 (q, J=7.32 Hz, 2H) 1.24 (t,
J=7.48 Hz, 3H). MS (ESI+) m/z 459 (M+H).sup.+.
Example 54
3-{2-(2,4-difluorophenoxy)-5-[2-(ethylsulfonyl)propan-2-yl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 54A
2-bromo-1-(2,4-difluorophenoxy)-4-(2-(ethylsulfonyl)propan-2-yl)benzene
[0981] Example 53B (469 mg, 1.2 mmol) in tetrahydrofuran (10 mL)
was added 60% sodium hydride in mineral oil (240 mg, 6.00 mmol) at
0.degree. C. The reaction mixture was stirred at room temperature
under nitrogen for 10 minutes. The iodomethane (0.750 mL, 12.00
mmol) was added. The reaction mixture was stirred at room
temperature for 20 hours. The reaction mixture was partitioned with
ethyl acetate and water. The organic layer was washed with
saturated aqueous sodium chloride, dried with anhydrous sodium
sulfate, filtered, and concentrated. The residue was purified by
flash chromatography (silica gel, 20 to 40% ethyl acetate in
heptanes) to provide the title compound (442 mg, 88%).
Example 54B
3-(2-(2,4-difluorophenoxy)-5-(2-(ethylsulfonyl)propan-2-yl)phenyl)-7-metho-
xy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[0982] Example 54B was prepared according to the procedure used for
the preparation of Example 52F, substituting Example 54A for
Example 52E. Purification by flash chromatography (silica gel, 0 to
50% ethyl acetate in heptanes) afforded the title compound (85 mg,
85%).
Example 54C
3-{2-(2,4-difluorophenoxy)-5-[2-(ethylsulfonyl)propan-2-yl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0983] Example 54C was prepared according to the procedure used for
the preparation of Example 53D, substituting Example 54B for
Example 53C. The reaction time was 16 hours instead of 24 hours.
Purification by flash chromatography (silica gel, 0.5 to 3.5%
methanol in dichloromethane) and trituration (10% ethyl acetate in
heptanes) afforded the title compound (70 mg, 87%). .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. ppm 10.93 (d, J=5.43 Hz, 1H) 7.72
(d, J=2.37 Hz, 1H) 7.56 (s, 1H) 7.40-7.52 (m, 2H) 7.19-7.31 (m, 1H)
7.06-7.16 (m, 1H) 6.85-6.94 (m, 1H) 6.79 (d, J=8.48 Hz, 1H) 6.57
(d, J=6.10 Hz, 1H) 4.10 (s, 3H) 2.88 (q, J=7.46 Hz, 2H) 1.77 (s,
6H) 1.05 (t, J=7.29 Hz, 3H). MS (ESI+) m/z 487 (M+H).sup.+.
Example 55
3-{2-(2,4-difluorophenoxy)-5-[1-(ethylsulfonyl)ethyl]phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 55A
2-bromo-1-(2,4-difluorophenoxy)-4-(1-(ethylsulfonyl)ethyl)benzene
[0984] To Example 53B (196 mg, 0.50 mmol) in tetrahydrofuran (10
mL) was added 60% sodium hydride in mineral oil (100 mg, 2.50 mmol)
at 0.degree. C. The reaction mixture was stirred at room
temperature under nitrogen for 10 minutes. Iodomethane (0.313 mL,
5.00 mmol) was added. The reaction mixture was stirred at room
temperature for 2 hours. The reaction mixture was partitioned with
ethyl acetate and water. The organic layer was washed with
saturated aqueous sodium chloride, dried with anhydrous sodium
sulfate, filtered, and concentrated. The residue was purified by
flash chromatography (silica gel, 20 to 40% ethyl acetate in
heptanes) to provide the title compound (174 mg, 86%).
Example 55B
3-(2-(2,4-difluorophenoxy)-5-(1-(ethylsulfonyl)ethyl)phenyl)-7-methoxy-1-m-
ethyl-1H-pyrrolo[2,3-c]pyridine
[0985] Example 55B was prepared according to the procedure used for
the preparation of Example 52F, substituting Example 55A for
Example 52E. Purification by flash chromatography (silica gel, 0 to
50% ethyl acetate in heptanes) afforded the title compound (200 mg,
98%).
Example 55C
3-{2-(2,4-difluorophenoxy)-5-[1-(ethylsulfonyl)ethyl]phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0986] Example 55C was prepared according to the procedure used for
the preparation of Example 53D, substituting Example 55B for
Example 53C. The reaction time was 16 hours instead of 24 hours.
Purification by flash chromatography (silica gel, 2 to 4% methanol
in dichloromethane afforded the title compound (180 mg, 95%).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.94 (d, J=5.09
Hz, 1H) 7.61 (d, J=2.03 Hz, 1H) 7.55 (s, 1H) 7.41-7.51 (m, 1H)
7.18-7.34 (m, 2H) 7.05-7.15 (m, 1H) 6.90 (dd, J=7.12, 5.76 Hz, 1H)
6.80 (d, J=8.48 Hz, 1H) 6.54-6.60 (m, 1H) 4.54-4.69 (m, 1H) 4.10
(s, 3H) 2.84-3.09 (m, 2H) 1.64 (d, J=7.12 Hz, 3H) 1.16 (t, J=7.29
Hz, 3H). MS (ESI+) m/z 473 (M+H).sup.+.
Example 56
3-{2-(2,4-difluorophenoxy)-5-[(1R)-1-(ethylsulfonyl)ethyl]phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0987] The product from Example 55C was purified by chiral
chromatography on a Chiralpak IA column eluting with a 3:7 mixture
of 0.1% diethylamine in methanol/carbondioxide. The title compound
was randomly assigned to the first of the 2 diastereomers eluted.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.94 (d, J=5.43
Hz, 1H) 7.61 (d, J=2.37 Hz, 1H) 7.55 (s, 1H) 7.40-7.52 (m, 1H) 7.31
(dd, J=8.65, 2.20 Hz, 1H) 7.19-7.28 (m, 1H) 7.04-7.15 (m, 1H)
6.86-6.94 (m, 1H) 6.80 (d, J=8.48 Hz, 1H) 6.57 (d, J=6.44 Hz, 1H)
4.58 (q, J=7.11 Hz, 1H) 4.10 (s, 3H) 2.92-3.03 (m, 2H) 1.64 (d,
J=7.12 Hz, 3H) 1.16 (t, J=7.46 Hz, 3H). MS (ESI+) m/z 473
(M+H).sup.+.
Example 57
3-{2-(2,4-difluorophenoxy)-5-[(1S)-1-(ethylsulfonyl)ethyl]phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0988] The product from Example 55C was purified by chiral
chromatography on a Chiralpak IA column eluting with a 3:7 mixture
of 0.1% diethylamine in methanol/carbondioxide. The title compound
was randomly assigned to the second of the 2 diastereomers eluted.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.94 (d, J=5.43
Hz, 1H) 7.61 (d, J=2.37 Hz, 1H) 7.55 (s, 1H) 7.41-7.51 (m, 1H) 7.31
(dd, J=8.48, 2.37 Hz, 1H) 7.19-7.29 (m, 1H) 7.04-7.15 (m, 1H)
6.84-6.95 (m, 1H) 6.80 (d, J=8.14 Hz, 1H) 6.57 (d, J=6.44 Hz, 1H)
4.61 (q, J=7.11 Hz, 1H) 4.10 (s, 3H) 2.89-3.04 (m, 2H) 1.64 (d,
J=7.12 Hz, 3H) 1.16 (t, J=7.46 Hz, 3H). MS (ESI+) m/z 473
(M+H).sup.+.
Example 58
3-{2-(2,4-difluorophenoxy)-5-[(phenylsulfonyl)methyl]phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 58A
(3-bromo-4-(2,4-difluorophenoxy)benzyl)(phenyl)sulfane
[0989] Example 58A (815 mg, 100%) was prepared according to the
procedure used for the preparation of Example 52D, substituting
sodium thiophenoxide for sodium thiomethoxide.
Example 58B
2-bromo-1-(2,4-difluorophenoxy)-4-(phenylsulfonylmethyl)benzene
[0990] Example 58B (867 g, 99%) was prepared according to the
procedure used for the preparation of Example 52E, substituting
Example 58A for Example 52D.
Example 58C
3-(2-(2,4-difluorophenoxy)-5-(phenylsulfonylmethyl)phenyl)-7-methoxy-1-met-
hyl-1H-pyrrolo[2,3-c]pyridine
[0991] Example 58C was prepared according to the procedure used for
the preparation of Example 52F, substituting Example 58B for
Example 52E. Purification by flash chromatography (silica gel, 0 to
50% ethyl acetate in heptanes) afforded the title compound (91 mg,
87%).
Example 58D
3-{2-(2,4-difluorophenoxy)-5-[(phenylsulfonyl)methyl]phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[0992] Example 58D was prepared according to the procedure used for
the preparation of Example 53D, substituting Example 58C for
Example 53C. The reaction time was 16 hours instead of 24 hours.
Purification by flash chromatography (silica gel, 2 to 4% methanol
in dichloromethane) afforded the title compound (68 mg, 79%).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.95 (d, J=5.43
Hz, 1H) 7.69-7.80 (m, 3H) 7.58-7.67 (m, 2H) 7.39-7.51 (m, 2H) 7.32
(d, J=2.03 Hz, 1H) 7.00-7.21 (m, 3H) 6.85 (dd, J=7.12, 5.76 Hz, 1H)
6.74 (d, J=8.14 Hz, 1H) 6.25 (d, J=6.10 Hz, 1H) 4.72 (s, 2H) 4.08
(s, 3H). MS (ESI+) m/z 507 (M+H).sup.+.
Example 59
3-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)pyridin-3-yl]-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 59A
7-methoxy-1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrr-
olo[2,3-c]pyridine
[0993] 3-Iodo-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine (3.89 g,
13.50 mmol) was flow purged with nitrogen for 30 minutes, then
treated with tetrahydrofuran (135 mL). The reaction mixture was
cooled to -78.degree. C. Butyllithium (5.40 mL, 13.50 mmol) was
added dropwise. The reaction mixture was stirred at -78.degree. C.
for 30 minutes.
2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.75 mL,
13.50 mmol) was added dropwise. The reaction mixture was stirred at
-78.degree. C. for 2.5 hours. The reaction mixture was poured onto
water and extracted twice with ethyl acetate. The organic layer was
washed with saturated aqueous sodium chloride, dried over anhydrous
magnesium sulfate, filtered, and concentrated. The residue was
purified by flash chromatography (silica gel, 100% heptane to 30%
ethyl acetate/heptane) to provide the title compound (2.75 g, 70%
yield).
Example 59B
3-bromo-2-chloro-5-(ethylsulfonyl)pyridine
[0994] Sodium sulfite (4.94 g, 39.2 mmol) and sodium bicarbonate
(3.46 g, 41.2 mmol) in water (100 mL) were heated to 75.degree. C.
3-bromo-2-chloropyridine-5-sulfonyl chloride (6.00 g, 20.6 mmol)
was added portionwise over 1 hour. The reaction mixture was stirred
at 75.degree. C. for 1 hour after complete addition. The mixture
was concentrated under vacuum. N,N-Dimethylformamide (37.5 mL),
sodium bicarbonate (3.46 g, 41.2 mmol) and iodoethane (1.658 mL,
20.62 mmol) were added. The resulting mixture was heated to
75.degree. C. for 2 hours then cooled to room temperature. The
mixture was partitioned between ethyl acetate and water. The
organic layer was washed with saturated aqueous sodium chloride,
dried over anhydrous magnesium sulfate, filtered, and concentrated.
The reaction mixture was purified by flash chromatography (silica
gel, 100% heptane to 100% ethyl acetate) to provide the title
compound (3.15 g, 53% yield).
Example 59C
3-(2-chloro-5-(ethylsulfonyl)pyridin-3-yl)-7-methoxy-1-methyl-1H-pyrrolo[2-
,3-c]pyridine
[0995] Example 59A (0.0643 g, 0.223 mmol), Example 59B (0.063 g,
0.223 mmol), cesium fluoride (0.102 g, 0.669 mmol), and
dichloropalladiumbis(triphenylphosphine) (7.83 mg, 0.011 mmol) in
1,2-dimethoxyethane (1.352 mL) and methanol (0.676 mL) were heated
in a Biotage Creator microwave at 120.degree. C. for 30 minutes for
30 minutes. The reaction mixture was partitioned between ethyl
acetate and water. The organic layer was washed with saturated
aqueous sodium chloride, dried over anhydrous magnesium sulfate,
filtered, and concentrated. The residue purified by flash
chromatography using an (silica gel, 20% ethyl acetate/heptane to
80% ethyl acetate/heptane) to provide the title compound (78.5 mg,
96% yield).
Example 59D
[0996] Example 59C (0.0548 g, 0.150 mmol), 2,4-difluorophenol
(0.021 mL, 0.225 mmol), and cesium carbonate (0.073 g, 0.225 mmol)
in dimethylsulfoxide (1.498 mL) were stirred at room temperature
over 4 nights. The reaction mixture was diluted with water and
extracted twice with ethyl acetate. The combined organic layers
were washed with saturated aqueous sodium chloride, dried over
anhydrous magnesium sulfate, filtered and. The reaction mixture was
purified by flash chromatography (silica gel, 20% ethyl
acetate/heptane to 80% ethyl acetate/heptane) to provide the title
compound (58.3 mg, 85% yield).
Example 59E
[0997] Example 59D (0.0583 g, 0.127 mmol) in dioxane (1.269 mL) was
treated with 4N hydrogen chloride in dioxane (1.586 mL, 6.34 mmol)
at 70.degree. C. overnight. The solvent was removed, and the
residue was purified by reverse-phase HPLC to provide the title
compound (16.9 mg, 30% yield). .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. ppm 11.07 (s, J=5.76 Hz, 1H) 8.45 (d, J=2.37 Hz, 1H) 8.28
(d, J=2.37 Hz, 1H) 7.86 (s, 1H) 7.52 (m, 2H) 7.19 (m, 1H) 6.98 (dd,
J=6.95, 5.93 Hz, 1H) 6.57 (dd, J=7.12, 1.02 Hz, 1H) 4.15 (s, 3H)
3.43 (q, J=7.35 Hz, 2H) 1.17 (t, J=7.29 Hz, 3H). MS (ESI+) m/z
446.2 (M+H).sup.+
Example 60
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 60A
5-bromo-6-(2,4-difluorophenoxy)nicotinic acid
[0998] 5-Bromo-6-chloronicotinic acid (3.00 g, 12.7 mmol),
2,4-difluorophenol (3.30 g, 25.4 mmol) and cesium carbonate (16.5
g, 50.8 mmol) were combined in DMSO (25.4 mL), heated at
100.degree. C. for 6 hours, cooled, diluted with 150 mL of iced
water and the pH was adjusted to pH 3 with 12M HCl. The resulting
solid was collected by filtration, washed with cold water and dried
to constant mass to afford the title compound (2.84 g, 64%).
Example 60B
(5-bromo-6-(2,4-difluorophenoxy)pyridin-3-yl)methanol
[0999] The product from Example 60A (1.0 g, 3.03 mmol) and borane
tetrahydrofuran complex (6.06 mL, 6.06 mmol) were combined in
tetrahydrofuran (15.15 mL) and heated at 50.degree. C. for 2 hours,
cooled, treated with 10 mL of methanol, heated at 50.degree. C. for
1 hour, cooled and concentrated. The residue was partitioned
between ethyl acetate and water. The organic layer was washed with
saturated aqueous sodium chloride, dried (anhydrous
Na.sub.2SO.sub.4), filtered, and concentrated. Purification by
chromatography (silica gel, 0-50% ethyl acetate in heptanes)
afforded the title compound (0.73 g, 76%).
Example 60C
3-bromo-5-(bromomethyl)-2-(2,4-difluorophenoxy)pyridine
[1000] A solution of the product from Example 60B (0.73 g, 2.309
mmol) in dichloromethane (11.55 mL) under nitrogen was treated
dropwise with tribromophosphine (0.218 mL, 2.309 mmol), stirred for
one hour and poured into ice water and the pH was adjusted to pH 9
by addition of solid sodium bicarbonate added portionwise. An
emulsion formed that was partially removed by filtration. The
aqueous layer was extracted with dichloromethane and the organics
were combined, washed with saturated aqueous sodium chloride, dried
(anhydrous Na.sub.2SO.sub.4) filtered, and concentrated to afford
the title compound (0.75 g, 86%).
Example 60D
3-bromo-2-(2,4-difluorophenoxy)-5-(methylthiomethyl)pyridine
[1001] The product from Example 60C (0.75 g, 1.979 mmol) and sodium
thiomethoxide (0.139 g, 1.979 mmol) were combined in
dimethylformamide (3.96 mL), stirred for 4 hours and partitioned
into ethyl acetate and cold water. The organic layer was washed
with saturated aqueous sodium chloride, dried (anhydrous
Na.sub.2SO.sub.4), filtered, and concentrated to afford the title
compound (0.66 g, 96%).
Example 60E
3-bromo-2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)pyridine
[1002] A solution of the product from Example 60D (0.66 g, 1.906
mmol) at 0.degree. C. in methanol (7.33 mL) was treated with a
solution of Oxone (2.461 g, 4.00 mmol) in water (7.33 mL), stirred
at ambient temperature for two hours and partitioned between ethyl
acetate and water. The organic layer was washed with saturated
aqueous sodium chloride, dried (anhydrous Na.sub.2SO.sub.4),
filtered, and concentrated. Purification by chromatography (silica
gel, 0-5% methanol in dichloromethane) afforded the title compound
(0.433 g, 60%).
Example 60F
3-(2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)pyridin-3-yl)-7-methoxy-
-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1003] The product from Example 59A (0.061 g, 0.212 mmol), the
product from Example 60E (0.08 g, 0.212 mmol),
tris(dibenzylideneacetone)dipalladium(0) (5.8 mg, 6.35 .mu.mol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (6.2
mg, 0.021 mmol) and potassium phosphate (0.157 g, 0.74 mmol) were
combined and sparged with argon for 15 minutes. Meanwhile a
solution of 4:1 dioxane/water (2 mL) was sparged with nitrogen for
15 minutes and transferred by syringe into the reaction vessel
under argon. The mixture was stirred at 60.degree. C. for 2 hours
and partitioned between ethyl acetate and water. The organic layer
was washed with saturated aqueous sodium chloride, dried (anhydrous
Na.sub.2SO.sub.4), treated with 3-mercaptopropyl functionalized
silica gel, filtered, and concentrated to afford the title compound
(0.1 g, 100%).
Example 60G
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1004] The product from Example 60F (0.097 g, 0.211 mmol) and 4 M
hydrogen chloride in dioxane (5 mL, 20.00 mmol) were combined and
heated at 70.degree. C. for 18 hours, cooled and concentrated. The
residue was partitioned between ethyl acetate and water adjusting
the pH to 7. The organic layer was washed with saturated aqueous
sodium chloride, dried (anhydrous Na.sub.2SO.sub.4), treated with
3-mercaptopropyl functionalized silica gel, filtered, and
concentrated. Purification by trituration (1:1
dichloromethane/heptane) afforded the title compound (0.077 g,
82%). .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 11.03 (d,
J=5.43 Hz, 1H) 8.02 (d, J=2.37 Hz, 1H) 7.95 (d, J=2.37 Hz, 1H) 7.75
(s, 1H) 7.39-7.50 (m, 2H) 7.10-7.19 (m, 1H) 6.93-6.97 (m, 1H) 6.66
(d, J=6.44 Hz, 1H) 4.57 (s, 2H) 4.14 (s, 3H) 2.98 (s, 3H). MS
(ESI+) m/z 446 (M+H).sup.+.
Example 61
3-[2-(4-fluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-p-
yrrolo[2,3-c]pyridin-7-one
[1005] The title compound was prepared according to the procedure
used for the preparation of Example 19 substituting 4-fluorophenol
for 3,4-difluorophenol. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 11.00 (d, J=5.5 Hz, 1H), 7.99 (d, J=2.3 Hz, 1H), 7.78 (dd,
J=8.7, 2.4 Hz, 1H), 7.69 (s, 1H), 7.28 (t, J=8.7 Hz, 2H), 7.20 (dd,
J=9.1, 4.6 Hz, 1H), 6.99 (d, J=8.7 Hz, 1H), 6.96-6.89 (m, 1H), 6.54
(d, J=6.4 Hz, 1H), 4.11 (s, 3H), 3.24 (s, 3H).). MS (ESI+) m/z 413
(M+H).sup.+.
Example 62
3-[2-(4-tert-butylphenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro--
7H-pyrrolo[2,3-c]pyridin-7-one
[1006] The title compound was prepared according to the procedure
used for the preparation of Example 19 substituting
4-tert-butylphenol for 3,4-difluorophenol. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.99 (d, J=5.1 Hz, 1H), 7.99 (d, J=2.4
Hz, 1H), 7.77 (dd, J=8.7, 2.4 Hz, 1H), 7.69 (s, 1H), 7.45 (d, J=8.7
Hz, 2H), 7.07 (d, J=8.7 Hz, 2H), 6.99 (d, J=8.7 Hz, 1H), 6.96-6.90
(m, 1H), 6.55 (d, J=6.9 Hz, 1H), 4.11 (s, 3H), 3.24 (s, 3H), 1.29
(s, 9H). MS (ESI+) m/z 451 (M+H).sup.+.
Example 63
1-methyl-3-[5-(methylsulfonyl)-2-(naphthalen-2-yloxy)phenyl]-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
[1007] The title compound was prepared according to the procedure
used for the preparation of Example 19 substituting 2-naphthol for
3,4-difluorophenol. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
11.00 (d, J=5.0 Hz, 1H), 8.05 (d, J=2.2 Hz, 1H), 8.01 (d, J=9.0 Hz,
1H), 7.95 (d, J=7.8 Hz, 1H), 7.87 (d, J=7.9 Hz, 1H), 7.79 (dd,
J=8.6, 2.2 Hz, 1H), 7.73 (s, 1H), 7.59 (s, 1H), 7.52 (dd, J=15.9,
7.5 Hz, 2H), 7.37 (dd, J=8.9, 2.2 Hz, 1H), 7.12 (d, J=8.6 Hz, 1H),
6.97-6.90 (m, 1H), 6.60 (d, J=7.0 Hz, 1H), 4.10 (s, 3H), 3.27 (s,
3H). MS (ESI+) m/z 445 (M+H).sup.+.
Example 64
1-methyl-3-[5-(methylsulfonyl)-2-(2,2,3,3,3-pentafluoropropoxy)phenyl]-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1008] The title compound was prepared according to the procedure
used for the preparation of Example 35 substituting
2,2,3,3,3-pentafluoropropanol for 2-cyclopentylethanol. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 11.01 (d, J=5.3 Hz, 1H), 7.91
(d, J=2.3 Hz, 1H), 7.86 (dd, J=8.7, 2.3 Hz, 1H), 7.54-7.45 (m, 2H),
6.95-6.89 (m, 1H), 6.44 (d, J=6.8 Hz, 1H), 5.03 (t, J=13.6 Hz, 2H),
4.11 (s, 3H), 3.24 (s, 3H). MS (ESI+) m/z 451 (M+H).sup.+.
Example 65
1-methyl-3-[5-(methylsulfonyl)-2-{2-[tricyclo[3.3.1.1.sup.3'7]dec-1-yl]eth-
oxy}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1009] The title compound was prepared according to the procedure
used for the preparation of Example 35 substituting
2-adamantanylethanol for 2-cyclopentylethanol. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 10.95 (d, J=5.0 Hz, 1H), 7.83 (d,
J=2.4 Hz, 1H), 7.79 (dd, J=8.6, 2.4 Hz, 1H), 7.56 (s, 1H), 7.35 (d,
J=8.7 Hz, 1H), 6.94-6.86 (m, 1H), 6.40 (d, J=6.9 Hz, 1H), 4.17 (t,
J=7.3 Hz, 2H), 4.11 (s, 3H), 3.20 (s, 3H), 1.88 (s, 3H), 1.70-1.44
(m, 14H). MS (ESI+) m/z 481 (M+H).sup.+.
Example 66
3-[2-(3-cyclopentylpropoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-
-7H-pyrrolo[2,3-c]pyridin-7-one
[1010] The title compound was prepared according to the procedure
used for the preparation of Example 35 substituting
3-cyclopentylpropanol for 2-cyclopentylethanol. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 10.97 (d, J=5.0 Hz, 1H), 7.84 (d,
J=2.4 Hz, 1H), 7.79 (dd, J=8.7, 2.4 Hz, 1H), 7.56 (s, 1H), 7.30 (d,
J=8.7 Hz, 1H), 6.94-6.86 (m, 1H), 6.42 (d, J=6.9 Hz, 1H), 4.10 (d,
J=9.0 Hz, 5H), 3.20 (s, 3H), 1.85-1.62 (m, 5H), 1.49 (ddd, J=15.1,
9.3, 5.4 Hz, 4H), 1.35 (dd, J=15.1, 7.1 Hz, 2H), 1.07-0.95 (m, 2H).
MS (ESI+) m/z 429 (M+H).sup.+.
Example 67
3-{2-[(1-acetylpiperidin-4-yl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1011] The title compound was prepared according to the procedure
used for the preparation of Example 35 substituting
1-(4-hydroxypiperidin-1-yl)ethanone for 2-cyclopentylethanol.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.96 (d, J=5.6 Hz,
1H), 7.86 (d, J=2.4 Hz, 1H), 7.78 (d, J=8.7 Hz, 1H), 7.60 (s, 1H),
7.42 (d, J=8.9 Hz, 1H), 6.96-6.88 (m, 1H), 6.44 (d, J=6.7 Hz, 1H),
4.85 (s, 1H), 4.12 (s, 3H), 3.58 (d, J=58.6 Hz, 3H), 3.21 (s, 3H),
1.94 (d, J=34.4 Hz, 5H), 1.62 (d, J=43.9 Hz, 3H). MS (ESI+) m/z 444
(M+H).sup.+.
Example 68
3-{2-[(cyclopentylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 68A
N-(cyclopentylmethyl)-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-
-4-(methylsulfonyl)aniline
[1012] The product from Example 44A (55 mg, 0.166 mmol) and
cyclopentanecarbaldehyde (58.64 mg, 0.597 mmol) in
dichloroethane/acetic acid (1:1, 1 mL) was heated in a sealed tube
at 60.degree. C. for 24 hours, cooled, and concentrated.
Purification by reverse phase HPLC (C18, CH.sub.3CN/water (0.1%
TFA), 10-100%) afforded the title compound (0.021 g, 31%).
Example 68B
3-{2-[(cyclopentylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1013] The product from Example 68A, (0.021 g) in dioxane (0.5 mL)
and 4N HCl in dioxane (0.5 mL) was heated at 70.degree. C. for 24
hours, cooled, and concentrated. Purification by reverse phase HPLC
(C18, CH.sub.3CN/water (0.1% TFA), 10-100%) afforded the title
compound (0.007 g, 27%) as the TFA salt. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.64 (dd, J=8.70, 2.29 Hz, 1H)
7.44-7.46 (m, 2H) 6.93 (d, J=7.02 Hz, 1H) 6.83 (d, J=8.85 Hz, 1H)
6.24 (d, J=6.71 Hz, 1H) 4.12 (s, 3H) 3.09 (s, 3H) 3.06 (d, J=7.32
Hz, 2H) 2.10-2.17 (m, 1H) 1.61-1.69 (m, 2H) 1.51-1.58 (m, 2H)
1.44-1.50 (m, 2H) 1.15-1.24 (m, 2H). MS (ESI+) m/z 400
(M+H).sup.+.
Example 69
1-methyl-3-{5-(methylsulfonyl)-2-[(2,2,2-trifluoroethyl)amino]phenyl}-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 69A
2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(methylsulfonyl)-N--
(2,2,2-trifluoroethyl)aniline
[1014] The title compound was prepared according to the procedure
used in Example 68A substituting trifluoroacetaldehyde for
cyclopentanecarbaldehyde (0.025 g, 36%).
Example 69B
1-methyl-3-{5-(methylsulfonyl)-2-[(2,2,2-trifluoroethyl)amino]phenyl}-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1015] The TFA salt of the title compound was prepared according to
the procedure used in Example 68B, substituting the product from
Example 69A for the product from Example 68A (0.004 g, 18%).
.sup.1H NMR (500 MHz, DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.69 (dd,
J=8.70, 2.29 Hz, 1H) 7.51 (d, J=2.14 Hz, 1H) 7.45 (s, 1H) 7.08 (d,
J=8.85 Hz, 1H) 6.93 (d, J=7.02 Hz, 1H) 6.20 (d, J=7.02 Hz, 1H) 4.12
(s, 3H) 3.12 (s, 3H). MS (ESI+) m/z 400 (M+H).sup.+.
Example 70
3-{2-[(2,2,3,3,4,4,4-heptafluorobutyl)amino]-5-(methylsulfonyl)phenyl}-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 70A
N-(2,2,3,3,4,4,4-heptafluorobutyl)-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]-
pyridin-3-yl)-4-(methylsulfonyl)aniline
[1016] The title compound was prepared according to the procedure
used in Example 68A substituting 2,2,3,3,4,4,4-heptafluorobutanal
for cyclopentanecarbaldehyde (0.010 g, 12%).
Example 70B
3-{2-[(2,2,3,3,4,4,4-heptafluorobutyl)amino]-5-(methylsulfonyl)phenyl}-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1017] The TFA salt of the title compound was prepared according to
the procedure used in Example 68B, substituting the product from
Example 70A for the product from Example 68A (0.003 g, 11%).
.sup.1H NMR (500 MHz, DMSO-d.sub.6/D.sub.2O). .delta. ppm 7.71 (dd,
J=8.70, 2.29 Hz, 1H) 7.51 (d, J=2.44 Hz, 1H) 7.44 (s, 1H) 7.02 (d,
J=8.85 Hz, 1H) 6.93 (d, J=6.71 Hz, 1H) 6.21 (d, J=7.02 Hz, 1H)
4.06-4.17 (m, 5H) 3.13 (s, 3H). MS (ESI+) m/z 398 (M+H).sup.+.
Example 71
3-[2-{[(1S,4R)-bicyclo[2.2.1]hept-2-ylmethyl]amino}-5-(methylsulfonyl)phen-
yl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 71A
N-((1S,4R)-bicyclo[2.2.1]heptan-2-ylmethyl)-2-(7-methoxy-1-methyl-1H-pyrro-
lo[2,3-c]pyridin-3-yl)-4-(methylsulfonyl)aniline
[1018] The title compound was prepared according to the procedure
used in Example 68A substituting
(1S,4R)-bicyclo[2.2.1]heptane-2-carbaldehyde for
cyclopentanecarbaldehyde (0.013 g, 18%).
Example 71B
3-[2-{[(1S,4R)-bicyclo[2.2.1]hept-2-ylmethyl]amino}-5-(methylsulfonyl)phen-
yl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1019] The TFA salt of the title compound was prepared according to
the procedure used in Example 68B, substituting the product from
Example 71A for the product from Example 68A (0.004 g, 15%).
.sup.1H NMR (500 MHz, DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.61-7.67
(m, 1H) 7.43-7.46 (m, 1H) 6.90-6.94 (m, 1H) 6.79-6.85 (m, 1H)
6.20-6.24 (m, 1H) 4.10-4.12 (m, 3H) 2.98-3.16 (m, 4H) 2.85 (dd,
J=13.28, 6.87 Hz, 1H) 2.13-2.19 (m, 1H) 2.00-2.11 (m, 1H) 1.62-1.74
(m, J=6.10 Hz, 1H) 1.41-1.50 (m, J=3.05 Hz, 2H) 1.22-1.34 (m, 2H)
1.01-1.14 (m, 3H). MS (ESI+) m/z 426 (M+H).sup.+.
Example 72
3-{2-[(2-cyclopentylethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 72A
N-(2-cyclopentylethyl)-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl-
)-4-(methylsulfonyl)aniline
[1020] The title compound was prepared according to the procedure
used in Example 68A substituting 2-cyclopentylacetaldehyde for
cyclopentanecarbaldehyde (0.005 g, 8%).
Example 72B
3-{2-[(2-cyclopentylethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1021] The TFA salt of the title compound was prepared according to
the procedure used in Example 68B, substituting the product from
Example 72A for the product from Example 68A (0.0017 g, 6%).
.sup.1H NMR (500 MHz, DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.65 (dd,
J=8.70, 2.29 Hz, 1H) 7.43-7.46 (m, 1H) 6.92 (d, J=7.02 Hz, 1H) 6.80
(d, J=8.85 Hz, 1H) 6.23 (d, J=7.02 Hz, 1H) 4.11 (s, 3H) 3.13-3.17
(m, 2H) 3.09 (s, 3H) 1.69-1.80 (m, J=17.09, 3.97 Hz, 3H) 1.43-1.60
(m, 6H) 1.01-1.12 (m, 2H). ESI.sup.+ m/z=414.0 (M+H).sup.+. MS
(ESI+) m/z 414 (M+H).sup.+.
Example 73
3-[2-(2-chloro-4-methylphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one
[1022] Example 48E (33 mg, 0.09 mmol) in dimethylsulfoxide (0.5 mL)
was treated with a solution of 2-chloro-4-methylphenol (28 mg, 0.2
mmol) dissolved in dimethylsulfoxide (0.4 mL), followed by cesium
carbonate (77 mg, 0.2 mmol). The reaction mixture was placed in an
Anton Paar microwave and heated for 40 minutes at 150.degree. C.
The reaction mixture was dried and 0.500 mL of dioxane was added
followed by 0.500 mL of 4M hydrochloric acid in dioxane. The
reaction mixture was heated at 70.degree. C. overnight. The
reaction mixture was concentrated to dryness and purified by
reverse phase HPLC (C18, CH.sub.3CN/water (0.1% TFA), 10-100%) to
provide the title compound. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.94 (d, J=2.44 Hz, 1H)
7.69-7.75 (m, 2H) 7.46-7.48 (m, 1H) 7.17-7.29 (m, 2H) 6.99 (d,
J=7.32 Hz, 1H) 6.82 (d, J=8.85 Hz, 1H) 6.60-6.65 (m, 1H) 4.12 (s,
3H) 3.31 (q, J=7.32 Hz, 2H) 2.34 (s, 3H) 1.16 (t, J=7.32 Hz, 3H);
MS (ESI+) m/z 457 (M+H).sup.+.
Example 74
3-[5-(ethylsulfonyl)-2-(pyridin-4-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-py-
rrolo[2,3-c]pyridin-7-one
[1023] The TFA salt of Example 74 was prepared according to the
procedure used for the preparation of Example 73, substituting
pyridin-4-ol for 2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 8.28 (d, 2H) 8.07-8.11 (m, 1H)
8.03 (d, J=2.14 Hz, 1H) 7.97 (d, J=8.24 Hz, 1H) 7.32 (s, 1H)
6.78-6.88 (m, 3H) 6.11 (d, J=7.02 Hz, 1H) 4.04 (s, 3H) 3.40-3.49
(m, 2H) 1.21 (t, J=7.32 Hz, 3H); MS (ESI+) m/z 410 (M+H).sup.+.
Example 75
3-{2-[(4,6-dimethylpyridin-3-yl)oxy]-5-(ethylsulfonyl)phenyl}-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1024] The TFA salt of Example 75 was prepared according to the
procedure used for the preparation of Example 73, substituting
4,6-dimethylpyridin-3-ol for 2-chloro-4-methylphenol. .sup.1H NMR
(500 MHz, DMSO-d.sub.6/D.sub.2O) .delta. ppm 8.47 (s, 1H) 8.00 (d,
J=2.14 Hz, 1H) 7.72-7.81 (m, 3H) 7.16 (d, J=8.85 Hz, 1H) 7.01 (d,
J=7.02 Hz, 1H) 6.58 (d, J=7.02 Hz, 1H) 4.11 (s, 3H) 3.35 (q, J=7.32
Hz, 2H) 2.61 (s, 3H) 2.52-2.55 (m, 3H) 2.33 (s, 3H); MS (ESI+) m/z
438 (M+H).sup.+.
Example 76
3-[2-(3,4-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
[1025] Example 76 was prepared according to the procedure used for
the preparation of Example 73, substituting 3,4-dichlorophenol for
2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.95 (d, J=2.14 Hz, 1H) 7.80
(dd, J=8.70, 2.29 Hz, 1H) 7.68 (s, 1H) 7.62-7.66 (m, 1H) 7.44 (d,
J=2.75 Hz, 1H) 7.21-7.26 (m, 1H) 7.10 (dd, J=8.85, 2.75 Hz, 1H)
6.98 (d, J=7.02 Hz, 1H) 6.53-6.57 (m, 1H) 4.09 (s, 3H) 3.34 (q,
J=7.02 Hz, 2H) 1.17 (t, J=7.32 Hz, 3H); MS (ESI+) m/z 477
(M+H).sup.+.
Example 77
3-{5-(ethylsulfonyl)-2-[4-(trifluoromethyl)phenoxy]phenyl}-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1026] Example 77 was prepared according to the procedure used for
the preparation of Example 73, substituting
4-(trifluoromethyl)phenol for 2-chloro-4-methylphenol. .sup.1H NMR
(500 MHz, DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.99 (d, J=2.44 Hz,
1H) 7.82 (dd, J=8.54, 2.44 Hz, 1H) 7.74 (d, J=8.85 Hz, 2H) 7.66 (s,
1H) 7.21-7.31 (m, 3H) 6.97 (d, J=7.02 Hz, 1H) 6.55 (d, J=7.02 Hz,
1H) 4.07 (s, 3H) 3.35 (q, J=7.32 Hz, 2H) 1.18 (t, J=7.32 Hz, 3H);
MS (ESI+) m/z 477 (M+H).sup.+.
Example 78
4-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridi-
n-3-yl)phenoxy]benzonitrile
[1027] Example 78 was prepared according to the procedure used for
the preparation of Example 73, substituting 4-hydroxybenzonitrile
for 2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.99 (d, J=2.14 Hz, 1H)
7.78-7.87 (m, 3H) 7.63 (s, 1H) 7.33-7.38 (m, 1H) 7.16 (d, J=8.85
Hz, 2H) 6.97 (d, J=7.02 Hz, 1H) 6.53 (d, J=7.02 Hz, 1H) 4.06 (s,
3H) 3.36 (q, J=7.32 Hz, 2H) 1.18 (t, J=7.32 Hz, 3H); MS (ESI+) m/z
434 (M+H).sup.+.
Example 79
3-[2-(4-chloro-3-ethylphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihyd-
ro-7H-pyrrolo[2,3-c]pyridin-7-one
[1028] Example 79 was prepared according to the procedure used for
the preparation of Example 73, substituting 4-chloro-3-ethylphenol
for 2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.93 (d, J=2.14 Hz, 1H) 7.77
(dd, J=8.70, 2.29 Hz, 1H) 7.67 (s, 1H) 7.41-7.47 (m, 1H) 7.08-7.12
(m, 2H) 6.94-7.00 (m, 2H) 6.55 (d, J=7.02 Hz, 1H) 4.10 (s, 3H) 3.32
(q, J=7.32 Hz, 2H) 2.67 (q, J=7.63 Hz, 2H) 1.11-1.20 (m, 6H); MS
(ESI+) m/z 471 (M+H).sup.+.
Example 80
4-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridi-
n-3-yl)phenoxy]-3-methoxybenzonitrile
[1029] Example 80 was prepared according to the procedure used for
the preparation of Example 73, substituting
4-hydroxy-3-methoxybenzonitrile for 2-chloro-4-methylphenol.
.sup.1H NMR (500 MHz, DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.92 (d,
J=2.44 Hz, 1H) 7.72 (dd, J=8.70, 2.29 Hz, 1H) 7.66-7.68 (m, 2H)
7.48 (dd, J=8.24, 1.83 Hz, 1H) 7.29 (d, J=8.24 Hz, 1H) 6.92-6.99
(m, 2H) 6.60 (d, J=7.02 Hz, 1H) 4.10 (s, 3H) 3.82 (s, 3H) 3.32 (q,
J=7.32 Hz, 2H) 1.16 (t, J=7.32 Hz, 3H); MS (ESI+) m/z 464
(M+H).sup.+.
Example 81
3-[5-(ethylsulfonyl)-2-(pyridin-3-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-py-
rrolo[2,3-c]pyridin-7-one
[1030] The TFA salt of Example 81 was prepared according to the
procedure used for the preparation of Example 73, substituting
pyridin-3-ol for 2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 8.55 (d, J=2.44 Hz, 1H) 8.48 (d,
J=4.27 Hz, 1H) 7.93-8.00 (m, 1H) 7.69-7.89 (m, 3H) 7.58-7.67 (m,
1H) 7.25-7.36 (m, 1H) 6.99 (d, J=7.02 Hz, 1H) 6.56 (d, J=7.02 Hz,
1H) 4.08 (d, J=5.19 Hz, 3H) 3.30-3.41 (m, 2H) 1.15-1.23 (m, 3H); MS
(ESI+) m/z 424 (M+H).sup.+.
Example 82
3-[2-(2,4-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
[1031] Example 82 was prepared according to the procedure used for
the preparation of Example 73, substituting 2,4-dichlorophenol for
2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.95 (d, J=2.14 Hz, 1H) 7.80 (d,
J=2.44 Hz, 1H) 7.75 (dd, J=8.54, 2.44 Hz, 1H) 7.70 (s, 1H) 7.49
(dd, J=8.70, 2.59 Hz, 1H) 7.30 (d, J=8.85 Hz, 1H) 6.98 (t, J=7.48
Hz, 2H) 6.60 (d, J=7.32 Hz, 1H) 4.11 (s, 3H) 3.32 (q, J=7.32 Hz,
2H) 1.16 (t, J=7.32 Hz, 3H); MS (ESI+) m/z 477 (M+H).sup.+.
Example 83
2-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridi-
n-3-yl)phenoxy]benzonitrile
[1032] Example 83 was prepared according to the procedure used for
the preparation of Example 73, substituting 2-hydroxybenzonitrile
for 2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 8.00 (d, J=2.14 Hz, 1H)
7.82-7.90 (m, 2H) 7.63-7.71 (m, 2H) 7.34 (t, J=7.63 Hz, 1H) 7.28
(d, J=8.54 Hz, 1H) 7.10 (d, J=8.54 Hz, 1H) 6.96 (d, J=7.02 Hz, 1H)
6.57 (d, J=7.02 Hz, 1H) 4.09 (s, 3H) 3.36 (q, J=7.32 Hz, 2H) 1.18
(t, J=7.32 Hz, 3H); MS (ESI+) m/z 434 (M+H).sup.+.
Example 84
3-[2-(2,3-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
[1033] Example 84 was prepared according to the procedure used for
the preparation of Example 73, substituting 2,3-dichlorophenol for
2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.97 (d, J=2.14 Hz, 1H) 7.77
(dd, J=8.70, 2.29 Hz, 1H) 7.70 (s, 1H) 7.55 (dd, J=8.24, 1.22 Hz,
1H) 7.43 (t, J=8.09 Hz, 1H) 7.23 (dd, J=8.24, 1.22 Hz, 1H) 6.99
(dd, J=7.78, 3.20 Hz, 2H) 6.61 (d, J=7.02 Hz, 1H) 4.08-4.13 (s, 3H)
3.33 (q, J=7.32 Hz, 2H) 1.17 (t, J=7.32 Hz, 3H); MS (ESI+) m/z 477
(M+H).sup.+.
Example 85
3-[2-(2-chloro-4-methoxyphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1034] Example 85 was prepared according to the procedure used for
the preparation of Example 73, substituting
2-chloro-4-methoxyphenol for 2-chloro-4-methylphenol. .sup.1H NMR
(500 MHz, DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.93 (d, J=2.44 Hz,
1H) 7.69-7.74 (m, 2H) 7.28-7.32 (m, 1H) 7.24 (d, J=2.75 Hz, 1H)
7.03 (dd, J=8.85, 3.05 Hz, 1H) 6.99 (d, J=7.02 Hz, 1H) 6.78 (d,
J=8.54 Hz, 1H) 6.63 (d, J=7.02 Hz, 1H) 4.13 (s, 3H) 3.81 (s, 3H)
3.30 (q, J=7.32 Hz, 2H) 1.15 (t, J=7.32 Hz, 3H); MS (ESI+) m/z 473
(M+H).sup.+.
Example 86
3-{5-(ethylsulfonyl)-2-[(6-methylpyrazin-2-yl)oxy]phenyl}-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1035] Example 86 was prepared according to the procedure used for
the preparation of Example 73, substituting 6-methylpyrazin-2-ol
for 2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 8.26 (s, 1H) 8.22 (s, 1H) 7.96
(d, J=2.14 Hz, 1H) 7.86 (dd, J=8.54, 2.44 Hz, 1H) 7.58 (s, 1H) 7.52
(d, J=8.54 Hz, 1H) 6.95 (d, J=6.71 Hz, 1H) 6.48 (d, J=7.02 Hz, 1H)
4.03 (s, 3H) 3.38 (q, J=7.53 Hz, 2H) 2.27 (s, 3H) 1.19 (t, J=7.32
Hz, 3H); MS (ESI+) m/z 425 (M+H).sup.+.
Example 87
3-[5-(ethylsulfonyl)-2-(pyridazin-4-yloxy)phenyl]-1-methyl-1,6-dihydro-7H--
pyrrolo[2,3-c]pyridin-7-one
[1036] Example 87 was prepared according to the procedure used for
the preparation of Example 73, substituting pyridazin-4-ol for
2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 8.19 (d, J=7.93 Hz, 1H)
7.98-8.07 (m, 2H) 7.89-7.95 (m, 2H) 7.43 (s, 1H) 6.85 (d, J=7.02
Hz, 1H) 6.31 (dd, J=7.93, 3.05 Hz, 1H) 5.98 (d, J=7.02 Hz, 1H) 4.08
(s, 3H) 3.43 (q, J=7.32 Hz, 2H) 1.20 (t, J=7.32 Hz, 3H); MS (ESI+)
m/z 411 (M+H).sup.+.
Example 88
3-[5-(ethylsulfonyl)-2-(pyrimidin-5-yloxy)phenyl]-1-methyl-1,6-dihydro-7H--
pyrrolo[2,3-c]pyridin-7-one
[1037] Example 88 was prepared according to the procedure used for
the preparation of Example 73, substituting pyrimidin-5-ol for
2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 8.99 (s, 1H) 8.66 (s, 2H) 7.98
(d, J=2.14 Hz, 1H) 7.83 (dd, J=8.70, 2.29 Hz, 1H) 7.71 (s, 1H) 7.34
(d, J=8.54 Hz, 1H) 6.99 (d, J=7.02 Hz, 1H) 6.56 (d, J=7.02 Hz, 1H)
4.08 (s, 3H) 3.35 (q, J=7.32 Hz, 2H) 1.18 (t, J=7.32 Hz, 3H); MS
(ESI+) m/z 411 (M+H).sup.+.
Example 89
3-{5-(ethylsulfonyl)-2-[(3-methylpyrazin-2-yl)oxy]phenyl}-1-methyl-1,6-dih-
ydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1038] Example 89 was prepared according to the procedure used for
the preparation of Example 73, substituting 3-methylpyrazin-2-ol
for 2-chloro-4-methylphenol. .sup.1H NMR (500 MHz,
DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.99-8.02 (m, 1H) 7.99 (s, 1H)
7.83 (d, J=8.24 Hz, 1H) 7.25 (s, 1H) 7.20 (d, J=4.58 Hz, 1H) 7.06
(d, J=4.58 Hz, 1H) 6.86 (d, J=7.02 Hz, 1H) 6.16 (d, J=7.02 Hz, 1H)
4.02 (s, 3H) 3.43 (q, J=7.32 Hz, 2H) 2.26-2.32 (m, 3H) 1.21 (t,
J=7.32 Hz, 3H); MS (ESI+) m/z 425 (M+H).sup.+.
Example 90
3-{5-(ethylsulfonyl)-2-[(1,3,5-trimethyl-1H-pyrazol-4-yl)oxy]phenyl}-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1039] Example 90 was prepared according to the procedure used for
the preparation of Example 73, substituting
1,3,5-trimethyl-1H-pyrazol-4-ol for 2-chloro-4-methylphenol.
.sup.1H NMR (500 MHz, DMSO-d.sub.6/D.sub.2O) .delta. ppm 7.90 (d,
J=2.14 Hz, 1H) 7.68-7.75 (m, 2H) 7.01 (d, J=7.02 Hz, 1H) 6.93 (d,
J=8.54 Hz, 1H) 6.55 (d, J=7.02 Hz, 1H) 4.14 (s, 3H) 3.68 (s, 3H)
3.29 (q, J=7.32 Hz, 2H) 2.05 (s, 3H) 1.94 (s, 3H) 1.16 (t, J=7.32
Hz, 3H); MS (ESI+) m/z 441 (M+H).sup.+.
Example 91
5-chloro-3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 91A
5-bromo-7-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1040] A solution of 5-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine
(Aldrich, 0.86 g, 3.72 mmol) in tetrahydrofuran (37.2 mL) was
treated with sodium hydride (0.297 g, 7.43 mmol) at ambient
temperature, stirred for 15 minutes, treated with iodomethane
(0.348 mL, 5.57 mmol), stirred for 1 hour at ambient temperature
and quenched with saturated aqueous ammonium chloride. The mixture
was partitioned with ethyl acetate and the organic layer was washed
with saturated aqueous sodium chloride, dried (anhydrous
Na.sub.2SO.sub.4), filtered, and concentrated. Purification by
chromatography (silica gel, 0-40% ethyl acetate in heptanes)
afforded the title compound (0.75 g, 82%).
Example 91B
5-bromo-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1041] The product from Example 91A (0.43 g, 1.752 mmol) and 0.5 M
sodium methoxide in methanol (15 mL, 7.50 mmol) were combined in a
sealed microwave tube, heated by microwave at 130.degree. C. for 45
minutes, cooled and concentrated. The residue was partitioned
between ethyl acetate and water adjusting the pH to 7 with 1 M HCl.
The organic layer was washed with saturated aqueous sodium
chloride, dried (anhydrous Na.sub.2SO.sub.4), filtered, and
concentrated to afford the title compound (0.41 g, 97%).
Example 91C
5-bromo-3-iodo-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1042] The product from Example 91B (0.82 g, 3.40 mmol) and
N-iodosuccinimide (0.918 g, 4.08 mmol) were combined in
dimethylformamide (17.01 mL), stirred for two hours at ambient
temperature, and quenched with 100 mL of 10% aqueous sodium
thiosulfate. The mixture was stirred for 15 minutes and the
resulting solid was collected by filtration, washed repeatedly with
water and dried to constant mass to afford the title compound (1.17
g, 94%).
Example 91D
2-(2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)phenyl)-4,4,5,5-tetrame-
thyl-1,3,2-dioxaborolane
[1043] The product from Example 52E (1.0 g, 2.65 mmol),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.346
g, 5.30 mmol), potassium acetate (1.041 g, 10.60 mmol) and
Pd(PPh.sub.3).sub.2Cl.sub.2 (0.112 g, 0.159 mmol) were combined and
sparged with argon for 30 minutes. To the solids was added argon
sparged dioxane (13.26 mL). The reaction mixture was heated for 18
hours under argon at 90.degree. C., cooled and partitioned between
ethyl acetate and water. The organic layer was washed with
saturated aqueous sodium chloride, dried with sodium sulfate,
treated with 3-mercaptopropyl functionalized silica gel, filtered,
and concentrated. Purification by chromatography (silica gel, 0-70%
ethyl acetate in heptanes) afforded the title compound (1.0 g,
89%).
Example 91E
5-bromo-3-(2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)phenyl)-7-metho-
xy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1044] The product from Example 91D (0.058 g, 0.136 mmol), the
product from Example 91C (0.05 g, 0.136 mmol),
tris(dibenzylideneacetone)dipalladium(0) (3.74 mg, 4.09 .mu.mol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (3.98
mg, 0.014 mmol) and potassium phosphate (0.087 g, 0.409 mmol) were
combined and sparged with argon for 15 minutes. Meanwhile a
solution of 4:1 dioxane/water (2 mL) was sparged with nitrogen for
15 minutes and transferred by syringe into the reaction vessel
under argon. The mixture was stirred for 2 hours at ambient
temperature and partitioned between ethyl acetate and water. The
organic layer was washed with saturated aqueous sodium chloride,
dried (anhydrous Na.sub.2SO.sub.4), treated with 3-mercaptopropyl
functionalized silica gel, filtered, and concentrated. Purification
by chromatography (silica gel, 10-50% ethyl acetate in heptanes)
afforded the title compound (0.064 g, 87%).
Example 91F
5-chloro-3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1045] The product from Example 91E (0.064 g, 0.119 mmol) and 4 M
hydrogen chloride in dioxane (2 mL, 8.00 mmol) were combined and
heated at 70.degree. C. for 2 hours, cooled and concentrated.
Purification by trituration (1:1 dichloromethane/heptane) afforded
the title compound (0.042 g, 74%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 11.91 (s, 1H) 7.60 (s, 1H) 7.57 (d,
J=2.03 Hz, 1H) 7.43-7.52 (m, 1H) 7.19-7.30 (m, 2H) 7.05-7.15 (m,
1H) 6.82 (d, J=8.14 Hz, 1H) 6.68 (s, 1H) 4.53 (s, 2H) 4.07 (s, 3H)
2.94 (s, 3H). MS (ESI+) m/z 479 (M+H).sup.+.
Example 92
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-ethyl-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 92A
3-(2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)phenyl)-7-methoxy-1-met-
hyl-5-vinyl-1H-pyrrolo[2,3-c]pyridine
[1046] Tributyl(vinyl)tin (0.053 g, 0.167 mmol), the product from
Example 91E (0.075 g, 0.140 mmol) and Pd(PPh.sub.3).sub.2Cl.sub.2
(9.80 mg, 0.014 mmol) were combined in dioxane (1.163 mL) and
sparged with argon for 15 minutes. The mixture was stirred for 2
hours at 100.degree. C., cooled and partitioned between ethyl
acetate and water. The organic layer was washed with saturated
aqueous sodium chloride, dried (anhydrous Na.sub.2SO.sub.4),
treated with 3-mercaptopropyl functionalized silica gel, filtered,
and concentrated. Purification by chromatography (silica gel, 0-40%
ethyl acetate in heptanes) afforded the title compound (0.041 g,
61%).
Example 92B
3-(2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)phenyl)-5-ethyl-7-metho-
xy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1047] The product from Example 92A (0.04 g, 0.083 mmol) and 10%
Pd/C (0.022 g, 0.021 mmol) were combined in ethyl acetate (3
mL)/ethanol (3 mL), degassed under vacuum, placed under a balloon
of hydrogen and stirred for 2 hours. The mixture was filtered
through Celite and the Celite pad was washed repeatedly with ethyl
acetate. The filtrate was concentrated to afford the title compound
(0.042 g, 105%).
Example 92C
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-ethyl-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1048] The product from Example 92B (0.04 g, 0.082 mmol) and 4M
hydrogen chloride in dioxane (5 mL, 20.00 mmol) were combined,
heated at 70.degree. C. for 3 hours, cooled and concentrated.
Purification by chromatography (silica gel, 0-4% methanol in
dichloromethane) afforded the title compound (0.035 g, 90%).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.87 (s, 1H) 7.58
(d, J=2.03 Hz, 1H) 7.49 (s, 1H) 7.41-7.52 (m, 1H) 7.17-7.28 (m, 2H)
7.05-7.14 (m, 1H) 6.82 (d, J=8.14 Hz, 1H) 6.38 (s, 1H) 4.51 (s, 2H)
4.07 (s, 3H) 2.94 (s, 3H) 2.43 (q, J=7.63 Hz, 2H) 1.14 (t, J=7.46
Hz, 3H). MS (ESI+) m/z 473 (M+H).sup.+.
Example 93
3,5-bis{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 93A
3,5-bis(2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)phenyl)-7-methoxy--
1-methyl-1H-pyrrolo[2,3-c]pyridine
[1049] The product from Example 91D (1.233 g, 2.180 mmol), the
product from Example 91C (0.8 g, 2.180 mmol),
tris(dibenzylideneacetone)dipalladium(0) (0.060 g, 0.065 mmol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (0.064
g, 0.218 mmol) and potassium phosphate (1.388 g, 6.54 mmol) were
combined and sparged with argon for 15 minutes. Meanwhile a
solution of 4:1 dioxane/water (18 mL) was sparged with nitrogen for
15 minutes and transferred by syringe into the reaction vessel
under argon. The mixture was stirred for 2 hours at ambient
temperature, and partitioned between ethyl acetate and water. The
organic layer was washed with saturated aqueous sodium chloride,
dried (anhydrous Na.sub.2SO.sub.4), treated with 3-mercaptopropyl
functionalized silica gel, filtered, and concentrated. Purification
by chromatography (silica gel, 10-50% ethyl acetate in heptanes)
afforded the title compound (0.104 g, 6%).
Example 93B
3,5-bis{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1050] The product from Example 93A (0.1 g, 0.132 mmol) and 4 M
hydrogen chloride in dioxane (5 mL, 20.00 mmol) were combined and
heated at 70.degree. C. for 4 hours, cooled and concentrated. The
residue was partitioned between ethyl acetate and water adjusting
the pH to 7. The organic layer was washed with saturated aqueous
sodium chloride, dried (anhydrous Na.sub.2SO.sub.4), filtered, and
concentrated. Purification by chromatography (0-4% methanol in
dichloromethane) afforded the title compound (0.07 g, 71%). %).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 11.12 (s, 1H) 7.59
(s, 2H) 7.54 (d, J=2.37 Hz, 1H) 7.36-7.50 (m, 4H) 7.17-7.30 (m, 2H)
7.02-7.15 (m, 2H) 6.80 (dd, J=8.31, 1.53 Hz, 2H) 6.74 (s, 1H) 4.48
(s, 2H) 4.46 (s, 2H) 4.12 (s, 3H) 2.93 (s, 3H) 2.91 (s, 3H). MS
(ESI+) m/z 741 (M+H).sup.+.
Example 94
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-(3,5-dimeth-
yl-1,2-oxazol-4-yl)-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 94A
4-(3-(2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)phenyl)-7-methoxy-1--
methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)-3,5-dimethylisoxazole
[1051] 3,5-dimethylisoxazole-4-boronic acid (0.016 g, 0.112 mmol),
the product from Example 91E (0.05 g, 0.093 mmol),
tris(dibenzylideneacetone)dipalladium(0) (2.56 mg, 2.79 mol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (2.72
mg, 9.30 mol) and potassium phosphate (0.059 g, 0.279 mmol) were
combined and sparged with argon for 15 minutes. Meanwhile a
solution of 4:1 dioxane/water (0.8 mL) was sparged with N.sub.2 for
15 minutes and transferred by syringe into the reaction vessel
under argon. The mixture was heated at 60.degree. C. for 2 hours
and partitioned between ethyl acetate and water. The organic layer
was washed with saturated aqueous sodium chloride, dried (anhydrous
Na.sub.2SO.sub.4), treated with 3-mercaptopropyl functionalized
silica gel, filtered, and concentrated to afford the title compound
(0.052 g, 100%).
Example 94B
3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-(3,5-dimeth-
yl-1,2-oxazol-4-yl)-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1052] The product from Example 94A (0.052 g, 0.094 mmol) and 4 M
hydrogen chloride in dioxane (5 mL, 20.00 mmol) were combined and
heated at 70.degree. C. for 4 hours, cooled and concentrated.
Purification by chromatography (silica gel, 0-4% methanol in
dichloromethane) afforded the title compound (0.042 g, 83%).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 11.09 (s, 1H)
7.60-7.64 (m, 2H) 7.41-7.53 (m, 1H) 7.21-7.32 (m, 2H) 7.06-7.16 (m,
1H) 6.81 (d, J=8.48 Hz, 1H) 6.57 (s, 1H) 4.51 (s, 2H) 4.13 (s, 3H)
2.92 (s, 3H) 2.35 (s, 3H) 2.18 (s, 3H). MS (ESI+) m/z 540
(M+H).sup.+.
Example 95
3-{2-(2,4-difluorophenoxy)-5-[(morpholin-4-ylsulfonyl)methyl]phenyl}-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 95A
4-fluoro-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)benzaldehyde
[1053] Example 2A (4.61 g, 16.0 mmol),
2-fluoro-5-formylphenylboronic acid (2.69 g, 16.0 mmol), potassium
phosphate (10.19 g, 48.0 mmol),
tris(dibenzylideneacetone)dipalladium (0.440 g, 0.480 mmol) and
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane
(0.421 g, 1.44 mmol) were combined and purged with nitrogen for 15
minutes. The mixture of dioxane (80 mL) and water (20 mL) was
purged with nitrogen for 15 minutes and transferred to the reaction
flask. The reaction mixture was heated at 60.degree. C. for 4
hours. The reaction mixture was partitioned with ethyl acetate and
water. The organic layer was washed with saturated aqueous sodium
chloride, dried with anhydrous sodium sulfate, treated with
3-mercaptopropyl functionalized silica gel, filtered, and
concentrated. The residue was purified by flash chromatography
(silica gel, 20 to 40% ethyl acetate in heptanes) to provide the
title compound (3.27 g, 72%).
Example 95B
4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-y-
l)benzaldehyde
[1054] A mixture of Example 95A (3.26 g, 11.47 mmol),
2,4-difluorophenol (1.492 g, 11.47 mmol) and cesium carbonate (4.11
g, 12.61 mmol) in dimethyl sulfoxide (40 mL) was heated at
100.degree. C. for 3 hours. The reaction mixture was partitioned
with ethyl acetate and water. The organic layer was washed with
saturated aqueous sodium chloride twice, dried with anhydrous
sodium sulfate, filtered, and concentrated. The residue was
purified by flash chromatography (silica gel, 20 to 40% ethyl
acetate in heptanes) to provide the title compound (3.98 g,
88%).
Example 95C
(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3--
yl)phenyl)methanol
[1055] Example 95B (3.73 g, 9.46 mmol) in the mixture of ethanol
(20 mL) and tetrahydrofuran (20 mL) was added sodium borohydride
(0.107 g, 2.84 mmol). The reaction mixture was stirred at room
temperature for 1 hour. The solvent was concentrated and the
residue was partitioned with ethyl acetate and water. The organic
layer was washed with saturated aqueous sodium chloride, dried with
anhydrous sodium sulfate, filtered, and concentrated to provide the
title compound (3.43 g, 91%).
Example 95D
3-(5-(bromomethyl)-2-(2,4-difluorophenoxy)phenyl)-7-methoxy-1-methyl-1H-py-
rrolo[2,3-c]pyridine
[1056] Example 95C (3.33 g, 8.40 mmol) in dichloromethane (40 mL)
was added phosphorus tribromide (0.792 mL, 8.40 mmol) dropwise. The
reaction mixture was stirred at room temperature for 3 hours and
concentrated. The residue was added water and the pH was adjusted
to basic with saturated aqueous sodium bicarbonate slowly, and
extracted with ethyl acetate. The organic layer was washed with
saturated aqueous sodium chloride, dried with anhydrous sodium
sulfate, filtered, and concentrated to provide the title compound
(3.83 g, 99%).
Example 95E
sodium
(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyr-
idin-3-yl)phenyl)methanesulfonate
[1057] Example 95D (2.296 g, 5.00 mmol), sodium sulfite (0.693 g,
5.50 mmol) and tetrabutylammonium iodide (0.923 g, 2.50 mmol) were
combined in the mixture of ethanol (125 mL) and water (125 mL). The
reaction mixture was heated at 70.degree. C. for 2 hours. The
solvent was evaporated and the residue was partitioned with ethyl
ether and water. The organic layer was washed with water. The
aqueous layers were combined and concentrated. The residue was
triturated with ethyl acetate and filtered. The filtrate was
concentrated to provide the title compound (1.76 g, 73%).
Example 95F
4-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzylsulfonyl)morpholine
[1058] Example 95E (96 mg, 0.20 mmol) in dichloromethane (2 mL) was
added a drop of dimethylformamide and oxalyl chloride (0.021 mL,
0.24 mmol). The reaction mixture was stirred at room temperature
for 30 minutes and concentrated. The residue was dissolved in
dichloromethane (2 mL), added morpholine (0.087 mL, 1.0 mmol) and
stirred at room temperature for 30 minutes. The solvent was
evaporated and the residue was triturated with water to provide the
title compound (92 mg, 87%).
Example 95G
3-{2-(2,4-difluorophenoxy)-5-[(morpholin-4-ylsulfonyl)methyl]phenyl}-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1059] Example 95F (90 mg, 0.17 mmol) in a solution of 4 M HCl in
dioxane (5 mL, 20 mmol) was heated at 70.degree. C. for 16 hours,
cooled and concentrated. The residue was purified by flash
chromatography (silica gel, 2 to 4% methanol in dichloromethane) to
provide the title compound (81 mg, 92%). .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. ppm 10.94 (d, J=5.09 Hz, 1H) 7.60 (d, J=2.37
Hz, 1H) 7.54 (s, 1H) 7.40-7.51 (m, 1H) 7.28 (dd, J=8.48, 2.37 Hz,
1H) 7.16-7.24 (m, 1H) 7.03-7.14 (m, 1H) 6.90 (dd, J=7.12, 5.76 Hz,
1H) 6.82 (d, J=8.14 Hz, 1H) 6.61 (dd, J=7.12, 1.02 Hz, 1H) 4.48 (s,
2H) 4.10 (s, 3H) 3.53-3.65 (m, 4H) 3.09-3.17 (m, 4H). MS (ESI+) m/z
516 (M+H).sup.+.
Example 96
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]methanesulfonamide
Example 96A
(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3--
yl)phenyl)methanesulfonamide
[1060] Example 95E (96 mg, 0.20 mmol) in dichloromethane (2 mL) was
added a drop of dimethylformamide and oxalyl chloride (0.021 mL,
0.24 mmol). The reaction mixture was stirred at ambient temperature
for 30 minutes and concentrated. The residue was dissolved in
dichloromethane (2 mL), added 0.5 M ammonia in dioxane (2.0 mL, 1.0
mmol) and stirred at ambient temperature for 30 minutes. The
solvent was evaporated and the residue was triturated with water to
provide the title compound (82 mg, 89%).
Example 96B
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]methanesulfonamide
[1061] Example 96A (80.0 mg, 0.174 mmol) in a solution of 4 M HCl
in dioxane (5 mL, 20 mmol) was heated at 70.degree. C. for 16
hours, cooled and concentrated. The residue was purified by flash
chromatography (silica gel, 2 to 4% methanol in dichloromethane) to
provide the title compound (61 mg, 79%). .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. ppm 10.93 (d, J=5.09 Hz, 1H) 7.55 (d, J=2.03
Hz, 1H) 7.53 (s, 1H) 7.39-7.50 (m, 1H) 7.14-7.26 (m, 2H) 7.01-7.14
(m, 1H) 6.75-6.91 (m, 4H) 6.61 (d, J=6.78 Hz, 1H) 4.29 (s, 2H) 4.10
(s, 3H). MS (ESI+) m/z 446 (M+H).sup.+.
Example 97
3-[2-(cyclopropylmethoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 97A
1-(3-bromo-4-fluorophenylsulfonyl)indoline
[1062] A mixture of 3-bromo-4-fluorobenzene-1-sulfonyl chloride
(2.53 g, 8.33 mmol), indoline (0.933 mL, 8.33 mmol), and
N,N-diisopropylethyl-amine (1.60 mL, 9.16 mmol) in tetrahydrofuran
(20 mL) was stirred at room temperature for 20 hours. The reaction
mixture was partitioned between water and ether. The organic layer
was washed with saturated aqueous sodium chloride, dried over
anhydrous magnesium sulfate, filtered, and concentrated to a solid
residue. Recrystallization from ether and heptane provided the
title compound (1.99 g, 67%).
Example 97B
1-(3-bromo-4-(cyclopropylmethoxy)phenylsulfonyl)indoline
[1063] A solution of cyclopropylmethanol (118 mg, 1.63 mmol) in
dioxane (10 mL) was treated with sodium hydride (60% oil
dispersion, 87 mg, 2.2 mmol). The mixture was stirred at ambient
temperature for 15 minutes and Example 97A (388 mg, 1.089 mmol) was
added to the reaction mixture in one portion as a solid. The
reaction mixture was heated at 65.degree. C. for 18 hours. After
cooling to ambient temperature, the reaction mixture was
partitioned between water and ethyl acetate. The aqueous layer was
extracted with additional ethyl acetate three times. The combined
organic layers were washed with saturated aqueous sodium chloride,
dried over anhydrous magnesium sulfate, filtered, and concentrated.
The crude product was purified by flash chromatography (silica gel,
10% ethyl acetate in heptanes) to provide 0.40 g (90%) of the title
compound.
Example 97C
3-(2-(cyclopropylmethoxy)-5-(indolin-1-ylsulfonyl)phenyl)-7-methoxy-1-meth-
yl-1H-pyrrolo[2,3-c]pyridine
[1064] Example 97C was prepared according to the procedure used for
the preparation of Example 11E, substituting Example 97B for
Example 11C.
Example 97D
3-[2-(cyclopropylmethoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1065] Example 97D was prepared according to the procedure used for
the preparation of Example 11F, substituting Example 97C for
Example 11E. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.97
(d, J=5.5 Hz, 1H), 7.70 (dd, J=8.7, 2.4 Hz, 1H), 7.65 (d, J=2.4 Hz,
1H), 7.47-7.56 (m, 2H), 7.23-7.31 (m, 1H), 7.14-7.22 (m, 2H), 7.03
(td, J=7.4, 0.9 Hz, 1H), 6.84 (dd, J=7.0, 5.8 Hz, 1H), 6.04 (dd,
J=7.0, 1.0 Hz, 1H), 4.10 (s, 3H), 3.95 (d, J=7.0 Hz, 2H), 3.89 (t,
J=8.4 Hz, 2H), 2.90 (t, J=8.4 Hz, 2H), 1.13-1.30 (m, 1H), 0.56-0.60
(m, 2H), 0.26-0.36 (m, 2H). MS (ESI+) m/z 476.2 (M+H).sup.+.
Example 98
3-[6-(cyclopropylmethoxy)-1H-indol-7-yl]-1-methyl-1,6-dihydro-7H-pyrrolo[2-
,3-c]pyridin-7-one
Example 98A
2-bromo-1-(cyclopropylmethoxy)-3-nitrobenzene
[1066] Example 98A was prepared according to the procedure used for
the preparation of Example 14A, substituting 2-bromo-3-nitrophenol
for 2-bromo-3-methyl-4-nitrophenol.
Example 98B
7-bromo-6-(cyclopropylmethoxy)-1H-indole
[1067] A 250 mL roundbottom flask with stirbar was charged with a
solution of Example 98A (6.18 g, 22.7 mmol) in tetrahydrofuran (80
mL) and cooled to -45.degree. C. under nitrogen. A solution of 0.7
M vinylmagnesium bromide in tetrahydrofuran (100 mL, 70.0 mmol) was
added over 20 minutes and the mixture stirred at -45.degree. C. for
30 minutes. The mixture was then poured into aqueous ammonium
chloride and extracted with 3.times.150 mL of ether. The combined
organics were dried over anhydrous magnesium sulfate. After
filtration and solvent removal the residues were adsorbed on silica
gel and chromatographed on a 150 g silica cartridge eluting with
0-10-100% ethyl acetate/heptane to provide 3.087 g, (51%) of the
title compound.
Example 98C
3-(6-(cyclopropylmethoxy)-1H-indol-7-yl)-7-methoxy-1-methyl-1H-pyrrolo[2,3-
-c]pyridine
[1068] A mixture of Example 59A (0.087 g, 0.3 mmol), Example 98B
(0.088 g, 0.33 mmol), tris(dibenzylideneacetone)dipalladium(0)
(0.0083 g, 0.009 mmol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane
(0.0088 g, 0.03 mmol), and sodium carbonate (0.137 g, 1.3 mmol) was
sparged with nitrogen for 30 minutes. To this was added a
nitrogen-sparged solution of dioxane/H.sub.2O (4:1, 1.875 mL). The
reaction mixture was heated at 60.degree. C. for 5 hours. The
reaction mixture was partitioned between ethyl acetate and water.
The organic layer was washed with saturated aqueous sodium
chloride, dried over anhydrous magnesium sulfate, treated with
mercapto-functionalized silica gel, filtered, and concentrated. The
residue was purified by flash chromatography (silica gel, 0 to 40%
ethyl acetate in heptanes) to give the title compound (0.09 g,
86%).
Example 98D
3-[6-(cyclopropylmethoxy)-1H-indol-7-yl]-1-methyl-1,6-dihydro-7H-pyrrolo[2-
,3-c]pyridin-7-one
[1069] A mixture of Example 98C (0.09 g, 0.26 mmol) in dioxane (5.2
mL) was treated with hydrogen chloride (4M in dioxane) (6.5 mL, 26
mmol) and heated at 75.degree. C. for 30 minutes. The reaction
mixture was neutralized with saturated sodium bicarbonate solution.
The resulting mixture was partitioned between ethyl acetate and
water. The organic layer was washed with saturated aqueous sodium
chloride, dried over anhydrous magnesium sulfate, filtered, and
concentrated. The residue was purified by flash chromatography
(silica gel, 0 to 20% methanol in dichloromethane). The material
was further purified by reverse phase HPLC (C18, CH.sub.3CN/water
(0.1% TFA), 10-80%) to provide the title compound (0.0066 g, 7.6%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.81 (d, J=4.88
Hz, 1H), 10.38 (s, 1H), 7.41 (m, 2H), 7.12 (t, J=2.75 Hz, 1H), 6.86
(d, J=8.54 Hz, 1H), 6.80 (dd, J=6.71, 5.80 Hz, 1H), 6.37 (dd,
J=3.05, 1.83 Hz, 1H), 6.14 (m, 1H), 4.15 (s, 3H), 3.74 (d, J=6.71
Hz, 2H), 1.03 (m, 1H), 0.40 (ddd, J=8.09, 5.95, 4.27 Hz, 2H), 0.15
(ddd, J=5.95, 4.58, 4.43 Hz, 2H). MS (ESI+) m/z 334.1
(M+H).sup.+.
Example 99
ethyl
5-(cyclopropylmethoxy)-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3--
c]pyridin-3-yl)-1H-indole-2-carboxylate
Example 99A
2-bromo-1-(cyclopropylmethoxy)-3-nitrobenzene
[1070] Example 98A was prepared according to the procedure used for
the preparation of Example 14A, substituting
2-bromo-3-hydroxybenzaldehyde for
2-bromo-3-methyl-4-nitrophenol.
Example 99B
(Z)-ethyl
2-azido-3-(2-bromo-3-(cyclopropylmethoxy)phenyl)acrylate
[1071] A 50 mL roundbottom flask with stirbar was charged with
sodium ethanolate, 21 wt % in ethanol (14 mL, 37.6 mmol), sealed
and cooled to -20.degree. C. under nitrogen. A mixture of Example
99A (6.38 g, 25.01 mmol) and ethyl 2-azidoacetate (10 g, 77 mmol)
were added dropwise over 15 minutes. The solution was stirred for
3.5 hours, then poured into a separatory funnel and extracted from
100 mL water with 3.times.100 mL ether. The combined organics were
washed with saturated aqueous sodium chloride, dried over magnesium
sulfate. After filtration and solvent removal the residues were
chromatographed on a 60 g silica cartridge eluting with 0-10-100%
ethyl acetate/heptane to provide 2.56 g (28%) of the title
compound.
Example 99C
ethyl 4-bromo-5-(cyclopropylmethoxy)-1H-indole-2-carboxylate
[1072] A 50 mL recovery flask with stirbar was charged with Example
99B (2.586 g, 7.06 mmol) and rhodium(II) heptafluorobutyrate dimer
(0.215 g, 0.203 mmol) in toluene (7 mL). The mixture was heated at
60.degree. C. for 46 hours, adsorbed on silica gel and
chromatographed on a 150 g silica gel cartridge eluting with
0-10-100% ethyl acetate/heptane to provide 0.88 g (37%) of the
title compound.
Example 99D
ethyl
5-(cyclopropylmethoxy)-4-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridi-
n-3-yl)-1H-indole-2-carboxylate
[1073] Example 99D (0.0345 g, 27%) was prepared according to the
procedure used for the preparation of Example 98C, substituting
Example 99C for Example 98B.
Example 99E
ethyl
5-(cyclopropylmethoxy)-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3--
c]pyridin-3-yl)-1H-indole-2-carboxylate
[1074] Example 99E (0.023 g, 79%) was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 99D for Example 1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 11.77 (d, J=1.53 Hz, 1H), 10.84 (d, J=5.19 Hz, 1H),
7.47 (s, 1H), 7.35 (d, J=8.85 Hz, 1H), 7.17 (d, J=8.85 Hz, 1H),
6.87 (d, J=1.53 Hz, 1H), 6.81 (m, 1H), 6.18 (d, J=7.02 Hz, 1H),
4.30 (q, J=7.02 Hz, 2H), 4.17 (s, 3H), 3.71 (d, J=6.71 Hz, 2H),
1.30 (t, J=7.02 Hz, 3H), 1.03 (m, 1H), 0.41 (m, 2H), 0.14 (m, 2H).
MS (ESI+) m/z 406.2 (M+H).sup.+.
Example 100
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-N-methylmethanesulfonamide
Example 100A
1-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)phenyl)-N-methylmethanesulfonamide
[1075] Example 95E (96 mg, 0.20 mmol) in dichloromethane (2 mL) was
added a drop of dimethylformamide and oxalyl chloride (0.021 mL,
0.24 mmol). The reaction mixture was stirred at ambient temperature
for 30 minutes and concentrated. The residue was dissolved in
dichloromethane (2 mL), treated with 2M methanamine in
tetrahydrofuran (0.50 mL, 1.0 mmol) and stirred at ambient
temperature for 30 minutes. The solvent was evaporated and the
residue was triturated with water to provide the title compound (86
mg, 91%).
Example 100B
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-N-methylmethanesulfonamide
[1076] Example 100A (84.0 mg, 0.177 mmol) in a solution of 4 M HCl
in dioxane (5 mL, 20 mmol) was heated at 70.degree. C. for 16
hours, cooled and concentrated. The residue was purified by flash
chromatography (silica gel, 2 to 4% methanol in dichloromethane) to
provide the title compound (61 mg, 75%). .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. ppm 10.93 (d, J=5.09 Hz, 1H) 7.55 (d, J=2.37
Hz, 1H) 7.53 (s, 1H) 7.39-7.51 (m, 1H) 7.14-7.26 (m, 2H) 7.04-7.13
(m, 1H) 6.85-6.97 (m, 2H) 6.80 (d, J=8.48 Hz, 1H) 6.61 (d, J=7.12
Hz, 1H) 4.36 (s, 2H) 4.10 (s, 3H) 2.59 (s, 3H). MS (ESI+) m/z 460
(M+H).sup.+.
Example 101
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-N,N-dimethylmethanesulfonamide
Example 101A
1-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)phenyl)-N,N-dimethylmethanesulfonamide
[1077] Example 101A (88 mg, 90%) was prepared according to the
procedure used for the preparation of Example 95F, substituting
dimethylamine for morpholine.
Example 101B
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-N,N-dimethylmethanesulfonamide
[1078] Example 101B was prepared according to the procedure used
for the preparation of Example 95G, substituting Example 101A for
Example 95F (64 mg, 77%). .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. ppm 10.94 (d, J=5.43 Hz, 1H) 7.59 (d, J=2.37 Hz, 1H) 7.54
(s, 1H) 7.38-7.50 (m, 1H) 7.27 (dd, J=8.48, 2.37 Hz, 1H) 7.15-7.24
(m, 1H) 7.04-7.14 (m, 1H) 6.90 (dd, J=7.12, 5.76 Hz, 1H) 6.81 (d,
J=7.80 Hz, 1H) 6.59 (d, J=6.10 Hz, 1H) 4.44 (s, 2H) 4.10 (s, 3H)
2.75 (s, 6H). MS (ESI+) m/z 474 (M+H).sup.+.
Example 102
N-cyclohexyl-1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-p-
yrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide
Example 102A
N-cyclohexyl-1-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2-
,3-c]pyridin-3-yl)phenyl)methanesulfonamide
[1079] Example 102A (72 mg, 89%) was prepared according to the
procedure used for the preparation of Example 95F, substituting
cyclohexanamine for morpholine.
Example 102B
N-cyclohexyl-1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-p-
yrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide
[1080] Example 102B (50 mg, 73%) was prepared according to the
procedure used for the preparation of Example 95G, substituting
Example 102A for Example 95F. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. ppm 10.93 (d, J=5.43 Hz, 1H) 7.56 (d, J=2.37 Hz, 1H) 7.52
(s, 1H) 7.39-7.50 (m, 1H) 7.01-7.27 (m, 4H) 6.81-6.93 (m, 1H) 6.79
(d, J=8.48 Hz, 1H) 6.62 (d, J=6.44 Hz, 1H) 4.32 (s, 2H) 4.10 (s,
3H) 2.95-3.08 (m, 1H) 1.72-1.87 (m, 2H) 1.57-1.69 (m, 2H) 1.41-1.55
(m, 1H) 0.97-1.27 (m, 5H). MS (ESI+) m/z 528 (M+H).sup.+.
Example 103
3-{2-(2,4-difluorophenoxy)-5-[(piperidin-1-ylsulfonyl)methyl]phenyl}-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 103A
3-(2-(2,4-difluorophenoxy)-5-((piperidin-1-ylsulfonyl)methyl)phenyl)-7-met-
hoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1081] Example 103A (71 mg, 90%) was prepared according to the
procedure used for the preparation of Example 95F, substituting
piperidine for morpholine.
Example 103B
3-{2-(2,4-difluorophenoxy)-5-[(piperidin-1-ylsulfonyl)methyl]phenyl}-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1082] Example 103B (45 mg, 67%) was prepared according to the
procedure used for the preparation of Example 95G, substituting
Example 103A for Example 95F. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. ppm 10.94 (d, J=5.43 Hz, 1H) 7.58 (d, J=2.03 Hz, 1H) 7.53
(s, 1H) 7.37-7.50 (m, 1H) 7.26 (dd, J=8.48, 2.37 Hz, 1H) 7.14-7.23
(m, 1H) 7.04-7.14 (m, 1H) 6.86-6.94 (m, 1H) 6.80 (d, J=8.48 Hz, 1H)
6.60 (d, J=6.78 Hz, 1H) 4.39 (s, 2H) 4.10 (s, 3H) 3.08-3.15 (m, 4H)
1.41-1.57 (m, 6H).). MS (ESI+) m/z 514 (M+H).sup.+.
Example 104
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-N-(1,3-thiazol-2-yl)methanesulfonamide
Example 104A
1-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)phenyl)-N-(thiazol-2-yl)methanesulfonamide
[1083] Example 104A was prepared according to the procedure used
for the preparation of Example 95F, substituting thiazol-2-amine
for morpholine. Purification by flash chromatography (silica gel, 2
to 4% methanol in dichloromethane) afforded the title compound (8
mg, 10%).
Example 104B
1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-N-(1,3-thiazol-2-yl)methanesulfonamide
[1084] Example 104B (4 mg, 51%) was prepared according to the
procedure used for the preparation of Example 95G, substituting
Example 104A for Example 95F. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. ppm 12.54 (s, 1H), 10.92 (d, J=5.7 Hz, 1H), 7.51 (d, J=2.2
Hz, 1H), 7.33-7.49 (m, 2H), 7.20 (dd, J=8.4, 2.1 Hz, 1H), 7.15 (d,
J=4.6 Hz, 1H), 6.93-7.12 (m, 2H), 6.88 (dd, J=7.0, 5.8 Hz, 1H),
6.76 (d, J=8.3 Hz, 1H), 6.72 (d, J=4.6 Hz, 1H), 6.55 (dd, J=7.0,
0.9 Hz, 1H), 4.32 (s, 2H), 4.08 (s, 3H). MS (ESI+) m/z 529
(M+H).sup.+.
Example 105
3-[2-(2,4-difluorophenoxy)-5-(piperazin-1-ylmethyl)phenyl]-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 105A
3-bromo-4-(2,4-difluorophenoxy)benzaldehyde
[1085] A suspension of 3-bromo-4-fluorobenzaldehyde (500 mg, 2.46
mmol), 2,4-difluorophenol (0.353 mL, 3.69 mmol) and cesium
carbonate (1204 mg, 3.69 mmol) in dimethylsulfoxide (24 mL) was
heated at 105.degree. C. overnight. The reaction mixture was
partitioned between ethyl acetate (200 mL) and 50% saturated
aqueous sodium chloride (200 mL). The layers were separated and the
aqueous layer was extracted with ethyl acetate (2.times.75 mL). The
combined organics were dried over anhydrous sodium sulfate,
filtered, and concentrated. The residue was purified by flash
column chromatography (silica gel, 2.5-100% ethyl acetate in
heptanes) to afford the title compound (524 mg, 68% yield).
Example 105B
4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-y-
l)benzaldehyde
[1086] Example 105B was prepared according to the procedure used
for the preparation of Example 11E, substituting Example 105A for
Example 11C and potassium phosphate for sodium carbonate. The crude
product was purified by flash column chromatography (silica gel,
0-30% ethyl acetate in heptane) to provide the title compound.
Example 105C
tert-butyl
4-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-
-c]pyridin-3-yl)benzyl)piperazine-1-carboxylate
[1087] A suspension of Example 105B (100 mg, 0.254 mmol), sodium
cyanoborohydride (47.8 mg, 0.761 mmol) and tert-butyl
piperazine-1-carboxylate (94 mg, 0.51 mmol) in a mixture of
methanol (3 mL), acetic acid (0.073 mL, 1.3 mmol), and
dichloromethane (1 mL) was heated at 75.degree. C. 2 hours. Upon
cooling, the reaction mixture was partitioned between 50% saturated
sodium bicarbonate solution (50 mL) and ethyl acetate (50 mL). The
organic layer was dried over anhydrous sodium sulfate, filtered,
and concentrated. The residue was purified by flash column
chromatography (silica gel, 0-3% methanol in dichloromethane) to
provide the title compound (66.7 mg, 47% yield).
Example 105D
3-[2-(2,4-difluorophenoxy)-5-(piperazin-1-ylmethyl)phenyl]-1-methyl-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1088] The TFA salt of Example 105D was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 105C for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.98 (d, J=5.49 Hz, 1H), 8.89 (s, 1H),
7.59 (s, 1H), 7.55 (s, 1H), 7.44-7.52 (m, 1H), 7.30 (dd, J=8.39,
1.68 Hz, 1H), 7.18-7.26 (m, 1H), 7.08-7.15 (m, 1H), 6.86-6.93 (m,
1H), 6.83 (d, J=8.24 Hz, 1H), 6.55 (d, J=6.41 Hz, 1H), 4.11 (s,
3H), 4.06 (s, 2H), 3.26 (s, 4H), 3.03 (s, 4H). MS (ESI+) m/z 451.0
(M+H).sup.+.
Example 106
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]ethanesulfonamide
Example 106A
N-benzyl-1-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl)methanamine
[1089] Example 106A was prepared according to the procedure used
for the preparation of Example 105C, substituting benzyl amine for
tert-butyl piperazine-1-carboxylate.
Example 106B
(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3--
yl)phenyl)methanamine
[1090] A solution of Example 106A (78 mg, 0.161 mmol) in
tetrahydrofuran (10 mL) was added to 20% palladium hydroxide on
carbon (16 mg, 0.012 mmol) in a 50 mL pressure bottle and the
mixture was stirred for 16 hours under a hydrogen atmosphere (30
psi). The mixture was filtered through a nylon membrane and
concentrated. The residue was purified by flash column
chromatography (silica gel, 0-5% 7N methanolic ammonia in
dichloromethane) to afford the title compound (57 mg, 90%
yield).
Example 106C
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)ethanesulfonamide
[1091] Example 106C was prepared according to the procedure used
for the preparation of Example 5C, substituting Example 106B for
Example 5B.
Example 106D
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]ethanesulfonamide
[1092] Example 106D was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 106C for
Example 1B, with the exception that the reaction mixture was heated
at 70.degree. C. The material was purified by flash chromatography
(silica gel, 0-5% methanol in dichloromethane) to provide the title
compound. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 10.94 (d,
J=4.58 Hz, 1H), 7.61 (s, 1H), 7.49-7.53 (m, 2H), 7.40-7.46 (m, 1H),
7.22 (dd, J=8.39, 1.98 Hz, 1H), 7.10-7.16 (m, 1H), 7.03-7.09 (m,
1H), 6.87-6.92 (m, 1H), 6.81 (d, J=8.24 Hz, 1H), 6.58 (d, J=7.02
Hz, 1H), 4.16 (s, 2H), 4.09 (s, 3H), 2.97 (q, J=7.32 Hz, 2H), 1.17
(t, J=7.32 Hz, 3H). MS (ESI+) m/z 474.2 (M+H).sup.+.
Example 107
5-(cyclopropylmethoxy)-N-methyl-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2-
,3-c]pyridin-3-yl)-1H-indole-2-carboxamide
Example 107A
5-(cyclopropylmethoxy)-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyri-
din-3-yl)-1H-indole-2-carboxylic acid
[1093] A 2 mL reaction vessel equipped with stirbar was charged
with Example 99E (17.9 mg, 0.044 mmol) and a solution of lithium
hydroxide monohydrate (42.0 mg, 1 mmol) in tetrahydrofuran (1
mL)/water (0.5 mL), then sealed. The mixture was heated at
100.degree. C. for 22 hours, cooled, then partitioned between
saturated aqueous sodium chloride acidified with 1 M HCl (25 mL)
and dichloromethane (3.times.25 mL). The combined organics were
dried over sodium sulfate. Filtration and solvent removal provided
the title compound (12 mg, 72%).
Example 107B
5-(cyclopropylmethoxy)-N-methyl-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2-
,3-c]pyridin-3-yl)-1H-indole-2-carboxamide
[1094] A 25 mL roundbottom flask with stirbar was charged with
Example 107A (11 mg, 0.029 mmol), EDC (10.4 mg, 0.054 mmol) and
HOBT (7.7 mg, 0.050 mmol) in dichloromethane (1 mL).
N-methylmorpholine (10 .mu.L, 0.091 mmol) was added, and the
mixture was stirred at ambient temperature. After 2 minutes, the
solution was treated with 2.0 M methylamine in tetrahydrofuran (125
.mu.L, 0.250 mmol), then stirred an additional 18 hours at ambient
temperature. The mixture was concentrated and the residue was
purified by reverse phase HPLC (C18, CH.sub.3CN/water (0.1% TFA),
10-100%) to afford the title compound (0.0035 g, 31%). .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. ppm 11.41 (bds, 1H), 10.82 (d,
J=5.4 Hz, 1H), 8.28 (bds, 1H), 7.42 (s, 1H), 7.32 (d, J=8.8 Hz,
1H), 7.05 (d, J=8.8 Hz, 1H), 6.88 (m, 1H), 6.81 (m, 1H), 6.18 (d,
J=6.1 Hz, 1H), 4.17 (s, 3H), 3.68 (m, 2H), 2.74 (s, 3H) 1.02 (m,
1H), 0.40 (m, 2H), 0.15 (m, 2H). MS (ESI+) m/z 391.2.
Example 108
4-chloro-3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 108A
5-chloro-4-methyl-3-nitropyridin-2-amine
[1095] 5-chloro-4-methylpyridin-2-amine (30 g, 210 mmol) was
dissolved in concentrated sulfuric acid (150 mL), and the solution
was cooled to -10.degree. C. Nitric acid (36 mL, 806 mmol) was
added dropwise. The reaction mixture was stirred at 55.degree. C.
for 3 hours. The reaction mixture was poured into an ice/water
mixture, and the pH was adjusted to 8 by addition of concentrated
aqueous ammonium hydroxide (22%). The resulting suspension was
filtered, and the solids were washed with water and dried under
vacuum to provide the title compound (23 g, 123 mmol, 58.3%
yield).
Example 108B
5-chloro-2-methoxy-4-methyl-3-nitropyridine
[1096] To a solution of methanol (600 mL) and acetyl chloride (7.61
mL, 107 mmol) was added Example 108A (67 g, 357 mmol), then
tert-butyl nitrite (225 mL, 1893 mmol) was added at a rate such
that the temperature did not exceed 5.degree. C. After complete
addition, cooling bath was removed and the reaction mixture was
allowed to warm to room temperature and stirred for 5 hours. The
reaction mixture was concentrated in vacuo to about half volume.
Then saturated aqueous sodium bicarbonate solution was added and
the precipitates were collected by filtration. The solid was dried
under vacuum to provide the title compound (62 g, 282 mmol, 79%
yield)
Example 108C
2-(5-chloro-2-methoxy-3-nitropyridin-4-yl)-N,N-dimethylethenamine
[1097] Example 108B (20 g, 99 mmol) was dissolved in
dimethylformamide (160 mL), and lithium methoxide (9.87 mL, 9.87
mmol, 1 M in MeOH) was added. The reaction mixture was heated to
80.degree. C. To this mixture was added dimethylformamide dimethyl
acetal (106 mL, 790 mmol) over 10 minutes. The reaction mixture was
stirred at 95.degree. C. for 12 hours. The reaction mixture was
cooled to room temperature and water was added carefully. The
resulting precipitate was collected by vacuum filtration, washed
with water, and dried to provide the title compound (21 g, 81 mmol,
83% yield).
Example 108D
4-chloro-7-methoxy-1H-pyrrolo[2,3-c]pyridine
[1098] To a solution of Example 108C (12 g, 46.6 mmol) in ethyl
acetate (150 mL) was added Raney-Ni (20.0 g, 4.66 mmol), and the
reaction mixture was stirred for 20 hours at room temperature under
30 atm. hydrogen. The reaction mixture was filtered and rinsed with
ethyl acetate. The filtrate was concentrated to a small volume, and
the precipitates were collected by filtration and dried to provide
the title compound (10 g, 93% yield).
Example 108E
[1099] To a solution of Example 108D (19 g, 104 mmol) in
acetonitrile (100 mL) was added N-iodosuccinimide (28.1 g, 125
mmol). The mixture was stirred at 20.degree. C. for 12 hours, and
then partitioned between ethyl acetate and water. The organic layer
was extracted twice with additional ethyl acetate. The combined
organic layers were washed with saturated aqueous sodium chloride,
dried over anhydrous magnesium sulfate, filtered, and concentrated
to provide the title compound (25 g, 78% yield)
Example 108F
4-chloro-3-iodo-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1100] Example 108E (5 g, 16.21 mmol) in dimethylformamide (60 mL)
was treated with sodium hydride (0.778 g, 32.4 mmol) at room
temperature for 20 minutes. To this solution was added iodomethane
(1.317 mL, 21.07 mmol). The reaction mixture was stirred at
20.degree. C. for 3 hours. The reaction mixture was partitioned
between water and ethyl acetate. The aqueous layer was extracted
with additional ethyl acetate twice. The combined organic layers
were washed with saturated aqueous sodium chloride, dried over
anhydrous magnesium sulfate, filtered, and concentrated. The
residue was purified by flash chromatography (silica gel 10% ethyl
acetate in hexanes) to provide the title compound (3 g, 57.4%
yield).
Example 108G
4-chloro-3-(2-fluoro-5-(methylsulfonyl)phenyl)-7-methoxy-1-methyl-1H-pyrro-
lo[2,3-c]pyridine
[1101] Example 108G was prepared according to the procedure used
for the preparation of Example 11E, substituting Example 17B for
Example 59A, and substituting Example 108F for Example 11C.
Example 108H
4-chloro-3-(2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl)-7-methoxy-1--
methyl-1H-pyrrolo[2,3-c]pyridine
[1102] Example 108H was prepared according to the procedure used
for the preparation of Example 2C, substituting Example 108G for
Example 2B, and heating for 12 hours instead of heating for 1
hour.
Example 108I
4-chloro-3-(2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl)-1-methyl-1H--
pyrrolo[2,3-c]pyridin-7(6H)-one
[1103] Example 108I was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 108H for
Example 1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 11.25
(m, 1H), 7.79-7.91 (m, 2H), 7.54 (s, 1H), 7.48 (ddd, J=11.1, 8.6,
2.7 Hz, 1H), 7.32 (td, J=9.1, 5.5 Hz, 1H), 7.10-7.22 (m, 1H),
6.99-7.04 (m, 1H), 6.91 (d, J=8.5 Hz, 1H), 4.10 (s, 3H), 3.21 (s,
3H). MS (ESI+) m/z 464.8 (M+H).sup.+.
Example 109
4-chloro-3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-
-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 109A
4-chloro-3-(2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl)-7-methoxy-1--
methyl-1H-pyrrolo[2,3-c]pyridine
[1104] Example 109A was prepared according to the procedure used
for the preparation of Example 2C, substituting Example 108G for
Example 2B, substituting 2-cyclopropylethanol for
2,4-difluorophenol, and heating for 12 hours instead of heating for
1 hour.
Example 109B
4-chloro-3-(2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl)-1-methyl-1H--
pyrrolo[2,3-c]pyridin-7(6H)-one
[1105] Example 109B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 109A for
Example 1B. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 11.18
(bs, 1H), 7.84 (dd, J=8.6, 2.5 Hz, 1H), 7.70 (d, J=2.4 Hz, 1H),
7.41 (s, 1H), 7.23 (d, J=8.7 Hz, 1H), 6.95 (s, 1H), 3.97-4.14 (m,
5H), 3.17 (s, 3H), 1.48 (q, J=6.5 Hz, 2H), 0.54-0.68 (m, 1H),
0.21-0.38 (m, 2H), -0.02--0.10 (m, 2H). MS (ESI+) m/z 421.0
(M+H).sup.+.
Example 110
3-{2-[(cyclopropylmethyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 110A
1-(methylsulfonylmethyl)-4-nitrobenzene
[1106] To a solution of 4-nitrobenzyl bromide (10.02 g, 46.4 mmol)
in dimethylformamide (25 mL) was added sodium methanesulfinate
(7.10 g, 69.6 mmol). The reaction mixture was stirred at 65.degree.
C. for 1 hour. The reaction mixture was cooled to room temperature,
diluted with water, stirred for 10 minutes and filtered to give the
title compound (9.27 g, 93%).
Example 110B
4-((methylsulfonyl)methyl)aniline
[1107] Example 110A (8.2 g, 38.1 mmol) and tetrahydrofuran (200 mL)
were added to wet 5% Pd/C (1.6 g, 0.376 mmol) in a pressure bottle.
The reaction mixture was stirred at 50.degree. C. for 2 hours under
30 psi hydrogen. The reaction mixture was filtered through a nylon
membrane, washed with the mixture of tetrahydrofuran and methanol,
and concentrated to give the title compound (6.21 g, 88%).
Example 110C
2-iodo-4-((methylsulfonyl)methyl)aniline
[1108] To a solution of Example 110B (1.117 g, 6.03 mmol) in
dimethylformamide (60.3 mL) was added N-iodosuccinimide (1.492 g,
6.63 mmol). The reaction mixture was stirred at room temperature
for 90 minutes. The reaction mixture was quenched with 10% sodium
thiosulfate and saturated aqueous sodium bicarbonate and extracted
with ethyl acetate three times. The combined organic layers were
washed with saturated aqueous sodium chloride, dried with anhydrous
magnesium sulfate, filtered, and concentrated. Water was added to
the residue, and the mixture was stirred at room temperature for 10
minutes and filtered to give the title compound (1.55 g, 83%).
Example 110D
N-(cyclopropylmethyl)-2-iodo-4-((methylsulfonyl)methyl)aniline
[1109] Example 110C (311 mg, 1.0 mmol), cyclopropanecarbaldehyde
(0.187 mL, 2.50 mmol) and acetic acid (0.572 mL, 10.00 mmol) were
combined in a mixture of dichloromethane (5 mL) and methanol (5
mL). The reaction mixture was heated at 50.degree. C. for 30
minutes, and then cooled to room temperature. MP-cyanoborohydride
(1271 mg, 2.36 mmol/g, 3.00 mmol) was added and the reaction
mixture was stirred at room temperature for 3 hours. The reaction
mixture was filtered, washed with dichloromethane and concentrated.
The residue was purified by flash chromatography (silica gel, 20 to
60% ethyl acetate in heptanes) to provide the title compound (296
mg, 81%).
Example 110E
N-(cyclopropylmethyl)-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-
-4-((methylsulfonyl)methyl)aniline
[1110] Example 110D (183 mg, 0.50 mmol), Example 59A (173 mg, 0.600
mmol), sodium carbonate (185 mg, 1.75 mmol),
tris(dibenzylideneacetone)dipalladium (13.7 mg, 0.015 mmol) and
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane (13.1
mg, 0.045 mmol) were combined in a microwave tube and purged with
nitrogen for 15 minutes. The mixture of dioxane (2 mL) and water
(0.5 mL) was purged with nitrogen for 15 minutes and transferred to
the microwave tube. The reaction mixture was heated at 60.degree.
C. for 4 hours. The reaction mixture was partitioned with ethyl
acetate and water. The organic layer was washed with saturated
aqueous sodium chloride, dried with anhydrous sodium sulfate,
treated with 3-mercaptopropyl functionalized silica gel, filtered,
and concentrated. The residue was purified by flash chromatography
(silica gel, 20 to 50% ethyl acetate in heptanes) to provide the
title compound (140 mg, 70%).
Example 110F
3-{2-[(cyclopropylmethyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1111] Example 110E (136 mg, 0.340 mmol) in a solution of 4M HCl in
dioxane (5 mL, 20.0 mmol) was heated at 70.degree. C. for 2 hours.
The reaction mixture was cooled and concentrated. The residue was
purified by flash chromatography (silica gel, 2 to 6% methanol in
dichloromethane) to provide the title compound (130 mg, 91%) as the
HCl salt. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.93 (d,
J=5.43 Hz, 1H) 7.41 (s, 1H) 7.18 (dd, J=8.31, 2.20 Hz, 1H) 7.11 (d,
J=2.03 Hz, 1H) 6.86 (dd, J=7.12, 5.76 Hz, 1H) 6.76 (d, J=8.14 Hz,
1H) 6.26 (dd, J=7.12, 1.02 Hz, 1H) 4.31 (s, 2H) 4.12 (s, 3H) 2.97
(d, J=6.78 Hz, 2H) 2.86 (s, 3H) 0.89-1.10 (m, 1H) 0.36-0.46 (m, 2H)
0.12-0.26 (m, 2H). MS (ESI+) m/z 386 (M+H).sup.+.
Example 111
3-{5-[(4-aminopiperidin-1-yl)methyl]-2-(2,4-difluorophenoxy)phenyl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 111A
tert-butyl
1-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-
-c]pyridin-3-yl)benzyl)piperidin-4-ylcarbamate
[1112] A solution of Example 105B (125 mg, 0.317 mmol), tert-butyl
piperidin-4-ylcarbamate (190 mg, 0.951 mmol) and acetic acid (0.181
mL, 3.17 mmol) in dichloromethane (3 mL) was heated at 50.degree.
C. for 1 hour. The reaction mixture was cooled in an ice bath and
the sodium triacetoxyborohydride (134 mg, 0.634 mmol) was added
portionwise over a few minutes. The reaction mixture was stirred 2
hours while warming to ambient temperature. The reaction mixture
was quenched with 1 M sodium hydroxide (2 mL) and partitioned
between saturated aqueous sodium bicarbonate solution (50 mL) and
ethyl acetate (50 mL). The layers were separated and the organic
layer was dried over anhydrous sodium sulfate, filtered, and
concentrated to provide the title compound (783 mg, 100%
yield).
Example 111B
3-{5-[(4-aminopiperidin-1-yl)methyl]-2-(2,4-difluorophenoxy)phenyl}-1-meth-
yl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1113] The TFA salt of Example 111B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 111A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 11.00 (d, J=5.49 Hz, 1H), 8.18 (d, J=3.66
Hz, 2H), 7.65 (d, J=1.83 Hz, 1H), 7.58 (s, 1H), 7.46-7.53 (m, 1H),
7.34 (dd, J=8.39, 2.29 Hz, 1H), 7.23-7.31 (m, 1H), 7.10-7.17 (m,
1H), 6.87-6.92 (m, 1H), 6.85 (d, J=8.24 Hz, 1H), 6.60 (d, J=6.71
Hz, 1H), 4.31 (s, 2H), 4.11 (s, 3H), 3.48 (d, J=11.60 Hz, 2H), 3.27
(s, 1H), 3.03 (s, 2H), 2.12 (d, J=12.21 Hz, 2H), 1.75 (s, 2H). MS
(ESI+) m/z 465.0 (M+H).sup.+.
Example 112
3-{2-(2,4-difluorophenoxy)-5-[(piperidin-4-ylamino)methyl]phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 112A
tert-butyl
4-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-
-c]pyridin-3-yl)benzylamino)piperidine-1-carboxylate
[1114] Example 112A was prepared according to the procedure used
for the preparation of Example 111A, substituting tert-butyl
4-aminopiperidine-1-carboxylate for tert-butyl
piperidin-4-ylcarbamate.
Example 112B
3-{2-(2,4-difluorophenoxy)-5-[(piperidin-4-ylamino)methyl]phenyl}-1-methyl-
-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1115] The TFA salt of Example 112B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 112A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 11.00 (d, J=5.19 Hz, 1H), 9.19 (s, 1H),
8.71 (s, 1H), 7.70 (d, J=2.14 Hz, 1H), 7.55 (s, 1H), 7.45-7.52 (m,
1H), 7.37 (dd, J=8.54, 2.14 Hz, 1H), 7.19-7.28 (m, 1H), 7.08-7.16
(m, 1H), 6.90 (dd, J=7.02, 5.80 Hz, 1H), 6.85 (d, J=8.24 Hz, 1H),
6.60-6.65 (m, 1H), 4.23 (s, 2H), 4.13-4.13 (m, 3H), 3.41 (d,
J=12.82 Hz, 3H), 2.91-3.03 (m, 2H), 2.26 (d, J=12.51 Hz, 2H),
1.69-1.83 (m, 2H). MS (ESI+) m/z 464.9 (M+H).sup.+.
Example 113
3-[2-(2,4-difluorophenoxy)-5-{[4-(dimethylamino)piperidin-1-yl]methyl}phen-
yl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 113A
1-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-TH-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)-N,N-dimethylpiperidin-4-amine
[1116] Example 113A was prepared according to the procedure used
for the preparation of Example 111A, substituting
N,N-dimethylpiperidin-4-amine for tert-butyl
piperidin-4-ylcarbamate.
Example 113B
3-[2-(2,4-difluorophenoxy)-5-{[4-(dimethylamino)piperidin-1-yl]methyl}phen-
yl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1117] The TFA salt of Example 113B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 113A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.71 (d, J=5.49 Hz, 1H), 7.39 (d, J=1.83
Hz, 1H), 7.29 (s, 1H), 7.17-7.25 (m, 1H), 7.09 (dd, J=8.39, 1.98
Hz, 1H), 6.95-7.03 (m, 1), 6.82-6.88 (m, 1H), 6.60-6.65 (m, 1H),
6.58 (d, J=8.54 Hz, 1H), 6.32 (d, J=7.02 Hz, 1H), 4.07 (s, 2H),
3.83 (s, 3H), 3.07-3.17 (m, 3H), 2.72 (s, 2H), 2.49 (s, 6H), 1.94
(s, 2H), 1.53-1.66 (m, 2H). MS (ESI+) m/z 493.0 (M+H).sup.+.
Example 114
3-[2-(2,4-difluorophenoxy)-5-{[(3,3-dimethylbutyl)amino]methyl}phenyl]-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 114A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)-3,3-dimethylbutan-1-amine
[1118] Example 114A was prepared according to the procedure used
for the preparation of Example 111A, substituting
3,3-dimethylbutan-1-amine for tert-butyl
piperidin-4-ylcarbamate.
Example 114B
3-[2-(2,4-difluorophenoxy)-5-{[(3,3-dimethylbutyl)amino]methyl}phenyl]-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1119] The TFA salt of Example 114B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 114A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 11.00 (d, J=5.49 Hz, 1H), 8.75 (s, 1H),
7.68 (d, J=2.14 Hz, 1H), 7.56 (s, 1H), 7.44-7.52 (m, 1H), 7.35 (dd,
J=8.54, 2.14 Hz, 1H), 7.20-7.27 (m, 1H), 7.10-7.16 (m, 1H), 6.90
(dd, J=7.02, 5.80 Hz, 1H), 6.85 (d, J=8.24 Hz, 1H), 6.63 (d, J=6.10
Hz, 1H), 4.16-4.23 (m, 2H), 4.11 (s, 3H), 2.94-3.04 (m, 2H),
1.49-1.57 (m, 2H), 0.87-0.94 (m, 9H). MS (ESI+) m/z 465.9
(M+H).sup.+.
Example 115
3-{2-(2,4-difluorophenoxy)-5-[(4-methoxypiperidin-1-yl)methyl]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 115A
3-(2-(2,4-difluorophenoxy)-5-((4-methoxypiperidin-1-yl)methyl)phenyl)-7-me-
thoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1120] Example 115A was prepared according to the procedure used
for the preparation of Example 111A, substituting
4-methoxypiperidine for tert-butyl piperidin-4-ylcarbamate.
Example 115B
3-{2-(2,4-difluorophenoxy)-5-[(4-methoxypiperidin-1-yl)methyl]phenyl}-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1121] The TFA salt of Example 115B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 115A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.99 (d, J=5.19 Hz, 1H), 7.68 (dd,
J=10.53, 1.98 Hz, 1H), 7.58 (s, 1H), 7.44-7.53 (m, 1H), 7.32-7.40
(m, 1H), 7.23-7.31 (m, 1H), 7.08-7.17 (m, 1H), 6.88-6.94 (m, 1H),
6.86 (dd, J=8.39, 2.29 Hz, 1H), 6.59 (d, J=7.02 Hz, 1H), 4.29-4.40
(m, 2H), 4.11 (s, 3H), 3.55 (s, 1H), 3.32-3.47 (m, 1H), 3.25 (d,
J=2.44 Hz, 3H), 3.20 (s, 1H), 2.92-3.12 (m, 2H), 2.17 (d, J=11.60
Hz, 1H), 2.01 (d, J=14.65 Hz, 1H), 1.72-1.86 (m, 1H), 1.45-1.59 (m,
1H). MS (ESI+) m/z 479.9 (M+H).sup.+.
Example 116
3-{2-(2,4-difluorophenoxy)-5-[(4-methylpiperazin-1-yl)methyl]phenyl}-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 116A
3-(2-(2,4-difluorophenoxy)-5-((4-methylpiperazin-1-yl)methyl)phenyl)-7-met-
hoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1122] Example 116A was prepared according to the procedure used
for the preparation of Example 111A, substituting
1-methylpiperazine for tert-butyl piperidin-4-ylcarbamate.
Example 116B
3-{2-(2,4-difluorophenoxy)-5-[(4-methylpiperazin-1-yl)methyl]phenyl}-1-met-
hyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1123] The TFA salt of Example 116B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 116A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 10.98 (d, J=5.49 Hz, 1H), 7.57 (s, 1H),
7.54 (s, 1H), 7.44-7.50 (m, 1H), 7.28 (dd, J=8.54, 1.53 Hz, 1H),
7.18-7.25 (m, 1H), 7.07-7.14 (m, 1H), 6.87-6.92 (m, 1H), 6.82 (d,
J=8.55 Hz, 1H), 6.55 (d, J=7.02 Hz, 1H), 4.11 (s, 3H), 3.96 (s,
2H), 3.47 (s, 4H), 3.25 (s, 4H), 2.81 (s, 3H). MS (ESI+) m/z 464.9
(M+H).sup.+.
Example 117
3-[2-(2,4-difluorophenoxy)-5-{[(3-methylbutyl)amino]methyl}phenyl]-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 117A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)-3-methylbutan-1-amine
[1124] Example 117A was prepared according to the procedure used
for the preparation of Example 111A, substituting
3-methylbutan-1-amine for tert-butyl piperidin-4-ylcarbamate.
Example 117B
3-[2-(2,4-difluorophenoxy)-5-{[(3-methylbutyl)amino]methyl}phenyl]-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1125] The TFA salt of Example 117B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 117A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 11.00 (d, J=5.49 Hz, 1H), 8.77 (s, 1H),
7.68 (d, J=2.14 Hz, 1H), 7.56 (s, 1H), 7.45-7.52 (m, 1H), 7.35 (dd,
J=8.54, 2.14 Hz, 1H), 7.19-7.28 (m, 1H), 7.09-7.16 (m, 1H), 6.90
(dd, J=6.87, 5.65 Hz, 1H), 6.85 (d, J=8.24 Hz, 1H), 6.63 (d, J=7.02
Hz, 1H), 4.18 (t, J=5.49 Hz, 2H), 4.11 (s, 3H), 2.92-3.02 (m, 2H),
1.57-1.69 (m, 1H), 1.53 (d, J=7.02 Hz, 2H), 0.88 (t, J=7.48 Hz,
6H). MS (ESI+) m/z 451.9 (M+H).sup.+.
Example 118
3-[5-{[(cyclopropylmethyl)amino]methyl}-2-(2,4-difluorophenoxy)phenyl]-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 118A
1-cyclopropyl-N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[-
2,3-c]pyridin-3-yl)benzyl)methanamine
[1126] Example 118A was prepared according to the procedure used
for the preparation of Example 111A, substituting
cyclopropylmethanamine for tert-butyl piperidin-4-ylcarbamate.
Example 118B
3-[5-{[(cyclopropylmethyl)amino]methyl}-2-(2,4-difluorophenoxy)phenyl]-1-m-
ethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1127] The TFA salt of Example 118B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 118A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.99 (d, J=5.19 Hz, 1H), 8.94 (s, 1H),
7.68 (d, J=2.14 Hz, 1H), 7.56 (s, 1H), 7.42-7.51 (m, 1H), 7.36 (dd,
J=8.54, 2.14 Hz, 1H), 7.19-7.28 (m, 1H), 7.08-7.17 (m, 1H),
6.88-6.95 (m, 1H), 6.85 (d, J=8.24 Hz, 1H), 6.64 (d, J=7.02 Hz,
1H), 4.18 (t, J=5.65 Hz, 2H), 4.11 (s, 3H), 2.82-2.93 (m, 2H),
0.99-1.14 (m, 1H), 0.55-0.64 (m, 2H), 0.32-0.40 (m, 2H). MS (ESI+)
m/z 465.9 (M+H).sup.+.
Example 119
3-[2-(2,4-difluorophenoxy)-5-{[(1H-imidazol-4-ylmethyl)amino]methyl}phenyl-
]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 119A
N-((1H-imidazol-4-yl)methyl)-1-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-met-
hyl-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl)methanamine
[1128] To a suspension of 1H-imidazol-4-ylmethylamine
dihydrochloride (269 mg, 1.59 mmol) in a mixture of dichloromethane
(3 mL) and methanol (1 mL) was added triethylamine (0.442 mL, 3.17
mmol). After stirring the mixture for five minutes, Example 105B
(125 mg, 0.317 mmol) and acetic acid (0.181 mL, 3.17 mmol) were
added. The mixture was heated at 50.degree. C. for 1 hour. The
mixture was cooled in an ice bath and sodium triacetoxyborohydride
(134 mg, 0.634 mmol) was added portionwise over several minutes.
After 15 minutes, the ice bath was removed and the reaction mixture
was stirred 2 hours while warming to ambient temperature. The
reaction mixture was quenched with 1 M sodium hydroxide (2 mL) and
partitioned between saturated aqueous sodium bicarbonate solution
(50 mL) and ethyl acetate (50 mL). The organic layer was dried over
anhydrous sodium sulfate, filtered, and concentrated. The residue
was purified by flash column chromatography (silica gel, 0-10% 7N
methanolic ammonia in methylene chloride) to provide the title
compound (90.3 mg, 62% yield).
Example 119B
3-[2-(2,4-difluorophenoxy)-5-{[(1H-imidazol-4-ylmethyl)amino]methyl}phenyl-
]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1129] The TFA salt of Example 119B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 119A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.97 (d, J=5.19 Hz, 1H), 9.43 (d, 1H),
8.77 (s, 1H), 7.66 (d, J=2.44 Hz, 1H), 7.62 (s, 1H), 7.53 (s, 1H),
7.42-7.49 (m, 1H), 7.33 (dd, J=8.54, 2.14 Hz, 1H), 7.18-7.27 (m,
1H), 7.06-7.15 (m, 1H), 6.86-6.91 (m, 1H), 6.82 (d, J=8.24 Hz, 1H),
6.66 (d, 1H), 4.29 (s, 2H), 4.22 (s, 2H), 4.09 (s, 3H), 3.54 (s,
1H). MS (ESI+) m/z 461.9 (M+H).sup.+.
Example 120
3-[5-(chloromethyl)-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one
Example 120A
[1130] A solution of Example 105B (100 mg, 0.254 mmol), sodium
cyanoborohydride (47.8 mg, 0.761 mmol), phenylmethanamine (0.083
mL, 0.761 mmol), and acetic acid (0.833 mL, 14.6 mmol) in
dichloromethane (2.5 mL) was heated at 50.degree. C. for 1 hour.
The reaction mixture was partitioned between saturated aqueous
sodium bicarbonate solution (100 mL) and ethyl acetate (100 mL).
The organic layer was dried over anhydrous sodium sulfate, filtered
and concentrated. The residue was purified by flash column
chromatography (silica gel, 0-4% methanol in methylene chloride) to
provide the title compound (87 mg, 87% yield).
Example 120B
3-[5-(chloromethyl)-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one
[1131] Example 120B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 120A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.93 (d, J=4.88 Hz, 1H), 7.56 (d, J=2.44 Hz, 1H), 7.53 (s,
1H), 7.39-7.47 (m, 1H), 7.30 (dd, J=8.39, 2.29 Hz, 1H), 7.17-7.24
(m, 1H), 7.04-7.11 (m, 1H), 6.86-6.92 (m, 1H), 6.77 (d, J=8.54 Hz,
1H), 6.52 (d, J=7.02 Hz, 1H), 4.79 (s, 2H), 4.08 (s, 3H). MS (ESI+)
m/z 401.1 (M+H).sup.+.
Example 121
3-{2-[(4-fluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 121A
2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-((methylsulfonyl)me-
thyl)aniline
[1132] Example 110C (1.25 g, 4.00 mmol), Example 59A (1.15 g, 4.00
mmol), potassium phosphate (2.97 g, 14.0 mmol),
tris(dibenzylideneacetone)dipalladium (0.110 g, 0.120 mmol) and
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane
(0.105 g, 0.360 mmol) were combined in a microwave tube and purged
with nitrogen for 15 minutes. A mixture of dioxane (12 mL) and
water (3 mL) was purged with nitrogen for 15 minutes and
transferred via cannula to the microwave tube. The reaction mixture
was heated at 60.degree. C. for 4 hours. The reaction mixture was
partitioned with ethyl acetate and water. The organic layer was
washed with saturated aqueous sodium chloride, dried with anhydrous
sodium sulfate, treated with 3-mercaptopropyl functionalized silica
gel, filtered, and concentrated. The residue was purified by flash
chromatography (silica gel, 20 to 80% ethyl acetate in heptanes) to
provide the title compound (0.985 g, 71%).
Example 121B
N-(4-fluorophenyl)-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4--
((methylsulfonyl)methyl)aniline
[1133] Example 121A (104 mg, 0.300 mmol), 1-bromo-4-fluorobenzene
(105 mg, 0.600 mmol), diacetoxypalladium (2.7 mg, 0.012 mmol),
dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine
(11.4 mg, 0.0239 mmol) and cesium carbonate (195 mg, 0.600 mmol)
were combined in a mixture of toluene (2.4 mL) and tert-butanol
(0.6 mL). The reaction mixture was heated in a microwave reactor at
150.degree. C. for 30 minutes. The reaction mixture was partitioned
with ethyl acetate and water. The organic layer was washed with
saturated aqueous sodium chloride, dried with anhydrous sodium
sulfate, treated with 3-mercaptopropyl functionalized silica gel,
filtered, and concentrated. The residue was purified by flash
chromatography (silica gel, 2 to 4% methanol in dichloromethane) to
provide the title compound (112 mg, 85%).
Example 121C
3-{2-[(4-fluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1134] Example 121B (110 mg, 0.250 mmol) in a solution of 4M HCl in
dioxane (5.0 mL, 20 mmol) was heated at 70.degree. C. for 2 hours.
The reaction mixture was cooled to ambient temperature and
concentrated. The residue was partitioned with ethyl acetate and
saturated aqueous sodium bicarbonate. The organic layer was washed
with saturated aqueous sodium chloride, dried with anhydrous sodium
sulfate, filtered, and concentrated. The residue was purified by
flash chromatography (silica gel, 2 to 4% methanol in
dichloromethane) to provide the title compound (86 mg, 81%).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.91 (d, J=5.76
Hz, 1H) 7.45 (s, 1H) 7.30 (s, 1H) 7.14-7.25 (m, 3H) 6.98-7.09 (m,
4H) 6.82 (dd, J=6.78, 5.76 Hz, 1H) 6.32 (dd, J=7.12, 1.02 Hz, 1H)
4.40 (s, 2H) 4.08 (s, 3H) 2.91 (s, 3H). MS (ESI+) m/z 426
(M+H).sup.+.
Example 122
3-{2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 122A
N-(2,4-difluorophenyl)-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl-
)-4-((methylsulfonyl)methyl)aniline
[1135] Example 121A (104 mg, 0.300 mmol),
1-bromo-2,4-difluorobenzene(116 mg, 0.600 mmol), diacetoxypalladium
(2.7 mg, 0.012 mmol),
dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine
(11.4 mg, 0.0239 mmol) and cesium carbonate (195 mg, 0.600 mmol)
were combined in a mixture of toluene (2.4 mL) and tert-butanol
(0.6 mL). The reaction mixture was heated in a microwave reactor at
150.degree. C. for 1 hour. The reaction mixture was partitioned
with ethyl acetate and water. The organic layer was washed with
saturated aqueous sodium chloride, dried with anhydrous sodium
sulfate, treated with 3-mercaptopropyl functionalized silica gel,
filtered, and concentrated. The residue was purified by flash
chromatography (silica gel, 1 to 2% methanol in dichloromethane) to
provide the title compound (62 mg, 45%).
Example 122B
3-{2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methy-
l-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1136] Example 122A (60.0 mg, 0.131 mmol) in a solution of 4M HCl
in dioxane (5.0 mL, 20 mmol) was heated at 70.degree. C. for 2
hours. The reaction mixture was cooled to ambient temperature and
concentrated. The residue was partitioned with ethyl acetate and
saturated aqueous sodium bicarbonate. The organic layer was washed
with saturated aqueous sodium chloride, dried with anhydrous sodium
sulfate, filtered, and concentrated. The residue was purified by
flash chromatography (silica gel, 2 to 4% methanol in
dichloromethane) to provide the title compound (46 mg, 79%).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.92 (d, J=6.10
Hz, 1H) 7.48 (s, 1H) 7.07-7.31 (m, 4H) 6.91-7.04 (m, 2H) 6.81-6.88
(m, 1H) 6.74 (dd, J=8.48, 2.37 Hz, 1H) 6.38 (d, J=6.44 Hz, 1H) 4.39
(s, 2H) 4.09 (s, 3H) 2.91 (s, 3H). MS (ESI+) m/z 444
(M+H).sup.+.
Example 123
3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1,4-dimethyl-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 123A
3-(2-fluoro-5-(methylsulfonyl)phenyl)-7-methoxy-1,4-dimethyl-1H-pyrrolo[2,-
3-c]pyridine
[1137] A mixture of Example 108G (1.5 g, 4.1 mmol), methylboronic
acid (1.217 g, 20.34 mmol), tris (dibenzylideneacetone) dipalladium
(0.186 g, 0.203 mmol) and
dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine
(0.097 g, 0.203 mmol) indioxane (40 mL) and water (10 mL) was
heated at 130.degree. C. for 2 hours under microwave conditions.
The mixture was diluted with ethyl acetate and washed with
saturated aqueous sodium bicarbonate. The organics were dried over
anhydrous magnesium sulfate, filtered, and concentrated. The
residue was purified by flash chromatography (silica gel, 10-100%
ethyl acetate in hexane) to provide the title compound (1.12 g, 52%
yield)
Example 123B
3-(2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl)-7-methoxy-1,4-dimethy-
l-1H-pyrrolo[2,3-c]pyridine
[1138] Example 123B was prepared according to the procedure used
for the preparation of Example 2C, substituting Example 123A for
Example 2B, and heating for 12 hours instead of heating for 1
hour.
Example 123C
3-(2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl)-1,4-dimethyl-1H-pyrro-
lo[2,3-c]pyridin-7(6H)-one
[1139] Example 123C was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 123B for
Example 1B. .sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. ppm
7.90-7.96 (m, 2H), 7.31 (s, 1H), 7.09-7.18 (m, 2H), 7.02 (d, J=8.4
Hz, 1H), 6.94-7.00 (m, 1H), 6.70 (s, 1H), 4.19 (s, 3H), 3.17 (s,
3H), 1.98 (d, J=1.0 Hz, 3H).
Example 124
3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1,4-dimethyl-1,6-dihy-
dro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 124A
3-(2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl)-7-methoxy-1,4-dimethy-
l-1H-pyrrolo[2,3-c]pyridine
[1140] Example 124A was prepared according to the procedure used
for the preparation of Example 2C, substituting Example 123A for
Example 2B, 2-cyclopropylethanol for 2,4-difluorophenol, and
heating for 12 hours instead of heating for 1 hour.
Example 124B
3-(2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl)-1,4-dimethyl-1H-pyrro-
lo[2,3-c]pyridin-7(6H)-one
[1141] Example 124B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 124A for
Example 1B. .sup.1H NMR (400 MHz, MeOH-d.sub.4) .delta. ppm 7.94
(dd, J=8.7, 2.5 Hz, 1H), 7.79 (d, J=2.5 Hz, 1H), 7.24 (d, J=8.8 Hz,
1H), 7.21 (s, 1H), 6.63 (d, J=1.0 Hz, 1H), 4.18 (s, 3H), 4.12 (t,
J=6.1 Hz, 2H), 3.13 (s, 3H), 1.84 (d, J=1.0 Hz, 3H), 1.51 (dd,
J=12.8, 6.3 Hz, 2H), 0.59 (d, J=7.6 Hz, 1H), 0.26-0.34 (m, 2H),
-0.07 (q, J=4.9 Hz, 2H).
Example 125
3-{2-(cyclopropylmethoxy)-5-[(3,3-difluoroazetidin-1-yl)sulfonyl]phenyl}-1-
-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 125A
1-((3-bromo-4-fluorophenyl)sulfonyl)-3,3-difluoroazetidine
[1142] Example 125A was prepared according to the procedure used
for the preparation of Example 97A, substituting
3,3-difluoroazetidine for indoline.
Example 125B
1-((3-bromo-4-(cyclopropylmethoxy)phenyl)sulfonyl)-3,3-difluoroazetidine
[1143] Example 125B was prepared according to the procedure used
for the preparation of Example 97B, substituting Example 125A for
Example 97A.
Example 125C
3-(2-(cyclopropylmethoxy)-5-((3,3-difluoroazetidin-1-yl)sulfonyl)phenyl)-7-
-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1144] Example 125C was prepared according to the procedure used
for the preparation of Example 11E, substituting Example 125B for
Example 11C.
Example 125D
3-{2-(cyclopropylmethoxy)-5-[(3,3-difluoroazetidin-1-yl)sulfonyl]phenyl}-1-
-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1145] Example 125D was prepared according to the procedure used
for the preparation of Example 11F, substituting Example 125C for
Example 11E. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 11.84
(s, 1H), 7.82-7.75 (m, 2H), 7.66 (s, 1H), 7.37-7.30 (m, 1H), 6.92
(dd, J=7.0, 5.7 Hz, 1H), 6.43 (dd, J=7.0, 1.1 Hz, 1H), 4.25 (t,
J=12.7 Hz, 2H), 4.13 (s, 3H), 4.03 (d, J=6.9 Hz, 2H), 1.29-1.20 (m,
1H), 0.60-0.47 (m, 2H), 0.44-0.29 (m, 2H).
Example 126
5-[(1Z)-2-chloro-4-hydroxybut-1-en-1-yl]-3-[2-(2,4-difluorophenoxy)-5-(eth-
ylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 126A
5-bromo-3-(5-(ethylsulfonyl)-2-fluorophenyl)-7-methoxy-1-methyl-1H-pyrrolo-
[2,3-c]pyridine
[1146] Example 126A was prepared according to the procedure used
for the preparation of Example 91E, substituting Example 48D for
Example 91D to provide the title compound.
Example 126B
4-(3-(5-(ethylsulfonyl)-2-fluorophenyl)-7-methoxy-1-methyl-1H-pyrrolo[2,3--
c]pyridin-5-yl)but-3-yn-1-ol
[1147] A mixture of Example 126A (300 mg, 0.702 mmol),
but-3-yn-1-ol (63.8 .mu.l, 0.843 mmol), Pd(dppf)CH.sub.2Cl.sub.2
(57.3 mg, 0.070 mmol), and copper(I) iodide (13.4 mg, 0.070 mmol)
in tetrahydrofuran (9 mL) and triethylamine (3 mL) was purged with
nitrogen and then stirred at 70.degree. C. in a sealed tube for 2.5
hours. The mixture was partitioned between water and ethyl acetate.
The aqueous phase was extracted with ethyl acetate (2.times.). The
combined organic phases were washed with water and saturated
aqueous sodium chloride, dried over anhydrous magnesium sulfate,
filtered, and concentrated. The residue was purified on silica gel
column (0-8% MeOH in dichloromethane) to give the title compound
(200 mg, 68.4% yield)
Example 126C
4-(3-(2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl)-7-methoxy-1-methyl--
1H-pyrrolo[2,3-c]pyridin-5-yl)but-3-yn-1-ol
[1148] A mixture of Example 126B (50 mg, 0.120 mmol),
2,4-difluorophenol (15.62 mg, 0.120 mmol) and cesium carbonate
(58.7 mg, 0.180 mmol) in dimethylsulfoxide (0.5 mL) was heated at
120.degree. C. in a microwave oven (Biotage Smith Synthesizer) for
45 minutes. The reaction mixture was partitioned between water and
ethyl acetate. The aqueous phase was extracted with ethyl acetate
(3.times.). The combined organic phases were washed with water
(2.times.), saturated aqueous sodium chloride, dried over anhydrous
magnesium sulfate, and filtered. The filtrate was concentrated and
the residue was absorbed on silica gel and purified by flash
chromatography (silica gel, 20-90% ethyl acetate/heptanes) to give
the title compound (38 mg, 60% yield)
Example 126D
5-[(1Z)-2-chloro-4-hydroxybut-1-en-1-yl]-3-[2-(2,4-difluorophenoxy)-5-(eth-
ylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1149] Example 126C (34 mg, 0.065 mmol) was treated with 4N HCl
dioxane solution (2 mL). The mixture was stirred at 50.degree. C.
for 4 hours. The mixture was cooled to ambient temperature, and
concentrated to 0.5 mL volume. Diethyl ether (4 mL) was added and
the resulting precipitate was collected to give the title compound
(12 mg, 34% yield). .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm
10.98 (s, 1H), 7.98 (d, J=2.3 Hz, 1H), 7.76 (s, 1H), 7.73 (dd,
J=8.6, 2.4 Hz, 1H), 7.63-7.51 (m, 1H), 7.46 (td, J=9.2, 5.6 Hz,
1H), 7.26 (d, J=1.3 Hz, 1H), 7.25-7.16 (m, 1H), 6.97 (dd, J=8.6,
1.1 Hz, 1H), 6.49 (s, 1H), 4.13 (s, 1H), 3.63 (t, J=6.3 Hz, 2H),
3.33-3.25 (m, 1H), 2.57 (t, J=6.2 Hz, 2H), 1.13 (t, J=7.3 Hz,
3H).
Example 127
3-[2-(2,4-difluorophenoxy)-5-{[(furan-3-ylmethyl)amino]methyl}phenyl]-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 127A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)-1-(furan-3-yl)methanamine
[1150] Example 127A was prepared according to the procedure used
for the preparation of Example 119A, substituting
furan-3-ylmethanamine hydrochloride for 1H-imidazol-4-ylmethylamine
dihydrochloride.
Example 127B
3-[2-(2,4-difluorophenoxy)-5-{[(furan-3-ylmethyl)amino]methyl}phenyl]-1-me-
thyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1151] The TFA salt of Example 127B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 127A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.98 (d, J=5.19 Hz, 1H), 9.22 (s, 1H),
7.82 (s, 1H), 7.74 (t, J=1.68 Hz, 1H), 7.67 (d, J=2.44 Hz, 1H),
7.56 (s, 1H), 7.44-7.52 (m, 1H), 7.34 (dd, J=8.54, 2.14 Hz, 1H),
7.19-7.27 (m, 1H), 7.08-7.17 (m, 1H), 6.87-6.93 (m, 1H), 6.84 (d,
J=8.24 Hz, 1H), 6.60-6.67 (m, 2H), 4.15-4.22 (m, 2H), 4.06-4.13 (m,
5H). MS (ESI+) m/z 461.9 (M+H).sup.+.
Example 128
3-[5-{[(2-cyclopentylethyl)amino]methyl}-2-(2,4-difluorophenoxy)phenyl]-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 128A
2-cyclopentyl-N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[-
2,3-c]pyridin-3-yl)benzyl)ethanamine
[1152] Example 128A was prepared according to the procedure used
for the preparation of Example 119A, substituting
2-cyclopentylethanamine hydrochloride for
1H-imidazol-4-ylmethylamine dihydrochloride.
Example 128B
3-[5-{[(2-cyclopentylethyl)amino]methyl}-2-(2,4-difluorophenoxy)phenyl]-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1153] The TFA salt of Example 128B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 128A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.99 (d, J=5.19 Hz, 1H), 8.77 (s, 1H),
7.68 (d, J=2.14 Hz, 1H), 7.54-7.57 (m, 1H), 7.44-7.52 (m, 1H), 7.35
(dd, J=8.54, 2.14 Hz, 1H), 7.19-7.27 (m, 1H), 7.08-7.16 (m, 1H),
6.88-6.93 (m, 1H), 6.85 (d, J=8.54 Hz, 1H), 6.63 (d, J=7.02 Hz,
1H), 4.18 (t, J=5.65 Hz, 2H), 4.11 (s, 3H), 2.91-3.01 (m, 2H),
1.69-1.83 (m, 3H), 1.43-1.67 (m, 6H), 1.02-1.14 (m, 2H). MS (ESI+)
m/z 477.9 (M+H).sup.+.
Example 129
3-[2-(2,4-difluorophenoxy)-5-{[4-(trifluoromethyl)piperidin-1-yl]methyl}ph-
enyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 129A
3-(2-(2,4-difluorophenoxy)-5-((4-(trifluoromethyl)piperidin-1-yl)methyl)ph-
enyl)-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1154] Example 129A was prepared according to the procedure used
for the preparation of Example 119A, substituting
4-(trifluoromethyl)piperidine hydrochloride for
1H-imidazol-4-ylmethylamine dihydrochloride.
Example 129B
3-[2-(2,4-difluorophenoxy)-5-{[4-(trifluoromethyl)piperidin-1-yl]methyl}ph-
enyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1155] The TFA salt of Example 129B was prepared according to the
procedure used for the preparation of Example 1C, substituting
Example 129A for Example 1B, and with the exception that the
reaction mixture was heated at 70.degree. C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.99 (d, J=5.49 Hz, 1H), 7.68 (d, J=1.83
Hz, 1H), 7.58 (s, 1H), 7.46-7.54 (m, 1H), 7.36 (dd, J=8.24, 2.14
Hz, 1H), 7.24-7.32 (m, 1H), 7.10-7.17 (m, 1H), 6.89-6.94 (m, 1H),
6.86 (d, J=8.54 Hz, 1H), 6.60 (d, J=6.71 Hz, 1H), 4.35 (s, 2H),
4.11 (s, 3H), 3.52 (d, J=12.51 Hz, 2H), 3.00 (s, 2H), 2.61-2.75 (m,
1H), 2.06 (d, J=13.12 Hz, 2H), 1.64-1.80 (m, 2H). MS (ESI+) m/z
517.9 (M+H).sup.+.
Example 130
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-2-methoxybenzenesulfonamide
Example 130A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)-2-methoxybenzenesulfonamide
[1156] A solution of Example 106B (70 mg, 0.177 mmol) in
dichloromethane (2.5 mL) was treated with
2-methoxybenzene-1-sulfonyl chloride (43.9 mg, 0.212 mmol) and
triethylamine (0.049 mL, 0.354 mmol). The reaction mixture was
stirred for 1 hour at ambient temperature and then partitioned
between 50% aqueous saturated sodium chloride (50 mL) and ethyl
acetate (50 mL). The organic layer was dried over anhydrous sodium
sulfate, filtered, and concentrated to provide the title compound
(104 mg, 100% yield).
Example 130B
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-2-methoxybenzenesulfonamide
[1157] Example 130B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 130A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.92 (d, J=5.19 Hz, 1H), 7.81 (t, J=6.26 Hz, 1H), 7.68 (dd,
J=7.78, 1.68 Hz, 1H), 7.48-7.55 (m, 1H), 7.38-7.45 (m, 2H), 7.32
(d, J=2.14 Hz, 1H), 6.94-7.11 (m, 5H), 6.85-6.90 (m, 1H), 6.65 (d,
J=8.24 Hz, 1H), 6.50 (d, J=7.02 Hz, 1H), 4.09 (s, 3H), 4.06 (d,
J=6.10 Hz, 2H), 3.76 (s, 3H). MS (ESI+) m/z 552.1 (M+H).sup.+.
Example 131
1-(4-chlorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydr-
o-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide
Example 131A
1-(4-chlorophenyl)-N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyr-
rolo[2,3-c]pyridin-3-yl)benzyl)methanesulfonamide
[1158] Example 131A was prepared according to the procedure used
for the preparation of Example 130A, substituting
(4-chlorophenyl)methanesulfonyl chloride for
2-methoxybenzene-1-sulfonyl chloride.
Example 131B
1-(4-chlorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydr-
o-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide
[1159] Example 131B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 131A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.93 (d, J=5.19 Hz, 1H), 7.69 (s, 1H), 7.50 (s, 1H), 7.39-7.49
(m, 4H), 7.32-7.39 (m, 2H), 7.10-7.21 (m, 2H), 7.02-7.09 (m, 1H),
6.84-6.90 (m, 1H), 6.80 (d, J=8.24 Hz, 1H), 6.56 (d, J=7.02 Hz,
1H), 4.36 (s, 2H), 4.14 (s, 2H), 4.10 (s, 3H). MS (ESI+) m/z 570.3
(M+H).sup.+.
Example 132
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-1-(4-methylphenyl)methanesulfonamide
Example 132A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)-1-(p-tolyl)methanesulfonamide
[1160] Example 132A was prepared according to the procedure used
for the preparation of Example 130A, substituting
p-tolylmethanesulfonyl chloride for 2-methoxybenzene-1-sulfonyl
chloride.
Example 132B
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-1-(4-methylphenyl)methanesulfonamide
[1161] Example 132B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 132A for
Example 1B, with the exception that the reaction mixture was heated
at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
10.93 (d, J=5.49 Hz, 1H), 7.61 (t, J=6.26 Hz, 1H), 7.50 (s, 1H),
7.39-7.48 (m, 2H), 7.09-7.24 (m, 6H), 7.02-7.09 (m, 1H), 6.84-6.90
(m, 1H), 6.80 (d, J=8.24 Hz, 1H), 6.57 (d, J=6.71 Hz, 1H), 4.27 (s,
2H), 4.06-4.14 (m, 5H), 2.29 (s, 3H). MS (ESI+) m/z 550.2
(M+H).sup.+.
Example 133
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-1-[4-(trifluoromethyl)phenyl]methanesulfonamide
Example 133A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)-1-(4-(trifluoromethyl)phenyl)methanesulfonamide
[1162] Example 133A was prepared according to the procedure used
for the preparation of Example 130A, substituting
(4-(trifluoromethyl)phenyl)methanesulfonyl chloride for
2-methoxybenzene-1-sulfonyl chloride.
Example 133B
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-1-[4-(trifluoromethyl)phenyl]methanesulfonamide
[1163] Example 133B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 133A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.93 (d, J=5.49 Hz, 1H), 7.70-7.79 (m, 3H), 7.57 (d, J=8.24
Hz, 2H), 7.51 (s, 1H), 7.48 (d, J=2.14 Hz, 1H), 7.40-7.47 (m, 1H),
7.10-7.21 (m, 2H), 7.03-7.10 (m, 1H), 6.85-6.89 (m, 1H), 6.80 (d,
J=8.24 Hz, 1H), 6.57 (d, J=7.02 Hz, 1H), 4.49 (s, 2H), 4.18 (d,
J=6.10 Hz, 2H), 4.09 (s, 3H). MS (ESI+) m/z 604.2 (M+H).sup.+.
Example 134
1-(4-cyanophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-
-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide
Example 134A
1-(4-cyanophenyl)-N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrr-
olo[2,3-c]pyridin-3-yl)benzyl)methanesulfonamide
[1164] Example 134A was prepared according to the procedure used
for the preparation of Example 130A, substituting
(4-cyanophenyl)methanesulfonyl chloride for
2-methoxybenzene-1-sulfonyl chloride.
Example 134B
1-(4-cyanophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-
-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide
[1165] Example 134B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 134A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.94 (d, J=5.49 Hz, 1H), 7.83 (d, J=8.24 Hz, 2H), 7.78 (t,
J=6.10 Hz, 1H), 7.55 (d, J=8.24 Hz, 2H), 7.51 (s, 1H), 7.39-7.49
(m, 2H), 7.10-7.22 (m, 2H), 7.02-7.10 (m, 1H), 6.84-6.91 (m, 1H),
6.80 (d, J=8.54 Hz, 1H), 6.56 (d, J=6.71 Hz, 1H), 4.50 (s, 2H),
4.16 (d, J=6.10 Hz, 2H), 4.10 (s, 3H). MS (ESI+) m/z 561.3
(M+H).sup.+.
Example 135
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-2,2,2-trifluoroethanesulfonamide
Example 135A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)-2,2,2-trifluoroethanesulfonamide
[1166] Example 135A was prepared according to the procedure used
for the preparation of Example 130A, substituting
2,2,2-trifluoroethanesulfonyl chloride for
2-methoxybenzene-1-sulfonyl chloride.
Example 135B
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-2,2,2-trifluoroethanesulfonamide
[1167] Example 135B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 135A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.93 (d, J=5.19 Hz, 1H), 8.32 (s, 1H), 7.48-7.53 (m, 2H),
7.38-7.48 (m, 1H), 7.21 (dd, J=8.24, 2.14 Hz, 1H), 7.10-7.18 (m,
1H), 7.03-7.10 (m, 1H), 6.85-6.92 (m, 1H), 6.81 (d, J=8.24 Hz, 1H),
6.57 (d, J=6.71 Hz, 1H), 4.42 (q, J=9.87 Hz, 2H), 4.23 (s, 2H),
4.10 (s, 3H). MS (ESI+) m/z 528.1 (M+H).sup.+.
Example 136
3-[5-(aminomethyl)-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H--
pyrrolo[2,3-c]pyridin-7-one
Example 136A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)propane-2-sulfonamide
[1168] Example 136A was prepared according to the procedure used
for the preparation of Example 130A, substituting
propane-2-sulfonyl chloride for 2-methoxybenzene-1-sulfonyl
chloride to provide the title compound as a mixture with unreacted
starting material.
Example 136B
3-[5-(aminomethyl)-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H--
pyrrolo[2,3-c]pyridin-7-one
[1169] Example 136B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 136A for
Example 1B, with the exception that the reaction mixture was heated
at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
10.98 (d, J=5.19 Hz, 1H), 8.20 (s, 2H), 7.64 (d, J=2.14 Hz, 1H),
7.54 (s, 1H), 7.43-7.50 (m, 1H), 7.32 (dd, J=8.54, 2.14 Hz, 1H),
7.16-7.24 (m, 1H), 7.07-7.15 (m, 1H), 6.87-6.93 (m, 1H), 6.84 (d,
J=8.54 Hz, 1H), 6.65 (d, J=6.71 Hz, 1H), 4.11 (s, 3H), 4.06 (d,
J=5.49 Hz, 2H). MS (ESI+) m/z 382.1 (M+H).sup.+.
Example 137
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]cyclopentanesulfonamide
Example 137A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)cyclopentanesulfonamide
[1170] Example 137A was prepared according to the procedure used
for the preparation of Example 130A, substituting
cyclopentanesulfonyl chloride for 2-methoxybenzene-1-sulfonyl
chloride.
Example 137B
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]cyclopentanesulfonamide
[1171] Example 137B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 137A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.93 (d, J=5.19 Hz, 1H), 7.58 (t, J=6.26 Hz, 1H), 7.48-7.53
(m, 2H), 7.39-7.47 (m, 1H), 7.21 (dd, J=8.54, 2.14 Hz, 1H),
7.01-7.16 (m, 2H), 6.85-6.91 (m, 1H), 6.81 (d, J=8.54 Hz, 1H), 6.57
(d, J=6.71 Hz, 1H), 4.19 (d, J=6.41 Hz, 2H), 4.09 (s, 3H),
3.39-3.50 (m, 1H), 1.81-1.89 (m, 4H), 1.59-1.71 (m, 2H), 1.48-1.58
(m, 2H). MS (ESI+) m/z 514.2 (M+H).sup.+.
Example 138
2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-p-
yrrolo[2,3-c]pyridin-3-yl)benzyl]thiophene-3-sulfonamide
Example 138A
2,5-dichloro-N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2-
,3-c]pyridin-3-yl)benzyl)thiophene-3-sulfonamide
[1172] Example 138A was prepared according to the procedure used
for the preparation of Example 130A, substituting
2,5-dichlorothiophene-3-sulfonyl chloride for
2-methoxybenzene-1-sulfonyl chloride.
Example 138B
2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-p-
yrrolo[2,3-c]pyridin-3-yl)benzyl]thiophene-3-sulfonamide
[1173] Example 138B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 138A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.93 (d, J=5.19 Hz, 1H), 8.56-8.79 (m, 1H), 7.39-7.50 (m, 2H),
7.37 (d, J=2.14 Hz, 1H), 7.14-7.18 (m, 1H), 7.03-7.13 (m, 3H),
6.85-6.93 (m, 1H), 6.71 (d, J=8.55 Hz, 1H), 6.54 (d, J=7.02 Hz,
1H), 4.20 (s, 2H), 4.10 (s, 3H). MS (ESI+) m/z 596.2
(M+H).sup.+.
Example 139
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-5-methyl-1,2-oxazole-4-sulfonamide
Example 139A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)-5-methylisoxazole-4-sulfonamide
[1174] Example 139A was prepared according to the procedure used
for the preparation of Example 130A, substituting
5-methylisoxazole-4-sulfonyl chloride for
2-methoxybenzene-1-sulfonyl chloride.
Example 139B
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-5-methyl-1,2-oxazole-4-sulfonamide
[1175] Example 139B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 139A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, pyridine-d.sub.5)
.delta. ppm 7.95 (d, J=2.14 Hz, 1H), 7.59 (s, 2H), 7.48 (dd, 1H),
7.06-7.19 (m, 3H), 6.87-6.98 (m, 3H), 5.57 (s, 2H), 4.63 (s, 2H),
4.16-4.22 (m, 3H), 2.44-2.53 (m, 3H). MS (ESI+) m/z 526.9
(M+H).sup.+.
Example 140
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide
Example 140A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)-3,5-dimethylisoxazole-4-sulfonamide
[1176] Example 140A was prepared according to the procedure used
for the preparation of Example 130A, substituting
3,5-dimethylisoxazole-4-sulfonyl chloride for
2-methoxybenzene-1-sulfonyl chloride.
Example 140B
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide
[1177] Example 140B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 140A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.93 (d, J=5.19 Hz, 1H), 8.47 (s, 1H), 7.37-7.49 (m, 3H), 7.12
(dd, J=8.24, 2.14 Hz, 1H), 7.01-7.09 (m, 2H), 6.85-6.92 (m, 1H),
6.75 (d, J=8.24 Hz, 1H), 6.52 (d, J=6.71 Hz, 1H), 4.05-4.14 (m,
5H), 2.51 (s, 3H), 2.28 (s, 3H). MS (ESI+) m/z 541.1
(M+H).sup.+.
Example 141
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]benzenesulfonamide
Example 141A
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin--
3-yl)benzyl)benzenesulfonamide
[1178] Example 141A was prepared according to the procedure used
for the preparation of Example 130A, substituting benzenesulfonyl
chloride for 2-methoxybenzene-1-sulfonyl chloride.
Example 141B
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)benzyl]benzenesulfonamide
[1179] Example 141B was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 141A for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.93 (d, J=5.19 Hz, 1H), 8.20 (s, 1H), 7.76-7.81 (m, 2H),
7.58-7.64 (m, 1H), 7.55 (t, J=7.32 Hz, 2H), 7.39-7.46 (m, 2H), 7.36
(d, J=2.14 Hz, 1H), 7.01-7.11 (m, 3H), 6.85-6.91 (m, 1H), 6.72 (d,
J=8.24 Hz, 1H), 6.50 (d, J=7.02 Hz, 1H), 4.09 (s, 3H), 4.03 (s,
2H). MS (ESI+) m/z 522.2 (M+H).sup.+.
Example 142
3-{2-[(cyclopropylmethyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-
-c]pyridin-7-one
Example 142A
2-bromo-N-(cyclopropylmethyl)aniline
[1180] Example 142A was prepared as described in Example 111A
substituting cyclopropanecarbaldehyde for Example 105B and
2-bromoaniline for tert-butyl piperidin-4-ylcarbamate. The isolated
product was purified by flash chromatography (silica gel, 0-10%
ethyl acetate in heptane) to give the title compound.
Example 142B
N-(cyclopropylmethyl)-2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-
aniline
[1181] Example 142B was prepared as described in Example 11E
substituting Example 142A for Example 11C, and with the exception
that the reaction mixture was heated at 75.degree. C. for 18 hours.
The isolated product was purified by flash chromatography (silica
gel, 0-5% methanol in methylene chloride) to give the title
compound.
Example 142C
3-{2-[(cyclopropylmethyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-
-c]pyridin-7-one
[1182] Example 142C was prepared according to the procedure used
for the preparation of Example 1C, substituting Example 142B for
Example 1B, and with the exception that the reaction mixture was
heated at 70.degree. C. The material was purified by flash
chromatography (silica gel, 1-7.5% methanol in dichloromethane) to
provide the title compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 10.99 (d, J=3.66 Hz, 1H) 7.56 (s, 1H) 7.34 (t, J=7.17
Hz, 1H) 7.23 (d, J=7.02 Hz, 2H) 7.11 (s, 1H) 6.85-6.92 (m, 1H) 6.17
(d, J=6.71 Hz, 1H) 4.12 (s, 3H) 3.69 (s, 1H) 2.99 (d, J=7.02 Hz,
2H) 0.89-1.00 (m, 1H) 0.37-0.45 (m, 2H) 0.11-0.18 (m, 2H). MS
(ESI+) m/z 294.0 (M+H).sup.+.
Example 143
3-{2-chloro-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
Example 143A
3-bromo-5-(bromomethyl)-2-chloropyridine
[1183] 3-Bromo-2-chloro-5-methylpyridine (4 g, 19.37 mmol),
N-bromosuccinimide (3.79 g, 21.3 mmol) and benzoic peroxyanhydride
(0.239 g, 0.969 mmol) were combined in carbon tetrachloride (40
mL), heated under reflux for 24 hours, cooled, and filtered to
remove succinimide. The filtrate was concentrated. The resulting
residue was purified by chromatography (silica gel, 0-30% ethyl
acetate in heptanes) to afford the title compound (1.9 g, 34%).
Example 143B
3-bromo-2-chloro-5-((methylsulfonyl)methyl)pyridine
[1184] Sodium methanesulfinate (0.748 g, 7.32 mmol) and the product
from Example 143A (1.9 g, 6.66 mmol) were combined in
N,N-dimethylformamide (4.44 mL) and heated at 65.degree. C. for 1
hour. The reaction mixture was cooled and diluted with 200 mL of
cold water producing a precipitate that was collected by filtration
and dried to constant mass affording the title compound (1.6 g,
84%).
Example 143C
3-(2-chloro-5-((methylsulfonyl)methyl)pyridin-3-yl)-7-methoxy-1-methyl-1H--
pyrrolo[2,3-c]pyridine
[1185] Example 143B (0.569 g, 2.0 mmol), Example 59A (0.576 g,
2.000 mmol), tris(dibenzylideneacetone)dipalladium (0) (0.055 g,
0.060 mmol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane
(0.058 g, 0.200 mmol) and potassium phosphate (1.486 g, 7.00 mmol)
were combined and sparged with argon for 15 minutes. Meanwhile a
solution of 4:1 dioxane/water (26 mL) was sparged with nitrogen for
15 minutes and transferred by syringe into the reaction vessel
under argon. The mixture was stirred for 3 hours at 60.degree. C.,
cooled, and partitioned between ethyl acetate and water. The
organic layer was washed with saturated aqueous sodium chloride,
dried over anhydrous sodium sulfate, treated with 3-mercaptopropyl
functionalized silica for 30 minutes, filtered and concentrated.
Purification by chromatography (silica gel, 1-4% methanol in
dichloromethane) afforded the title compound (0.56 g, 77%).
Example 143D
3-{2-chloro-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-methyl-1,6-dihydro-7-
H-pyrrolo[2,3-c]pyridin-7-one
[1186] Example 143C (0.055 g, 0.150 mmol) and 4 M hydrogen chloride
in dioxane (5 mL, 20.00 mmol) were combined and heated at
85.degree. C. for 20 hours. The mixture was cooled and
concentrated. Purification by trituration in 9:1 heptanes/ethyl
acetate afforded the title compound (0.05 g, 95%). .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 11.04 (d, J=5.43 Hz, 1H) 8.35 (d, J=2.03
Hz, 1H) 7.94 (d, J=2.37 Hz, 1H) 7.68 (s, 1H) 6.89-6.97 (m, 1H) 6.39
(d, J=6.44 Hz, 1H) 4.65 (s, 2H) 4.14 (s, 3H) 3.01 (s, 3H). MS
(ESI+) m/z 352 (M+H).sup.+.
Example 144
3-[2-{[trans-4-(dimethylamino)cyclohexyl]oxy}-5-(pyrrolidin-1-ylsulfonyl)p-
henyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 144A
1-((3-bromo-4-fluorophenyl)sulfonyl)pyrrolidine
[1187] To a solution of 3-bromo-4-fluorobenzene-1-sulfonyl chloride
(0.83 g, 2.73 mmol) in tetrahydrofuran (10 mL) under argon was
added diisopropylethylamine (0.525 mL, 3.00 mmol) followed by
pyrrolidine (0.183 mL, 2.73 mmol). The reaction mixture was stirred
at ambient temperature for 2 hours. The reaction mixture was
partitioned between diethyl ether and aqueous ammonium chloride.
The organic layer was separated, dried over anhydrous magnesium
sulfate, filtered, and concentrated. The resulting residue was
triturated with diethyl ether/heptane at -20.degree. C. to provide
the title compound (0.56 g, 67% yield).
Example 144B
(trans)-4-(2-bromo-4-(pyrrolidin-1-ylsulfonyl)phenoxy)-N,N-dimethylcyclohe-
xanamine
[1188] To (trans)-4-(dimethylamino)cyclohexanol (0.290 g, 1.95
mmol) in dioxane (12 mL) stirring at ambient temperature under
argon was added sodium hydride (0.161 g, 4.02 mmol, 60% oil
dispersion). The mixture was stirred for 15 minutes and then
Example 144A (0.40 g, 1.298 mmol) was added as a solid in one
portion. The mixture was heated at 75.degree. C. for 7 hours and
then at 95.degree. C. overnight. The mixture was cooled to ambient
temperature and partitioned between saturated aqueous sodium
chloride and ethyl acetate. The organic phase was dried over
anhydrous magnesium sulfate, filtered, and concentrated. The
residue was purified by flash chromatography (silica gel,
dichloroethane/5-10% methanol gradient) to provide the title
compound (0.12 g, 21% yield).
Example 144C
(trans)-4-(2-(7-methoxy-1-methyl-TH-pyrrolo[2,3-c]pyridin-3-yl)-4-(pyrroli-
din-1-ylsulfonyl)phenoxy)-N,N-dimethylcyclohexanamine
[1189] A mixture of Example 144B (60 mg, 0.14 mmol) and Example 59A
(40.1 mg, 0.14 mmol) was degassed under argon. To this mixture was
added dioxane (8 mL) followed by degassing with argon. To this
mixture was added potassium phosphate, dibasic (109 mg, 0.626 mmol)
and water (2.000 mL) followed by degassing with argon. To this
mixture was added
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane (6.91
mg, 0.024 mmol) and then immediately
tris(dibenzylideneacetone)dipalladium (0) (8.92 mg, 9.74 .mu.mol)
followed by degassing with argon. The reaction mixture was heated
at 100.degree. C. for 1 hour. The mixture was cooled to ambient
temperature and partitioned between saturated aqueous sodium
chloride and ethyl acetate. The organic phase was dried over
anhydrous magnesium sulfate, filtered, and concentrated to provide
the title compound (0.042 g, 59% yield)
Example 144D
3-[2-{[trans-4-(dimethylamino)cyclohexyl]oxy}-5-(pyrrolidin-1-ylsulfonyl)p-
henyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1190] To Example 144C (42 mg, 0.082 mmol) stirring under argon was
added 4N hydrogen chloride in dioxane (5 mL, 20.00 mmol). The
reaction mixture was heated at 70.degree. C. for 3 hours and then
cooled to ambient temperature. Diethyl ether (5 mL) was added and
the resulting solid was collected by filtration and washed with
heptane. The solid was purified by reverse phase HPLC (C18,
CH.sub.3CN/water (0.1% trifluoroacetic acid), 10-100%) to provide
the title compound as the trifluoroacetic acid salt (0.035 g, 70%
yield). .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.96 (d, J=5.5
Hz, 1H), 9.43 (s, 1H), 7.72 (d, J=2.4 Hz, 1H), 7.68 (dd, J=8.6, 2.4
Hz, 1H), 7.55 (s, 1H), 7.36 (d, J=8.9 Hz, 1H), 6.92 (dd, J=7.0, 5.8
Hz, 1H), 6.39-6.35 (m, 1H), 4.52 (m, 1H), 4.11 (s, 3H), 3.28-3.06
(m, 4H), 2.76 (s, 3H), 2.74 (s, 3H), 2.23 (d, J=10.1 Hz, 2H), 2.03
(d, J=11.1 Hz, 2H), 1.73-1.65 (m, 4H), 1.65-1.34 (m, 4H). MS (ESI+)
m/z 499.1 (M+H).sup.+.
Example 145
3-{5-fluoro-2-[(4-fluorophenyl)amino]pyridin-3-yl}-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one
Example 145A
5-fluoro-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-ami-
ne
[1191] 3-Bromo-5-fluoropyridin-2-amine (0.25 g, 1.309 mmol),
Example 59A (0.377 g, 1.309 mmol),
tris(dibenzylideneacetone)dipalladium (0) (0.036 g, 0.039 mmol),
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane
(0.038 g, 0.131 mmol) and sodium carbonate (0.486 g, 4.58 mmol)
were combined and sparged with argon for 15 minutes. Meanwhile a
solution of 4:1 dioxane/water (9 mL) was sparged with nitrogen for
15 minutes and transferred by syringe into the reaction vessel
under argon. The mixture was stirred for 4 hours at 60.degree. C.,
cooled and partitioned into water and ethyl acetate. The organic
layer was washed with water, saturated aqueous sodium chloride,
dried over anhydrous sodium sulfate, treated with 3-mercaptopropyl
functionalized silica for 30 minutes, filtered and concentrated.
Purification by chromatography (silica gel, 0-3% methanol in
dichloromethane) afforded the title compound (0.23 g, 64%).
Example 145B
5-fluoro-N-(4-fluorophenyl)-3-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-
-3-yl)pyridin-2-amine
[1192] 1-bromo-4-fluorobenzene (0.129 g, 0.735 mmol), Example 145A
(0.1 g, 0.367 mmol), diacetoxypalladium (3.30 mg, 0.015 mmol),
dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine
(0.014 g, 0.029 mmol) and cesium carbonate (0.239 g, 0.735 mmol)
were combined in tert-butanol (0.360 mL)/toluene (1.80 mL) and
heated by microwave at 150.degree. C. for 40 minutes. The mixture
was cooled and partitioned between ethyl acetate and water. The
organic layer was washed with saturated aqueous sodium chloride,
dried over anhydrous sodium sulfate, treated with 3-mercaptopropyl
functionalized silica for 30 minutes, filtered and concentrated.
Purification by chromatography (silica gel, 0-40% ethyl acetate in
heptanes) afforded the title compound (0.097 g, 72%).
Example 145C
3-{5-fluoro-2-[(4-fluorophenyl)amino]pyridin-3-yl}-1-methyl-1,6-dihydro-7H-
-pyrrolo[2,3-c]pyridin-7-one
[1193] Example 145B (0.097 g, 0.265 mmol) and 4M hydrogen chloride
in dioxane (5 mL, 20.00 mmol) were heated at 90.degree. C. for 4
hours, cooled and concentrated. Purification of the residue by
trituration in diethyl ether afforded the title compound (0.11 g,
99%). .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.98 (d, J=5.43
Hz, 1H) 8.07 (d, J=2.71 Hz, 1H) 7.80 (s, 1H) 7.61 (s, 1H) 7.44-7.56
(m, 3H) 7.00-7.08 (m, 2H) 6.84-6.90 (m, 1H) 6.26 (d, J=5.76 Hz, 1H)
4.12 (s, 3H). MS (ESI+) m/z 353 (M+H).sup.+.
Example 146
3-[5-amino-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[-
2,3-c]pyridin-7-one
Example 146A
3-(2-(2,4-difluorophenoxy)-5-nitrophenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridi-
n-7(6H)-one
[1194] A solution of Example 2C (1.133 g, 2.75 mmol) in dioxane (35
mL) was treated with 4 N HCl in dioxane (35 mL, 140 mmol) and
stirred at 70.degree. C. overnight. The solution was cooled,
diluted with 200 mL ethyl acetate, then washed with 200 mL of 1:1
saturated aqueous sodium chloride/sodium bicarbonate and dried over
anhydrous sodium sulfate. Filtration and solvent removal provided
1.085 g of the product as a yellow solid.
Example 146B
3-(5-amino-2-(2,4-difluorophenoxy)phenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridi-
n-7(6H)-one
[1195] Example 146B was prepared according to the procedure used
for the preparation of Example 2D, substituting Example 146A for
Example 2C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 10.88
(d, J=5.0 Hz, 1H), 7.36 (s, 1H), 7.29 (m, 1H), 6.93-6.79 (m, 2H),
6.76-6.68 (m, 3H), 6.56-6.46 (m, 2H), 5.04 (s, 2H), 4.03 (s, 3H).
MS (ESI+) m/z 368.2 (M+H).sup.+.
Example 147
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-4-methylpentanamide
[1196] A solution of Example 146B and diisopropylethyl amine (0.15
M and 0.44 M in N,N-dimethylacetamide, respectively, 275 .mu.L,
0.04 mmol Example 146 (1.0 equivalent) and 0.12 mmol
diisopropylethyl amine (3.0 equivalents)),
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (0.17 M in N,N-dimethylacetamide, 275 .mu.L,
0.048 mmol, 1.2 equivalents), and 4-methylpentanoic acid (0.41 M in
N,N-dimethylacetamide, 122 .mu.L, 0.048 mmol, 1.2 eq) were mixed
through a perfluoroalkoxy mixing tube (0.2 mm inner diameter), and
loaded into an injection loop. The reaction segment was injected
into the flow reactor (Hastelloy coil, 0.75 mm inner diameter, 1.8
mL internal volume) set at 100.degree. C., and passed through the
reactor at 180 .mu.L min.sup.-1 (10 minute residence time). Upon
exiting the reactor, the solution was loaded directly into an
injection loop and purified by preparative HPLC on a Phenomenex
Luna C8(2) 5 .mu.m 100 .ANG. AXIA column (50 mm.times.21.2 mm),
eluting with a gradient of acetonitrile (A) and 0.1% ammonium
acetate in water (B) at a flow rate of 30 mL/min (0-0.5 min 5% A,
0.5-6.5 min linear gradient 5-100% A, 6.5-8.5 min 100% A, 8.5-9.0
min linear gradient 100-5% A, 9.0-10 min 5% A) to provide the title
compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.85 (d,
J=2.6 Hz, 1H), 7.51 (s, 1H), 7.46-7.32 (m, 2H), 7.08-6.97 (m, 2H),
6.95 (d, J=7.0 Hz, 1H), 6.85 (d, J=8.7 Hz, 1H), 6.63 (d, J=7.0 Hz,
1H), 4.07 (s, 3H), 2.32 (t, J=7.5 Hz, 2H), 1.61-1.46 (m, 3H), 0.90
(d, J=6.2 Hz, 6H). MS (ESI+) m/z 466.1 (M+H).sup.+.
Example 148
2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-p-
yrrolo[2,3-c]pyridin-3-yl)phenyl]benzamide
[1197] Example 148 was prepared according to the procedure used for
the preparation of Example 147, substituting 2,5-dichlorobenzoic
acid for 4-methylpentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.94 (d, J=2.6 Hz, 1H), 7.71 (dd, J=2.1, 0.8
Hz, 1H), 7.65-7.54 (m, 4H), 7.39 (ddd, J=11.2, 8.6, 2.8 Hz, 1H),
7.15-7.00 (m, 2H), 6.96 (d, J=7.0 Hz, 1H), 6.91 (d, J=8.8 Hz, 1H),
6.66 (d, J=7.0 Hz, 1H), 4.09 (s, 3H). MS (ESI+) m/z 539.9
(M+H).sup.+.
Example 149
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-2-(2-methoxyphenyl)acetamide
[1198] Example 149 was prepared according to the procedure used for
the preparation of Example 147, substituting
-(2-methoxyphenyl)acetic acid for 4-methylpentanoic acid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 7.88 (d, J=2.6 Hz, 1H), 7.52
(s, 1H), 7.43 (dd, J=8.8, 2.6 Hz, 1H), 7.36 (ddd, J=11.2, 8.5, 2.8
Hz, 1H), 7.30-7.19 (m, 2H), 7.09-6.95 (m, 3H), 6.97-6.87 (m, 2H),
6.85 (d, J=8.7 Hz, 1H), 6.62 (d, J=7.0 Hz, 1H), 4.07 (s, 3H), 3.86
(m, 2H), 3.77 (s, 3H). MS (ESI+) m/z 516.1 (M+H).sup.+.
Example 150
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]pyridine-2-carboxamide
[1199] Example 150 was prepared according to the procedure used for
the preparation of Example 147, substituting pyridine-2-carboxylic
acid for 4-methylpentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.76 (ddd, J=4.7, 1.7, 0.9 Hz, 1H), 8.20-8.12
(m, 2H), 8.08 (td, J=7.6, 1.7 Hz, 1H), 7.74 (dd, J=8.8, 2.6 Hz,
1H), 7.69 (ddd, J=7.5, 4.7, 1.3 Hz, 1H), 7.57 (s, 1H), 7.39 (ddd,
J=11.2, 8.6, 2.8 Hz, 1H), 7.16-7.00 (m, 2H), 6.97 (d, J=7.0 Hz,
1H), 6.90 (d, J=8.8 Hz, 1H), 6.74 (d, J=7.0 Hz, 1H), 4.10 (s, 3H).
MS (ESI+) m/z 473.1 (M+H).sup.+.
Example 151
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-5-methylpyrazine-2-carboxamide
[1200] Example 151 was prepared according to the procedure used for
the preparation of Example 147, substituting
5-methylpyrazine-2-carboxylic acid for 4-methylpentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.16 (d, J=1.4 Hz, 1H),
8.70 (d, J=1.4 Hz, 1H), 8.12 (d, J=2.6 Hz, 1H), 7.73 (dd, J=8.8,
2.6 Hz, 1H), 7.57 (s, 1H), 7.39 (ddd, J=11.2, 8.6, 2.8 Hz, 1H),
7.17-7.00 (m, 2H), 6.97 (d, J=7.0 Hz, 1H), 6.89 (d, J=8.8 Hz, 1H),
6.74 (d, J=7.0 Hz, 1H), 4.09 (s, 3H), 2.64 (s, 3H). MS (ESI+) m/z
487.8 (M+H).sup.+.
Example 152
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-3-phenylpropanamide
[1201] Example 152 was prepared according to the procedure used for
the preparation of Example 147, substituting 3-phenylpropionic acid
for 4-methylpentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 7.83 (d, J=2.6 Hz, 1H), 7.51 (s, 1H), 7.44-7.16 (m, 7H),
7.08-6.97 (m, 2H), 6.95 (d, J=7.0 Hz, 1H), 6.84 (d, J=8.7 Hz, 1H),
6.62 (d, J=7.0 Hz, 1H), 4.07 (s, 3H), 2.93 (t, J=7.6 Hz, 2H), 2.64
(t, J=7.6 Hz, 2H). MS (ESI+) m/z 500.1 (M+H).sup.+.
Example 153
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-4-phenoxybutanamide
[1202] Example 153 was prepared according to the procedure used for
the preparation of Example 147, substituting 4-phenoxybutanoic acid
for 4-methylpentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 7.85 (d, J=2.6 Hz, 1H), 7.51 (s, 1H), 7.48-7.31 (m, 2H),
7.32-7.25 (m, 2H), 7.10-6.88 (m, 6H), 6.85 (d, J=8.7 Hz, 1H), 6.63
(d, J=7.0 Hz, 1H), 4.07 (s, 3H), 4.02 (t, J=6.2 Hz, 2H), 2.51 (m,
2H), 2.05 (m, 2H). MS (ESI+) m/z 530.1 (M+H).sup.+.
Example 154
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-2-(3-phenoxyphenyl)acetamide
[1203] Example 154 was prepared according to the procedure used for
the preparation of Example 147, substituting 3-phenoxyphenylacetic
acid for 4-methylpentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.84 (d, J=2.6 Hz, 1H), 7.51 (s, 1H),
7.46-7.31 (m, 5H), 7.18-7.09 (m, 2H), 7.09-6.97 (m, 5H), 6.94 (d,
J=7.0 Hz, 1H), 6.92-6.82 (m, 2H), 6.61 (d, J=7.0 Hz, 1H), 4.07 (s,
3H), 3.64 (s, 2H). MS (ESI+) m/z 578.0 (M+H).sup.+.
Example 155
4-(acetylamino)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1-
H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]benzamide
[1204] Example 155 was prepared according to the procedure used for
the preparation of Example 147, substituting 4-(acetylamino)benzoic
acid for 4-methylpentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.01 (m, 1H), 7.95 (m, 2H), 7.71 (m, 2H),
7.63 (m, 1H), 7.56 (s, 1H), 7.45-7.31 (m, 1H), 7.13-7.01 (m, 2H),
6.96 (d, J=7.0 Hz, 1H), 6.89 (m, 1H), 6.70 (d, J=7.0 Hz, 1H), 4.09
(s, 3H), 3.00 (s, 3H). MS (ESI+) m/z 529.0 (M+H).sup.+.
Example 156
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-4-(phenoxymethyl)benzamide
[1205] Example 156 was prepared according to the procedure used for
the preparation of Example 147, substituting
4-(phenoxymethyl)benzoic acid for 4-methylpentanoic acid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 8.02 (d, J=2.6 Hz, 1H),
8.01-7.94 (m, 2H), 7.67-7.50 (m, 4H), 7.38 (ddd, J=11.2, 8.6, 2.7
Hz, 1H), 7.35-7.27 (m, 2H), 7.19-6.99 (m, 4H), 7.01-6.93 (m, 2H),
6.90 (d, J=8.8 Hz, 1H), 6.70 (d, J=7.0 Hz, 1H), 5.22 (bds, 2H),
4.09 (s, 3H). MS (ESI+) m/z 578.0 (M+H).sup.+.
Example 157
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-2-oxo-1-phenylpyrrolidine-3-carboxamide
[1206] Example 157 was prepared according to the procedure used for
the preparation of Example 147, substituting
2-oxo-1-phenylpyrrolidine-3-carboxylic acid for 4-methylpentanoic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.93 (d, J=2.6
Hz, 1H), 7.69-7.63 (m, 2H), 7.54 (s, 1H), 7.48 (dd, J=8.8, 2.6 Hz,
1H), 7.46-7.32 (m, 3H), 7.23-7.16 (m, 1H), 7.12-6.98 (m, 2H), 6.95
(d, J=7.0 Hz, 1H), 6.89 (d, J=8.8 Hz, 1H), 6.64 (d, J=7.0 Hz, 1H),
4.08 (s, 3H), 3.92 (m, 2H), 2.40 (m, 2H). MS (ESI+) m/z 555.0
(M+H).sup.+.
Example 158
2-(1,2-benzoxazol-3-yl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-d-
ihydro-H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide
[1207] Example 158 was prepared according to the procedure used for
the preparation of Example 147, substituting
2-(1,2-benzoxazol-3-yl)acetic acid for 4-methylpentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.91 (d, J=8.0 Hz, 1H),
7.86 (d, J=2.6 Hz, 1H), 7.77-7.64 (m, 2H), 7.52 (s, 1H), 7.48-7.32
(m, 3H), 7.11-6.98 (m, 2H), 6.93 (d, J=7.0 Hz, 1H), 6.87 (d, J=8.8
Hz, 1H), 6.60 (d, J=7.0 Hz, 1H), 4.17 (d, J=6.9 Hz, 2H), 4.07 (s,
3H). MS (ESI+) m/z 527.0 (M+H).sup.+.
Example 159
2-(5-chloro-2-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6-
,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide
[1208] Example 159 was prepared according to the procedure used for
the preparation of Example 147, substituting
(5-chloro-2-fluorophenyl)acetic acid for 4-methylpentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.87 (d, J=2.6 Hz, 1H),
7.54-7.29 (m, 5H), 7.19 (td, J=8.5, 3.1 Hz, 1H), 7.10-6.97 (m, 2H),
6.94 (d, J=7.0 Hz, 1H), 6.86 (d, J=8.8 Hz, 1H), 6.61 (d, J=7.0 Hz,
1H), 4.07 (s, 3H), 3.86 (m, 2H). MS (ESI+) m/z 538.0
(M+H).sup.+.
Example 160
2-(4-chloro-2-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6-
,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide
[1209] Example 160 was prepared according to the procedure used for
the preparation of Example 147, substituting
2-(4-chloro-2-fluorophenyl)acetic acid for 4-methylpentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.86 (d, J=2.6 Hz, 1H),
7.52 (s, 1H), 7.47-7.30 (m, 4H), 7.28 (dd, J=8.1, 2.1 Hz, 1H),
7.10-6.97 (m, 2H), 6.94 (d, J=7.0 Hz, 1H), 6.86 (d, J=8.8 Hz, 1H),
6.61 (d, J=7.0 Hz, 1H), 4.07 (s, 3H), 3.86 (m, 2H). MS (ESI+) m/z
538.0 (M+H).sup.+.
Example 161
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-2-(6-methylpyridin-3-yl)acetamide
[1210] Example 161 was prepared according to the procedure used for
the preparation of Example 147, substituting
2-(6-methylpyridin-3-yl)acetic acid for 4-methylpentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.38 (d, J=2.3 Hz, 1H),
7.86 (d, J=2.6 Hz, 1H), 7.65 (dd, J=7.9, 2.4 Hz, 1H), 7.51 (s, 1H),
7.46-7.31 (m, 2H), 7.25 (d, J=7.9 Hz, 1H), 7.09-6.97 (m, 2H), 6.94
(d, J=7.0 Hz, 1H), 6.85 (d, J=8.8 Hz, 1H), 6.61 (d, J=7.0 Hz, 1H),
4.07 (s, 3H), 3.66 (m, 2H), 2.45 (s, 3H). MS (ESI+) m/z 501.0
(M+H).sup.+.
Example 162
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-2-(3,4-dihydro-2H-chromen-6-yl)acetamide
[1211] Example 162 was prepared according to the procedure used for
the preparation of Example 147, substituting
2-(3,4-dihydro-2H-chromen-6-yl)acetic acid for 4-methylpentanoic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.87 (d, J=2.6
Hz, 1H), 7.51 (s, 1H), 7.43 (dd, J=8.8, 2.6 Hz, 1H), 7.40-7.31 (m,
1H), 7.08-6.96 (m, 4H), 6.94 (d, J=7.0 Hz, 1H), 6.85 (d, J=8.8 Hz,
1H), 6.71-6.59 (m, 2H), 4.10 (t, J=4.9 Hz, 2H), 4.07 (s, 3H), 3.50
(s, 2H), 2.71 (m, 2H), 1.96-1.83 (m, 2H). MS (ESI+) m/z 542.1
(M+H).sup.+.
Example 163
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-2-(2-methyl-1,3-thiazol-5-yl)acetamide
[1212] Example 163 was prepared according to the procedure used for
the preparation of Example 147, substituting
2-(2-methyl-1,3-thiazol-5-yl)acetic acid for 4-methylpentanoic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.84 (d, J=2.7
Hz, 1H), 7.52 (s, 1H), 7.47 (s, 1H), 7.42 (dd, J=8.8, 2.6 Hz, 1H),
7.37 (ddd, J=11.1, 8.8, 2.8 Hz, 1H), 7.04 (ddd, J=8.0, 7.0, 4.2 Hz,
2H), 6.95 (d, J=7.0 Hz, 1H), 6.86 (d, J=8.8 Hz, 1H), 6.61 (d, J=7.0
Hz, 1H), 4.08 (s, 3H), 3.88 (s, 2H), 2.61 (s, 3H). MS (ESI+) m/z
507.0 (M+H).sup.+.
Example 164
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-2-(1,5-dimethyl-1H-pyrazol-3-yl)acetamide
[1213] Example 164 was prepared according to the procedure used for
the preparation of Example 147, substituting
2-(1,5-dimethyl-1H-pyrazol-3-yl)acetic acid for 4-methylpentanoic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.87 (d, J=2.6
Hz, 1H), 7.52 (s, 1H), 7.43 (dd, J=8.8, 2.6 Hz, 1H), 7.41-7.31 (m,
1H), 7.30-6.72 (m, 4H), 6.63 (d, J=7.0 Hz, 1H), 5.98 (s, 1H), 4.07
(s, 3H), 3.65 (s, 3H), 3.51 (s, 2H), 2.21 (s, 3H). MS (ESI+) m/z
503.7 (M+H).sup.+.
Example 165
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-2-[4-(2-fluorophenyl)-1H-pyrazol-1-yl]acetamide
[1214] Example 165 was prepared according to the procedure used for
the preparation of Example 147, substituting
2-[4-(2-fluorophenyl)-1H-pyrazol-1-yl]acetic acid for
4-methylpentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
7.94-7.85 (m, 3H), 7.53 (s, 1H), 7.46-7.31 (m, 3H), 7.32-7.22 (m,
2H), 7.12-6.98 (m, 2H), 6.94 (d, J=7.0 Hz, 1H), 6.88 (d, J=8.8 Hz,
1H), 6.70 (dd, J=3.8, 2.3 Hz, 1H), 6.62 (d, J=7.0 Hz, 1H), 5.11 (s,
2H), 4.07 (s, 3H). MS (ESI+) m/z 570.0 (M+H).sup.+.
Example 166
methyl (2E)-3-[(4-fluorophenyl)
{2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-[(methyls-
ulfonyl)methyl]phenyl}amino]prop-2-enoate
[1215] Example 121C (34 mg, 0.080 mmol) and methyl
3,3-dimethoxypropanoate (0.113 mL, 0.800 mmol) were combined in
acetic acid (0.5 mL). The reaction mixture was heated at 90.degree.
C. for 6 hours, cooled, and concentrated. The residue was
partitioned with ethyl acetate and saturated aqueous sodium
bicarbonate. The organic layer was washed with saturated aqueous
sodium chloride, dried with anhydrous sodium sulfate, filtered, and
concentrated. The residue was purified by reverse phase HPLC (C8,
methanol/water (10 mM ammonium acetate), 10-100%) to provide the
title compound (14 mg, 34%). .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. ppm 10.90 (d, J=4.07 Hz, 1H) 7.91 (d, J=13.22 Hz, 1H) 7.63
(d, J=1.70 Hz, 1H) 7.42-7.56 (m, 2H) 6.97-7.08 (m, 3H) 6.77-6.90
(m, 3H) 6.32 (d, J=6.78 Hz, 1H) 4.63 (s, 2H) 4.58 (d, J=13.22 Hz,
1H) 3.97 (s, 3H) 3.54 (s, 3H) 2.99 (s, 3H). MS (ESI+) m/z 510
(M+H).sup.+.
Example 167
4-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3--
c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile
[1216] A solution of Example 146B (0.163 M in
N,N-dimethylacetamide, 253 .mu.L, 0.041 mmol, 1.0 equivalent),
acetic acid (4.3 M in methanol, 187 .mu.L, 0.82 mmol, 20
equivalents), NaBH.sub.3CN (0.32 M in methanol, 187 .mu.L, 0.061
mmol, 1.5 equivalents) and 4-cyanobenzaldehyde (0.4 M in
N,N-dimethylacetamide, 153 .mu.L, 0.061 mmol, 1.5 equivalents) were
mixed through a perfluoroalkoxy mixing tube (0.2 mm inner
diameter), and loaded into an injection loop. The reaction segment
was injected into the flow reactor (Hastelloy coil, 0.75 mm inner
diameter, 1.8 mL internal volume) set at 50.degree. C., and passed
through the reactor at 180 .mu.L min.sup.-1 (10 minute residence
time). Upon exiting the reactor, the solution was loaded directly
into an injection loop and purified by preparative HPLC on a
Phenomenex Luna C8(2) 5 .mu.m 100 .ANG. AXIA column (50
mm.times.21.2 mm), eluting with a gradient of acetonitrile (A) and
0.1% ammonium acetate in water (B) at a flow rate of 30 mL/min
(0-0.5 min 5% A, 0.5-6.5 min linear gradient 5-100% A, 6.5-8.5 min
100% A, 8.5-9.0 min linear gradient 100-5% A, 9.0-10 min 5% A) to
provide the title compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 7.81 (m, 1H), 7.59 (d, J=8.0 Hz, 2H), 7.36 (s, 1H), 7.27
(m, 1H), 6.90 (m, 1H), 6.81-6.71 (m, 3H), 6.60 (d, J=2.8 Hz, 1H),
6.55 (dd, J=8.7, 2.9 Hz, 1H), 6.19 (d, J=7.0 Hz, 1H), 4.40 (bds,
2H), 4.01 (s, 3H). MS (ESI+) m/z 483.0 (M+H).sup.+.
Example 168
3-[2-(2,4-difluorophenoxy)-5-{[3-(4-methoxyphenoxy)benzyl]amino}phenyl]-1--
methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1217] Example 168 was prepared according to the procedure used for
the preparation of Example 167, substituting
3-(4-methoxyphenoxy)benzaldehyde for 4-cyanobenzaldehyde. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 7.38-7.23 (m, 3H), 7.11 (d,
J=7.7 Hz, 1H), 6.98-6.87 (m, 6H), 6.83-6.70 (m, 4H), 6.61 (d, J=2.8
Hz, 1H), 6.54 (dd, J=8.7, 2.8 Hz, 1H), 6.20 (d, J=7.0 Hz, 1H), 4.27
(bs, 2H), 4.01 (s, 3H), 3.74 (s, 3H). MS (ESI+) m/z 580.0
(M+H).sup.+.
Example 169
3-[2-(2,4-difluorophenoxy)-5-{[(3-methylpyridin-2-yl)methyl]amino}phenyl]--
1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1218] Example 169 was prepared according to the procedure used for
the preparation of Example 167, substituting
3-methylpyridin-2-carboxaldehyde for 4-cyanobenzaldehyde. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 8.37 (dd, J=4.9, 1.6 Hz, 1H),
7.65-7.58 (m, 1H), 7.40 (s, 1H), 7.31-7.21 (m, 2H), 6.91-6.84 (m,
3H), 6.85-6.64 (m, 3H), 6.50 (d, J=7.0 Hz, 1H), 4.36 (bs, 2H), 4.03
(s, 3H), 2.37 (s, 3H). MS (ESI+) m/z 473.1 (M+H).sup.+.
Example 170
3-[5-{[4-(benzyloxy)benzyl]amino}-2-(2,4-difluorophenoxy)phenyl]-1-methyl--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1219] Example 170 was prepared according to the procedure used for
the preparation of Example 167, substituting
4-(benzyloxy)benzaldehyde for 4-cyanobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 7.47-7.41 (m, 2H), 7.43-7.18 (m, 7H),
7.02-6.95 (m, 2H), 6.93-6.84 (m, 1H), 6.82-6.69 (m, 3H), 6.66 (d,
J=2.8 Hz, 1H), 6.56 (dd, J=8.7, 2.8 Hz, 1H), 6.28 (d, J=7.0 Hz,
1H), 5.08 (s, 2H), 4.21 (bds, 2H), 4.01 (s, 3H). MS (ESI+) m/z
564.0 (M+H).sup.+.
Example 171
3-[5-{[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino}-2-(2,4-di-
fluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1220] Example 171 was prepared according to the procedure used for
the preparation of Example 167, substituting
5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-carboxaldehyde for
4-cyanobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
7.62-7.34 (m, 6H), 7.27 (ddd, J=11.3, 8.6, 2.8 Hz, 1H), 7.02-6.85
(m, 1H), 6.87-6.72 (m, 4H), 6.64 (dd, J=8.7, 2.8 Hz, 1H), 6.52 (d,
J=7.0 Hz, 1H), 4.11 (bds, 2H), 4.03 (s, 3H), 2.29 (s, 3H). MS
(ESI+) m/z 572.0 (M+H).sup.+.
Example 172
3-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-H-pyrrolo[2,3-c-
]pyridin-3-yl)phenyl]amino}methyl)benzonitrile
[1221] Example 172 was prepared according to the procedure used for
the preparation of Example 167, substituting 3-cyanobenzaldehyde
for 4-cyanobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 7.81 (s, 1H), 7.77-7.70 (m, 2H), 7.58 (t, J=7.7 Hz, 1H),
7.36 (s, 1H), 7.27 (ddd, J=11.3, 8.6, 2.9 Hz, 1H), 6.94-6.85 (m,
1H), 6.83-6.72 (m, 3H), 6.63 (d, J=2.8 Hz, 1H), 6.57 (dd, J=8.7,
2.8 Hz, 1H), 6.18 (d, J=7.0 Hz, 1H), 4.37 (bds, 2H), 4.01 (s, 3H).
MS (ESI+) m/z 483.1 (M+H).sup.+.
Example 173
3-{2-(2,4-difluorophenoxy)-5-[(4-phenoxybenzyl)amino]phenyl}-1-methyl-1,6--
dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1222] Example 173 was prepared according to the procedure used for
the preparation of Example 167, substituting
4-(phenoxy)benzaldehyde for 4-cyanobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 7.44-7.35 (m, 5H), 7.27 (ddd, J=11.3,
8.6, 2.9 Hz, 1H), 7.14 (t, J=7.4 Hz, 1H), 7.03-6.95 (m, 4H),
6.94-6.71 (m, 4H), 6.67 (d, J=2.8 Hz, 1H), 6.58 (dd, J=8.7, 2.8 Hz,
1H), 6.28 (d, J=7.0 Hz, 1H), 4.28 (bds, 2H), 4.02 (s, 3H). MS
(ESI+) m/z 550.1 (M+H).sup.+.
Example 174
3-{2-(2,4-difluorophenoxy)-5-[(3,3-dimethylbutyl)amino]phenyl}-1-methyl-1,-
6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1223] Example 174 was prepared according to the procedure used for
the preparation of Example 167, substituting 3,3-dimethylbutanal
for 4-cyanobenzaldehyde. 10 .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 7.39 (s, 1H), 7.26 (ddd, J=11.4, 8.6, 2.9 Hz, 1H),
6.93-6.66 (m, 5H), 6.59-6.49 (m, 2H), 4.03 (s, 3H), 3.06-2.98 (m,
2H), 1.54-1.46 (m, 2H), 0.94 (s, 9H). MS (ESI+) m/z 452.1
(M+H).sup.+.
Example 175
3-{5-[(2,6-difluorobenzyl)amino]-2-(2,4-difluorophenoxy)phenyl}-1-methyl-1-
,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1224] Example 175 was prepared according to the procedure used for
the preparation of Example 167, substituting
2,6-difluorobenzaldehyde for 4-cyanobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 7.45-7.36 (m, 2H), 7.26 (ddd, J=11.3,
8.6, 2.9 Hz, 1H), 7.11 (t, J=7.8 Hz, 2H), 6.92-6.84 (m, 2H),
6.84-6.71 (m, 3H), 6.64 (dd, J=8.7, 2.8 Hz, 1H), 6.49 (d, J=7.0 Hz,
1H), 4.30 (bds, 2H), 4.03 (s, 3H). MS (ESI+) m/z 494.0
(M+H).sup.+.
Example 176
3-{2-(2,4-difluorophenoxy)-5-[(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylm-
ethyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1225] Example 176 was prepared according to the procedure used for
the preparation of Example 167, substituting
(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-carboxaldehyde for
4-cyanobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
7.39 (s, 1H), 7.27 (m, 1H), 7.12 (m, 1H), 6.89 (d, J=7.1 Hz, 1H),
6.84-6.72 (m, 4H), 6.64-6.48 (m, 2H), 4.16 (s, 2H), 4.03 (s, 3H),
3.97 (m, 2H), 2.96 (m, 2H), 2.80 (m, 2H). MS (ESI+) m/z 488.0
(M+H).sup.+.
Example 177
3-[5-{[2-(benzyloxy)-3-methoxybenzyl]amino}-2-(2,4-difluorophenoxy)phenyl]-
-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1226] Example 177 was prepared according to the procedure used for
the preparation of Example 167, substituting
2-(benzyloxy)-3-methoxybenzaldehyde for 4-cyanobenzaldehyde.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.44-7.20 (m, 7H),
7.10-7.03 (m, 1H), 7.04-6.97 (m, 1H), 6.96-6.85 (m, 2H), 6.74 (m,
3H), 6.57 (d, J=2.8 Hz, 1H), 6.45 (dd, J=8.7, 2.8 Hz, 1H), 6.22 (d,
J=7.0 Hz, 1H), 4.98 (s, 2H), 4.17 (bds, 2H), 4.00 (s, 3H), 3.86 (s,
3H). MS (ESI+) m/z 594.0 (M+H).sup.+.
Example 178
2-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3--
c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile
[1227] Example 178 was prepared according to the procedure used for
the preparation of Example 167, substituting 2-cyanobenzaldehyde
for 4-cyanobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 7.85 (dd, J=7.7, 1.3 Hz, 1H), 7.75-7.67 (m, 1H), 7.63 (d,
J=7.8 Hz, 1H), 7.53-7.45 (m, 1H), 7.38 (s, 1H), 7.27 (ddd, J=11.3,
8.6, 2.9 Hz, 1H), 6.95-6.86 (m, 1H), 6.84-6.74 (m, 3H), 6.64 (d,
J=2.8 Hz, 1H), 6.58 (dd, J=8.7, 2.8 Hz, 1H), 6.23 (d, J=7.0 Hz,
1H), 4.48 (bds, 2H), 4.02 (s, 3H). MS (ESI+) m/z 483.1
(M+H).sup.+.
Example 179
3-{2-(2,4-difluorophenoxy)-5-[(quinolin-4-ylmethyl)amino]phenyl}-1-methyl--
1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
[1228] Example 179 was prepared according to the procedure used for
the preparation of Example 167, substituting
quinolin-4-carboxaldehyde for 4-cyanobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.85 (d, J=4.4 Hz, 1H), 8.28 (d, J=8.4
Hz, 1H), 8.09 (d, J=8.4 Hz, 1H), 7.86-7.78 (m, 1H), 7.68 (t, J=7.9
Hz, 1H), 7.56 (d, J=4.5 Hz, 1H), 7.35 (s, 1H), 7.27 (ddd, J=11.3,
8.6, 2.9 Hz, 1H), 6.95-6.86 (m, 1H), 6.83-6.73 (m, 2H), 6.68-6.55
(m, 3H), 6.15 (d, J=7.0 Hz, 1H), 4.85 (bds, 2H), 3.98 (s, 3H). MS
(ESI+) m/z 509.1 (M+H).sup.+.
Example 180
N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)phenyl]-1-phenylmethanesulfonamide
[1229] Example 146B (0.056 g, 0.152 mmol), phenylmethanesulfonyl
chloride (0.060 g, 0.315 mmol) and triethylamine (0.090 mL, 0.646
mmol) in dichloromethane (1.980 mL) were combined and the solution
was stirred at ambient temperature for 18 hours. The mixture was
concentrated, then 1 M sodium hydroxide (0.66 mL, 0.660 mmol) and
tetrahydrofuran (1.320 mL) were added and the mixture was stirred
at ambient temperature for 90 minutes, and then heated to
60.degree. C. for 2 hours. The mixture was cooled and partitioned
between 40 mL each of ethyl acetate and saturated aqueous ammonium
chloride. The organic phase was dried over anhydrous sodium
sulfate, filtered, concentrated, and the residue purified by
reverse phase HPLC (C18, CH.sub.3CN/water (0.1% trifluoroacetic
acid), 10-100%) to provide the title compound. .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 10.96 (m, 1H), 9.79 (bds, 1H), 7.50 (s,
1H), 7.44-7.25 (m, 7H), 7.12-6.99 (m, 3H), 6.91 (dd, J=7.0, 5.7 Hz,
1H), 6.85 (d, J=8.7 Hz, 1H), 6.55 (dd, J=7.0, 1.2 Hz, 1H), 4.47 (s,
2H), 4.09 (s, 3H). MS (ESI) 522.1 (M+H).sup.+.
Example 181
1-(2-chloro-5-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6-
,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide
[1230] Example 181 was prepared according to the procedure used for
the preparation of Example 180, substituting
(2-chloro-5-fluorophenyl)methanesulfonyl chloride for
phenylmethanesulfonyl chloride. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 10.96 (bds, 1H), 10.09 (s, 1H), 7.54-7.20 (m, 6H),
7.11-6.97 (m, 3H), 6.99-6.81 (m, 2H), 6.54 (dd, J=7.0, 1.2 Hz, 1H),
4.67 (s, 2H), 4.08 (s, 3H). MS (ESI) 574.0 (M+H).sup.+.
Example 182
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-5-(morpholin-4-ylmethyl)-7-oxo-6,7--
dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide
Example 182A
5-bromo-3-(2-fluoro-5-nitrophenyl)-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyr-
idine
[1231] Example 182A was prepared according to the procedure used
for the preparation of Example 91E, substituting
(2-fluoro-5-nitrophenyl)boronic acid for Example 91D.
Example 182B
5-bromo-3-(2-(2,4-difluorophenoxy)-5-nitrophenyl)-7-methoxy-1-methyl-1H-py-
rrolo[2,3-c]pyridine
[1232] A mixture of Example 182A (367 mg, 0.965 mmol),
2,4-difluorophenol (111 .mu.l, 1.158 mmol) and cesium carbonate
(472 mg, 1.448 mmol) in 8 mL DMSO was heated under nitrogen at
90.degree. C. for 1.5 hours. The mixture was partitioned between
water and ethyl acetate (80 mL). The aqueous phase was extracted
with ethyl acetate (2.times.60 mL). The combined organics were
washed with water (2.times.), saturated aqueous sodium chloride,
and dried over anhydrous magnesium sulfate, filtered. The filtrate
was concentrated and the residue was purified by column
chromatography on silica gel with a gradient of 10-70% ethyl
acetate in heptanes to give the title compound (331 mg, 0.742 mmol,
77% yield) as a yellow solid.
Example 182C
4-((3-(2-(2,4-difluorophenoxy)-5-nitrophenyl)-7-methoxy-1-methyl-1H-pyrrol-
o[2,3-c]pyridin-5-yl)methyl)morpholine
[1233] A mixture of Example 182B (110 mg, 0.224 mmol), potassium
trifluoro(morpholinomethyl)borate (55.7 mg, 0.269 mmol), palladium
(II) acetate (3.02 mg, 0.013 mmol),
dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine
(12.83 mg, 0.027 mmol), and Cs.sub.2CO.sub.3 (219 mg, 0.673 mmol)
in 4 mL dioxane-water (9:1) was heated under nitrogen in Biotage
Initiator microwave oven at 150.degree. C. for 45 minutes. Water
was added, extracted with ethyl acetate (2.times.), washed with
water (2.times.), saturated aqueous sodium chloride, and dried over
anhydrous magnesium sulfate, filtered. The filtrate was
concentrated, and the residue was purified by column chromatography
on silica gel with a gradient of 0-8% methanol in dichloromethane
to give the title compound (60 mg, 0.118 mmol, 52.4% yield).
Example 182D
4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-5-(morpholinomethyl)-1H-pyrr-
olo[2,3-c]pyridin-3-yl)aniline
[1234] A mixture of Example 182C (58 mg, 0.114 mmol), ammonium
chloride (6.08 mg, 0.114 mmol), iron (50.8 mg, 0.909 mmol), in 4 mL
tetrahydrofuran and 4 mL ethanol and 2 mL water was heated at
reflux for 3 hours. The mixture was diluted with ethyl acetate,
washed with water and saturated aqueous sodium chloride, dried over
anhydrous magnesium sulfate, and filtered. The filtrated was
concentrated to give the title compound (54 mg, 0.112 mmol, 99%
yield).
Example 182E
N-(4-(2,4-difluorophenoxy)-3-(7-methoxy-1-methyl-5-(morpholinomethyl)-1H-p-
yrrolo[2,3-c]pyridin-3-yl)phenyl)ethanesulfonamide
[1235] To a solution of Example 182D (54 mg, 0.112 mmol) in 5 mL
dichloromethane was added diisopropylethylamine (58.9 .mu.L, 0.337
mmol) and ethanesulfonyl chloride (26.6 .mu.L, 0.281 mmol). The
mixture was stirred at ambient temperature for 16 hours. Another
1.5 equivalents ethanesufonyl chloride (16 .mu.L) and 2.0
equivalents diisopropylethylamine (39 .mu.L) were added. The
mixture was continued to stir overnight. The mixture was
concentrated. The residue was taken into dioxane (6 mL) and treated
with sodium hydroxide (2810 .mu.L, 2.81 mmol, 1N aqueous solution).
The mixture was heated at 60.degree. C. for 1 hour to hydrolyze the
bis-sulfonamide to the manosulfonamide. To the reaction mixture,
saturated ammonium chloride solution was added, extracted with
ethyl acetate (3.times.), washed with saturated aqueous sodium
chloride, dried over anhydrous magnesium sulfate, and filtered. The
filtrate was concentrated and the residue was purified by column
chromatography on silica gel with a gradient of 0-8% methanol in
dichloromethane to give the title compound (10 mg, 0.017 mmol, 16%
yield).
Example 182F
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-5-(morpholin-4-ylmethyl)-7-oxo-6,7--
dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide
[1236] Example 182E (8 mg, 0.014 mmol) was treated with 2 mL 4M
hydrochloric acid dioxane solution and the resulting suspension was
heated at 70.degree. C. for 3 hours. Another 2 mL 4N hydrochloric
acid dioxane solution was added and continued to stir for another 3
hours. The suspension was concentrated and the residue was
triturated in a small amount of diethyl ether to give the title
compound as hydrochloric acid salt (6 mg, 10.08 .mu.mol, 72.2%
yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.04 (s, 1H),
9.81 (d, J=10.8 Hz, 1H), 7.58 (s, 1H), 7.44 (dd, J=17.9, 5.4 Hz,
2H), 7.14 (t, J=8.7 Hz, 2H), 7.05 (t, J=8.0 Hz, 1H), 6.86 (d, J=8.7
Hz, 1H), 6.80 (s, 1H), 4.21 (s, 2H), 4.08 (s, 3H), 3.91 (s, 2H),
3.82-3.65 (m, 3H), 3.34 (s, 1H), 3.11 (dd, J=14.4, 7.1 Hz, 3H),
1.23 (t, J=7.2 Hz, 3H). MS (ESI+) m/z 559.0 (M+H).sup.+.
Example 183
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-7-oxo-5-(piperidin-4-yl)-6,7-dihydr-
o-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide
Example 183A
tert-butyl
4-(3-(2-(2,4-difluorophenoxy)-5-nitrophenyl)-7-methoxy-1-methyl-
-1H-pyrrolo[2,3-c]pyridin-5-yl)-5,6-dihydropyridine-1
(2H)-carboxylate
[1237] A mixture of Example 182B (238 mg, 0.485 mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (150 mg, 0.485 mmol),
phenylallylchloro[1,3-bis(diisopropylphenyl)-2-imidazol-2-ylidene]palladi-
um(II) (31.4 mg, 0.048 mmol) and potassium phosphate (309 mg, 1.454
mmol) in 9 mL tetrahydrofuran and 3 mL water was heated at
60.degree. C. for 3 hours. Water was added, extracted with ethyl
acetate (3.times.), washed with saturated aqueous sodium chloride,
dried over anhydrous magnesium sulfate, and filtered. The filtrate
was concentrated and the residue was purified by column
chromatography on silica gel with a gradient of 0-50% ethyl acetate
in heptanes to give the title compound (212 mg, 0.358 mmol, 73.8%
yield) as a yellow solid.
Example 183B
tert-butyl
4-(3-(5-amino-2-(2,4-difluorophenoxy)phenyl)-7-methoxy-1-methyl-
-1H-pyrrolo[2,3-c]pyridin-5-yl)piperidine-1-carboxylate
[1238] A mixture of Example 183A (200 mg, 0.338 mmol),
tetrafluoroethanol (20 mL), and 5% Pd/C (45 mg, 0.188 mmol) in a 50
mL pressure bottle was stirred at ambient temperature for 16 hours
under 30 psi of hydrogen and at ambient temperature. The mixture
was filtered through a nylon membrane. The filtrate was
concentrated to give the title compound (205 mg, 0.363 mmol, 101%
yield), which was used without further purification.
Example 183C
tert-butyl
4-(3-(2-(2,4-difluorophenoxy)-5-(ethylsulfonamido)phenyl)-7-met-
hoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)piperidine-1-carboxylate
[1239] To a solution of Example 183B (205 mg, 0.363 mmol) in 10 mL
dichloromethane was added N-ethyl-N-isopropylpropan-2-amine (254
.mu.L, 1.452 mmol) and ethanesulfonyl chloride (120 .mu.L, 1.271
mmol). The mixture was stirred at ambient temperature overnight.
The mixture was concentrated. The viscous oil residue was taken
into dioxane (10 mL) and treated with sodium hydroxide (5446 .mu.L,
5.45 mmol, 1N aqueous solution). The mixture was stirred at ambient
temperature for 80 minutes and then quenched with saturated
ammonium hydroxide solution, and partitioned between water and
ethyl acetate. The aqueous phase was extracted with ethyl acetate
(2.times.). The combined organic phases were washed with saturated
aqueous sodium chloride, dried over anhydrous magnesium sulfate,
and filtered. The filtrate was concentrated and the residue was
purified by column chromatography on silica gel with a gradient of
0-60% ethyl acetate in heptanes to give the title compound (110 mg,
0.167 mmol, 46.1% yield).
Example 183D
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-7-oxo-5-(piperidin-4-yl)-6,7-dihydr-
o-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide
[1240] Example 183C (95 mg, 0.145 mmol) was treated with
hydrochloric acid (2 mL, 4M dioxane solution) and the resulting
suspension was heated at 70.degree. C. for 3 hours. Another 2 mL of
4N hydrochloric acid solution was added and continued to stir for
another 3 hours. The reaction mixture was concentrated and the
residue was triturated with diethyl ether to give the title
compound as hydrochloric acid salt (65 mg, 0.097 mmol). .sup.1H NMR
(500 MHz, DMSO-d.sub.6) .delta. 10.97 (d, J=8.7 Hz, 1H), 9.83 (s,
1H), 8.97 (d, J=10.3 Hz, 1H), 8.70 (d, J=11.6 Hz, 1H), 7.51 (s,
1H), 7.44 (d, J=2.7 Hz, 1H), 7.41 (dd, J=11.2, 2.7 Hz, 1H),
7.13-7.02 (m, 3H), 6.86 (d, J=8.7 Hz, 1H), 6.29 (d, J=8.9 Hz, 1H),
4.06 (s, 3H), 3.34 (s, 2H), 3.12 (q, J=7.3 Hz, 2H), 2.91 (q, J=12.1
Hz, 2H), 2.70 (t, J=11.9 Hz, 1H), 2.06 (d, J=13.2 Hz, 2H), 1.71
(dd, J=22.5, 12.6 Hz, 2H), 1.24 (t, J=7.3 Hz, 3H). MS (ESI+) m/z
543.2 (M+H).sup.+.
Example 184
N-[6-(2,4-difluorophenoxy)-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)pyridin-3-yl]ethanesulfonamide
Example 184A
3-bromo-2-(2,4-difluorophenoxy)-5-nitropyridine
[1241] A mixture of 3-bromo-2-chloro-5-nitropyridine (0.237 g, 1
mmol), 2,4-difluorophenol (0.13 g, 1 mmol) and cesium carbonate
(0.326 g, 1 mmol) in dimethyl sulfoxide (2 mL) was reacted in a
Biotage microwave reactor at 80.degree. C. for 30 minutes. The
reaction mixture was partitioned between ethyl acetate and water,
washed with saturated aqueous sodium chloride, dried over anhydrous
magnesium sulfate, filtered and concentrated. The residue was
purified by flash chromatography (silica gel, 0-20% ethyl acetate
in heptanes) to provide 0.312 g (94%) of the title compound.
Example 184B
3-(2-(2,4-difluorophenoxy)-5-nitropyridin-3-yl)-7-methoxy-1-methyl-1H-pyrr-
olo[2,3-c]pyridine
[1242] Example 59A (0.086 g, 0.3 mmol), Example 184A (0.119 g, 0.36
mmol), tris(dibenzylideneacetone)palladium(0) (0.0082 g, 0.009
mmol),
1,3,5,7-tetramethyl-8-phenyl-2,4,6-trioxa-8-phosphaadamantane
(0.0088 g, 0.030 mmol) and sodium carbonate (0.137 g, 1.29 mmol)
were combined and sparged with nitrogen for 30 minutes. To this
were added nitrogen-sparged 1,4-dioxane (1.5 mL) and water (0.375
mL) via syringe. The reaction mixture was stirred at 60.degree. C.
for 4 hours, cooled to ambient temperature and slurried in water.
The solid was collected by filtration and then triturated in
methanol. The resulting solid was dissolved in ethyl acetate,
treated with 3-mercaptopropyl-functionalized silica gel for 20
minutes, dried over anhydrous magnesium sulfate, filtered through a
plug of Celite, concentrated and dried in a vacuum oven at
60.degree. C. to give 0.097 g (78%) of the title compound.
Example 184C
6-(2,4-difluorophenoxy)-5-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-y-
l)pyridin-3-amine
[1243] Example 184B (0.095 g, 0.23 mmol) in a mixture of
tetrahydrofuran (1 mL), ethanol (0.5 mL) and water (0.25 mL) was
treated with zinc dust (0.226 g, 3.46 mmol) and ammonium chloride
(0.123 g, 2.304 mmol) and stirred for 30 minutes. The solids were
removed by filtration through a plug of Celite. The filtrate was
concentrated and the solid was slurried in water, collected by
filtration, and dried in a vacuum oven to give 0.07 g (79%) of the
title compound.
Example 184D
3-(5-amino-2-(2,4-difluorophenoxy)pyridin-3-yl)-1-methyl-1H-pyrrolo[2,3-c]-
pyridin-7(6H)-one
[1244] Example 184C (0.0673 g, 0.176 mmol) in 1,4-dioxane (1.7 mL)
was treated with hydrogen chloride solution (4 M in 1,4-dioxane)
(0.44 mL, 1.76 mmol), heated at 80.degree. C. for 9 hours, cooled
to ambient temperature and concentrated to dryness to give 0.078 g
(100%) of the title compound as the di-HCl salt.
Example 184E
N-(6-(2,4-difluorophenoxy)-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]-
pyridin-3-yl)pyridin-3-yl)ethanesulfonamide
[1245] Example 184D (0.078 g, 0.176 mmol) in tetrahydrofuran (3 mL)
was treated sequentially with N-ethyl-N-isopropylpropan-2-amine
(0.154 mL, 0.88 mmol) and ethanesulfonyl chloride (0.05 mL, 0.528
mmol) and stirred at ambient temperature overnight. The reaction
mixture was concentrated, dissolved in dichloromethane (1 mL),
treated with N-ethyl-N-isopropylpropan-2-amine (0.154 mL, 0.88
mmol) and ethanesulfonyl chloride (0.1 mL, 1.056 mmol) and stirred
at ambient temperature for 4 hours. The reaction mixture was then
concentrated and the residue was taken up in 1,4-dioxane (1 mL),
treated with sodium hydroxide solution (4 M aqueous) (0.5 mL, 2
mmol) and heated at 70.degree. C. for 2 hours. Additional sodium
hydroxide solution (4 M aqueous) (1 mL, 4 mmol) was added and
heating was continued for 2 hours at 80.degree. C. The reaction
mixture was cooled to ambient temperature, neutralized with
hydrochloric acid solution (2 M aqueous), partitioned between ethyl
acetate and water, washed with saturated aqueous sodium chloride,
dried over anhydrous magnesium sulfate, filtered, and concentrated.
The residue was purified by flash chromatography (silica gel, 0-8%
methanol in dichloromethane) to provide the title compound as an
impure mixture. The material was further purified by reverse phase
HPLC (C18, acetonitrile/water (0.1% trifluoroacetic acid), 10-90%)
to give 0.0272 g (31%) of the title compound as the trifluoroacetic
acid salt. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.04 (d,
J=5.49 Hz, 1H), 9.85 (s, 1H), 7.85 (d, J=2.75 Hz, 1H), 7.81 (d,
J=2.75 Hz, 1H), 7.76 (s, 1H), 7.43 (m, 2H), 7.13 (m, 1H), 6.97 (m,
1H), 6.60 (d, J=7.02 Hz, 1H), 4.13 (s, 3H), 3.13 (q, J=7.32 Hz,
2H), 1.23 (t, J=7.32 Hz, 3H). MS (ESI+) m/z 461.1 (M+H).sup.+.
Example 185
N-[3-{5-[1-(cyclopropylcarbonyl)piperidin-4-yl]-1-methyl-7-oxo-6,7-dihydro-
-1H-pyrrolo[2,3-c]pyridin-3-yl}-4-(2,4-difluorophenoxy)phenyl]ethanesulfon-
amide
[1246] Example 183D (hydrochloric acid salt) (32 mg, 0.055 mmol)
was suspended in 1 mL dimethylformamide, treated with
cyclopropanecarboxylic acid (5.23 mg, 0.061 mmol),
1H-benzo[d][1,2,3]triazol-1-ol hydrate (10.16 mg, 0.066 mmol),
N.sup.1-((ethylimino)methylene)-N.sup.3,N.sup.3-dimethylpropane-1,3-diami-
ne hydrochloride (12.71 mg, 0.066 mmol) and triethylamine (23.11
.mu.L, 0.166 mmol). The mixture was stirred at ambient temperature
for 2 hours. The mixture was concentrated. To the oil residue was
added water. The precipitate was collected via filtration, and the
solid collected was dried in vacuum, and then triturated in small
amount of diethyl ether to give the title compound (22 mg, 0.036
mmol, 65.2% yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.93 (bs, 1H), 9.79 (s, 1H), 7.52-7.18 (m, 2H), 7.14-6.95 (m, 3H),
6.86 (d, J=8.7 Hz, 1H), 6.32 (s, 1H), 4.55-4.21 (m, 2H), 4.05 (s,
3H), 3.10 (q, J=7.3 Hz, 2H), 2.40-1.62 (m, 3H), 1.64-1.34 (m, 2H),
1.23 (t, J=7.3 Hz, 3H), 0.84-0.63 (m, 4H). MS (ESI+) m/z=611.1
(M+H).sup.+.
Example 186
N-[4-(2,4-difluorophenoxy)-3-{5-[1-(ethylsulfonyl)piperidin-4-yl]-1-methyl-
-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethanesulfonamide
[1247] A suspension of Example 183D (hydrochloric acid salt) (24
mg, 0.041 mmol) in 1 mL dimethylformamide was treated with
triethylamine (17.33 .mu.L, 0.124 mmol) and ethanesulfonyl chloride
(4.40 .mu.L, 0.050 mmol) at 0.degree. C. The mixture was stirred at
0.degree. C. for 4 hours and then concentrated. To the oil residue
was added water. The resulting solid was collected via filtration,
dried in vacuum, and then triturated in small amount of diethyl
ether to give the title compound (14 mg, 0.022 mmol, 53.2% yield).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.94 (bs, 1H), 9.80
(s, 1H), 7.50 (s, 1H), 7.47-7.36 (m, 2H), 7.14-6.98 (m, 3H), 6.86
(d, J=8.7 Hz, 1H), 6.34 (s, 1H), 4.05 (s, 2H), 3.74-3.66 (m, 2H),
3.17-3.00 (m, 4H), 2.88-2.77 (m, 2H), 1.98-1.86 (m, 2H), 1.67-1.48
(m, 2H), 1.29-1.14 (m, 6H). MS (ESI+) m/z=635.1 (M+H).sup.+.
Example 187
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-[3-(1H-imidaz-
ol-1-yl)propyl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-car-
boxamide
Example 187A
5-bromo-7-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1248] Sodium hydride (60% dispersion in oil, 1.45 g, 36.3 mmol)
was added portionwise to a 0.degree. C. solution of
5-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine (CAS 1198096-48-8) (4.2
g, 18.14 mmol) and tetrahydrofuran (42 mL). After 15 minutes at
0.degree. C. iodomethane (1.7 mL, 27.2 mmol) was added. The
reaction mixture was stirred at 0.degree. C. for 30 minutes and at
ambient temperature for 2 hours. The reaction mixture was cooled to
0.degree. C. and 30 mL saturated aqueous ammonium chloride solution
was added, followed by addition of saturated aqueous sodium
chloride. The mixture was extracted with ethyl acetate. The organic
extract was washed with saturated aqueous sodium chloride, dried
(anhydrous sodium sulfate), filtered, and concentrated to afford 5
g yellow solid. The crude product was purified by flash
chromatography (silica gel, 2-20% ethyl acetate in heptanes) to
provide 3.7 g (84%) of the title compound.
Example 187B
5-bromo-3-iodo-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridine
[1249] A solution of Example 187A (3.24 g, 13.44 mmol) and
dimethylformamide (37 mL) was cooled to 0.degree. C. After the
addition of 1-iodopyrrolidine-2,5-dione (3.6 g, 16.00 mmol), the
reaction mixture was stirred at ambient temperature for 3 hours.
The solution was cooled to 0.degree. C. and 60 mL water was added
followed by aqueous sodium bisulfate (60 mL, 10%) solution. The
mixture was stirred for 1 hour at ambient temperature. Solid was
collected by filtration, rinsed with water and was dried under
vacuum to provide 4.9 g (99%) of the title compound.
Example 187C
5-bromo-3-(2-chloro-5-nitrophenyl)-7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyr-
idine
[1250] A nitrogen degassed solution of Example 187B (1.0 g, 2.72
mmol), (2-chloro-5-nitrophenyl)boronic acid (0.549 g, 2.72 mmol),
1,3,5,7-tetramethyl-8-phenyl-2,4,6-trioxa-8-phosphaadamantane (40
mg, 0.137 mmol), tris(dibenzylideneacetone)dipalladium(0) (64 mg,
0.070 mmol), dioxane (10 mL) and water (3.2 mL) was stirred at
60.degree. C. for 2.5 hours. The reaction mixture was cooled to
ambient temperature, and was extracted with 150 mL of a solution of
chloroform containing 25% isopropyl alcohol. The organic extract
was washed with water, saturated aqueous sodium chloride, then 2
more times with water. The organic layer (containing suspended
solid) was concentrated to afford a yellow solid which was
dissolved in 200 mL of warm chloroform containing 30% isopropyl
alcohol, and was treated with 2 g mercaptopropyl functionalized
silica gel. The mixture was filtered through Celite while warm. The
filtrate was concentrated to provide 0.98 g (91%) of the title
compound.
Example 187D
methyl
3-(5-amino-2-(2,4-difluorophenoxy)phenyl)-7-methoxy-1-methyl-1H-pyr-
rolo[2,3-c]pyridine-5-carboxylate
[1251] A solution of Example 187C (750 mg, 1.530 mmol) in methanol
(10 mL) was added to
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (56.0
mg, 0.076 mmol) and triethylamine (0.426 mL, 3.06 mmol) in a 50 mL
pressure bottle. The mixture was pressurized with carbon monoxide
(60 psi), and was stirred for 16 hours at 100.degree. C. After
cooling to ambient temperature, the suspension (catalyst not
filtered) was concentrated to afford 1.25 g of a black semi-solid
which was dissolved in dichloromethane and was filtered through
Celite. Solvent was concentrated and the residue was purified by
flash chromatography (silica gel, 7-75% ethyl acetate in heptanes)
to provide 340 mg (51%) of the title compound.
Example 187E
3-(2-(2,4-difluorophenoxy)-5-(ethylsulfonamido)phenyl)-7-methoxy-1-methyl--
1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid
[1252] Ethanesulfonyl chloride (0.22 mL, 2.322 mmol) was added
dropwise to a 0.degree. C. solution of Example 187D (340 mg, 0.774
mmol), triethylamine (0.45 mL, 3.23 mmol) and dichloromethane (8
mL). The reaction mixture was stirred at ambient temperature for
overnight. Sodium hydroxide solution (2.7 mL 10%) was added to the
reaction mixture. The solution was stirred at 85.degree. C. for 1.5
hours. The reaction mixture was cooled to ambient temperature and
saturated aqueous ammonium chloride was added, followed by the
addition of 1N HCl. The pH of the mixture was about 3. The solution
was extracted with ethyl acetate. The extract was washed with
water, saturated aqueous sodium chloride, dried (anhydrous
magnesium sulfate), filtered, and concentrated to afford 440 mg
brown oil. The reaction mixture was then stirred at 95.degree. C.
for 2 hours with 9 mL dioxane and aqueous sodium hydroxide (2.8 mL,
10%). The reaction mixture was cooled to ambient temperature, and
water was added. The solution was acidified with 1N HCl to pH3 and
was extracted with ethyl acetate. The extract was washed with
water, saturated aqueous sodium chloride, dried (anhydrous
magnesium sulfate), filtered, and concentrated to provide 380 mg
(95%) of the title compound.
Example 187F
3-(2-(2,4-difluorophenoxy)-5-(ethylsulfonamido)phenyl)-1-methyl-7-oxo-6,7--
dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid
[1253] A solution of Example 187E (335 mg, 0.647 mmol), 4M hydrogen
chloride in dioxane (2.0 mL, 8.00 mmol) and dioxane (10 mL) was
stirred at 75.degree. C. for 4 hours. The reaction mixture was
cooled to ambient temperature and was concentrated to dryness. The
residue was dried (in-vacuo) to provide 315 mg (97%) of the title
compound.
Example 187G
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-[3-(1H-imidaz-
ol-1-yl)propyl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-car-
boxamide
[1254] Example 187F (15 mg, 0.03 mmole) was dissolved in
dimethylformamide (1.0 mL) and carbonyldiimidazole (6 mg, 0.04
mmol) was added. The reaction mixture was placed on a shaker at
ambient temperature for 4 hours. To this mixture was then added a
solution of 3-(1H-imidazol-1-yl)propan-1-amine (5.0 mg, 0.04 mmol)
and diisopropylethylamine (0.075 mL, 10% in dimethylformamide). The
reaction mixture was placed on a shaker at ambient temperature
overnight. The reaction mixture was filtered and was purified by
reverse phase HPLC (Phenomenex Luna C8(2) 5 .mu.m 100 .ANG. AXIA
column (30 mm.times.75 mm). A gradient of acetonitrile (A) and 0.1%
trifluoroacetic acid in water (B) was used, at a flow rate of 50
mL/min (0-0.5 min 10% A, 0.5-6.0 min linear gradient 10-100% A,
6.0-7.0 min 100% A, 7.0-8.0 min linear gradient 100-10% A). Samples
were injected in 1.5 mL DMSO:methanol (1:1). An Agilent 1100 Series
Purification system was used, consisting of the following modules:
Agilent 1100 Series LC/MSD SL mass spectrometer with
API-electrospray source; two Agilent 1100 Series preparative pumps;
Agilent 1100 Series isocratic pump; Agilent 1100 Series diode array
detector with preparative (0.3 mm) flow cell; Agilent
active-splitter, IFC-PAL fraction collector/autosampler. The
make-up pump for the mass spectrometer used 3:1 methanol:water with
0.1% formic acid at a flow rate of 1 mL/min. Fraction collection
was automatically triggered when the extracted ion chromatogram
(EIC) for the target mass exceeded the threshold specified in the
method. The system was controlled using Agilent Chemstation (Rev B.
10.03), Agilent A.sup.2Prep, and Leap FractPal software, with
custom Chemstation macros for data export, to provide the title
compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.05 (t,
J=1.5 Hz, 1H), 7.76 (t, J=1.7 Hz, 1H), 7.66 (t, J=1.6 Hz, 1H), 7.61
(s, 1H), 7.42-7.29 (m, 3H), 7.24-7.09 (m, 2H), 7.04 (tdd, J=9.4,
3.0, 1.4 Hz, 1H), 6.90 (d, J=8.7 Hz, 1H), 4.25 (t, J=6.9 Hz, 2H),
4.11 (s, 3H), 3.26 (t, J=6.6 Hz, 2H), 3.12 (q, J=7.3 Hz, 2H), 2.07
(p, J=6.8 Hz, 2H), 1.24 (t, J=7.3 Hz, 3H). MS (APCI) m/z 611.1
(M+H).sup.+.
Example 188
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-[2-(dimethyla-
mino)ethyl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxa-
mide
[1255] Example 188 was prepared according to the procedure used for
the preparation of Example 187G, substituting
N.sup.1,N.sup.1-dimethylethane-1,2-diamine for
3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.62 (s, 1H), 7.41-7.33 (m, 2H), 7.31 (s,
1H), 7.18 (dd, J=8.9, 2.6 Hz, 1H), 7.16-7.10 (m, 1H), 7.09-7.01 (m,
1H), 6.90 (d, J=8.7 Hz, 1H), 4.11 (s, 3H), 3.60 (t, J=5.9 Hz, 2H),
3.25 (t, J=6.0 Hz, 2H), 3.12 (q, J=7.3 Hz, 2H), 2.85 (s, 6H), 1.24
(t, J=7.3 Hz, 3H). MS (APCI) m/z 574.0 (M+H).sup.+.
Example 189
N-(cyanomethyl)-3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-
-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide
[1256] Example 189 was prepared according to the procedure used for
the preparation of Example 187G, substituting 2-aminoacetonitrile
for 3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.61 (s, 1H), 7.40-7.35 (m, 2H), 7.35-7.29
(m, 1H), 7.20 (dd, J=8.8, 2.7 Hz, 1H), 7.13 (td, J=9.2, 5.5 Hz,
1H), 7.03 (tdd, J=9.0, 3.0, 1.4 Hz, 1H), 6.92 (d, J=8.8 Hz, 1H),
4.31 (s, 2H), 4.11 (s, 3H), 3.12 (q, J=7.4 Hz, 2H), 1.25 (t, J=7.3
Hz, 3H). MS (APCI) m/z 542.0 (M+H).sup.+.
Example 190
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-(3-hydroxypro-
pyl)-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide
[1257] Example 190 was prepared according to the procedure used for
the preparation of Example 187G, substituting 3-aminopropan-1-ol
for 3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.59 (s, 1H), 7.40-7.31 (m, 3H), 7.17 (td,
J=8.7, 3.1 Hz, 2H), 7.05 (tdd, J=9.3, 2.9, 1.5 Hz, 1H), 6.89 (d,
J=8.8 Hz, 1H), 4.11 (s, 3H), 3.46 (t, J=6.3 Hz, 2H), 3.30 (t, J=7.1
Hz, 2H), 3.13 (q, J=7.4 Hz, 2H), 1.68 (p, J=6.7 Hz, 2H), 1.25 (t,
J=7.3 Hz, 3H). MS (APCI) m/z 561.0 (M+H).sup.+.
Example 191
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-5-(morpholin-4-ylcarbonyl)-7-oxo-6,-
7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide
[1258] Example 191 was prepared according to the procedure used for
the preparation of Example 187G, substituting morpholine for
3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.61 (s, 1H), 7.43-7.32 (m, 2H), 7.18-6.98
(m, 3H), 6.65 (s, 1H), 4.09 (s, 3H), 3.66-3.54 (m, 4H), 3.49 (d,
J=5.5 Hz, 4H), 3.10 (q, J=7.3 Hz, 2H), 1.24 (t, J=7.3 Hz, 3H). MS
(APCI) m/z 573.0 (M+H).sup.+.
Example 192
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo--
N-(pyridin-3-ylmethyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide
[1259] Example 192 was prepared according to the procedure used for
the preparation of Example 187G, substituting
pyridin-3-ylmethanamine for 1,3-diamine for
3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.79 (d, J=2.0 Hz, 1H), 8.77-8.69 (m, 1H),
8.37 (dt, J=8.2, 1.7 Hz, 1H), 7.92 (dd, J=8.1, 5.5 Hz, 1H), 7.61
(s, 1H), 7.40 (s, 1H), 7.37 (d, J=2.8 Hz, 1H), 7.36-7.31 (m, 1H),
7.17 (dd, J=8.8, 2.7 Hz, 1H), 7.12 (td, J=9.2, 5.5 Hz, 1H), 7.02
(tdd, J=9.2, 3.0, 1.4 Hz, 1H), 6.90 (d, J=8.8 Hz, 1H), 4.62 (s,
2H), 4.11 (s, 3H), 3.10 (q, J=7.3 Hz, 2H), 1.22 (t, J=7.3 Hz, 3H).
MS (APCI) m/z 594.0 (M+H).sup.+.
Example 193
N-{4-(2,4-difluorophenoxy)-3-[1-methyl-7-oxo-5-(pyrrolidin-1-ylcarbonyl)-6-
,7-dihydro-H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide
[1260] Example 193 was prepared according to the procedure used for
the preparation of Example 187G, substituting pyrrolidine for
3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.62 (s, 1H), 7.44-7.30 (m, 2H), 7.14 (dd,
J=8.8, 2.6 Hz, 1H), 7.11 (dd, J=9.1, 5.5 Hz, 1H), 7.04 (tdd, J=9.2,
3.0, 1.2 Hz, 1H), 6.88 (d, J=8.8 Hz, 1H), 6.85 (s, 1H), 4.10 (s,
3H), 3.10 (q, J=7.4 Hz, 2H), 1.84 (s, 4H), 1.23 (t, J=7.3 Hz, 3H).
MS (APCI) m/z 557.0 (M+H).sup.+.
Example 194
N-[4-(2,4-difluorophenoxy)-3-{5-[(4-hydroxypiperidin-1-yl)carbonyl]-1-meth-
yl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethanesulfonamid-
e
[1261] Example 194 was prepared according to the procedure used for
the preparation of Example 187G, substituting piperidin-4-ol for
3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.60 (s, 1H), 7.43-7.32 (m, 2H), 7.16-7.11
(m, 1H), 7.09 (dd, J=9.0, 5.6 Hz, 1H), 7.07-6.99 (m, 1H), 6.87 (d,
J=8.8 Hz, 1H), 6.59 (s, 1H), 4.09 (s, 3H), 3.18 (s, 4H), 3.10 (q,
J=7.3 Hz, 2H), 1.72 (s, 2H), 1.37 (s, 2H), 1.23 (t, J=7.3 Hz, 4H).
MS (APCI) m/z 587.1 (M+H).sup.+.
Example 195
N-(cyclopentylmethyl)-3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]p-
henyl}-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide
[1262] Example 195 was prepared according to the procedure used for
the preparation of Example 187G, substituting
cyclopentylmethanamine for 1,3-diamine for
3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.59 (s, 1H), 7.43-7.30 (m, 3H), 7.24-7.13
(m, 2H), 7.03 (tdd, J=9.2, 3.0, 1.6 Hz, 1H), 6.88 (d, J=8.8 Hz,
1H), 4.11 (s, 3H), 3.21-3.15 (m, 2H), 3.12 (q, J=7.3 Hz, 2H), 2.11
(p, J=7.4 Hz, 1H), 1.67 (dq, J=12.9, 7.1 Hz, 2H), 1.57 (ddt,
J=10.6, 8.3, 4.1 Hz, 2H), 1.51 (dq, J=8.0, 5.4, 4.2 Hz, 2H), 1.23
(q, J=7.3 Hz, 5H). MS (APCI) m/z 585.0 (M+H).sup.+.
Example 196
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-N-[2-(-
morpholin-4-yl)ethyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carbox-
amide
[1263] Example 196 was prepared according to the procedure used for
the preparation of Example 187G, substituting
2-morpholinoethanamine for 3-(1H-imidazol-1-yl)propan-1-amine.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.62 (s, 1H), 7.42-7.35
(m, 2H), 7.33 (d, J=3.1 Hz, 1H), 7.18 (dd, J=8.8, 2.7 Hz, 1H),
7.15-7.09 (m, 1H), 7.09-7.00 (m, 1H), 6.91 (d, J=8.8 Hz, 1H), 4.11
(s, 3H), 3.98 (d, J=16.8 Hz, 2H), 3.68 (s, 2H), 3.63 (t, J=6.2 Hz,
2H), 3.52 (s, 2H), 3.30 (t, J=6.2 Hz, 2H), 3.18 (s, 2H), 3.13 (p,
J=7.3, 6.6 Hz, 5H), 1.24 (t, J=7.3 Hz, 3H). MS (APCI) m/z 616.2
(M+H).sup.+.
Example 197
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-N-[2-(-
4-methylpiperazin-1-yl)ethyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine--
5-carboxamide
[1264] Example 197 was prepared according to the procedure used for
the preparation of Example 187G, substituting
2-(4-methylpiperazin-1-yl)ethanamine for
3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.62 (s, 1H), 7.38 (d, J=2.5 Hz, 1H), 7.36
(t, J=2.7 Hz, 1H), 7.34 (s, 1H), 7.18 (dd, J=8.8, 2.7 Hz, 1H), 7.13
(td, J=9.2, 5.6 Hz, 1H), 6.91 (d, J=8.7 Hz, 1H), 4.11 (s, 3H), 3.96
(s, 1H), 3.55 (t, J=6.3 Hz, 4H), 3.29 (d, J=59.7 Hz, 6H), 3.12 (q,
J=7.3 Hz, 2H), 3.06 (t, J=6.3 Hz, 2H), 2.85 (s, 3H), 1.24 (t, J=7.3
Hz, 3H). MS (APCI) m/z 629.1 (M+H).sup.+.
Example 198
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo--
N-[2-(piperidin-1-yl)ethyl]-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carbox-
amide
[1265] Example 198 was prepared according to the procedure used for
the preparation of Example 187G, substituting
2-(piperidin-1-yl)ethanamine for
3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.62 (s, 1H), 7.38 (dd, J=4.4, 2.9 Hz, 1H),
7.37-7.33 (m, 1H), 7.32 (s, 1H), 7.21-7.08 (m, 2H), 7.05 (tdd,
J=8.9, 2.9, 1.3 Hz, 1H), 6.91 (d, J=8.7 Hz, 1H), 4.11 (s, 3H), 3.62
(t, J=6.3 Hz, 2H), 3.52 (d, J=12.2 Hz, 2H), 3.21 (t, J=6.3 Hz, 2H),
3.12 (q, J=7.3 Hz, 2H), 2.93 (td, J=12.2, 11.7, 3.0 Hz, 2H), 1.85
(d, J=14.4 Hz, 2H), 1.66 (dt, J=26.6, 13.8 Hz, 3H), 1.50-1.33 (m,
1H), 1.24 (t, J=7.3 Hz, 3H). MS (APCI) m/z 614.1 (M+H).sup.+.
Example 199
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo--
N-(tetrahydrofuran-3-ylmethyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-car-
boxamide
[1266] Example 199 was prepared according to the procedure used for
the preparation of Example 187G, substituting
(tetrahydrofuran-3-yl)methanamine for
3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.60 (s, 1H), 7.40-7.32 (m, 3H), 7.20-7.12
(m, 2H), 7.08-6.98 (m, 1H), 6.89 (d, J=8.8 Hz, 1H), 4.11 (s, 3H),
3.79-3.73 (m, 1H), 3.70-3.66 (m, 1H), 3.66-3.59 (m, 1H), 3.45 (dd,
J=8.6, 5.3 Hz, 1H), 3.24 (dd, J=7.4, 5.3 Hz, 2H), 3.12 (q, J=7.3
Hz, 2H), 2.46 (p, J=6.5 Hz, 1H), 1.95 (dtd, J=13.5, 8.0, 5.7 Hz,
1H), 1.58 (dq, J=13.1, 6.7 Hz, 1H), 1.24 (t, J=7.3 Hz, 3H). MS
(APCI) m/z 587.0 (M+H).sup.+.
Example 200
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N,1-dimethyl-7--
oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide
[1267] Example 200 was prepared according to the procedure used for
the preparation of Example 187G, substituting methanamine for
3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.59 (s, 1H), 7.39-7.34 (m, 2H), 7.32 (s,
1H), 7.19 (dd, J=8.8, 2.7 Hz, 1H), 7.13 (td, J=9.2, 5.6 Hz, 1H),
7.04 (tdd, J=9.2, 2.9, 1.3 Hz, 1H), 6.91 (d, J=8.8 Hz, 1H), 4.10
(s, 3H), 3.12 (q, J=7.3 Hz, 2H), 2.78 (s, 3H), 1.24 (t, J=7.3 Hz,
3H). MS (APCI) m/z 517.0 (M+H).sup.+.
Example 201
3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-(furan-3-ylme-
thyl)-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide
[1268] Example 201 was prepared according to the procedure used for
the preparation of Example 187G, substituting furan-3-ylmethanamine
for 3-(1H-imidazol-1-yl)propan-1-amine. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.60 (d, J=3.7 Hz, 3H), 7.38 (s, 1H),
7.38-7.30 (m, 2H), 7.17 (dd, J=8.9, 2.7 Hz, 1H), 7.15-7.09 (m, 1H),
7.01 (tdd, J=9.1, 2.8, 1.4 Hz, 1H), 6.88 (d, J=8.8 Hz, 1H),
6.50-6.44 (m, 1H), 4.29 (s, 2H), 4.10 (s, 3H), 3.10 (q, J=7.3 Hz,
2H), 1.22 (t, J=7.3 Hz, 3H). MS (APCI) m/z 583.0 (M+H).sup.+.
Example 202
3-{3-cyclopropyl-2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]p-
henyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 202A
1-bromo-4-((methylsulfonyl)methyl)benzene
[1269] A 250 mL round-bottomed flask was charged with 4-bromobenzyl
bromide (5 g, 20 mmol) and N,N-dimethylformamide (10.81 mL). Sodium
methanesulfinate (3.06 g, 30 mmol) was added. The reaction mixture
was stirred at 65.degree. C. for 1 hour. The reaction mixture was
cooled to ambient temperature and diluted with water. The resulting
suspension was stirred for 10 minutes and filtered. The solid was
rinsed with water and dried under vacuum to provide the title
compound (4.75 g, 95% yield).
Example 202B
2,4-difluoro-N-(4-((methylsulfonyl)methyl)phenyl)aniline
[1270] A 100-mL microwave tube was charged with 2,4-difluoroaniline
(1.235 mL, 12.26 mmol), Example 202A (3.05 g, 12.26 mmol),
diacetoxypalladium (0.055 g, 0.245 mmol),
dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine
(0.234 g, 0.49 mmol), cesium carbonate (5.59 g, 17.16 mmol),
toluene (40.9 mL) and tert-butanol (8.17 mL). The tube was sealed,
and the reaction mixture was heated in a Milestone Ethos microwave,
5 minute ramp to 150.degree. C., then 10 minutes fixed hold time.
The reaction mixture was filtered through a 10 g Celite SPE column
and rinsed with ethyl acetate. The filtrate was concentrated. The
residue was purified by flash chromatography (20-100% ethyl acetate
in heptanes) to provide 3.44 g (94%) of the title compound.
Example 202C
2-bromo-N-(2,4-difluorophenyl)-4-((methylsulfonyl)methyl)aniline
[1271] A 500 mL round-bottomed flask was charged with Example 202B
(3.44 g, 11.57 mmol) and acetic acid (116 mL). The reaction mixture
was placed into a water bath. N-bromosuccinimide (2.06 g, 11.57
mmol) was added in 2 portions 10 minutes apart. The reaction
mixture was stirred at ambient temperature for 1.5 hours. The
reaction mixture was quenched with aqueous sodium thiosulfate
solution (200 mL, 10%) and diluted with water. The reaction mixture
was extracted twice with ethyl acetate. The combined organic layers
were washed twice with sodium hydroxide solution (2 M aqueous)
(until the pH of the aqueous was >7) and once with saturated
aqueous sodium chloride solution, dried over anhydrous magnesium
sulfate, filtered, and concentrated. The residue was taken up into
ethyl acetate, then treated with heptanes. The resulting slurry was
stirred for 30 minutes and filtered to provide 3.82 g (88% yield)
of the title compound.
Example 202D
2-cyclopropyl-N-(2,4-difluorophenyl)-4-((methylsulfonyl)methyl)aniline
[1272] A 5-mL microwave vial was charged with Example 202C (0.2287
g, 0.608 mmol), cyclopropylboronic acid (0.209 g, 2.432 mmol),
cesium carbonate (0.99 g, 3.04 mmol) and dichloropalladium (II)
bistriphenylphosphine (0.021 g, 0.03 mmol). The tube was sealed,
and the mixture was sparged with nitrogen for 30 minutes. Degassed
1,4-dioxane (2.53 mL) and water (0.507 mL) were added. The reaction
mixture was heated at 100.degree. C. overnight. The reaction
mixture was partitioned between ethyl acetate and water. The
organic layer was washed with saturated aqueous sodium chloride
solution, dried over anhydrous magnesium sulfate, filtered, and
concentrated. The residue was purified by flash chromatography
(10-70% ethyl acetate in heptanes) to provide 0.143 g (70%) of the
title compound.
Example 202E
2-bromo-6-cyclopropyl-N-(2,4-difluorophenyl)-4-((methylsulfonyl)methyl)ani-
line
[1273] Example 202E (0.1114 g, 63%) was prepared according to the
procedure used for the preparation of Example 202C, substituting
Example 202D for Example 202B.
Example 202F
2-cyclopropyl-N-(2,4-difluorophenyl)-6-(7-methoxy-1-methyl-1H-pyrrolo[2,3--
c]pyridin-3-yl)-4-((methylsulfonyl)methyl)aniline
[1274] Example 59A (0.066 g, 0.228 mmol), Example 202E (0.1 g, 0.24
mmol), tris(dibenzylideneacetone)dipalladium(0) (0.00627 g, 0.00685
mmol),
1,3,5,7-tetramethyl-8-phenyl-2,4,6-trioxa-8-phosphaadamantane
(0.00667 g, 0.023 mmol) and sodium carbonate (0.104 g, 0.982 mmol)
were combined and sparged with nitrogen for 30 minutes. To this
were added nitrogen-sparged 1,4-dioxane (1.1 mL) and water (0.275
mL) via syringe. The reaction mixture was stirred at 60.degree. C.
for 5 hours. The reaction mixture was partitioned between ethyl
acetate and water. The organic layer was washed with saturated
aqueous sodium chloride, treated with
3-mercaptopropyl-functionalized silica gel for 20 minutes, dried
over anhydrous magnesium sulfate, filtered through a plug of
Celite, and concentrated. The residue was purified by flash
chromatography (silica gel, 0-10% ethyl acetate in dichloromethane)
to give 0.0941 g (83%) of the title compound.
Example 202G
3-(3-cyclopropyl-2-((2,4-difluorophenyl)amino)-5-((methylsulfonyl)methyl)p-
henyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one
[1275] Example 202F (0.094 g, 0.189 mmol) in methanol (2 mL) was
treated with hydrogen chloride solution (4 M in 1,4-dioxane, 0.945
mL, 3.78 mmol) and heated at 90.degree. C. for 3.67 hours. The
reaction mixture was cooled to room temperature and concentrated.
The residue was purified by flash chromatography (silica gel, 0-6%
methanol in dichloromethane) to give 0.100 g (>100%) of the
title compound. Approximately one-third of the material was further
purified by reverse phase HPLC (C18, acetonitrile/water (0.1%
trifluoroacetic acid), 10-70%) to provide 0.031 g (33.9%) of the
title compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.86
(d, J=5.49 Hz, 1H), 7.30 (d, J=1.83 Hz, 1H), 7.26 (s, 1H), 7.04 (m,
2H), 6.95 (d, J=1.53 Hz, 1H), 6.81 (m, 1H), 6.64 (m, 1H), 6.43 (d,
J=7.02 Hz, 1H), 6.15 (m, 1H), 4.47 (s, 2H), 3.98 (s, 3H), 2.92 (s,
3H), 1.99 (m, 1H), 0.84 (m, 2H), 0.60 (m, 2H). MS (ESI+) m/z 484.1
(M+H).sup.+.
Example 203
1-methyl-3-{5-[(methylsulfonyl)methyl]-2-(pyridin-2-ylamino)phenyl}-1,6-di-
hydro-7H-pyrrolo[2,3-c]pyridin-7-one
Example 203A
N-(2-(7-methoxy-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-((methylsulfonyl-
)methyl)phenyl)pyridin-2-amine
[1276] Example 121A (0.05 g, 0.145 mmol), 2-bromopyridine (0.028
mL, 0.29 mmol), diacetoxypalladium (0.0016 g, 0.00724 mmol),
dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine
(0.0069 g, 0.014 mmol), and cesium carbonate (0.094 g, 0.29 mmol)
were combined in a 5-mL microwave vial. Toluene (1.2 mL) and
tert-butanol (0.3 mL) were added. The vial was capped and the
mixture was reacted at 150.degree. C. for 30 minutes in a Biotage
microwave reactor. Additional 2-bromopyridine (0.028 mL, 0.29
mmol), diacetoxypalladium (0.0016 g, 0.00724 mmol) and
dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine
(0.0069 g, 0.014 mmol) were added and the mixture was reacted in a
Biotage microwave reactor for another 40 minutes at 150.degree. C.
The reaction mixture was partitioned between ethyl acetate and
water. The organic layer was washed with saturated aqueous sodium
chloride, treated with 3-mercaptopropyl-functionalized silica gel
for 20 minutes, dried over anhydrous magnesium sulfate, filtered
through a plug of Celite and concentrated. The residue was purified
by flash chromatography (silica gel, 0-90% ethyl acetate in
dichloromethane) to give 0.04 g (65.4%) of the title compound.
Example 203B
1-methyl-3-(5-((methylsulfonyl)methyl)-2-(pyridin-2-ylamino)phenyl)-1H-pyr-
rolo[2,3-c]pyridin-7(6H)-one
[1277] A mixture of Example 203A (0.062 g, 0.147 mmol) in methanol
(1 mL) was treated with hydrogen chloride solution (4 M in
1,4-dioxane, 1 mL, 4 mmol) and heated at 75.degree. C. for 2.5
hours. Additional hydrogen chloride solution (4 M in 1,4-dioxane, 1
mL, 4 mmol) was added and heating was continued for another 3.5
hours. The reaction mixture was then concentrated and the residue
was purified by preparative HPLC on a Phenomenex Luna C8(2) 5 .mu.m
100 .ANG. AXIA column (30 mm.times.75 mm). A gradient of 20-100%
acetonitrile (A) and 10 mM ammonium acetate in water (B) was used,
at a flow rate of 50 mL/minute (0-0.5 minutes 20% A, 0.5-7.0
minutes linear gradient 20-95% A, 7.0-10.0 minutes 100% A,
10.0-12.0 minutes linear gradient 100-20% A to give the title
compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.89 (d,
J=5.19 Hz, 1H), 8.08 (m, 1H), 7.98 (d, J=8.24 Hz, 1H), 7.89 (s,
1H), 7.47 (m, 1H), 7.42 (s, 1H), 7.34 (d, J=2.14 Hz, 1H), 7.27 (dd,
J=8.24, 2.14 Hz, 1H), 6.79 (dd, J=6.71, 5.80 Hz, 1H), 6.76 (d,
J=8.24 Hz, 1H), 6.70 (m, 1H), 6.25 (d, J=6.71 Hz, 1H), 4.45 (s,
2H), 4.09 (s, 3H), 2.93 (s, 3H). MS (ESI+) m/z 409.1
(M+H).sup.+.
Biological Examples
Bromodomain Domain Binding Assay
[1278] A time-resolved fluorescence resonance energy transfer
(TR-FRET) assay was used to determine the affinities of compounds
of the Examples listed in Table 1 for each bromodomain of BRD4.
His-tagged first (BD1: amino acids K57-E168) and second (BD2: amino
acids E352-E168) bromodomains of BRD4 were expressed and purified.
An Alexa647-labeled BET-inhibitor was used as the fluorescent probe
in the assay.
Synthesis of Alexa647-labeled bromodomain inhibitor compound
2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triaz-
olo[4,3-a][1,4]diazepin-6-yl)acetic acid
[1279] Methyl
2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triaz-
olo[4,3-a][1,4]diazepin-6-yl)acetate (see e.g., WO
2006129623)(100.95 mg, 0.243 mmol was suspended in 1 mL methanol to
which was added a freshly prepared solution of lithium hydroxide
monohydrate (0.973 mL, 0.5 M, 0.487 mmol) and shaken at ambient
temperature for 3 hours. The methanol was evaporated and the pH
adjusted with aqueous hydrochloric acid (1 M, 0.5 mL, 0.5 mmol) and
extracted four times with ethyl acetate. The combined ethyl acetate
layers were dried over magnesium sulfate and evaporated to afford
2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triaz-
olo[4,3-a][1,4]diazepin-6-yl)acetic acid (85.3 mg, 87.0%); ESI-MS
m/z=401.1 [(M+H).sup.+] which was used directly in the next
reaction.
N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-tr-
imethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamide
bis(2,2,2-trifluoroacetate)
[1280]
2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4-
]triazolo[4,3-a][1,4]diazepin-6-yl)acetic acid)(85.3 mg, 0.213
mmol) was combined with 2,2'-(ethane-1,2-diylbis(oxy))diethanamine
(Sigma-Aldrich, 0.315 mg, 2.13 mmol) were combined in 5 mL
anhydrous dimethylformamide.
(1H-benzo[d][1,2,3]triazol-1-yloxy)tripyrrolidin-1-ylphosphonium
hexafluorophosphate(V) (PyBOB, CSBio, Menlo Park Calif.; 332 mg,
0.638 mmol) was added and the reaction shaken at ambient
temperature for 16 hours. The reaction was diluted to 6 mL with
dimethylsulfoxide:water (9:1, v:v) and purified in two injections
with time collection Waters Deltapak C18 200.times.25 mm column
eluted with a gradient of 0.1% trifluoroacetic acid (v/v) in water
and acetonitrile. The fractions containing the two purified
products were lyophilized to afford
N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-t-
rimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamid-
e bis(2,2,2-trifluoroacetate) (134.4 mg, 82.3%); ESI-MS m/z=531.1
[(M+H)+]; 529.1 [(M-H).sup.-] and
(S,Z)--N,N'-(2,2'-(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(2-((6-
S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,-
3-a][1,4]diazepin-6-yl)acetamide) bis(2,2,2-trifluoroacetate) (3.0
mg, 1.5%); ESI-MS m/z=913.2 [(M+H)+]; 911.0 [(M-H).sup.-].
N-(2-(2-(2-amido-(Alexa647)-ethoxy)ethoxy)ethyl)-2-((6S,Z)-4-(4-chlorophen-
yl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6--
yl)acetamide(2,2,2-trifluoroacetate)
[1281]
N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-((6S,Z)-4-(4-chlorophenyl)-2-
,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ac-
etamide bis(2,2,2-trifluoroacetate) (5.4 mg, 0.0071 mmol) was
combined with Alexa Fluor.RTM. 647 carboxylic Acid, succinimidyl
ester (Life Technologies, Grand Island, N.Y.; 3 mg, 0.0024 mmol)
were combined in 1 mL anhydrous dimethylsulfoxide containing
diisopropylethylamine (1% v/v) and shaken at ambient temperature
for 16 hours. The reaction was diluted to 3 mL with
dimethylsulfoxide: water (9:1, v:v) and purified in one injection
with time collection Waters Deltapak C18 200.times.25 mm column
eluted with a gradient of 0.1% trifluoroacetic acid (v/v) in water
and acetonitrile. The fractions containing the purified product
were lyophilized to afford
N-(2-(2-(2-amido-(Alexa647)-ethoxy)ethoxy)ethyl)-2-((6S,Z)-4-(4-chlorophe-
nyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-
-yl)acetamide(2,2,2-trifluoroacetate) (1.8 mg); MALDI-MS
m/z=1371.1, 1373.1 [(M+H).sup.+] as a dark blue powder.
Assay
[1282] Compound dilution series were prepared in DMSO via an
approximately 3-fold serial dilution from one of the following:
Assay method A: 250 .mu.M-4.2 nM Assay method B: 0.47 mM to 7.8 nM
Assay method C: 500 .mu.M-8.5 nM Assay method D: 2.5 mM-800 nM
Assay method E: 0.047 mM to 0.78 nM or 5-fold serial dilution from
Assay method D
[1283] For Assay methods A, C, and D: Compounds were then diluted
6:100 in assay buffer (20 mM Sodium Phosphate, pH 6.0, 50 mM NaCl,
1 mM Ethylenediaminetetraacetic acid, 0.01% Triton X-100, 1 mM
DL-Dithiothreitol) to yield 3.times. working solutions. Six
microliters (.mu.L) of the working solution was then transferred to
white, low-volume assay plates (Costar #3673). A 1.5.times. assay
mixture containing His-tagged bromodomain, Europium-conjugated
anti-His antibody (Invitrogen PV5596) and the Alexa-647-conjugated
probe molecule was also prepared. Twelve .mu.L of this solution
were added to the assay plate to reach a final volume of 18
.mu.L.
[1284] For Assay methods B and E: Compound dilutions were added
directly into white, low-volume assay plates (Perkin Elmer
Proxiplate 384 Plus#6008280) using a Labcyte Echo in conjunction
with Labcyte Access and Thermo Multidrop CombinL robotics.
Compounds were then suspended in eight microliters (.mu.L) of assay
buffer (20 mM Sodium Phosphate, pH 6.0, 50 mM NaCl, 1 mM
Ethylenediaminetetraacetic acid disodium salt dihydrate, 0.01%
Triton X-100, 1 mM DL-Dithiothreitol) containing His-tagged
bromodomain, Europium-conjugated anti-His antibody (Invitrogen
PV5596) and Alexa-647-conjugated probe.
[1285] The final concentration of 1.times. assay mixture for assay
methods A, B, C, D, and E contains 2% DMSO, 8 nM His-tagged
bromodomain, 1 nM Europium-conjugated anti-His-tag antibody and 100
nM or 30 nM probe (for BDI or BDII, respectively) and compound
concentration in the range of: 5 .mu.M-85 pM for method A, 9.19
.mu.M-150 pM for method B, 10 .mu.M-169 pM for method C, 50
.mu.M-16 nM for method D, and 0.92 .mu.M-15 pM for method E.
[1286] After a one-hour equilibration at room temperature, TR-FRET
ratios were determined using an Envision multilabel plate reader
(Ex 340, Em 495/520).
[1287] TR-FRET data were normalized to the means of 24 no-compound
controls ("high") and 8 controls containing 1 .mu.M un-labeled
probe ("low"). Percent inhibition was plotted as a function of
compound concentration and the data were fit with the 4 parameter
logistic equation to obtain IC.sub.50s. Inhibition constants
(K.sub.i) were calculated from the IC.sub.50s, probe K.sub.d and
probe concentration. Typical Z' values were between 0.65 and 0.75.
The minimum significant ratio was determined to evaluate assay
reproducibility (Eastwood et al., (2006) J Biomol Screen, 11:
253-261). The MSR was determined to be 2.03 for BDI and 1.93 for
BDII, and a moving MSR (last six run MSR overtime) for both BDI and
BDII was typically <3. The K.sub.i values are reported in Table
1.
[1288] MX-1 Cell Line Proliferation Assay
[1289] The impact of compounds of the Examples on cancer cell
proliferation was determined using the breast cancer cell line MX-1
(ATCC) in a 3-day proliferation assay and the data are reported in
Table 1. MX-1 cells were maintained in RPMI 1640 medium (Sigma)
supplemented with 10% FBS at 37.degree. C. and an atmosphere of 5%
CO.sub.2. For compound testing, MX-1 cells were plated in 96-well
black bottom plates at a density of 5000 cells/well in 90 .mu.L of
culture media and incubated at 370 overnight to allow cell adhesion
and spreading. Compound dilution series were prepared in DMSO via a
3-fold serial dilution from 3 mM to 0.1 .mu.M. The DMSO dilution
series were then diluted 1:100 in phosphate buffered saline, and 10
.mu.L of the resulted solution were added to the appropriate wells
of the MX-1 cell plate. The final compound concentrations in the
wells were 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001, 0.0003 and
0.0001 .mu.M. After the addition of compounds, the cells were
incubated for 72 more hours and the amounts of viable cells were
determined using the Cell Titer Glo assay kit (Promega) according
to manufacturer suggested protocol.
[1290] Luminescence readings from the Cell Titer Glo assay were
normalized to the DMSO treated cells and analyzed using the
GraphPad Prism software with sigmoidal curve fitting to obtain
EC.sub.50s. The minimum significant ratio (MSR) was determined to
evaluate assay reproducibility (Eastwood et al., (2006) J Biomol
Screen, 11: 253-261). The overall MSR was determined to be 2.1 and
a moving MSR (last six run MSR overtime) has been <2.
TABLE-US-00001 TABLE 1 TR-FRET TR-FRET Binding Ki Binding Ki BRD4
BRD4 Cellular TR-FRET (BDI_K57- (BDII_E352- proliferation Example #
Protocol E168) (.mu.M) M457) (.mu.M) EC.sub.50 (.mu.M) 1 A 0.085
0.313 0.584 2 B 0.0062 0.013 0.038 3 A 0.026 0.043 0.161 4 A 0.0059
0.0072 0.056 5 C 0.010 0.029 0.067 6 C 0.0028 0.057 0.036 7 C
0.0040 0.016 0.093 8 C 0.0016 0.0064 0.033 9 C 0.012 0.029 0.128 10
C 0.0180 0.142 0.225 11 C 0.0089 0.031 0.037 12 C 0.684 1.17 NA 13
C 0.173 0.213 0.136 14 C 0.073 1.34 0.506 15 C 0.0033 0.012 0.021
16 D 0.0021 0.027 0.059 17 A 0.034 0.038 0.107 18 A 0.012 0.021
0.068 19 C 0.016 0.080 0.176 20 C 0.018 0.165 0.181 21 C 0.438
0.721 NA 22 C 0.015 0.120 0.384 23 C 0.013 0.117 0.256 24 C 0.017
0.089 0.231 25 E 0.014 0.060 0.08 26 C 0.0070 0.060 0.123 27 C
0.0080 0.032 0.176 28 C 0.0093 0.053 0.129 29 C 0.012 0.089 0.191
30 C 0.045 0.312 >3 31 C 0.021 0.087 0.398 32 C 0.0061 0.011
0.127 33 C 0.034 0.274 0.716 34 C 0.0016 0.029 0.095 35 C 0.042
0.111 NA 36 C 0.146 0.515 NA 37 C 0.052 0.099 NA 38 C 0.090 0.435
NA 39 C 0.063 0.051 NA 40 C 0.023 0.064 0.087 41 C 0.063 0.406
0.403 42 C 0.013 0.079 0.221 43 C 2.58 2.54 NA 44 C 0.014 0.089
0.136 45 C 0.037 0.070 0.279 46 C 0.205 1.09 0.479 47 B 0.033 0.124
NA 48 C 0.014 0.040 0.114 49 C 0.013 0.024 0.052 50 C 1.71 >4.44
NA 51 C 0.047 0.062 0.201 52 C 0.0046 0.0071 0.02 53 C 0.0032
0.0066 0.039 54 C 0.0034 0.026 0.021 55 C 0.0042 0.0099 0.029 56 B
0.013 0.018 0.036 57 B 0.014 0.037 0.066 58 B 0.072 0.088 0.057 59
B 0.606 0.600 NA 60 B 0.016 0.0062 0.037 61 C 0.018 0.043 0.125 62
C 0.357 0.291 NA 63 C 0.074 0.066 0.187 64 B 0.036 0.057 0.084 65 B
0.416 2.64 NA 66 B 0.219 0.741 NA 67 B 0.045 1.38 >3 68 B 0.103
0.124 0.038 69 B 0.773 2.29 NA 70 B 0.613 1.66 NA 71 B 0.197 0.285
0.255 72 B 0.492 0.967 NA 73 B 0.043 0.021 0.194 74 B >2.38
0.388 NA 75 B 0.131 0.042 NA 76 B 0.077 0.064 NA 77 B 0.062 0.139
NA 78 B 0.020 0.073 0.088 79 B 0.150 0.084 NA 80 B 0.056 0.053 NA
81 B 0.081 0.100 NA 82 B 0.066 0.049 NA 83 B 0.043 0.046 0.10 84 B
0.055 0.025 NA 85 B 0.044 0.017 NA 86 B 0.697 0.764 NA 87 B 1.52
0.565 NA 88 B 0.287 0.739 NA 89 B >2.38 1.22 NA 90 B 0.054 0.039
0.096 91 B 0.0054 0.0095 0.008 92 B 0.0017 0.0018 0.008 93 B 0.484
0.619 NA 94 B 0.168 1.87 NA 95 B 0.0042 0.0021 0.008 96 B 0.0069
0.011 0.015 97 B 0.158 0.081 0.398 98 B 0.992 2.03 NA 99 B >2.38
2.43 NA 100 B 0.0041 0.0048 0.009 101 B 0.0022 0.0025 0.005 102 B
0.095 0.081 0.739 103 B 0.0084 0.0049 0.089 104 B 0.072 0.107 >3
105 B 0.528 0.329 0.806 106 B 0.031 0.067 0.338 107 B >2.38
0.407 NA 108 B 0.093 0.181 0.46 109 B 0.057 0.067 0.268 110 B 0.061
0.215 0.136 111 B 0.908 0.337 0.713 112 B 1.05 1.05 NA 113 B 0.583
0.506 1.63 114 B 1.41 1.20 >3 115 B 1.35 1.33 1.42 116 B 0.093
0.145 0.578 117 B 0.776 0.750 NA 118 B 0.776 0.382 1.51 119 B 0.599
0.478 >3 120 B 0.077 0.208 0.306 121 B 0.012 0.079 0.04 122 B
0.025 0.055 0.044 123 B 0.130 0.428 NA 124 B 0.127 0.104 NA 125 B
0.069 0.092 0.267 126 B 0.0083 0.0057 0.0819 127 B 0.619 0.476
0.947 128 B 1.49 0.654 >3 129 B 1.14 1.19 NA 130 B 0.247 1.15
>3 131 B 0.281 1.25 1.4 132 B 0.249 1.24 0.658 133 B 0.049 2.68
1.68 134 B 0.103 0.518 0.456 135 B 0.027 0.109 0.388 136 B 1.09
1.32 NA 137 B 0.106 0.374 0.872 138 B 1.15 >4 NA 139 B 0.129
0.525 >3 140 B 0.490 0.817 1.82 141 B 0.064 0.495 0.98 142 B
0.87 2.31 NA 143 B 0.446 1.68 NA 144 E 0.0082 0.107 0.0731 145 E
0.174 0.296 NA 146 B 0.0253 0.0901 NA 147 B 0.0594 0.134 NA 148 E
0.0651 0.150 0.17 149 E 0.0416 0.054 NA 150 E 0.0220 0.145 NA 151 E
0.0161 0.032 0.20 152 B 0.141 0.0953 NA 153 B 0.321 0.293 NA 154 B
1.76 0.828 1.59 155 E 0.0278 0.163 0.31 156 E 0.598 >0.92 NA 157
E 0.118 0.333 NA 158 B 0.0764 0.153 NA 159 B 0.0624 0.0596 NA 160 B
0.101 >0.408 NA 161 B >0.238 0.0791 NA 162 B 0.146 0.183 NA
163 B 0.024 0.0813 NA 164 B 0.011 0.073 NA 165 B 0.214 0.105 NA 166
B 0.109 0.047 NA 167 B 0.0328 0.156 0.338 168 B 0.386 1.2 NA 169 E
0.0265 0.107 0.132 170 B 0.216 1.10 1.02 171 B 0.176 0.384 0.198
172 E 0.071 0.226 NA 173 B 0.214 0.781 NA 174 E 0.0575 0.215 NA 175
E 0.0691 0.285 NA 176 E 0.0423 0.101 0.289 177 E 0.133 0.248
>3.0 178 E 0.0308 0.239 0.233 179 E 0.0699 0.231 NA 180 E 0.0349
0.0593 >1.0 181 E 0.0658 0.128 >1.0 182 E 0.0292 0.0999 NA
183 E 0.00263 0.0134 0.356 184 E 0.00531 0.00472 0.309 185 E
0.00429 0.00794 0.0614 186 E 0.00038 0.00082 0.0134 187 E 0.00121
0.00202 0.0647 188 E 0.00142 0.0135 0.0299 189 E 0.00195 0.00882
0.0779 190 E 0.00201 0.00385 0.082 191 E 0.00763 0.0546 NA 192 E
0.00090 0.0013 0.0107 193 E 0.0043 0.0413 0.111 194 E 0.0105 0.0685
NA 195 E 0.0104 0.0127 0.162 196 E 0.00166 0.00964 0.0309 197 E
0.00205 0.00423 0.0676 198 E 0.00318 0.0109 NA 199 E 0.00363 0.0065
0.0368 200 E 0.00324 0.00456 0.0436 201 E 0.00347 0.0114 NA 202 E
0.00582 0.0163 0.0983 203 E 0.0138 0.0439 0.118 NA = Not
Determined
[1291] LPS (Lipopolysaccharide) Induced IL-6 Production Mouse
Assay
[1292] Compounds of the Examples listed in Table 2 were assayed for
their ability to inhibit LPS (lipopolysaccharide) induced IL-6
(Interleukin-6) production in mice. Fox Chase SCID.RTM. female mice
(Charles Rivers Labs, 5 per group) received an intraperitoneal
challenge of lipopolysaccharide (2.5 mg/kg, L2630 E. coli 0111:B4)
one hour after oral administration of compounds. Mice were
euthanized 2 hours after lipopolysaccharide injection, blood was
removed by cardiac puncture, and then the serum harvested from the
blood samples was frozen at -80.degree. C. On the day of the assay
the serum samples were brought to room temperature and then diluted
1:20 in phosphate-buffered saline containing 2% bovine serum
albumin. Interleukin-6 measurements were performed using a cytokine
assay from Meso Scale Discovery (Gaithersburg, Md.) for mouse serum
analysis according to the manufacturer's protocol and read on a
SECTOR Imager 6000 (Meso Scale Discovery, Gaithersburg, Md.)
instrument. Statistical analysis was performed using Prism software
(version 5.0) incorporating Dunnett's one way ANOVA. The IL-6 mean
and standard deviation of the group of vehicle treated animals were
compared with the IL-6 mean and standard deviation of the group
treated with drug. A p value <0.05 means that there is less than
a 5% probability that the mean values in the two groups are equal.
The % inhibition values in Table 2 all exhibited a p value less
than 0.05.
TABLE-US-00002 TABLE 2 Inhibition of LPS induced IL-6 production %
inhibition at Compound of Example # 3 mg/kg 2 27 4 40 11 66 15 44
16 69 17 49 25 62 32 33 52 77 53 74 60 62
Xenograft Tumor Growth Inhibition Assay
[1293] The effect of compounds of the examples to inhibit the
growth of OPM-2 xenograft tumors implanted in mice was evaluated. A
suspension of cancer cells (5.times.10.sup.6 per 0.1 mL) prepared
in RPMI culture medium (Invitrogen, Carlsbad, Calif.) was diluted
1:1 with a solution of Matrigel.TM. (BD Biosciences, Franklin
Lakes, N.J.) and inoculated subcutaneously into the right hind
flank of female SCID-beige (Charles River Labs) mice. Randomization
into treatment and vehicle control groups (10/group) occurred when
the mean tumor volume reached approximately 250 mm.sup.3. Compounds
were formulated in 10% EtOH, 30% PEG 400, 60% Phosol 53 MCT.
Administration of compound or vehicle was initiated on the day
following randomization and continued for 21 days. Tumors were
measured twice a week throughout the treatment period using a pair
of calipers and tumor volumes were calculated according to the
formula V=L.times.W.sup.2/2 (V: volume, mm.sup.3; L: length, mm; W:
width, mm). Tumor growth inhibition (TGI) was calculated based on
the mean tumor volume measured on the first day that the mean
volume of the vehicle group exceeded 2000 mm.sup.3 according to the
formula:
% TGI=100-mean tumor volume of treatment group/mean tumor volume of
control group.times.100.
[1294] Results are shown in Table 3.
TABLE-US-00003 TABLE 3 OPM-2 human multiple myeloma cancer
xenograft model Compound of Dose % removed from Example # (mg/kg)
route, regimen % TGI.sup.a study.sup.b 17 10 PO, QDx21 60*** 10 17
30 PO, QDx21 64*** 10 52 1 PO, QDx21 13 0 52 3 PO, QDx21 16 10
.sup.aThe p values (as indicated by asterisks) are derived from
Student's T test comparison of treatment group vs. control group.
*p < 0.05, **p < 0.01, ***p < 0.001. .sup.bPercentage of
treatment group that were removed from study due to morbidity or
weight loss in excess of 20%.
[1295] It is understood that the foregoing detailed description and
accompanying examples are merely illustrative and are not to be
taken as limitations upon the scope of the invention, which is
defined solely by the appended claims and their equivalents.
Various changes and modifications to the disclosed embodiments will
be apparent to those skilled in the art. Such changes and
modifications, including without limitation those relating to the
chemical structures, substituents, derivatives, intermediates,
syntheses, formulations and/or methods of use of the invention, may
be made without departing from the spirit and scope thereof. All
publications, patents, and patent applications cited herein are
hereby incorporated by reference in their entirety for all
purposes.
* * * * *